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Functional capacity is an important predictor of mortality in patients with cardiovascular disease. 
Exercise walk tests, such as the modified shuttle walking test (MSWT) and the six-minute 
walking test (6-MWT), are the recommended protocols in the United Kingdom for evaluating 
functional capacity and the effects of therapeutic interventions on patients enrolled in cardiac 
rehabilitation (CR) programmes. Due to a lack of research into factors associated with walking 
test performance in cardiac patients, the main aim of this study is to identify whether routinely 
taken measures (clinical and non-clinical) and biomechanical parameters can predict test 
performance. A further aim is to establish reference equations or normative values to predict 
performance in this population. Finally, this research aims to improve the safety of exercise 
testing and training in community-based CR settings.  
After determining the long-term reliability of the MSWT, this study investigated the claim that 
only sex, age and anthropometric parameters (stature and weight), and not biomechanical or 
simple clinical parameters, can predict functional capacity assessed by the MSWT, in patients 
with less severe cardiac diseases or by the 6-MWT, in heart failure patients. Overweight heart 
failure patients showed a 13-fold increase, and older patients (>75 years) had a 5-fold increase, 
in the risk of poor prognosis via 6-MWT assessment. Furthermore, it is shown here that the 
effect of stature on the magnitude of change in MSWT results is powerful, and can be used to 
estimate functional capacity improvement in the cardiac population. Finally, poor functional 
capacity was shown to have no association with risk of cardiovascular events during exercise, 
and that exercise testing and training can be carried out safely in supervised community-based 
CR settings. These findings have implications in clinical practice and CR programme 
improvement, as they can help clinicians to make better-informed decisions about cardiac 
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CHAPTER 1.  ITRODUCTIO AD OVERVIEW OF THESIS 
1.1.  Motivation  
The literature review for this thesis began in September 2008. It was conducted to evaluate the 
research related to cardiac rehabilitation (CR). A search was carried out using the following 
keywords: ‘cardiac rehabilitation’, ‘cardiac diseases’, ‘coronary heart disease’, ‘exercise’, 
‘national survey’. The motivation for the thesis came from the results of this search.  
Specifically, the motivation came from the results of recent surveys in the United Kingdom 
(UK), conducted by Brodie et al. (2006) and Bethell et al. (2007). Despite the well-established 
benefits of CR for cardiac patients (Oldridge et al., 1988; O’Connor et al., 1989, Jolliffe et al., 
2000), these surveys showed that only 28.5% of eligible cardiac patients attend CR programmes 
(Bethell et al., 2007), while there is a waiting list from three weeks to nine months for patients to 
join outpatient (phase III, UK classification) CR (Brodie et al., 2006). Two of the main reasons 
for the poor provision of CR are insufficient financial support for services and the low 
recognition by cardiologists and patients of the importance of CR (Brodie et al., 2006; Bethell et 
al., 2007). These results were reflected on and analysed in order to suggest possible solutions to 
improve and increase CR provision.  
The focus of this thesis was the improvement of existing functional walking assessment tests 
used in CR. Such tests have the potential to replace traditional laboratory-based tests, which are 
expensive and time consuming and for which patients often need to wait. This, in turn, could 
reduce long waiting times and the cost of CR services. Laboratory-based tests have the capability 
to produce direct functional capacity outcomes, but the need for specialist equipment and highly 




Such tests include the modified shuttle walking test (MSWT) and the six-minute walk test (6-
MWT). 
1.2.  Aim of the thesis  
The overall aim of this thesis was to investigate which factors can predict responses in functional 
capacity (i.e., the capability to maintain the activities of daily living) during two commonly used 
walking tests for CR patients: the MSWT and the 6-MWT. The intention was also to develop 
normative values for functional capacity when using the MSWT for this population; these values 
are for use in norm-referenced standards for individual patients entering CR.  
Such data could help clinicians to stratify patients according to functional capacity more 
effectively, help them to set better goals and make better-informed decisions about patients 
enrolled in a CR programme. A secondary aim was to investigate the safety of exercise testing 
and training in community-based CR settings. In this way, functional capacity evaluation and CR 
services can be improved, encouraging participation in CR training programmes. 
1.3.  Structure and main outcomes of the thesis 
This thesis is divided into seven chapters. Chapter 1 is a general introduction, which continues 
in Chapter 2 with a review of the relevant literature pertaining to cardiovascular diseases and 
CR. The literature review summarises existing knowledge on the topic and highlights gaps in the 
research literature. Chapter 3 provides an investigation into the long-term reliability of the 
MSWT. This study was carried out because the literature review showed that only short-term 
reliability had been assessed. Long-term reliability is important in CR because the MSWT is 
often administered to patients pre- and post- CR, a gap of four to twelve weeks. To assess the 




apart. The data showed no systematic bias but a relatively large random variation in test 
performance over the test period. It is concluded that the test can be used effectively in CR. Tests 
need to be both reliable, valid and much of the rest of the thesis concerns test validity.  
Performance on the 6-MWT is strongly influenced by age and stature of patients, but no 
comparable data were available for the MSWT. The aim of Chapter 4 is, therefore, to determine 
associations between anthropometric and gait parameters with distance walked during the 
MSWT. This chapter, as a pilot study, provides a preliminary reference equation to estimate 
MSWT performance in patients participating in maintenance (phase IV, UK classification) CR 
programme. The results show that only one gait parameter (step length) and two anthropometric 
measures (stature, leg length) are associated with MSWT performance. Step length is the best 
predictive measure of MSWT performance, followed by stature. It is concluded here, with regard 
to clinical practice implications, that tall cardiac patients have an advantage in the MSWT and 
that practitioners should account for stature when interpreting distance walked.  
Exploring the important role of simple anthropometric variables on the estimation of MSWT 
performance, in combination with the frequent use of the 6-MWT as an outcome measure in 
heart failure (HF) patients, Chapter 5 evaluates the degree to which non-clinical variables (age, 
anthropometric, gait parameters) may have an impact on 6-MWT performance in the HF  
population. Similar to Chapter 4, the results show that only age and anthropometric variables 
(stature, body mass, body mass index) are independent predictors of 6-MWT performance, and 
they must be considered when interpreting performance in this population. It is concluded that 
age and anthropometric factors can be used in the prognostic stratification of HF patients and the 




Chapters 4 and 5 eliminate a large number of gait and clinical parameters from the prediction of 
walk test performance, while suggesting that anthropometric variables may influence test 
performance in some patients. If decisions on exercise prescription and rehabilitation are taken 
based on test performance, the influence of such factors may be of importance. To date, 
normative data, developed using baseline anthropometric features, for functional capacity during 
treadmill testing, have been established only in American patient populations. Chapter 6, which 
considers only routinely measured variables (age, sex, anthropometric variables and simple 
clinical variables), tries to determine normative values for MSWT performance and MSWT 
performance changes in UK cardiac patients receiving phase III CR. The results reveal that age, 
sex and stature are the best predictive measures for pre-rehabilitation MSWT performance, while 
stature is the best predictor of magnitude of change in MSWT performance during phase III CR. 
It is concluded that normative values derived from these determinants can be used to estimate a 
normal improvement in functional capacity for CR patients. The interpretation of outcome 
measures obtained from the MSWT can help clinicians to make better-informed decisions about 
patients at the entrance to or discharge from a CR programme.  
There are clear benefits to be gained from functional capacity testing and exercise training in 
cardiac patients, but there had been no verification regarding the safety of exercise testing or 
training when applied in a supervised, community-based CR population. Chapter 7 evaluates 
the safety of the MSWT and exercise training for cardiac patients in phase IV community-based 
CR settings. The findings show only minor cardiovascular events provoked during the MSWT or 
exercise training, and no event-related hospitalisation, syncope episodes or fatality. Poor 
functional capacity is not shown to be associated with the risk of a cardiac event during exercise. 
It is concluded here that the MSWT and exercise training can be carried out safely in supervised 




The appendices to this thesis are divided into three parts. Appendix A contains the results and 
discussion of subsections 6.3.2. and 6.4.2, respectively (‘Validating the prediction equation 
developed in Chapter 4’). Appendix B presents the research ethics committee approval for 
Chapter 6. Appendix C presents the publications related to the work presented in this thesis. 
Appendices D and E provide descriptions of the oral and poster presentations respectively that 
were produced in the course of this work.   
The topic of this thesis is unique, as no previous data concerning the aspects described here were 
available at the time of this study. 
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CHAPTER 2.  ITRODUCTIO TO CARDIOVASCULAR DISEASES AD CARDIAC REHABILITATIO: 
A REVIEW OF THE LITERATURE 
2.1.  Introduction: Objectives and definition of cardiac rehabilitation  
2.1.1.  Epidemiology of cardiovascular disease 
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity throughout the 
world (Murray and Lopez 1997; Gaziano 2005; Amendezo et al., 2008). A five-year 
retrospective study of mortality in hospitals (Papadopoulos et al., 2008) showed that coronary 
heart disease (CHD) (10.3%) and heart failure (HF) (7.9%) were the second and third most 
common causes of mortality of the 5,836 deaths studied. The number of people aged 65 and over 
will increase
 
by 53% between 2001 and 2031, based on data selected from hospitals in the 
United Kingdom (UK) (Majeed and Aylin 2005). The number of people
 
aged under 65 is 
predicted to change little during this period. The increase in the number of older people is likely 
lead
 




2031, it is 
estimated that in the UK, and probably in most other developed countries, the number of cases of 
CHD will have increased by 44%, HF will have increased by 54% and atrial
 
fibrillation will have 
increased
 
by 46% (Majeed and Aylin 2005).  
Myocardial infarction (MI) is one of the diseases most frequently encountered by hospital 
doctors, and bypass graft surgery (CABG) is one of the most frequent surgical interventions. 
20% of patients who have had an MI die suddenly; 10% die within 24 hours (West 2003). These 
patients, who experience an acute cardiac event, underwent a cardiac surgical intervention or 
suffer from chronic heart disease, need rehabilitation and initiation of secondary prevention 




2.1.2.  Introduction to cardiac rehabilitation 
The management of cardiac diseases can be usefully discussed in terms of its components. These 
include the clinical evaluation of the cardiac disorder; including the risk factors, pharmacological 
treatment, surgical intervention (revascularisation) and secondary prevention. Secondary 
prevention, which is usually obtained through medication and life style changes, targets the 
reduction of risk of a new cardiac event in the future (Lockhart et al., 2000). 
2.1.2.1.  Definition of cardiac rehabilitation  
Cardiac rehabilitation (CR) consists of the primary care of patients with cardiac diseases, and 
secondary prevention. The World Health Organisation (WHO) has defined CR as ‘The sum of 
activities required to influence favourably the underlying cause of the disease, as well as to 
ensure the patient the best possible physical, mental and social conditions, so that they may, by 
their own efforts, preserve or resume when lost, as normal a place as possible in the life of the 
community’ (WHO 1993). 
A more recent definition by the Scottish Intercollegiate Guidelines Network (SIGN), supported 
and endorsed as a guideline for the UK by the British Association for Cardiac Rehabilitation 
(BACR), was: ‘Cardiac rehabilitation is the process by which patients with cardiac disease, in 
partnership with a multidisciplinary team of health professionals, are encouraged and supported 
to achieve and maintain optimal physical and psychosocial health’ (SIGN 2002).  
SIGN’s definition seems to be more substantial, and emphasises the importance of physical and 
psychological balance. So, CR is the sum of physical activities and interventions that are 
designed to improve the physical, psychological
 
and social functioning of patients with CVD 
disorders,
 




atherosclerotic process, in order to reduce the associated morbidity and mortality. Patients should 
be able to preserve by their own
 
efforts a normal place in the community and
 
lead a good quality 
of mental and social life (Coats et al., 1995; SIGN 2002; Taylor et al., 2004).  
Overall uptake of CR by MI, CABG and percutaneous coronary intervention (PCI) patients in 
the UK has been estimated at only 17%, 44% and 6%, respectively (Evans et al., 2002). 
Historically, CR in the UK has lagged behind the United States (US), Canada and Northern 
Europe; areas in which where there are still low levels of participation (Thomas et al., 1996; 
Grenier et al., 1999; Beswick et al., 2005). 
Richardson et al. (2000) studied cardiac patients who took part in CR over a 10-year period 
(from 1986 to 1996). In 1986, the programme started with 53 patients; by 1996 this had 
increased to 309. They noted that the majority of patients involved in CR were elderly men (>65 
years), who were in a high-risk category, with the potential to obtain the greatest benefit from a 
CR programme. Other investigators have observed that all types of people with cardiac disorders 
participate in CR programmes (McGee and Horgan 1992; Pell and Morrison 1998; Taylor et al., 
2001), while patients with MI, males and the middle aged, seem more willing to follow a CR 
programme than other groups (Thompson et al., 1997). Above all, men who participate in CR 
outnumber women, but the predominant age range cannot be predicted.  
2.2.  Risk factors for coronary heart disease 
Cardiovascular risk factors are traditionally divided into two categories: modifiable and non-
modifiable risk factors. The main modifiable cardiovascular risk factors are dyslipedemia 
(particularly high levels of low-density lipoprotein [LDL] and low levels of high-density 
lipoprotein [HDL]), hypertension, diabetes (glucose intolerance), obesity (mainly central 




hyperhomocystinaemia and psychological factors. The non-modifiable risk factors are: age, sex 
and hereditary factors (Poulter 2003). In the following sections, non-modifiable and modifiable 
cardiovascular risk factors will be discussed separately.  
2.2.1.  on-modifiable risk factors  
Non-modifiable risk factors cannot be changed; it remains important, however, to be aware of an 
individual’s overall CHD risk in order to focus on the elimination of modifiable risk factors.  The 
non-modifiable risk factors including age, sex and hereditary factors are discussed below. 
2.2.1.1.  Age 
Coronary heart disease is a progressive, degenerative progress that affects the coronary arteries. 
There is a slow but progressive accumulation of atherosclerotic plaque in coronary arteries, 
which starts in childhood and develops throughout life. The probability of an acute coronary 
event relates to the total burden of coronary plaque (Schisterman and Whitcomb 2004). Coronary 
heart disease often occurs under the age of 60. By this age, 1/15 men and 1/17 women will have 
a CHD (Castelli 1984).  
2.2.1.2.  Sex  
The literature identifies sex differences in the prevalence of cardiac diseases. For many years, it 
was thought that men were more affected by cardiac disorders than women. The lifetime risk of 
coronary events seems to be 1/2 for men and 1/3 for women by the age of 40, while at the age of 
70 it seems to be 1/3 for men and 1/4 for women (Lloyd-Jones et al., 1999). This sex ratio 
decreases with age and varies between populations. Among middle-aged people, the sex ratio in 
CHD mortality is higher in the white than in the black population. At the age of 45, white men 




the risk of a CHD compared with black women. At age 95, men and women have an equal risk 
ratio across both racial types (Ho et al., 2005).   
The main cause for the difference in prevalence between the sexes is biological factors, and 
many relates to differences in the reproductive system and hormones. Particularly, endogenous 
oestrogens have a protective role in the development of CVD in women (van der Schouw et al., 
1996; Hu et al., 1999).  
A study of 1,684 participants (Tremollieres et al., 1999) showed that the relative risk of CVD in 
postmenopausal women increased by 13% in comparison with perimenopausal women. This 
agrees with the findings of Azizi and Ainy (2003), which showed that CHD risk factors, such as 
cholesterol levels, glucose levels and BP, changed after menopause. The metabolic syndrome, 
which also includes cardiac disorders, is related to depressive
 
symptoms and the stressful life 
events that women may encounter in middle age (Raikkonen et al., 2007). This seems to relate to 
the menopause and the hormonal changes that woman undergo at this time (Smoller et al., 2007). 
According to Matthews et al. (2001), cardiovascular risk for women increases around this time, 
especially during menopause, because of changes in BP and
 




Oestrogen is believed to have cardioprotective effect in women; however in past trials (1960s 
and 1970s), men showed no beneficial therapeutic effect from being given high doses of 
oestrogen (The Coronary Drug Project Research Group 1973). Lawlor et al. (2001) found 
differences in the incidence of CHD between the sexes in different geographic areas and they 
stated that CHD does not relate exclusively to sex differences such as the hormone oestrogen 
(Henttonen et al., 2007; Smoller et al., 2007). They suggested that the higher risk that men may 




higher incidence of CHD in men is related to dietary habits; for example, in the way that they 
prepare food. Some other studies have focused on the relationship between different methods of 
socialisation and reaction to heart diseases. Women seem to be more socially supported than 
men, which appears to be cardioprotective (Berkman and Syme 1979). 
Rosengren et al. (2001) studied patients on the Swedish National Acute Myocardial Infarction 
Register, which included over 350,000 cases of nonfatal and fatal acute MI. Younger women 
who were hospitalised had higher short-term and long-term mortality in comparison with men of 
the same age. There was no difference in the mortality rates of men and women with MI, who 
were non-hospitalised (aged between 50 and 70 years old). They also demonstrated that women 
over the age of 70 years old had a better survival rate within 28 days and 1 year after the MI, 
while women under 50 had higher mortality within 28 days and 1 year after the MI, compared 
with men. These findings are in contrast with other studies that have demonstrated that there are 
significant differences between men and women’s mortality after an MI (Udvarhelyi et al., 1992; 
Brett and Madans 1995; Kober et al., 1996). The differences in the results may be associated 
with the fact that some of the post-MI patients were also suffering from other diseases such as 
diabetes, hypertension and HF, which may have affected the results.  
A combination of factors is responsible for the sex differences observed in CHD epidemiology. 
Females’ endogenous oestrogens and healthier lifestyles seem to play a cardioprotective role in 
CHD. This might have changed, as women have begun to indulge in habits that used to be 
regarded as a male ‘privilege’. Thus, there is a need for a new epidemiological study, to update 
lifestyles and habits, so that it will be possible to confirm, or not, the previously assumed sex 




2.2.1.3.  Hereditary factors 
Coronary heart disease runs in families. Family history is an independent risk factor for
 
atherosclerotic disease in men and women (Juonala et al., 2006). A positive family history of 
CHD is associated
 
with early markers of subclinical atherosclerosis. This is explained by the fact 
that people with a positive family history are more vulnerable to metabolic risk factors, such as 
high LDL, low HDL, high triglycerides and high-glucose levels (Juonala et al., 2006). The 
absolute cardiovascular risk increases in middle age to 50% for men and 70% for women, when 
at least one parent had a cardiovascular disorder before the age of 55 (in the father) or 65 (in the 
mother) (Lloyd-Jones et al., 2004; Murabito et al., 2005).  
Some forms of CVD are more common in specific racial and ethnic groups. For instance, black 
adults, in contrast with white, may be at higher risk of CHD because of dietary habits and 
anthropometric differences, but they have higher HDL and lower triglyceride levels. These 
cardioprotective phenotypes are an advantage and may be due to genetic influences (Whittle et 
al., 2002). An epidemiological study carried out from 1990 to 2000 demonstrated that black 
people and Asian Indian people have the highest mortality rates due to CHD; they have been 
identified as particularly high risk populations (Palaniappan et al., 2004).  
2.2.2.  Modifiable risk factors  
The main modifiable cardiovascular risk factors – dyslipedemia, hypertension, diabetes, obesity, 
smoking, excess alcohol, physical inactivity, inflammatory markers, hyperhomocystinaemia, 
psychological factors- are discussed below. There are quantitative studies in this area, and each 




2.2.2.1.  Dyslipidaemia 
Studies have attempted to explain how hyperlipidaemia is linked to MI. It was initially thought 
that the cholesterol obtained from the diet records is associated with the blood cholesterol levels 
to create atherosclerosis. Atherosclerosis, as mentioned above, occurs with CHD (Connor 1999). 
The pathophysiologic association between dyslipidaemia and atherosclerosis is described further 
in the section below (see 2.4.1.2.1. Atherosclerosis). This process begins with the oxidation of 
LDL, and leads to reduction in nitric oxide (NO) availability, which involves vascular injury, 
inflammation and vessel remodelling. This endothelial dysfunction plays a key role in 
atherosclerotic plaque destabilisation and rapture, promoting the development of acute vascular 
syndromes (Vogel 1999; Bae 2001).  
Panagiotakos et al. (2004a, 2004b) demonstrated, in a sample of 2,282 Greek people, that the 
Mediterranean lifestyle, and especially the diet, affects the management of hyperlipidaemia and 
assists the reduction of LDL-cholesterol levels. The Mediterranean diet
 
in the general population 
appears to improve the survival of patients
 
with CHD (Panagiotakos et al., 2004a, 2004b; 
Trichopoulou et al., 2005).  
Lavie and Milani (1999) demonstrated that a majority of CHD patients has 
hypertriglyceridaemia, and low levels of HDL cholesterol. CR and exercise training usually 
affects the HDL more than the LDL cholesterol. Exercise has more of an effect in terms of 
reducing triglycerides than it does in terms of LDL reduction. On the other hand, HDL is usually 
increased after a long-term exercise programme. Reductions in triglyceride levels and increases 





2.2.2.2.  Hypertension 
Hypertension is defined as a systolic blood pressure (SBP) of 160 mmHg, and a diastolic blood 
pressure (DBP) of 95 mmHg (Wolf-Maier et al., 2004).  Elevated BP is a risk factor
 
for death 
from CHD. Among the risk factors, hypertension is significantly associated with CHD, playing 
an important role in its pathogenesis. The WHO reported that hypertension causes 7.1 million 
deaths annually (Whitworth 2003). A 25-year follow-up study, which took place among six 
populations (in the US, Europe, Japan and the Mediterranean), showed that the relative risk of 
death due to CHD was 1.17 per 10 mmHg increase in SBP, and 1.13 per 5 mmHg increase in 
DBP (Van den Hoogen et al., 2000). Data from randomised control studies showed that 
reductions in SBP of 10 mmHg, and DBP of 5mmHg, decrease the risk of CHD by 20–25% 
(Collins et al., 1990; Collins and Peto 1994; Pahor et al., 2000; Lawes et al., 2002; Law et al., 
2003; Turnbull 2003).  
There are several mechanisms by which hypertension leads to the development of acute CHD 
syndrome. Hypertension is associated with endothelial dysfunction and thus with the 
development of atherosclerosis (Ferroni et al., 2006; Landmesser and Drexler 2007). Abnormal 
endothelial function is defined as an alteration in the functioning of the endothelial cells, 
resulting in a reduction in NO synthesis and an increase in oxidative stress (Landmesser and 
Drexler 2007). The increase in oxidant stress results in several modifications to the vascular 
wall. In particular, oxidant stress results in an increase in lipid oxidation and platelet activation; 
it plays a significant role in the promotion of a prothrombotic state in the vascular system 
(Mariano et al., 2003; Ferroni et al., 2006). When this occurs, there is a formation of 
atheromatous plaque and thus vascular luminal narrowing, reducing blood flow and triggering 




Nitric oxide prevents oxidation of LDL
 
cholesterol. Oxidation of LDL has been defined as a key 
factor in accelerating the atherosclerotic process (Steinberg and Witztum 2002; Stocker and 
Keaney 2004; Rubbo and O'Donnell 2005; Huang et al., 2008); the increased levels of oxidised 
LDL relate to plaque rapture and instability (Piek et al., 2000; Meuwissen et al., 2006). When 
this occurs, plasma and macrophage accumulate in coronary rapture plaques, and cause 
progression of plaque inflammation, plaque instability and acute coronary syndromes (Ehara et 
al., 2002; Huang et al., 2008). Thus, it seems clear that oxidised LDL levels relate significantly 
and directly to the severity of acute coronary syndromes (Ehara et al., 2001; Ehara et al., 2002; 
Huang et al., 2008). The atherosclerosis process is described in detail in the section below (see 
2.4.1.2.1. Atherosclerosis).  
2.2.2.3.  Diabetes mellitus 
The American Heart Association (AHA) has established that diabetes is a major cardiovascular 
risk for both women and men (Grundy et al., 1999). Diabetes mellitus (or type 2 diabetes) is 
associated with insulin secretion insulin resistance, resulting dyslipidemia (Pyorala et al., 1987; 
Juutilainen et al., 2005). Dyslipidemia is one of the most important mechanism by which 
diabetes promotes atherosclerotic lesion formation (Dokken 2008). Individuals with type 2 
diabetes have a two- to four-fold increase in risk of CHD compared with non-diabetic people 
(Ferdinand 2006); over 50% of patients with diabetes mellitus die of CHD (Pyorala et al., 1987; 
Juutilainen et al., 2005). 
An 18-year follow-up study showed that patients with type 2 diabetes, who had not had a 
previous CHD event, had an increased risk of acute coronary syndrome over non-diabetic people 
with prior evidence of CHD, especially in women (Juutilainen et al., 2005). The results of this 




2.2.2.4.  Smoking  
Smoking acts synergistically
 
with other risk factors to increase the risk of CHD. Both women 
and men in middle age who are current smokers have a two- to three-fold increased mortality 
risk (Ekberg-Aronsson et al., 2007). Smoking has an unfavourable effect on endothelial function. 
Specifically, smoking causes arterial wall thickening, increases inflammation, thrombosis, 
oxidation of LDL cholesterol, oxidative stress and hence contribute to the development of 
atherosclerosis (Poredos et al., 1999; Ambrose and Barua 2004; Thomas et al., 2008). Active 
female smokers reach menopause on average two years earlier than non-smokers; ex-smokers 
reach it one year earlier. This fact results in an earlier loss of the protective effect of oestrogen 
(Hu et al., 1999; Kinney et al., 2006). The acute effects of smoking are increased BP and heart 
rate (HR), vasospasm of the coronary arteries and reduction in the oxygen carrying capacity of 
the blood (Primatesta et al., 2001; Barutcu et al., 2005) creating an increased demand for oxygen 
but reduced ability to an increase supply.  
Cigarette smoking is associated with acute and chronic cardiovascular events for both active and 
passive (environmental) smokers (Ambrose and Barua 2004). Passive smoking is also related to 
endothelial dysfunction and the development of atherosclerosis, at higher rates compared with 
non-smokers and at a lower rate compared with active smokers, in healthy young adults (Woo et 
al., 2000; Holay et al., 2004). There is also a relationship between the number of cigarettes 
smoked daily and the risk of CVD. The risk increases with an increase in the number of 
cigarettes smoked each day and the total number of years as a smoker (Prescott et al., 2002; 
Godtfredsen 2003). Specifically, smoking very little per day (3–5 gr) can be a significant risk 
factor for developing MI and other cardiovascular disorders, which increases mortality. For 




sudden cardiac death and mortality by 50%. Women seem to be more affected than men 
(Prescott et al., 2002).  
An analysis of the Framingham Heart study focused on the relationship between smoking and 
the reaction in the cardiovascular system regarding age; it demonstrated that smokers’ life spans 
are shorter than the population average both in terms of CVD mortality and from other causes of 
death (Mamun et al., 2004). Women who had never smoked lived about 6.22 more years, and 
men 4.93 more years, free of CVD. The incidence of CVD in people who smoke is continuously 
higher before the age of 70 for males and females. 6/10 non-smoking males and 7/10 non-
smoking females could reach the age of 70 with no sign of heart disease; while 4/10 male and 
6/10 female smokers would be expected to reach the same age having contracted cardiovascular 
disorders (Mamun et al., 2004).  
2.2.2.5.  Physical inactivity 
Physical inactivity is an independent risk factor for CVD, diabetes mellitus and hypertension 
(Yung et al., 2009); it seems to have a similar risk ratio to other risk factors, such as smoking, 
dyslipidaemia and hypertension (Nanchahal et al., 2005). On the other hand, physical activity in 
leisure is cardioprotective, reducing the risk of death from CHD (Barengo et al., 2004; Khaw et 
al., 2006). Physical activity improves endothelial function, improving dilation of the coronary 
arteries. It also decreases total cholesterol, triglycerides, body fat and BP, while it increases 
‘protective’ HDL and insulin sensitivity (Couillard et al., 2001; Panagiotakos et al., 2003; Yang 
et al., 2008). However, there is an association between the intensity of physical activity and 
mortality. The effects of physical activity can be graded, and greater cardiovascular protection is 





2.2.2.6.  Overweight and obesity 
The impact of obesity in terms of cardiovascular risk has been clearly demonstrated in the 
‘Framingham Heart Study’, the ‘Nurses Health Study’ in women, the ‘Buffalo Health Study’ and 
the ‘Cancer Prevention Study II’ (Hubert et al., 1983; Manson et al., 1990; Keil et al., 1993; 
Dorn et al., 1997). Obesity interacts with other cardiovascular risk factors and independently 
increases the risk of CHD and mortality.  
Obesity is defined as a body mass index (BMI) equal to or above 30 kg·m
-2
, while ‘overweight’ 
is defined as a BMI of equal to or above 25 kg·m
-2
 (WHO 2000). The WHO uses BMI cut-off 
points for each different population type, taking into account their health risks. There is evidence 
that risk of chronic disease in some populations, like Asians, can increase progressively beyond a 
BMI of 21 (WHO 2004). Abdominal obesity also increases cardiovascular risk in men and 
women (Yarnell et al., 2001; Lakka et al., 2002; Onat et al., 2004; Canoy 2008). Abdominal 
obesity is defined as a waist circumference measurement of over 102 cm in men and 88 cm in 
women (National Institutes of Health 1998).  
BMI, waist circumference, waist-to-hip ratio (WHR), abdominal fat and measures of intra-
abdominal fat are all associated with common carotid artery plaques (Rubba et al., 2001; Takami 
et al., 2001; De Michele et al., 2002). Among normal and moderately overweight people, BMI 
and WHR were related to diastolic hypertension (White et al., 1986). Guagnano et al. (1997) 
demonstrated that among a sample of averagely obese women (mean BMI of 36 kg·m
-2
), WHR is 
related to diastolic and systolic hypertension, while BMI was not correlated to diastolic or 
systolic hypertension. The Atherosclerosis Risk in Communities study documented that there is a 
linear increase in CHD risk as BMI increases, although WHR seems to be a better predictor for a 
cardiac event, especially in women (Folsom et al., 1998). A more recent study confirmed that a 
BMI of up to 35 kg·m
-2 




concentrations and increased blood glucose concentrations in non-diabetic people (Whitelaw et 
al., 2001). 
De Michele et al. (2002) concluded that BMI and WHR were significant predictors of carotid 
wall thickness in a sample of 310 women; they also noticed that obese woman (BMI 30 kg·m
-2
) 
had higher SBP and DBP, triglycerides, fasting glucose and insulin, and lower HDL 
concentrations, compared with lean women. According to this study, obesity is defined either by 
BMI or WHR, or by abdominal fat; it is combined with a number of cardiovascular factors and 
they increase the risk of a new or secondary cardiac event. 
Lavie and Milani (1997) reported that 40% of people with cardiovascular disorders are 
overweight. A number of studies have focused on the relationship between obesity and the 
development of atherosclerosis, which is the main condition that leads to CVD. Atherosclerosis 
can begin at a young age, as deposits of cholesterol
 
on the large, muscular arteries (Berenson et 
al., 1992; Mahoney et al., 1996; McGill et al., 2000). Control of the risk factors would be a good 
method of primary prevention. McGill et al. (2000) analysed the levels of atherosclerosis in 
arteries and tissues, in 3,000 young persons (age of 15 to 34) who had died from non-CVD 
factors. Higher BMI is associated with fatty streaks and raised atherosclerotic lesions in both 
coronary
 
arteries in young men but not in women. 
Based on McGill’s (2000) study, Grundy (2002) concluded there may be two reasons for the lack 
of a significant correlation between obesity and atherosclerosis in women. The first reason is that 
perimenopausal women have a delay in the development of atherosclerotic plaques on the 
arteries; the second is that men tend to have an abdominal fat accumulation, and hence a higher 




obesity, like BMI; however abdominal fat distribution is becoming recognised as a more 
important risk factor for CHD than BMI. 
2.2.2.7.  Inflammatory markers  
Inflammation is a significant feature of atherosclerotic lesions. Elevated plasma levels, C-
reactive protein (CRP) and fibrinogen are markers of inflammation in subclinical and clinical 
atherosclerosis, and they have been established like cardiovascular risk factors (Liuzzo et al., 
1994; Hirschfield and Pepys 2003; Kamath and Lip 2003; Naghavi et al., 2003a, 2003b; Khreiss 
et al., 2004). The concentrations of C-reactive protein in blood plasma are associated with 
coronary events in patients with stable and unstable angina. CRP concentrations correlate with 
other cardiovascular risk factors, such as age, BMI, smoking, lipids, cardiac medical history, 
coronary stenosis and lower left ventricular ejection fraction (LVEF). 33% of cardiovascular 
events occur in patients with a high CRP concentration (>3.6 mg·l
-1
). High rates of CRP 
concentration in the plasma double the risk of a coronary event (Haverkate et al., 1997). The 
exact mechanism these inflammatory markers play in the arteriosclerosis process is still not fully 
known. 
2.2.2.8.  Hyperhomocystinaemia 
Homocysteine is an amino acid that forms when the essential amino acid is metabolised to 
cysteine. A meta-analysis of 30 studies found that for every 2.5 mmol·l
-1
 increase in plasma total 
homocysteine levels, the risk of MI increases by about 10% (Homocysteine  Studies 
Collaboration 2002).  
Hyperhomocystinaemia is associated with atherosclerotic
 
vascular disease and other conditions, 




CVD associated with elevated homocysteine levels may be a result of endothelial function, the 
promotion of LDL protein oxidation, its reduction of NO synthesis and its stimulation of 
increased platelet adhesion (Fallon et al., 2001; Faraci 2003; Lentz 2005; Griffiths et al., 2006). 
Hyperhomocystinaemia can also be caused by nutritional deficiencies (folate, vitamin B12), 
alcoholism, hypothyroidism, and genetic or renal defects (Lentz 2005). There may be benefits of 
lowering fasting homocysteine levels, to <10 mmol·l
-1
; the treatment of hyperhomocystinaemia 
includes dietary additions of folate and vitamins B12 and B6. In case that dietary source is 
ineffective, supplements of vitamins, including at least 400 mg of folic acid, 2 mg of vitamin B6 
and 6 mg of B12, are recommended (Booth and Wang 2000).  
2.2.2.9.  Excess alcohol  
Moderate alcohol consumption (equal to or less than 2 glasses of wine, 2 pints of beer per day) 
has a cardioprotective effect. A standard drink of wine contains 4 ounces (113 g) and beer 12 
ounces (340 g) of alcohol (Karatzi et al., 2004; Elkind et al., 2006; Suzuki et al., 2009). The 
mechanism of this effect may be explained by alcohol’s favourable effect on HDL, serum lipids, 
thrombotic tendency, insulin resistance, vasodilatation and thus on endothelial function (Hines 
and Rimm 2001; Elkind et al., 2006; Suzuki et al., 2009).  
Higher alcohol intake (≥3 drinks per day) is associated with hypertension, increased triglyceride 
levels (especially with the consumption of beer and spirits), arrhythmias, dilated cardiomyopathy 
and higher levels of CHD mortality (Shaper and Wannamethee 2000; Foerster et al., 2009).  
2.2.2.10.  Psychological factors 
Psychological distress is a significant risk factor for CHD, and it is one of the major predictors of 




study, which included people from 52 countries, found that psychosocial factors were a strong, 
independent risk factor for MI; indeed, they accounted for almost a third of the population’s risk 
factor (Rosengren et al., 2004; Yusuf et al., 2004).  
Most research has focused on the high prevalence of depression in patients with CHD, and on 
depression as a CHD risk factor. Anxiety and hostility are associated with an increased 
prevalence of CHD events (Lavie and Milani 2004, 2006; Rozanski et al., 2005). These 
psychological risk factors are related to dyslipidemia, hypertension, obesity, inflammatory 
biomarkers, coronary calcium and atherosclerosis (Whiteman et al., 2000; Rutledge et al., 2001).  
Coronary heart disease is also related to a certain personality type, defined as type A (Rosenman 
et al., 1964; Friedman 1989). Type A is used to describe persons who are depressed, highly 
competitive, urgent, aggressive, ambitious, obsessed with finishing everything on time and those 
who easily express hostility and anger. More recently, hostility has been linked with metabolic 
syndrome and an increased risk of mortality, especially in younger patients (Boyle et al., 2005; 
Todaro et al., 2005).  
The mechanism by which psychological and behavioural risk factors may cause premature CHD 
is unclear, but according to Lavie and Milani (2006) these are likely to be multifactorial. 
Psychological factors may increase platelet activation, level of catecholamines and coronary 
vasoconstriction, resulting in CHD (Lavie and Milani 2006). Also, anxiety may increase 
sympathetic activity, reduce vagal tone and increase the risk of malignant ventricular 
arrhythmias, all of which may lead to sudden cardiac death (Lavie and Milani 2004, 2006).  
Some of these risk factors are identifiable because they can be used to identify high-risk 
individuals for developing CHD. Studies have attempted to determine associations between the 




which are ‘effect’ (i.e., obesity, diabetes). In this case cardiovascular risk clustering may be a 
useful and reliable tool to evaluate cardiovascular abnormalities. The next section will discuss 
the most widely used risk calculations to estimate the risk of developing CHD or suffering an 
acute coronary event.  
2.3.  Cardiac risk stratification 
Risk stratification is often used as an important tool for evaluating an individual’s risk of 
developing CHD. Such stratification may be beneficial in primary or secondary prevention of 
CHD.  There are several different algorithms available to evaluate risk of CHD. Some of the 
most important assessment systems are: the Framingham Risk Score (FRS), the Prospective 
Cardiovascular Münster (PROCAM) algorithm, the European Society of Cardiology [ESC] score 
(SCORE), the Cardiovascular Risk Management (GRACE) model, the Coronary Artery 
Calcification (CAC) score and the QRISK2.  
The Framingham Heart Study began in 1948 to examine the epidemiology of CVD in the US, by 
analysing men and women from 35 to 62 years old (Dawber et al., 1951). The Framingham study 
became the worldwide gold standard for cardiovascular epidemiology (Dawber et al., 1963; 
Jaquish 2007), and this risk prediction algorithm is frequently referred to in the literature. The 
Framingham Risk Score is frequently used in developed countries (for example, in the US). The 
Framingham Risk Score uses a scoring system including assessing the following CVD risk 
factors: hypertension, smoking, total cholesterol and HDL cholesterol. The total score is assessed 
using Framingham scoring tables, which provide an individual’s 10-year risk for developing 
CVD. There are separate score tables and charts for women and men (National Cholesterol 
Education Program Expert Panel on Detection 2002; McPherson et al., 2006). A projected 10-




risk; a score between 10 and 20% is considered a moderate risk (National Cholesterol Education 
Program Expert Panel on Detection 2002) (see table 2.1).  
The Framingham Risk Score is higher than those of PROCAM and ESC algorithms. The FRS 
overestimated the risk of CHD in European countries (UK, Italy) with a lower incidence of 
coronary events (Menotti et al., 2000; Brindle et al., 2003). The Framingham study is 
(chronologically) older than the other two, and at the beginning of the data collection, CHD had 
a high incidence, which declined over the following years (Assmann et al., 2002). 
Table 2.1.    Framingham risk levels and desirable lipid results (Guidelines and Protocols Advisory 
Committee 2008) 




) TC/HDL RATIO 
High  ≥ 20%  < 2.5 < 0.85 < 4.0 
Moderate  10 % - 19 % < 3.5 < 1.05 < 5.0 
Low  < 10% < 5.0 < 1.25 < 6.0 
Definition of abbreviations:  Apo B = apolipoprotein B; CHD = coronary heart disease; LDL =  low-
density lipoprotein; TC/HDL = total cholesterol/high-density lipoprotein ratio  
The PROCAM study in Europe provides another algorithm for individual stratification in 
relation to developing CHD. The PROCAM score is based on data from a German study and it 
estimates the risk of suffering an MI or acute coronary event. The algorithm is mostly based on 
men, aged 35 to 65 years. The variables that the PROCAM study used were age, LDL and HDL 
cholesterol levels, triglycerides, smoking, diabetes mellitus, MI in family history and SBP 
(Assmann et al., 2002). The PROCAM predicted event rate is about 25% lower than the 
Framingham score and 80% higher than the ESC event rate (Agabiti-Rosei et al., 2008).  
The ESC algorithm, SCORE (Systematic Coronary Risk Evaluation), was based on an analysis 
of European data from 12 countries. The SCORE is based on factors, such as sex, age, total 




prevention of total CVD. The SCORE project aimed to estimate the total number of 
cardiovascular events rather than the risk of CHD (Conroy et al., 2003). However, SCORE event 
rates were lower than the Framingham and PROCAM event rates (Agabiti-Rosei et al., 2008). In 
each of the three risk algorithms (FRS, PROCAM, SCORE), some prognostic variables, such as 
cardiac and ECG markers, were not included.  
These prognostic variables were included in a more recent research. The global registry of acute 
coronary events (GRACE) was used to estimate the risk of death for patients with acute coronary 
syndrome. The study took place in 94 hospitals across 14 countries (in Europe, North and South 
America, Australia, and New Zealand). The GRACE risk prediction tool includes nine variables: 
age, presence of HF, peripheral vascular disease, SBP, HF class, initial serum creatinine 
concentration, positive initial cardiac markers, cardiac arrest on admission and ST-segment 
changes (Fox et al., 2006). This model takes into account many variables; however it is 
applicable only for patients who had experienced an acute coronary syndrome (i.e., MI). This 
algorithm is used for risk stratification in the secondary prevention of CVD. 
The new Cardiovascular Risk Management (CARISSMA) system covers more, important 
prognostic variables, such as functional capacity, body weight and number of cigarettes 
consumed per day. CARISSMA provides more detailed cardiac risk stratification and details of 
treatment that could be provided in primary prevention, especially at moderate risk levels for 
CHD (Gohlke et al., 2007).  
The Coronary Artery Clacification (CAC) score has been used in the prediction of 
atherosclerotic CVD events in symptomatic or asymptomatic individuals. The calcium score is 
assessed by computed tomography and is related to the extent of atherosclerosis in combination 






calcification, the more likely it is that a coronary event may occur (Wexler et al., 
1996). A zero CAC score relates to a very low risk of a coronary event. People with a zero CAC 
score may not have developed any coronary plaque; however, they may have early stages of 
plaque accumulation (fatty streaking) that is undetectable (Raggi et al., 2001; Nasir et al., 2006). 
The CAC score is combined with the FRS score. The CAC score can modify the predicted FRS 
score, especially at a moderate-risk level (when FRS is predicted to be in the range
 
of 10 to 19% 
over 10 years). The CAC score does not significantly change the predicted risk for people with 
an FRS of lower than 10% or higher than 20% (Greenland et al., 2004). 
The QRISK2 risk score has been recently developed at the University of Nottingham for use in 
the UK. This calculator includes risk factors such as age, sex, smoking status, total and HDL 
cholesterol, BMI, family history of CVD and SBP (Hippisley-Cox et al., 2007). This risk 
calculator is used to predict the 10 year risk of developing CVD. It has been validated on large 
UK databases, including more than a million patients (Hippisley-Cox et al., 2008; Collins and 
Altman 2010). This calculator takes into consideration more risk factors than established FRS. It 
has been demonstrated that QRISK2 risk calculator is more accurate to predict the development 
of CVD in UK population than FRS (Collins and Altman 2010).  
Cardiovascular risk prediction models are constantly changing, being adapted to accommodate 
new risk factors. Different cardiovascular risk prediction models have been developed to provide 
country-specific risk prediction. The diverse risk stratification models share a common primary 
goal; to identify high-risk individuals and manage primary and secondary prevention of CHD. 
The following section will analyze the most common forms of CVD, to ensure a better 





2.4.  Cardiovascular Diseases 
2.4.1.  Coronary heart disease   
2.4.1.1.  Definition of coronary heart disease 
Coronary heart disease (CHD) is the consequence of the atherosclerotic plaque that forms in the 
larger arteries. Cholesterol is a constituent of atherosclerotic plaque. Coronary heart disease 
accounts for nearly 50% of all CVD deaths (Nasir et al., 2006).  
2.4.1.2.  ature and causes of coronary heart disease 
Complex interactions between diet, lifestyle and lipoprotein
 
metabolism determine the progress 
of atherogenesis; the development of atherosclerotic plaques inside the vessels. This process 
results in atherosclerosis (McGill et al., 2000).  
2.4.1.2.1.  Atherosclerosis 
The atherosclerotic process starts in childhood with the development of atherosclerotic lesions, 
defined as a fatty streak in the intima of the large, muscular arteries (Holman et al., 1958). Fatty 
streaks begin to appear first in the aorta and then in coronary arteries 5 to 10 years later (Strong 
and McGill 1962; McGill 1968). Fatty streaks and raised lesions in both the aorta and the 
coronary arteries contain atherogenic lipoproteins and macrophage foam (Hata et al., 1974; 
Guyton and Klemp 1994; Chilton 2004). 
The mechanism by which the fatty streak transforms to atherosclerotic lesions (plaques) is 
consistent with the cellular
 
and molecular mechanisms derived when the oxidised LDL, 
macrophages and scavenger receptors involved. LDL has oxidant properties, and HDL has 




arterial lumen. Each macrophage is a versatile receptor, and some of the arterial macrophages 
react with oxidised LDL. Factors including LDL concentration, LDL oxidation, macrophage 
lipid accumulation, fewer antioxidants and genetic factors, lead to the development of a 
fibromuscular cap and then to fibrous plaque in the lumen of the arteries (Gelissen et al., 1996; 
Giry et al., 1996; Wang et al., 1996). Inflammatory cytokines attract more macrophages and 
these stimulate muscle cells
 
to accumulate lipid, so a chronic inflammatory
 
process is continued. 
Over the years, these fibrous plaques enlarge and provoke haemorrhages, ulceration or rupture, 
and thrombosis. The clinical disease depends on which artery has been affected (McGill et al., 
2000). 
Such pathophysiology explains how the fatty streak transforms to pathologic lesions and then to 
fibrous plaques, which play a critical role in the development of acute coronary syndromes 
(Chilton 2004). Plaques vary in their characteristics, but all types of plaque can result in a serious 
coronary
 
syndrome (Naghavi et al., 2003a, 2003b). When the lumen of the coronary arteries 
decrease by more than 50%, blood supply to the myocardium becomes limited. The advanced 
atherosclerotic lesions
 
and the development of atherosclerotic disease are associated with a 
number of clinical risk factors such as age, sex, genetic factors, high LDL-cholesterol 
concentrations, low HDL-cholesterol concentrations, hypertension, smoking, diabetes,
 
obesity 
and psychological factors (McGill et al., 2000). Atherosclerosis is the pathology underlying most 








2.4.2.  Manifestations of coronary heart disease 
2.4.2.1.  Angina  
2.4.2.1.1.  Definition and causes of angina pectoris 
The ESC (1997) defines angina pectoris as the clinical diagnosis that is usually caused by CHD; 
it is described mainly in relation to chest pain or discomfort. According to the American Heart 
Association (AHA) and the American College of Cardiology (ACC) guidelines for the 
management of patients with chronic stable angina, angina results from ischaemia, due to 
imbalance between oxygen demand and supply to the heart muscle (Gibbons et al., 1999). The 
underlying cause of angina is coronary atherosclerosis, but in some cases can result of 
cardiomyopathies or aortic stenoses (Collins and Fox 1990). 
2.4.2.1.2.  Functional classification of angina  
The Canadian Cardiovascular Society (CCS) defined a four-level angina functional classification 
for patients, according to the symptoms experienced. Class I refers to patients without symptoms 
during ordinary physical activity in whom angina may occur during laborious, prolonged work 
or exercise. Class II angina is detectable when walking, climbing stairs, or during fast uphill 
walking. This classification refers to angina experienced after a meal, in cold and windy weather, 
or under stressful conditions; it also encompasses angina that occurs while walking more than 
two blocks and climbing more than a stairway under normal conditions and at a normal pace. 
Angina Class III relates to walking one to two blocks, or climbing a stairway at a normal pace. 





Table 2.2.  Canadian Cardiovascular Society Angina Classification (Campeau 1976) 
Class Activity that occurs angina Limitations in ordinary physical activity 
Class I Exhausted and prolonged exertion None 
Class II Climbing > 2 blocks Slight limitation 
Class III Climbing < 2blocks Marked limitations 
Class IV At rest Inability to carry on any physical activity 
without discomfort (severe) 
2.4.2.1.3.  Types of angina 
2.4.2.1.3.1.  Stable Angina 
Diagnosis of stable angina is usually based on a patient’s history and pattern of symptoms. 
Stable angina is described as chest discomfort, which can be referred to the jaw, shoulder, back 
or arm. Chest pain is usually observed on exertion and lessens when the patient rests (Snow et 
al., 2004; Jawad and Arora 2008). 
Patients with chronic angina need evaluation for CHD. A resting electrocardiogram (ECG) does 
not usually help, as it does not identify abnormalities (unless it takes place during angina event). 
Patients with suspected angina can undertake a stress test during which the heart’s electrical 
activity is recorded by ECG during exercise on a treadmill or bike. Coronary angiography is 
usually required to confirm CHD and identify its extension and severity (Snow et al., 2004; 
Jawad and Arora 2008). 
2.4.2.1.3.2.  Unstable angina 
Unstable angina is defined as one of the following: angina with symptoms at rest; angina with 
symptoms at exertion, meeting the CCS criteria for class III, or even IV, variant angina, post MI 




refers to refractory angina and describes it as a chronic condition (>3 months duration), which is 
caused by myocardial ischaemia and cannot been treated by medical care or surgical intervention 
(CABG, PCI) (Mannheimer et al., 2002).  
2.4.2.1.3.3.  Prinzmetal (variant) angina 
Prinzmetal et al. (1959) first described another form of angina – Prinzmetal or variant angina. 
Prinzmetal’s angina is characterised by episodes of chest pain that occur at rest or when asleep, 
and it is caused by coronary vasospasm. It is associated with atherosclerosis of the vessels and 
the vasospasm usually occurs close to the blockage. It is associated with ventricular arrhythmias, 
ventricular tachycardia, ventricular
 
fibrillation, acute MI and sudden cardiac death (Keller and 
Lemberg 2004).  
2.4.2.1.4.  Mortality and prognosis of angina 
The prognosis of angina is quite difficult as it relates to many parameters, such as the severity of 
the angina (see notes on the CCS classification
 
system, above), duration of symptoms, type of 
angina, previous MI, symptoms after revascularisation, severity of left ventricular damage, 
number of vessels involved, parts of arteries affected, diabetes and ST-segment changes on the 
resting ECG (Daly et al., 2006; Jones et al., 2006). These parameters can be used as criteria to 
estimate prognosis, including the probability
 
of death or MI one year after the presentation
 
of 
stable angina (Daly et al., 2006).  
The incidence of total morbidity and mortality rates in angina patients ranges from 2.8 to 6.6 in 
100 patients per year; the incidence of cardiovascular death ranges from 1.4 to 6.5 in 100 
patients per annum; and the (nonfatal) MI rate ranges from 0.3 to 5.5 in 100 patients per year 




2.4.2.1.5.  Management of angina (medical treatment) 
The first approach to an angina event is to give anti-anginal drugs, which include three main 
categories: nitrates, β-blockers and calcium antagonists. Nitrates help by increasing the blood 
supply in the veins and the most usual form administered is glyceryl trinitrate (Jones and West 
1995). Nitrates usually relieve pain and can increase exercise tolerance. If nitrates are used 
frequently for more than 24 hours, the patient can become tolerant to the drug. So, a high dose of 
nitrates once a day (i.e., 16 mg molsidomine) is recommended (Messin et al., 2005). 
Beta-blockers decrease BP and HR (Jones and West 1995). Patients with angina should be given 
high doses of β-blockers to reduce resting HR to 55–60 beats per minute (bpm). Third-generation 
β-blockers generate vasolidation, increase coronary blood flow and improve microvascular 
angina pectoris or silent ischaemia in patients with artery stenosis (Galderisi and D'Errico 2008).  
Calcium antagonists relax the arteries, including the coronary arteries. There are two groups of 
calcium antagonists: those which increase the HR, and those that decrease it. The antagonists 
that decrease the HR cannot be combined with β-blockers (Dunselman et al., 1997; Knight and 
Fox 1998; Emanuelsson et al., 1999). 
Aspirin produces good results in the acute phase of unstable angina and is associated with a 
reduced incidence of MI (Theroux et al., 1988; The RISC Group 1990). Aspirin combined with 
heparin also reduces the risk of CHD events and refractory angina incidents (The RISC Group 
1990; FRISC study group 1996). Harding et al. (2002) concludes that an early clinical 
assessment and stratification of the patients according to their risk levels is essential to ensure 





2.4.2.1.6.  Management and follow-up of unstable angina 
Unstable angina may lead either to nonfatal MI, or to death, or to a lessening of the symptoms. 
Patients with unstable angina should be admitted as an emergency to a coronary care unit. ECG 
monitoring is important, while anti-anginal drugs, aspirin and heparin should be administrated as 
soon as possible. Patients who do not get relief from their symptoms, and patients at high risk, 
should have revascularisation therapy with CABG or a PCI intervention (Reeder 2000; Aronow 
2003).  
2.4.2.1.7.  The role of cardiac rehabilitation for patients with angina 
The effects of CR and especially of exercise training in patients with angina pectoris have been 
studied for years. Exercise training is useful for patients with angina pectoris
 
who are not 
involved in revascularisation intervention (Clausen and Trap-Jensen 1976). Exercise can 
improve the endothelial function; reduce HR exertion and the severity of angina pectoris 
(Hambrecht et al., 2000b).  
2.4.2.2.  Myocardial infarction  
2.4.2.2.1.  Definition of myocardial infarction 
Myocardial infarction is the irreversible necrosis of heart muscle and occurs secondary to 
prolonged ischaemia. It is usually caused by an imbalance between myocardial oxygen demand 
and supply. This is usually the result of the atheromatous plaque rupture and thrombus formation 






2.4.2.2.2.  Presentation of myocardial infarction 
Chest pain is the most frequently experienced primary feature for diagnosis of MI in women and 
men (Milner et al., 1999; Albarran et al., 2007). Usually, patients with MI present with chest 
pain and other typical symptoms, such as fatigue, weakness, sweating and nausea (Milner et al., 
1999; Omran and Al-Hassan 2006; Albarran et al., 2007). Women are more likely to present 
with dyspnea, palpitations, nausea, diaphoresis, fatigue, mid-back pain, arm or shoulder pain, 
neck pain and syncope (Milner et al., 1999, 2002; Patel et al., 2004; Omran and Al-Hassan 2006; 
Albarran et al., 2007). However, there are more similarities than differences in the way that male 
and female patients present with MI.  
2.4.2.2.3.  Diagnosis of myocardial infarction 
Symptoms may be a strong indicator of MI, but the diagnosis can only be confirmed by specific 
clinical measurements. The most common medical examinations are echocardiography and 
enzyme measurements (troponin, creatine kinase [CK], creatine kinase MB [CK-MB]). ECG 
changes, such as depression or elevation in the ST-segment, and an elevation in the development 
of pathologic Q waves indicate ischaemia (Alpert et al., 2000; Galvani et al., 2002). 
Measurements of troponin, CK and CK-MB are used as diagnostic tools and prognostic criteria 
in MI (Alpert et al., 2000; Galvani et al., 2002; Roger et al., 2006). Karras and Kane (2001) 
suggested that the cardiac troponins are the more useful and sensitive tool in the diagnosis of MI. 
It is preferable to CK and CK-MB because the latter start to rise a few hours from onset. Patients 
who present typical symptoms, such as chest pain, are advised to wait a few hours after the onset 
of symptoms, before cardiac marker testing. CK-MB is a reliable and sensitive measure which 




any time following the onset of chest pain are predictive of an adverse cardiac event (Karras and 
Kane 2001).  
Previously, myoglobin appeared promising as a marker of early cardiac ischaemia, but it now 
appears to be only marginally more sensitive than CK-MB soon after symptom onset.  
Myoglobin is less sensitive than CK-MB at >8 hours after chest pain starts (Karras and Kane 
2001). Within 6-8 hours of the initial symptoms, cardiac markers are highly sensitive and 
effective in the diagnosis of MI. The accuracy of the diagnosis is also related to the time that the 
patient had to go to the emergency department. In this time, the biochemical markers of 
myocardial necrosis may have normalised (Alpert et al., 2000; Galvani et al., 2002).  
Troponin is a sensitive diagnostic marker for MI, but it is insensitive as an indicatory of the 
extent of the MI. In contrast, CK-MB can determine with accuracy the extent of the MI (Costa et 
al., 2008). Troponin could not be looked at on its own, because only half of the patients that had 
elevated troponin levels met the criteria for having undergone an MI (Lim et al., 2005).  Above 
all, it seems that an isolated cardiac serum marker cannot be used as an ideal marker of MI, 
which explains why so many examinations are made when an MI is suspected. 
2.4.2.2.4.  The role of cardiac rehabilitation after myocardial infarction 
Cardiac rehabilitation is designed to reduce coronary artery risk factors, promote a healthy 
lifestyle and decrease rates of morbidity and mortality following MI (Goto et al., 2002, 2003a). 
Data from meta-analyses of more than 4,000 post-MI patients showed that exercise-based CR, 
compared with usual medical care, is associated with reductions in cardiovascular mortality and 
fatal reinfarction (20-25%) throughout at least 2 years after MI (Oldridge et al., 1988; O’Connor 




In particular, patients with MI who attended CR showed significant improvements in 
physiological and psychological parameters. Exercise training improves functional capacity, 
muscle strength and maximal oxygen uptake (VO2max) (Izawa et al., 2004). Adams et al. (1999) 
and Izawa et al. (2004) used aerobic and resistance training, at an intensity of 60–80% (11–13 on 
the Borg scale) over an 8-week programme; they found important physiological benefits (17% 
muscle strength increase) without any cardiac or orthopaedic injury. Moreover, regular exercise 
training can improve endothelium vasodilatation, lessen epicardial coronary stenosis and, as a 
result of these improved factors, can reduce myocardial ischaemia (Hambrecht et al., 2000b, 
2003) and improve symptom-free periods (Hambrecht et al., 2004).  
Cardiac rehabilitation has shown significant improvements in the psychological area as well, 
such as decreased depression, more effective stress management and an improvement in health-
related quality of life (HRQOL) (Sledge et al., 2000; Izawa et al., 2004). Resistance and aerobic 
exercise can improve physiological and psychological outcomes in patients with MI; however, 
long-term follow-up studies with larger samples are essential for CR to be established as 
beneficial and safe for use in recovery from MI. Further discussions of issues related to CR in 
post-MI patients will be found in the next chapters.  
Except CHD, other serious cardiovascular conditions are heart failure (HF), valvular heart 
disease and arrhythmias (Fleisher et al., 2007) and they will be analyzed below.  
2.4.3.  Other forms of cardiovascular disease 
2.4.3.1.  Heart failure   
Heart failure (HF) is one of the most prevalent forms of heart disease in the elderly, affecting 




an imbalance occurs between cardiac output and the body’s requirements. The most common 
symptoms in HF patients are muscle weakness, fatigue, exercise intolerance, cachexia and 
dyspnoea as a result of reduced oxygen delivery to the working skeletal muscle (Troosters et al., 
2004). Heart failure cannot actually be cured, but can be treated to relieve the symptoms, 
improve the quality of life and prolong patient’s life (Alhaddad 1999; Dunderdale et al., 2005; 
Davies et al., 2010) 
2.4.3.1.1.  The role of cardiac rehabilitation for patients with heart failure 
In light of the main symptoms HF patients experience, exercise interventions have concentrated 
on improving the skeletal muscle function, and especially muscle strength and tolerance 
(Dickstein et al., 2008). Systematic reviews show that improvements in muscle strength and 
exercise tolerance by exercise training reduce morbidity (hospitalization) and mortality in HF 
patients, compared with usual care (Smart and Marwick 2004; Dickstein et al., 2008; Smart and 
Steele 2010). A meta-analysis of 9 studies, involving 801 HF patients, showed that exercise 
training is significantly associated with lower mortality and admission to hospital (hazard ratio 
0.65, 95% confidence interval [CI] 0.46 to 0.92, p <0.005) compared to non-exercisers. The 
mean follow-up was approximately from 5 months to 6 years (Piepoli et al., 2004). Debate still 
surrounds the type and intensity of exercise should be recommended to HF patients. 
There is some evidence that both aerobic and resistance exercises can reduce the levels of 
catecholamine concentration (Tyni-Lenne et al., 2001) and improve neurohormonal modulation 
(renin angiotensin system). Neurohormonal modulation has an impact on quality of life (Maria 
Sarullo et al., 2006) and improves exercise tolerance and functional capacity (Belardinelli et al., 




adaptations due to exercise, but there was insufficient reporting on the improvement that exercise 
may bring about on the central cardiovascular function. 
Sturm et al. (1999) demonstrated that moderate aerobic exercise (at 50% of VO2max) increases 
peak oxygen uptake and functional capacity, in patients with severe HF. The authors (Sturm et 
al., 1999) reported that at this level of exercise patients could work individually, without 
supervision by a CR professional. Belardinelli et al. (1995) found that low intensity exercise (at 
40% of VO2max) can also help patients with stable HF. Low intensity exercise improved 
mitochondrial energy metabolism by improving the oxidative capacity of the trained muscles. In 
this way, functional muscular performance can be improved, as well.  
Silva et al. (2002) examined patients with the signs and symptoms of HF; they studied the result 
of exercise on this group in comparison with a control group. The exercise programme that they 
used was performed at intervals: 3 days a week, 30–60 minutes per day, for 3 months, at an 
intensity of 60–80% of peak HR. It included walking and stretching exercises using the upper 
and lower limbs. In contrast with other investigators, Silva et al. (2002) used a high intensity 
exercise programme, but the patients who took part were examined by a cardiologist to be sure 
that they did not have any of the exclusion criteria, such as arrhythmia, angina, MI in the last 3 
months, hypertrophic myocardiopathy, cardiopathy that required surgery, or hypertension. The 
results of this control study showed that exercise programmes increase distance walking, 
decrease resting HR and reduce the double product at peak exercise levels (HR × SBP). Double 
product is the indirect index of myocardial oxygen demand (Williams et al., 2007). You Fang 
and Marwick (2003) refer to long-term programmes (3–6 months) that can maximise the benefits 




To summarise, the characteristics of a CR programme for patients with HF, in order for it to be 
safe and for patients to obtain the maximum benefit, could aim for the following constituent 
parts:  
• Frequency: 3 days per week 
• Intensity: moderate 
• Type of exercise: interval, aerobic and resistance exercise 
• Duration: 30–60 minutes, over a longer term (3–6 months) 
2.4.3.2.  Valvular heart disease 
2.4.3.3.1.  ature and causes of valvular heart disease 
Disorders of the heart valves (mitral, aortic, tricuspid or pulmonary valves) and their structural 
abnormalities are referred to as valvular heart disease. Valvular heart disease can affect blood 
flow in two ways: (i) due to valve stenosis, blood flow is obstructed; (ii) valve does not close 
properly, occurring blood regurgitation. Several conditions can cause valvular heart disease, the 
most common of which are congenital factors (i.e., inherited connective tissue disorders), 
rheumatic fever, CHD, cardiomyopathy and degenerative changes in the valves. The most 
common symptoms of valvular heart disease are dyspnea on exertion or rest, fatigue, palpitations 
and ankle oedema (Rapaport 1975; Soler-Soler and Galve 2000; Boudoulas 2002).  
Many cases of valvular disorders, valve repair or replacement, are treated with surgery (Rapaport 
1975). Recovery from heart valve surgery is a gradual process, which usually involves firstly 
healing of the surgical wound and then gradual increase in muscle strength and endurance by 
participating in outpatient exercise-based CR programmes (Gohlke-Barwolf et al., 1992; Jairath 





2.4.3.3.2.  The role of cardiac rehabilitation for patients with valvular heart disease 
Cardiac rehabilitation is effective following the onset of most cardiovascular system diseases, 
but there is a paucity of research focused on the effects of exercise following the surgical repair 
of valvular heart disease. Meurin et al. (2005) demonstrated that patients who had undertaken 
CR programmes soon after their operations (within 1–3 weeks after the mitral operation), for 
about three weeks, showed improvement in VO2max and lactate threshold, while their LVEF and 
diastolic diameter also increased significantly. Although there was no healthy control group to 
validate the results, no worsening of post-surgical mitral regurgitation was observed during the 
CR programme. There were no ischaemic or hemorrhagic strokes, peripheral thromboembolic 
events, severe HF or arrhythmias.  
There are limitations to the studies that have focused on the assessment of exercise results after 
valvular surgery. Their non-randomised design means it is difficult to separate natural recovery 
from effects or CR. Despite this weakness, most studies demonstrate that exercise can maintain 
and improve patient outcome following surgery as well as having a positive effect on cardiac risk 
factors (Sire 1987; Toyomasu et al., 1990; Gohlke-Barwolf et al., 1992; Jairath et al., 1995).  
2.4.3.3.  Arrhythmias 
It is useful here to make some reference to HR abnormalities, which are defined as arrhythmias. 
There are many different types of cardiac arrhythmia caused by abnormalities of the electrical 
conductance system of the myocardium. The most common types are atrial fibrillation, 
paroxysmal atrial tachycardia, bradycardia, ventricular arrhythmias, supraventricular 
tachycardia; and ventricular fibrillation, which is a cause of cardiac arrest and sudden cardiac 
death. Ventricular arrhythmias can be detected in individuals with or without a cardiac disorder. 




Asymptomatic ventricular arrhythmias commonly occur in stable post-MI patients, and in 
patients with cardiomyopathy or HF (Zipes et al., 2006; Epstein et al., 2008; Jaeger 2010).  
The most common heart diseases have been discussed in this section along with brief examples 
of the role that exercise training may play in their treatment. This discussion was essential in 
order to understand the role of CR. The following sections will analyze the role of exercise 
training in revascularization procedures and will introduce the existing clinical guidelines on CR.   
2.5.  Revascularisation procedures and the role of cardiac rehabilitation 
Intensive lifestyle modification can help prevent or reverse CHD in some cases (Ornish et al., 
1990). However, patients with advanced CHD or previous adverse cardiovascular events (i.e., 
MI) may benefit more from revascularization procedures, compared with usual medical care and 
lifestyle changes alone (O'Keefe et al., 2009). Percutaneous coronary intervention with 
intracoronary stent implantation and CABG are the usual therapeutic procedures for patients 
with significant CHD (Hambrecht et al., 2004).  
Tsai et al. (2006) found that patients involved in exercise training for 8 weeks after PCI, 
independent of the device used (balloon or stent), had better cardiac autonomic function, 
increased parasympathetic modulation and, as a result, a lower HR, in comparison with a non-
exercising control group. The Exercise Training Intervention after Coronary Angioplasty 
(ETICA) trial recruited a sample of 130 patients, post-PCI, to an exercise training or control 
group. Exercise-trained people participated in a six month programme comprising three weekly 
sessions of 30 minutes cycling at 60% of VO2max, followed by 15 minutes of stretching. VO2max 
increased by 26% for patients who exercised; their functional capacity and quality of life were 
also improved. During the follow-up period, (33±7 months), exercise-trained patients had fewer 




procedures and lower hospital readmission rates (Belardinelli et al., 2001). Aerobic exercise 
training in elective cardiac surgery patients can improve respiratory efficiency and left 
ventricular systolic function; it can provide a level of protection against a new coronary event 
(Vasiliauskas et al., 2007). A follow-up control study with a larger sample is now essential in 
this area.  
2.6.  Current clinical guidelines and cardiac rehabilitation phases  
Cardiac rehabilitation is a key component in the management of cardiovascular disorders, 
especially in developed countries such as the UK and US. Over the past twenty years, 
participation in CR programmes has become more commonplace (Paquet et al., 2005), and CR is 
now included in some national healthcare guidelines.  
2.6.1.  United Kingdom guidelines for cardiac rehabilitation 
Guidelines for the provision of CR in the UK are available from:  
a. BACR guidelines (Coats et al., 1995; BACR 2007); 
b. SIGN guidelines (2002), endorsed by the BACR;  
c. National Service Framework (NSF) guidelines (2000) for CHD;  
d. National Institute for Health and Clinical Excellence (NICE) (2008).  
The NSF (2000) states that major lifestyle risk factors for CHD are lack of exercise, smoking and 
an unhealthy diet. People who are physically inactive have a two-fold greater risk of CHD than 
those who exercise regularly (Department of Health 2000). Lifestyle changes (in terms of 
exercise, weight management, smoking cessation) constitute the basic component of CR 




management, psychological recovery, cardiac drug therapy and self-management strategies for 
long-term use (BACR 2007).  
Cardiac rehabilitation services should be delivered by a highly trained healthcare team, including 
a consultant cardiologist, a cardiac nurse, an exercise professional, a dietician, a physiotherapist, 
an occupational therapist and a psychologist (Department of Health 2000; BACR 2006). In most 
(96%) of the CR services established in the UK, more than five healthcare professionals are 
included in the rehabilitation team (Brodie et al., 2006).  
2.6.1.1.  Cardiac rehabilitation phases in the United Kingdom 
According to SIGN (2002), and the BACR (1995), CR is divided into four phases in the UK. 
Each phase includes some specific criteria suitable to the patient’s stage of recovery, to help the 
patient improve their physiological and psychological parameters. Phase I is carried out in the 
hospital. It contains a summary of medical evaluations, advice and education for the patient, to 
help them overcome the disease, make a fuller recovery and understand their illness (SIGN 
2006).  
Phase II takes place when the patient leaves the hospital, before they are involved in a 
methodological rehabilitation programme. During this phase, patients can elect to have a home 
visit and on-call support from CR professionals who are able to check their progress, or to attend 
a supervised cardiac programme suitable for each patient’s circumstances (SIGN 2002). At this 
stage, the patient usually receives a manual on home-based exercise rehabilitation after a heart 
attack (SIGN 2002). This phase typically lasts 2-6 weeks, depending on whether the patient is fit 




Phase III comprises a supervised group rehabilitation programme, which typically has an eight-
week duration. It includes exercise programmes, advice on how patients can reduce the risk 
factors associated with CHD (such as smoking cessation, healthy diet, weight management) in 
order to lead a healthier lifestyle, and psychological support to help the patient return quickly to 
a healthy social life (SIGN 2002; BACR 2006).  
Phase IV is the final CR stage. It consists of a long-term maintenance programme, building on 
the principles established in phase III. The aim is to encourage patients to maintain over their 
lifespan the benefits and lifestyle changes gained during phase III. This phase can be hospital, 
community or home-based, supervised or independent (BACR 2006).  
Despite efforts to promote the existing guidelines, there is evidence that only a few CR centres 
(21%) in the UK follow exactly the recommendations by national guidelines (Brodie et al., 
2006). This will be discussed further below. The research in this thesis will use the UK 
guidelines, but US guidelines remain relevant due to the large amount of research completed in 
North America.  
2.6.2.  American  guidelines for cardiac rehabilitation 
The most common US guidelines for the provision of CR are those of:  
a.        the American Heart Association (AHA) (2006); 
b.    the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) 
(2004). 
The AHA recommends the following guidelines for patients with coronary and other 
atherosclerotic vascular diseases: (1) physicians should assess the patient’s cardiac risk with a 




minutes of moderate intensity aerobic activity, such as brisk walking, on most, preferably all, 
days of the week, supplemented by daily lifestyle changes. Medically supervised programmes 
should be given to high-risk patients (i.e., after recent acute coronary syndrome, 
revascularisation or HF); (4) the goal of rehabilitation should be to follow exercise programmes 
for 30 minutes, 7 days/week, with a minimum frequency of 5 days/week (Smith et al., 2006). 
The AACVPR recommends the use of exercise testing, pre- and post-rehabilitation. The 
outcomes can provide important information on a patient’s functional capacity (American 
Association of Cardiovascular and Pulmonary Rehabilitation 2004).  
2.6.2.1.  Cardiac rehabilitation phases in the United States 
According to the AHA guidelines (1994), the CR service is divided into three phases. Phase I is 
an inpatient process. The patient is given encouragement and advice about the disease and the 
recovery process. Phase II is a discharge process. After 2–6 weeks of recovery at home, patients 
can participate in a supervised exercise programme, which lasts 3–6 months.  Phase III is a long-
term maintenance exercise programme. Guidance states that, in this phase, ECG monitoring may 
not be necessary. Chapter 7 (see ‘Safety of exercise training and exercise testing for cardiac 
patients, in a supervised, community-based cardiac rehabilitation programme’) will address this 
issue in the present thesis.  
Cardiac rehabilitation and service provision varies across countries due to differences in culture, 
demographic characteristics and socioeconomic status (Davidson et al., 2010). However, all 
national and international CR committees encourage attendance at CR programmes and they 





2.7.  Goals of cardiac rehabilitation 





(a) to reduce the disability of the patient, particularly in older people after an MI;  
(b) to improve functional capacity;  
(c) to prevent secondary cardiovascular
 
events, hospitalisation and death from cardiac causes;  
(d) to identify coronary risk factors in order to reduce morbidity and mortality due to cardiac 
diseases.  
The primary goal of CR is to improve the physiological and psychological parameters of the 
patient so that they can return to a normal life (Balady et al., 1994).  These goals are achievable 
through a programme of prescribed exercise and interventions
 
designed to modify coronary risk 
factors with the use of optimised
 
drug therapy and appropriate lifestyle changes (Hambrecht et 
al., 2000a, 2000b; Ades 2001; Pasquali et al., 2001; Balady et al., 2007; Lavie et al., 2009). In 
order to achieve these goals, clinical guidelines for CR were designed across various 
populations. 
2.8.  The role of exercise training in cardiac rehabilitation 
Cardiac rehabilitation is secondary prevention, which should include patient assessment, risk 
factor reduction, as well as nutritional recommendations, psychological support, exercise training 
appropriate to the patient’s cardiovascular disorder and the cardioprotective drugs prescribed 
(Leon et al., 2005). Regular exercise is associated with a 50% lower risk of CVD mortality in 
adults with CHD risk factors (Ardern et al., 2005). The exercise pattern, which is associated with 
the reduction of mortality, includes an exercise programme undertaken 4 to 5 times per week, for 
30 minutes per session (i.e., 130 to 138 minutes per week). The results of this study were 




unclear if the changes in the cardiovascular system could be maintained over the year (Ardern et 
al., 2005). In its primary role, physical activity can prevent the onset of pathology, and in its 
secondary role, it can prevent the onset of a new cardiac event. The following section will 
demonstrate the important role of exercise in the secondary prevention of CVD. 
2.8.1.  Physiological effects of exercise training 
The benefits of exercise training, as part of CR, are multifactorial and there are several studies in 
this area. A full review is, however, beyond the scope of this section and the present study will 
review some findings of the area. Exercise training that contains aerobic activities, such as 
walking, climbing stairs or cycling, can improve the functional capacity of the participants (Leon 
et al., 2005). Low functional capacity is an independent CVD risk factor associated with 
increased rates of cardiovascular morbidity and mortality (Myers et al., 2002; Kavanagh et al., 
2003; Mark and Lauer 2003). Exercise increases the VO2max  level from 11% to 66% after 3 to 6 
months in cardiac patients, with the greatest improvements seen among those patients with the 
lowest initial VO2max levels (Belardinelli et al., 1995, 1999; Sturm et al., 1999).  
Exercise improves myocardial function by increasing VO2max (and hence myocardial oxygen 
delivery), increasing the size of the myocardial cells and increasing their contractility. 
Experimental protocols in animals have shown that exercise training can increase the width and 
length of myocardial cells by 20 to 22% and estimated volume by 46%. All these adaptations can 
be reversed after a 2–4 week detraining period (Kemi et al., 2004, 2005). Moreover, contractility 
can be improved with exercise after an acute coronary event (i.e., MI). Changes in the expression 
of troponin I isoforms have been identified with exercise. Specifically, there is an increase in the 
a-myosin heavy chain expression, which is associated with increased ATPase activity and 






 release from the sarcoplasmic reticulum, contributing to smooth muscle 
contractile activation (Wisloff et al., 2001, 2002). Such animal investigations are of great 
scientific interest; however, further studies in humans are required to confirm the results.  
In humans, it has been demonstrated that exercise promotes hemodynamic adaptation and 
changes in regional blood flow. It increases functional capacity by decreasing the HR and SBP 
(Balady and Weiner 1992; Balady et al., 1994). Autonomic imbalance, increase in autonomic 
parasympathetic, and/or decrease in cardiac sympathetic activity, are associated with lower HR 
in those who undertake endurance training (Sandercock et al., 2005).  
Exercise has also a favorable effect on the brain natriuretic peptide (BNP) and the N-terminal 
pro-B-type natriuretic peptide (NT-pro-BNP). BNP is a peptide hormone produced by the 
cardiac ventricles as an inactive hormone BNP, which are split into the active hormone BNP and 
the inactive NT-pro-BNP. BNP has several effects, including vasodilatation, sodium output and 
increased urinary volume. BNP also decreases the function of the sympathetic nervous system 
and the rennin-angiotensin system (Hall 2004). Both BNP and NT-pro-BNP increase left 
ventricular wall stress and, as a result, can be used as prognostic tools of mortality and morbidity 
in patients with HF and CHD (Kragelund et al., 2005), especially in elderly people (Ueda et al., 
2003). Exercise reduces NT-pro-BNP plasma levels, which react to left ventricular wall stress 
(Giallauria et al., 2006a, 2006b); this leads to an improvement in arterial endothelial function 
(Walther et al., 2004). 
Exercise improves endothelial function in healthy people, but the most significant improvement 
can be noticed in patients with endothelial dysfunction (Hambrecht et al., 2000b; Moyna and 
Thompson 2004). Exercise leads to an increase in acetylcholine concentration, in the arteries, 




exercise, independent of cholesterol levels, does not improve the endothelial function in young, 
healthy adults, but it can have a beneficial effect in young people with endothelial dysfunction, 
such as those with hypertension (Hambrecht et al., 2000b; Moyna and Thompson 2004). The 
mechanism of this increased vasodilatation could include the fact that exercise increases the 
release of NO and prostacyclin. Exercise also increases vascular expression, modulates the flow 
of paracrine substances, and decreases the sympathetic vasoconstrictive tone (Niebauer and 
Cooke 1996; Cheng et al., 1999; Maiorana et al., 2003).  
Exercise training affects the management of certain metabolic CHD risk factors, including 
obesity, diabetes, hypertension and hypercholesterolemia (Lavie and Milani 1996, 1997; Morrin 
et al., 2000; Bader et al., 2001). In combination with a low-fat diet and a weight reduction 
programme, if required, exercise reacts on lipid profiles, insulin resistance and abdominal 
obesity. Physical activity can increase the HDL cholesterol concentration by 5 to 16%. Evidence 
that exercise affects LDL and total cholesterol levels is more mixed (Bittner and Oberman 1993). 
Controlled trials of CHD patients on a regime of exercise plus a low-fat diet show significant 
reductions in total cholesterol, LDL and triglyceride levels, accompanied by increases in HDL 
levels (Schuler et al., 1992a, 1992b; Allison et al., 1999; Taylor et al., 2004).  
Exercise training may reduce also inflammation, which plays a significant role in the progress of 
atherosclerosis and the progress of cardiovascular pathogenesis. The National Health and 
Nutrition Examination Survey (NHANES) III, sampled 13,748 adults and demonstrated that the 
intensity of the exercise is inversely related to C-reactive proteins, plasma fibrinogens and the 
white blood cell count (Ford 2002a). In the same way, the Attica study showed that light to 
moderate exercise can cause a reaction in the inflammation markers, although a lot of studies 
suggest only vigorous activity has a beneficial effect on cardiovascular risk (Pitsavos et al., 




intensity exercise enhances the endothelial vasodilatation function (Goto et al., 2003b). These 
findings are important, when considering the intensity of exercise required, and provide strong 
evidence for the value of vigorous exercise activity in relation to the cardiovascular system.  
In patients with CHD, exercise increases the ischaemic threshold (double product at which 1 mm 
ST depression was first recorded), which means that cardiovascular events tend to occur at 
higher work levels (Jensen et al., 1980; Todd and Ballantyne 1990). The mechanism that might 
change the ischaemic threshold needs to be determined. Todd et al. (1992) demonstrated that 
intense exercise for ten minutes daily over six months had similar effectiveness (i.e., in the 
reduction of HR, ST threshold, double product ST threshold) to medical treatment with β-
blockers in patients with stable angina. Additionally, however, physical training increased 
exercise tolerance by twice the amount that β-blockers did. There are insufficient reports that 
document the increase in the ischaemic threshold, probably due to the inherent difficulties in 
performing such studies. In these studies, exercise testing or training should reach the ischaemic 
threshold, which might not be pleasant or safe for patients. 
The evidence presented above suggests that the physiological adaptations to aerobic conditioning 
can benefit the primary and secondary prevention of CHD. Many of these adaptations can only 
be identified via maximal treadmill test assessment, which however requires expensive 
equipment and specialized staff. Exercise can promote not only physiological but also 
psychological adaptations. The overall objective of CR is to take advantage of these dual effects 
and to restore and maintain both physiological and psychological status (Coats et al., 1995; 






2.8.2.  Psychological effects of exercise training 
Exercise training has a positive effect in improving psychological factors, such as anxiety, 
depression, mood and general quality of life (Lavie and Milani 2004, 2005, 2006). Kennedy et 
al. (2003) investigated the psychological effects of CR in women aged between 33 and 82 years 
old. The women participated for 7 weeks in a supervised aerobic CR programme, and for 7 
weeks in an unsupervised home exercise programme that ran alongside lifestyle modifications. 
After 14 weeks of CR, the participants were assessed using a modified treadmill test, BP 
measurements, a blood lipid test and a Cardiac Quality of Life Index questionnaire. Quality of 
life and psychosocial symptoms (worry and depressive symptoms) were also improved after 14 
weeks of CR. The results of the study are in line with other investigations (Verrill et al., 2001; 
Lavie and Milani 2004, 2006) but the lack of a control group, and the fact that it was a lengthy 
period of unsupervised training, threaten the validity of the results. Patients’ education about the 
severity of their illness can make them more responsible for the underlying processes of the 
disease and help them to manage their own recovery. This fact, in addition to the effectiveness of 
their socialisation with other patients at various stages of recovery, improves the social and 
mental recovery process (Lavie and Milani 2005, 2006). 
Lavie and Milani (2004) demonstrated that CR and exercise training programmes reduce levels 
of anxiety by more than half. In patients with high anxiety, exercise marks improvements in 
functional capacity, lipids (HDL, total cholesterol/HDL ratio, and triglycerides/HDL ratio), 
behavioural characteristics and in obesity indices (weight, percentage of fat and body mass 
index), including improvements in quality of life (Lavie and Milani 2004, 2006).  
Exercise CR programmes improves emotional well-being and maximizes caloric expenditure, 
contributing in the treatment of obesity (Bader et al., 2001; Lavie and Milani 2004, 2006; Sierra-




obese (Bader et al., 2001; Sierra-Johnson et al., 2005). The follow section will introduce the role 
of exercise in weight reduction for overweight or obese people.  
2.8.3.  Exercise and obesity in cardiac patients 
Obesity is an independent CVD risk factor (primary and secondary) and exercise, when 
combined with calorific restriction, is efficient in terms of weight reduction (Lavie and Milani 
1997; Ades et al., 2010). Weight reduction in overweight and obese patients can reduce other 
cardiac risk factors and also act as an important tool in the secondary prevention of CHD. 
Coronary heart disease patients who enter CR not only show great improvement in BMI 
(reduction of more than 2%) but also show improvement in almost all the lipid fractions (an 
LDL/HDL reduction of 6%), BP, insulin resistance, clotting abnormalities, behavioural 
characteristics (anxiety, depression) and general quality of life issues by the end of CR 
programme (Lavie and Milani 1997; Ades et al., 2010).  
For obese cardiac patients, exercise is beneficial in terms of weight control or reduction, 
physiological parameters and psychological status. Thus, CR exercise, as a comprehensive 
secondary prevention program, should include weight loss programmes for obese or overweight 
patients (Ades et al., 2010). The beneficial effect of regular exercise training in obesity is not 
limited to weight reduction (Kokkinos et al., 2001, 2006, 2007). There is little information 
regarding the exact amount of exercise training required for obese people, but it is clear that 
endurance exercise and dietary caloric restriction can both help in the management of obesity.   
2.8.4.  Exercise and hypertension 
For cardiac patients who participate in CR programmes, exercise can reduce SBP by 3.2 mmHg 




hypertensive patients. For hypertensive patients, systematic exercise for three months reduces 
BP, with SBP and DBP reductions of approximately 11 mmHg and 8 mmHg, respectively. There 
is also some evidence to suggest that exercise training may lead to regression of pathological left 
ventricular hypertrophy in hypertensive patients (Kokkinos and Papademetriou 2000; Kokkinos 
et al., 2001, 2006, 2007). As a result of these factors, exercise can significantly improve the 
quality of life (Jolliffe et al., 2000; Kokkinos and Papademetriou 2000; Kokkinos et al., 2001, 
2006, 2007).  
Regular aerobic endurance exercise can decelerate and restore in some ways the age-associated 
reduction in central, arterial compliance. This means that middle-aged and older people, who 
exercise regularly, can have a lower incidence of CVD (Tanaka et al., 2000). Moreover, a 
moderate intensity (30% of the maximum voluntary contraction force) of isometric training, 
carried out for a short duration, can also change the function of the autonomic neurological 
system, which leads to a reduction of resting HR and BP in older people with hypertension 
(Taylor et al., 2003). However, the small sample (n=9, control group: n=8) of this study (Taylor 
et al., 2003) threatens the validity of the results. The effectiveness of isometric exercise on 
hypertension requires further study.  
Moderate physical activity reduces the risk of CHD in a number of populations as follows: by 
12% for controlled hypertensive patients, by 5% for uncontrolled hypertensive patients and 9% 
for hypertensive patients (who are not taking any medication) (Chrysohoou et al., 2003). 
Exercise training in combination with (a Mediterranean) diet reduces CHD risk as follows: by 
25% in hypertensive controlled patients, by 11% in untreated patients and 17% in uncontrolled 




Exercise training programmes can modify CHD risk factors (hypertension, obesity) and reduce 
the impact of established CHD. However, there is always a risk of developing a cardiac event 
during exercise in this population. In the following section, the main issues regarding safety of 
CR will be presented.  
2.9.  Safety of exercise for cardiac patients 
Although CR and particularly exercise can reduce cardiac mortality and morbidity, 
cardiovascular events can also occur during an exercise stress test or an exercise training 
programme. According to recent studies the event risk during exercise in CR centres is low, 1.4 
per 10,000 tests and 20.2 per million patient exercise hours (Pavy et al., 2006); however cardiac 
events cannot be predicted (Vongvanich et al., 1996; Pavy et al., 2006). Existing data are largely 
limited to low or moderate CVD patients. The benefit-risk ratio of exercise-based CR has not yet 
been well established, while the existing data are limited to low or moderate CVD patients. More 
studies are needed to determine event rates during exercise. Further discussion on this topic will 
follow in Chapter 7 (see ‘Safety of exercise training and exercise testing for cardiac patients, in 
a supervised, community-based cardiac rehabilitation programme’).  
Despite the unpredictability of cardiovascular events, clinical guidelines encourage CVD patients 
to participate in exercise-based CR programmes due to the benefits derived from such 
participation (SIGN 2002; Leon et al., 2005). To eliminate potential cardiac events during 
exercise, clinical risk stratification based on the assessment of cardiovascular function and 
functional status should, therefore, be used in deciding which patients should admit to exercise 





2.10.  Evaluation of functional capacity in cardiac patients  
Cardiac patients’ functional capacity is the best predictor of overall mortality when measured 
against all the other cardiovascular risk factors (Myers et al., 2002). Functional capacity can be 
expressed in metabolic equivalents (METs) (Peeters and Mets 1996). A functional capacity of 
>10 ΜΕΤs indicates good prognosis, in contrast with a functional capacity of <5 ΜΕΤs, 
independent of cardiac disorder; each 1 MET increase in functional capacity results in a 10% 
reduction in mortality, during an average of 6 years of follow-up (Franklin et al., 2003). It is, 
therefore, clinically useful to be able to measure such an important prognostic factor in a reliable 
and valid way. In routinely clinical practice, reliable and valid prognostic stratification patients 
can help in lifestyle modifications and therapeutic decisions making. What follows is a brief 
review of this topic but the reader is directed to Chapters 3, 4, 5 and 6 where more detail is 
given. 
There are many tests which can be used to detect the level of functional capacity and changes in 
functional capacity after a CR treatment. Most of the tests that are used to evaluate the effects of 
CR exercise programmes concentrate on either the measurement of VO2max or HR (HR recovery, 
time of HR recovery after the exercise), or the distance covered during the test (Guyatt et al., 
1985a; Singh et al., 1994; Cole et al., 1999, 2000; Nishime et al., 2000; Shetler et al., 2001; 
Messinger-Rapport et al., 2003; Tiukinhoy et al., 2003). Laboratory-based treadmill and cycle 
ergometer protocols are the gold standard in clinical assessment in determining cardiorespiratory 
function due to their ability to provide a direct and easy measurement of maximal aerobic 
capacity (VO2max) via gas analysis (Myers et al., 2000; American College of Sports Medicine 
2001). Despite the capability of laboratory-based tests to produce such direct and detailed 
outcome measures, the process is costly and time consuming. Moreover most of CVD patients 




et al., 2001). SIGN (2002) and the AACVPR guidelines (Sanderson et al., 2004) recommend the 
use of simple sub-maximal walking tests to assess cardiac patients for exercise prescription.  
The six-minute walking test (6-MWT) and the shuttle walking test (SWT) are used frequently in 
CR services because they require little equipment and basic staff training (Guyatt et al., 1985a; 
Singh et al., 1992).  The 6-MWT has high prognostic value in patients with mild to moderate 
HF. Patients with a 6-MWT score lower than 300 m have a higher mortality rate than those with 
a 6-MWT score greater than 300 m (Rostagno et al., 2003). The results of this study (Rostagno 
et al., 2003) were confirmed by a more recent study (Arslan et al., 2007). Despite the limitations 
of the latest study, such as its small sample size and short duration, the 6-MWT has been 
established as a reliable and independent predictor of cardiac death. Moreover, other studies have 
shown that the 6-MWT can give the same results as a sub-maximal treadmill exercise test, with 
close to 85% of the age predicted HR target (Elved et al., 2006), or close to 80% of VO2max 
(Kervio et al., 2004).  Several studies have focused on how closely distance walked on SWT is 
related to traditional measurements, like VO2max. Distance walked in SWT appears strongly 
related to VO2max produced during the traditional treadmill protocol (Singh et al., 1994; Fowler 
et al., 2005).  
The 6-MWT and the SWT are frequently used in CR, there is a knowledge gap surrounding 
potential factors (clinical and non-clinical) which affect test performance; while there are no 
established normative values of functional capacity for these walking tests. This research gap 
creates the opportunity to investigate this area further.  
Exercise testing facilitates exercise prescription and makes it safe for CVD patients. Exercise 
may not be beneficial for all patients, due to a number of absolute contraindications to CR 




greater than the benefits (Thompson 2005). It would be of interest to explore whether or not the 
prognosis for those CVD patients who cannot be tested is worse than for those who are able to 
perform (even low levels) of exercise testing.   
2.11.  Patients for cardiac rehabilitation 





all patients with a diagnosis of acute MI and for those with 
CHD risk factors such as hypertension, hypercholesterolemia and
 





It is also appropriate for patients who have undergone cardiac surgical 
procedures, such as a CABG, PCI and valvular heart surgery (Balady et al., 2000; Hambrecht et 
al., 2000a; Ades 2001; Pasquali et al., 2001; Leon et al., 2005; Meurin et al., 2005). Patients 
with chronic stable angina, stable HF, those who have undergone cardiac transplantation, 
peripheral arterial disease with claudication, or other forms of CVD could also participate in CR 
programmes (Balady et al., 2000; Hambrecht et al., 2000a; Ades 2001; Pasquali et al., 2001).  
2.11.2.  Contra-indications to exercise 
Exercise is proscribed or restricted in cardiac patients with the following pathology or 
symptoms: (1) during the first week after an MI and in those with unstable angina; (2) patients 
with increasing angina or reduced effort tolerance should not be enrolled in exercise programmes 
until their status is clarified and appropriate treatment is initiated; (3) patients having ventricular 
tachycardia should not exercise until the rhythm is controlled (resting HR> 100 bpm); (4) after 
CABG surgery, patients can exercise after one to two weeks if no events are found, the incision 
is closed and they can exercise without any serious discomfort; (5) patients with postoperative 
thrombophlebitis should be effectively anticoagulated for at least two weeks before exercise 




myocarditis or uncontrolled diabetes should avoid exercise (Gonzalez et al., 2004; Thompson 
2005).  
When exercise is indicated, there are a number of ways of delivering CR across a local health 
economy. Models of CR services in the UK are discussed below.  
2.12.  Models of cardiac rehabilitation  
Cardiac rehabilitation can take place in hospital or in the community, where patients can be 
supervised by specialised staff (Brodie et al., 2006). Home-based programmes have also been 
developed in the UK. The NSF for CHD guidance refers to numerous home-based services 
which can be supervised by nurses or general practitioners (Higgins et al., 2001; Robertson and 
Kayhko 2001) or supported by telephone (Lewin et al., 1992). Patients attending a home-based 
programme could also be supported by electronic media that include education and instruction 
for safe exercise (Southard et al., 2003); in some cases, support can be provided through 
telemetrically monitored cycle ergometers (Brodie et al., 2006). Patients at high risk after a 
cardiac event usually join hospital-based programmes (Brodie et al., 2006).  
According to the Birmingham Rehabilitation Uptake Maximisation Study (Jolly et al., 2007), of 
525 patients, there was no difference in clinical outcomes between patients with low and 
moderate risk levels after a cardiac event who participated in home-based CR programmes, and 
those who participated in centre-based CR programmes. The cost of home-based CR was higher 
than centre-based CR, but participation levels in the former were greater than in the latter.  
A recent meta-analysis of 12 studies, involving 1,938 participants, showed that home-based CR 
has the same effectiveness in terms of quality of life as centre-based CR, in low-risk post-MI, 




that patients should have the opportunity to choose whether to participate in home-based CR, 
receiving a manual-based programme, or in centre-based CR.  
Similarly, hospital versus community-based phase III CR seems to be the same valuable and 
effective service for patients. No significant difference in functional capacity improvement was 
observed between hospital-based and community-based CR group (Blake et al., 2009; Robinson 
et al., 2009).  Maintaining patients’ attendance is more difficult in the community settings (Blake 
et al., 2009). The reasons for the lower exercise adherence in community-based CR, compared to 
participation in hospital-based CR, have not yet well addressed (Blake et al., 2009). Much effort 
has been invested into improving home-based and community-based programmes; more research 
is still required to demonstrate their safety. Further research is also needed on the long-term 
benefits of home-based and centre-based CR on CVD mortality. Home-based CR has not yet 
shown that it can reduce mortality like centre-based CR does (Jolly et al., 2006). These further 
studies could guarantee the continuity of community-based and home-based CR as an alternative 
tool in the secondary prevention of cardiac disorders. One of the reasons for creating home- and 
community-based services is to reduce some of the barriers to CR reported by non-attendees. 
2.13.  Barriers to cardiac rehabilitation 
The physiological and psychological benefits of participation in CR programmes are established 
(Oldridge et al., 1988; O'Connor et al., 1989; Jolliffe et al., 2000). Despite these benefits, there is 
evidence that there are still many barriers that may lead patients to interrupt or permanently 
withdraw from rehabilitation, or not to follow a programme in the first place (Brodie et al., 
2006). Less than 1/3 of patients finally participate in CR, in European countries (EUROASPIRE 
II Study Group 2001; Vanhees et al., 2002). Some of the most reported barriers to participation 




There are also between-sex disparities, age-related differences, and a consensus that the 
importance of CR has not yet been recognised by the public (Ades 2001; Allen et al., 2004; Leon 
et al., 2005).  
Yohannes et al. (2007) found that 22% of patients (from n=189) interrupted a CR programme: 
most were female, younger in age, with high anxiety and lower illness perception. A study across 
30 CR centres found that older people were less likely to be invited by staff to follow CR 
programmes than younger ones. Age and factors connected with older age, such as lower 
exercise tolerance, medical aliments and poor access to transport, may prevent older people 
using CR programmes (Clark et al., 2002). On such occasions, the CR supervisors may play a 
key role. They should determine access for these patients to healthcare by clinical need, not age. 
Above all, the most significant barrier to CR participation is the failure of doctors to motivate 
patients to participate in these programmes; doctors also fail to point out to patients the progress 
they have made over the course of a programme they have undertaken. 
Other studies have investigated that there are a number of physical or medical conditions which 
leads the patients to interrupt or withdraw permanently from an exercise programme. Nishi et al. 
(2007) demonstrated that, in HF patients, the main disorders that associated with interruption or 
withdrawal from the programme were: pacemakers, a large left ventricular end-diastolic 
diameter ≥ 65mm, low exercise tolerance or greater ventilatory drive. Webb-Peploe et al. (2000) 
agree that these disorders were the most common, in addition to ischaemic cardiomyopathy. 
Vanhees et al. (2004) showed that a ventricular tachycardia event was one of the main factors 
that led patients to stop attending a CR exercise programme. The fact that these cohort studies 
were not controlled, the sample was not representative of the whole population, and the exercise 




of the results. The results would be more valid if the exercise programme was matched to the 
patients according to their psychosocial and physiological characteristics.   
2.14.  Conclusion 
A number of high-quality studies demonstrate the benefits of CR in terms of increased survival, 
reduced morbidity and improved quality of life in CVD patients. Evidence is more limited for 
improvement in many risk factors, such as functional capacity, due to CR. Medications can 
modify almost all CVD risk factors, but only exercise can improve functional capacity and thus 
quality of life. Outcomes of CR, such as improvements in functional capacity, should be 
evaluated via reliable and valid exercise testing procedures. The standard Bruce treadmill test 
remains the most valid assessment in common use, but has numerous, methodological, temporal, 
financial and practical limitations. This thesis will look at the validity, reliability and usefulness 
of the most common functional walking tests (SWT and 6-MWT), and it will identify the 
predictors for functional outcome in these walking tests. The following chapters will, also, try to 
address research gaps relating to the safety of CVD patients in CR settings. The research in this 
thesis aims to improve the CR evaluation process, in terms of exploring the determinants of 
functional performance measures, which represents an important factor for the success of the CR 
service. 
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CHAPTER 3.  LOG-TERM RELIABILITY OF THE MODIFIED SHUTTLE WALKIG TEST I 
CLIICALLY STABLE CARDIOVASCULAR DISEASE PATIETS 
3.0.  Abstract 
The shuttle walking test (SWT) is a valuable tool for assessing and monitoring changes in 
patients’ functional capacity during cardiac rehabilitation. Much evidence suggests that the SWT 
is a valid, reliable, sensitive and useful tool for detecting cardiorespiratory capacity. However, as 
most of the scientific sources refer to short-term tests, the purpose of this study was to examine 
over longer term the reliability of a modified SWT (MSWT) in clinically stable cardiac patients.  
A convenience sample of 30 phase IV (UK classification) cardiac rehabilitation patients (50% 
males, 50% females, age: 67.1±8.1 years) participated in this study. A test–retest design was 
used and the patients were assessed twice using the MSWT, with a minimum of eight weeks 
between test administrations. Using the 15-level MSWT, the patients were required to walk up 
and down a 10 m course at increasing speeds, indicated by an audible signal. Heart rate and Borg 
rating of perceived exertion (RPE) score were recorded at the end of each level. Intraclass 
correlation coefficient (ICC) and limits of agreement (LoA) were used to assess reliability.  
In the assessment of test–retest reliability, there were no significant differences between the two 
assessments in respect of the distance walked (MSWD), maximal walking speed, maximum 
heart rate and RPE scale (p>0.05). However, there were significant correlations between the 
MSWD (Pearson’s r=0.80, p<0.001) and maximal walking speed in the two trials (Pearson’s 
r=0.76, p<0.001). There was a small increase in the MSWD, from trial 1 to trial 2, from 502 
(±161) m to 509 (±146) m – a difference of 7 m. The maximum heart rate decreased from 128 
(±18) beats per minute in the trial 1 to 127 (±18) beats per minute in the trial 2. The mean RPE 




Test–retest reliability in terms of the ICC was high for the MSWD, maximal walking speed, 
maximum heart rate and time taken to recover, while it was moderate for heart rate recovery and 
low for the maximum RPE value. The high ICC for MSWD (R=0.80) indicated good reliability, 
while the LoA indicated a small systematic test–retest bias of -7 m. The LoA for MSWD were 
large, ranging from -203 m to 189 m. 
The results confirmed that long test–retest durations appeared to have no learning effect in the 
MSWT, negating the need for a practice walk. The long-term random variation in the MSWT 
was larger than in previous studies. This was most probably due to greater physiological and 
psychological variation in the patients when tested over an eight-week period, when compared 
with that seen in day-to-day testing. Factors influencing the long-term reliability of the MSWT 
required further elucidation. 
3.1.  Introduction  
The benefits of cardiac rehabilitation (CR) programmes in improving health and quality of life of 
patients with cardiac disorders are well established (Goto et al., 2003a; Izawa et al., 2004) and 
were described in Chapter 2 of the present work (see ‘Introduction to cardiovascular diseases 
and cardiac rehabilitation: a review in the literature’). Low functional capacity was identified as 
the strongest predictor of overall mortality above all other cardiovascular risk factors in cardiac 
patients (Myers et al., 2000). One aim of CR should be to increase functional capacity, but in 
order to verify such changes reliable functional capacity tests, which can be carried out CR 
practitioners such as nurses and physiotherapists, are needed. 
As mentioned in Chapter 2, in the UK a phase IV CR programme is provided for patients with 
cardiac disorders, such as those with post-myocardial infarction (MI), post-revascularisation, 




disease. Patients who join phase IV CR programmes should be clinically stable and should be 
free of specified cardiac symptoms and signs (see table 3.1). According to the British 
Association for Cardiac Rehabilitation (BACR) guidelines (Bell et al., 1995; BACR 2006), 
phase IV is a long-term follow-up training programme, where the goal is the maintenance of 
physical activity and lifestyle changes in cardiac patients.  
Various cardiorespiratory assessment tests and functional measurements have been developed in 
order for patients who participate in the programme to receive feedback on their cardiovascular 
capacity and functional capacity levels.  
Table 3.1.   Contraindications to exercise (BACR 2006) 
Unstable angina 
• new event of angina within the past 4 weeks  
• angina occurring at rest  
• angina occurring more easily on less effort  
• angina that does not respond so easily to nitrates medicines  
Uncontrolled blood pressure, where SBP >180 mmHg and/or DBP >100 mmHg 
BP decreases more than 20 mmHg during the exercise training  
Resting tachycardia, where HR>100bpm 
Uncontrolled atrial or ventricular arrhythmias  
Unstable diabetes 
Unstable heart failure 
A fever or systematic illness  
Definition of abbreviations: MSWD=modified shuttle walk distance; bpm=beats per minute 
3.1.1.  Evaluation of functional capacity in cardiac patients 
Graded exercise tests aim to provoke a physiological response to continuously increasing 
exercise intensities (Mora et al., 2003; Jouven et al., 2005). The cardiorespiratory system is 
challenged as the intensity increases, and the body’s ability to cope with these demands can be 




Several cardiorespiratory assessment tests and functional measurements have been developed to 
determine prognosis, prescribe exercise and assess the efficacy of CR. It is standard practice to 
evaluate, through exercise testing, the improvement of HR response to exercise, HR recovery and 
the total time taken to attain HR recovery (Cole et al., 1999, 2000; Nishime et al., 2000; Messinger-
Rapport et al., 2003; Tiukinhoy et al., 2003). Heart rate recovery is a predictor of mortality in 
asymptomatic (Cole et al., 1999, 2000; Messinger-Rapport et al., 2003) and symptomatic patients 
with cardiovascular disease (CVD) (Nishime et al., 2000; Shetler et al., 2001; Elved et al., 2006).  
A multivariate analysis of 2,994 asymptomatic women without evidence of CVD showed that 
women with a low functional capacity of <7.5 METs and poor HR recovery of >55 beats per minute 
(bpm) (measured at two minutes after testing) had a 3.5 fold increased risk of cardiac mortality 
during a mean follow-up of 20 years (Mora et al., 2003). The authors (Mora et al., 2003) concluded 
that exercise testing (Bruce treadmill test) has prognostic ability when functional capacity-related 
outcome measures, such as low functional capacity, poor HR recovery were analysed. Similar, 
Jouven et al. (2005) analyzed 5,713 asymptomatic men without diagnosis of CVD and showed that 
poor HR recovery of >40 bpm or <25 bpm (measured at two minutes after bike exercise testing) is 
associated with a 2.1 fold increased risk of sudden death and 1.3 fold increased risk of death from 
any cause, at a mean follow-up of 23 years. The authors (Jouven et al., 2005) observed, also, an 
increased risk of sudden cardiac death (relative risk 3.92), when the resting HR was >75 bpm. These 
examples of the diversity and functionality of outcome measures obtained from incremental exercise 
testing illustrate their importance in clinical assessment. 
Walk tests are the most commonly utilized tool for assessing the functional capacity of cardiac 
patients, the effectiveness of a CR programme and prognosis of CVD. Treadmill tests are a well-
established means of assessing functional capacity in patients with cardiac disorders. The most 




recent study in America reporting that 82% of treadmill tests used either the typical Bruce test or a 
modified Bruce test (Myers et al., 2000).  
3.1.1.1.  The Bruce treadmill test 
The Bruce treadmill test was developed specifically for the diagnosis of coronary heart disease 
(CHD) (Bruce et al., 1963). The Bruce Protocol is an incremental treadmill exercise test where 
the incline and speed increase every three minutes, while the patient has to work until 
exhaustion. A modified Bruce treadmill test was developed with a more gradual initial workload, 
for patients with lower functional capacity (see table 3.2) (Foster et al., 1984). 
Table 3.2.   The modified Bruce treadmill test protocol (Bruce 1971; Bruce et al., 1973) 
Stage Grade (%) Speed (mph) Duration (min) 
0 0 1.7 3 
0.5 5 1.7 3 
1 10 1.7 3 
2 12 2.5 3 
3 14 3.4 3 
4 16 4.2 3 
5 18 5.0 3 
6 20 5.5 3 
7 22 6.0 3 
 Definition of abbreviations: mph=miles per hour 
Unfortunately, such formal tests are not always easy for clinicians to conduct, either because the 
equipment is not available to them or the tests are too expensive for both patients and clinicians. 
For these reasons, clinicians sometimes assess the functional capacity of patients using simpler 




3.1.1.2.  Functional walking tests  
There are several walking function tests in cardiorespiratory assessment, which are based on one 
of the following factors: time, distance or walking speed. The most commonly used time-based 
walking function tests in cardiorespiratory assessment are of the following durations: 2, 5, 6, 9 
and 12 minutes. The distance covered over a given time (2 to 12 minutes) is considered as the 
score for the time-based tests. The most common distance-based walking function tests are 
carried out over the following distances: 100 m, half a mile, and 2 km. The time taken to cover a 
given distance (100 to 2 km) is considered as the score for the distance-based tests (Solway et 
al., 2001). The most common velocity-based walking function tests in cardiorespiratory 
assessment are: the self-paced six-minute walking test (6-MWT) and the controlled-paced 
incremental shuttle walking test (SWT). The distance covered, commonly, constitutes as the 
score for the velocity-based tests (Solway et al., 2001).  
The two most popular and recently developed walking tests for cardiorespiratory assessment are 
reviewed below: the 6-MWT and the incremental SWT.  
3.1.1.2.1.  The six-minute walking test 
The 6-MWT (Guyatt et al. 1985) is a functional capacity test commonly used in both clinical 
assessment and research settings. It is a simple, safe, reliable, valid and inexpensive measure and 
is used to evaluate the functional capacity of cardiorespiratory disorders. The 6-MWT is self-
paced, allows intermittent rest periods and is usually used to assess patients with severe 
cardiorespiratory problems. The 6-MWT is described in further detail in Chapter 5 of the present 





3.1.1.2.2.  The shuttle walking test 
3.1.1.2.2.1.  Shuttle walking test: development  
More recently, the 12-level SWT was originally developed (Singh et al., 1992) for patients with 
respiratory diseases. This test has also been used as an assessment tool for patients with CVD, 
and by creating the modified (15-level) version (MSWT) (Bradley et al., 1999, 2000). This test is 
used to evaluate the improvement of functional capacity after a CR programme in patients with 
HF, and for those who have had cardiovascular surgery or pacemaker insertion (Payne and 
Skehan 1996; Tobin and Thow 1999; Francis 2000; Morales et al., 2000).  
The test is easy to perform and inexpensive as it requires only simple equipment, such as an 
audio player, the test CD, a HR monitor, two cones and a 10 m walkway. The SWT is a safe test, 
in that it increases incrementally the speed of walking (Jolly et al., 2008), causing less 
physiological stress for the patient than the ‘gold standard’ treadmill test (Singh et al., 1994; 
Zwierska et al., 2004; Fowler et al., 2005). During the SWT, participants have to walk back and 
forth between two cones, at an incrementally increased speed, which is controlled by an audio 
signal. The test is stopped when the subject is not able to reach the cone in the required time 
and/or when the subject wishes to withdraw from the test.  
3.1.1.2.2.2.  Shuttle walking test: use in prognosis 
Morales et al. (2000) reported that the SWT, but not the 6-MWT, could be used as a predictor of 
cardiovascular events within one year of patients with HF. In their study, in which 46 patients 
with HF, it was found at 17 month average follow-up that 33% of patients had undergone a 
major cardiac event, such as cardiac death, urgent transplantation, or hospital admission for 
medical or mechanical support. They showed that those patients who walked <450 m in the test 




year). The authors concluded that the SWT can be used as a predictor of cardiovascular events. 
Lewis et al. (2001) compared the SWT with the gold standard measurement (the treadmill test) 
in a group of patients with severe HF (n=25) and concluded that a distance of >450 m covered 




; this indicates that patients with values 
below this level have a high risk of short-term mortality. This study (Lewis et al., 2001) is 
described in more detail below.  
3.1.1.2.2.3.  Shuttle walking test: validity and reliability 
Clinical tests should be valid and reliable. Reliability refers to the reproducibility of the 
measurement and defines the degree to which two or more repeated measurements could provide 
similar results (de Vet et al., 2006). Validity refers the degree to which a test or test’s outcome 
addresses its intended purpose (Messick 1998). The SWT has been shown, by the following 
studies, that is a valid measure of cardiorespiratory capacity (compared with the gold standard 
measurement) and reliable according to its high test–retest reproducibility. 
Singh et al. (1994) were the first to evaluate the validity of the SWT, by comparing it with the 
gold standard treadmill test. They found a strong correlation between exercise performance and 
VO2max in patients with airflow limitations (n=29). In their first experiment, they found a strong 
relationship between the distance walked in the SWT and the VO2max measured during a 
treadmill test (r=0.88). They created a predictive equation (with 95% confidence intervals) for 
VO2max (see equation 3.1).  
Equation 3.1.  Singh et al. (1994) 
VO2max= 4.19 × (1.12–7.17) + 0.025 × (0.018–0.031) × SWD 








The high correlation between the exercise performance (distance walked) and VO2max was 
verified in a second experiment assessing the physiological responses to the SWT (r=0.81). They 
concluded the SWT showed a high correlation to the conventional measurement of functional 
capacity, which is the maximal oxygen consumption, while the SWT can be used as a predictor 
of the VO2max. They concluded the SWT was a valid, simple, incrementally maximal exercise 
test that can be used safely in the evaluation of cardiorespiratory capacity. Despite producing 
comparable final walking speeds, maximum HR was higher in the treadmill test than in the 
SWT. As mentioned in Chapter 2, increased HR is related with an increase in double product, 
which is an indirect index of myocardial oxygen demand (Williams et al., 2007). This might 
suggest the treadmill test provokes greater physiological stress on the cardiovascular system than 
the walking test.  Regarding that these tests applied in patients with established CVD and 
cardiovascular events tend to occur when oxygen demand exceeds supply, SWT appears to be 
safer than treadmill test for CVD patients. 
Lewis et al. (2001) combined the SWT and the treadmill exercise test for patients (n=25) being 
assessed for cardiac transplantation. The results of patients undergoing three SWTs and two 
treadmill tests, during which VO2max was recorded, showed that the distance walked during the 
SWT was highly correlated with the VO2max reached during the test. These authors also 
developed a predictive equation for estimating VO2max (equation 3.2).  
Equation 3.3.  Lewis et al. (2001) 
VO2max = 6.4 + (0.022 × SWD)                                                                                             




); SWD is distance walked in the shuttle walling test 
(m). 
The authors (Lewis et al., 2001) concluded that the SWT is a reliable tool, which can be used to 
evaluate the functional capacity of patients with severe HF and also to predict VO2max in this 




threshold (blood lactate concentration) during the treadmill test, while some terminated the test 
because of angina symptoms. As normal anaerobic threshold usually occurs at more than 40% of 
the predicted VO2max (Pepera et al., 2008; Chin et al., 2010), the VO2max and peak VO2 
measurements were not the same in each patient of the Lewis et al. (2001) study. Most of the 
patients did not reach maximal parameters (VO2max) during the treadmill test. Thus, the peak 
VO2 achieved did not reflect the true maximal functional capacity during the treadmill test.  
Fowler et al. (2005) investigated the validity and reliability of the incremental SWT patients 
(n=39) six to eight weeks after coronary artery bypass graft (CABG) surgery. Patients completed 
three SWTs and a treadmill test one week later. Eleven of the patients were assessed once more, 
using the SWT after attending a six-week hospital-based CR programme. There were strong 
correlations and no significant differences between the distances recorded in the three SWTs. 
The treadmill test, however, produced higher maximum HRs and breathlessness scores than the 
SWT. This again suggests the treadmill test causes greater physiological stress than the SWT. 
The SWT was able, also, to detect changes in cardiorespiratory capacity after the CR 
programme. The authors concluded that the SWT is a valid, reliable and sensitive tool for 
investigating changes in exercise tolerance for patients who have had a CABG surgery. They 
also found a learning effect between the first and second SWT (mean difference 40 m), but not 
between the second and third. As a result, they noticed that a pre-practice of the test was not 
necessary but that it would be useful for clinical reasons in order for the results to be established 
on a stable baseline. These results were taken over a short period (1 week). Given that MSWT is 
used to assess changes in functional capacity during a six to twelve-week CR programme, a 
follow-up study using results taken over a longer period would be more clinically useful.  
In addition to comparing walking tests with treadmill protocols, it is also of interest to compare 




incremental SWT and a constant-pace SWT (walking speed 4 km·h
-1
) − with a constant 
workload treadmill test (walking speed 3.2 km·h
-1
 at 12% gradient) for evaluating the functional 
capacity of patients with intermittent claudication (n=55). They found that the claudication 
distance (where the pain was first determined) and the maximum walking distance (the distance 
patients covered until they could no longer tolerate claudication pain) achieved during the two 
SWTs were similar. These distances were almost twice those achieved during the treadmill test. 
Test–retest reliability for maximal walking distance was better than that for claudication distance 
in each of the three tests. Test–retest reliability was higher for all measures during the 
incremental SWT than in the constant-pace SWT or treadmill test. Higher maximum HR and 
blood pressure were observed during the treadmill test in comparison to the shuttle walking tests. 
This might be explained by the fact that most patients said they preferred the incremental SWT 
to the treadmill test, for instance, because they were frightened of falling on the treadmill, or 
because they found the treadmill more difficult and too fast. The constant-pace SWT also failed 
to detect the real maximum walking distance in patients with mild claudication symptoms 
(because some of the patients were walking for more than 10 minutes without any claudication 
pain). The incremental shuttle walking test was shown to be a good tool for assessing the effects 
of lower to high severity peripheral arterial diseases. The authors concluded that the SWT has 
the same reliability as the treadmill test but that the former has the advantage of being easier, 
cheaper and less stressful for the patients.  
Jolly et al. (2008) found a significant increase in the distance walked between the practice test 
and the second SWT in a group of 353 cardiac patients. There were no significant differences for 
maximum HR and rating of perceived exertion score (RPE) between the two trials. The authors 
concluded that the increase in distance covered during the second trial might be due to 




unfortunately, no third test was conducted to test the hypothesis that a learning effect was 
present.  
There is evidence to suggest that the SWT is a reliable, valid and sensitive tool for measuring 
cardiorespiratory capacity. In the UK, the SWT is currently the recommended protocol (Scottish 
Intercollegiate Guidelines Network [SIGN] 2002; BACR 2006) to assess functional capacity in 
patients with HF, post-MI patients and patients who have undergone cardiovascular surgery or 
pacemaker insertion (Payne and Skehan 1996; Tobin and Thow 1999; Francis 2000; Lewis et al., 
2001; Woolf-May and Ferrett 2008). The results of the test can be also used for prescribing 
exercises in CR programmes.  
3.1.1.2.2.3.1.  Shuttle walking test and duration of reliability  
Only the short-term test–retest reliability of the SWT has been reported (Fowler et al., 2005; 
Campo et al., 2006). This has a potential impact upon relevant outcome measures, such as 
distance walked. A short-term test–retest may have an impact on the performance outcome. A 
shorter interval between tests would mean the pacing and protocol would be more prominent in 
the subject’s memory, allowing them to have a possible advantage over a subject who has had a 
longer interval between tests.  
There are questions to be raised about the potential learning effect due to the tests being so close 
together, alongside whether a sufficient rest period was provided. Often in clinical studies, 
repeated exercise tests are carried out on the same day or within a few days of each other. Short 
time periods between tests are common in all SWT studies, assessing the repeatability of 




There are no available data regarding the long-term reliability of SWT. Reasons for this are 
unclear. It may be that in an attempt to control external influencing factors, such as an increase in 
functional capacity, repeated tests are carried out in close succession to ensure that the 
repeatability of outcome measures is being recorded and not an increase in functional capacity or 
the effect of an intervention. The difficulty of protocols assessing SWTs via short-term retest 
periods is that it is not representative of pre- and post-rehabilitation assessment. In normal care, 
an exercise stress test would occur to evaluate patients’ functional capacity, in order to enable 
effective exercise prescription. The patient would then enter an eight to ten week CR 
programme; on successful completion of the programme, the patient would be re-assessed with 
the same exercise test for improvements in functional capacity as an indication of the 
effectiveness of the programme and an increase in the patient’s functional capacity. 
It would clearly be useful to investigate the SWT’s reliability over longer periods in clinically 
stable cardiac patients, in order to judge whether potential learning effects could be minimised. 
According to Fowler et al. (2005), due to the learning effect over short-term test–retest durations, 
the benefits of CR intervention may not be recognised. On the other hand, it seems less likely 
that the participants will remember their performance measures over a long time. It seems likely 
that this learning effect would be removed if tests were conducted with a longer interval (before 
the retest), so that participants would be unable to recall the exact protocol and pacing of the test. 
The need for a practice test may thus be shown to be unnecessary. To achieve this goal, longer 
periods of time would need to be left between tests in studies undertaken to gain greater insight 






3.1.2.  Methods to assess reliability 
The most common and frequently referenced methods in the literature for assessing the 
reliability of equipment or measurements are reliability and agreement parameters (Bland and 
Altman 1986, 1990; de Vet et al., 2006).   
3.1.2.1.  Reliability parameters  
The reliability of a measurement is an important process, in order that primary outcome 
measures can be used for clinical reasons (Lachin 2004). It reflects the ability of instruments to 
discriminate among subjects in a sample population, despite measurement errors (de Vet et al., 
2006). The intraclass correlation coefficient (ICC) is commonly used as metric of reliability. The 
ICC gives a direct coefficient of the agreement between repeated measurements and it ranges 
between 0 (representing an unreliable measurement) and 1 (indicating perfect reliability). 
Various forms of ICCs exist (Shrout and Fleiss 1979). Some studies support their use (Lee et al., 
1989, 1992), while others (Bland and Altman 1986, 1990) have found this technique 
inappropriate for assessing the reliability of a measurement.  
3.1.2.2.  Agreement parameters      
Bland and Altman (1986, 1990) recommended the use of agreement parameters, which are based 
on graphical techniques and calculations (the mean and standard deviation of differences 
between measurements). Agreement parameters estimate the measurement error in repeated 
measurements and assess how close the results of test-retest measurements are (Bland and 
Altman 1986, 1990; de Vet et al., 2006). It was also found that the agreement measurements 
relate to the measurement error, in contrast with reliability (ICC), which is based more on the 
heterogeneity of the study sample (Bland and Altman 1986, 1990; de Vet et al., 2006). The 




health status, agreement parameters are preferred (de Vet et al., 2006). It has been suggested that 
both reliability and agreement parameters are important when assessing the reproducibility of a 
measurement, because neither test alone can provide sufficient information (Rankin and Stokes 
1998; Weir 2005).   
3.1.3.  Aim and hypothesis 
There is a lack of reliability studies in relation to specific cardiac patient groups, as well as an 
obvious gap in research concerning long-term retest periods. The present study will focus on the 
long-term retest reliability of the MSWT in clinically stable cardiac patients. 
The hypothesis of this study was that the MSWT is a reliable tool for use in the long-term 
assessment of cardiovascular function in clinically stable CVD patients. 
3.2.  Methods 
3.2.1.  Study Population  
Thirty CVD patients (15 males and 15 females; age range: 55-80 years) volunteered to 
participate in this study. All patients were defined as clinically stable according to the BACR 
(2006) criteria. The majority of these patients had undergone a heart operation, CABG or 
percutaneous coronary intervention (PCI). There were also patients with stable angina, patients 
who had affected by an MI or patients who had undergone both an MI and a surgical procedure 
on the heart. Other diseases (which were the reason the patients joined the CR programme) 
included HF, arrhythmias, hypertension and chronic obstructive pulmonary disease (asthma, 
chronic bronchitis). There were also a low proportion of patients with diabetes, while the half of 
the group had a history of high cholesterol, and attempted to control it with medical support 




patients had someone in their family with cardiac diseases or disorders; 33% had a family 
member (parent, sister or brother) who had died from a heart attack event. Also, according to the 
pharmacological history, 53% of patients were using β-blockers but none changed their 
medication from test to retest. Table 3.3 represents the descriptive characteristics and baseline 
measurements of the patients. The means of body mass index (BMI) were similar to both of the 
two sexes.   
All patients were attending a community-based phase IV CR programme at the University of 
Essex. They were mainly cardiac patients, who had finished phase III CR at the local General 
Hospital, or who had been referred to phase IV CR by their general practitioner. This phase IV 
CR programme offers the opportunity of life-long supervised exercise. The programme 
comprises a twice-weekly, 60 minute, circuit-based exercise session, in accordance with the 
BACR guidelines (Bell et al., 1995; BACR 2006); it is designed to maintain the functional 
capacity gains achieved in phase III CR. All patients had been enrolled on the programme for a 
minimum of ten weeks. All patients met the inclusion criteria for the community-based phase IV 
CR programme, which excluded patients with severe locomotor limitations. During the study, 
the patients continued taking their normal prescribed medications. 
Patients were verbally recruited by instructors prior to two consecutive exercise classes. Each 
volunteer gave written informed consent, after receiving an information sheet outlining an 
explanation of the procedure. The study took place between January 2008 and March 2009. All 
procedures were approved by The University Ethics Committee and conformed to the 





Table 3.3. Descriptive characteristics and baseline measurements of cardiac rehabilitation patients 
Clinical characteristics and baseline 
measurements 
Values 
Number of patients 30 
Age   (years)  (mean ± SD) 67.1 ±  8.1 
Sex   
      Males 
      Females 
 
15 (50%)  
15 (50%) 
 
Body mass index    (kg·m
-2
)  (mean ± SD) 
 
Trial 1:  27.4 ± 3.7 
Trial 2:  27.4 ± 3.8 
 
Waist Circumference  (cm)  (mean ± SD) 
 
Trial 1:  96.2 ± 11.6 
Trial 2:  95.4 ± 11.3 
Medical History/Reason for joining CR  
MI                                                               
Stable Angina                                                              
Surgical procedure (CABG, PCI)                                              
MI and surgical procedure                               
MI and non-surgical procedure                       
Heart Failure      
Hypertension     
Arrhythmias          
Other                                            
 
  
n=5   (17%) 




n=3   (10%)  
n=5   (17%)                                               
n=2   (7%)                                                    
n=2   (7%)                                                                                                                   
Diabetic (diabetes mellitus) n=2   (7%) 
 




Excess Alcohol  
 




n=2   (7%) 
 
Family History 
 Heart attack death 
 Heart Failure  
 CABG 
 Angina  




n=5   (17%) 
n=2   (7%) 




            β-blockers  
            Statin 
            Aspirin 
            Nitrates 




n=14 (47%)  
n=13 (43%) 
n=6   (20%) 
n=10 (33%) 
Definition of abbreviations: MI=myocardial infarction; CABG=coronary artery bypass graft; 





 3.2.2.  Study design 
To determine the long-term reliability of the MSWT, patients were assessed twice, with a 
minimum of eight weeks between assessments. During this period, patients continued to attend 
phase IV CR programmes. 
Before the initial MSWT, each participant had a primary health assessment (pre-exercise health 
questionnaire) and interview (medical, pharmacological and family history). During this time, 
anthropometric measurements such as stature, mass and waist circumference were recorded (see 
table 3.3). Stature was recorded using a stadiometer (Seca 240 stature measuring rod, Germany) 
and body mass was recorded with a weight scale (Seca 888 Class III Floor Scale, Germany) 





). Additionally, waist circumference was measured with a tape at the level of the 
natural waist, at the narrowest point between the ribs and the iliac crest (Lohman et al., 1988). 
The health assessment and anthropometric measurements were replicated prior to the second 
MSWT.  
Patients were fitted with a HR monitor (Polar Electro Sports Tester S810I, Heart Rate Monitor, 
Kempele, Finland) and instructed to lie supine on a bed with their head supported by a pillow. 
They lay still for 10 minutes without talking or moving. After this period of relaxation, the 
patients were asked to stand up, and then to sit on the edge, where the HR, according to Polar 
instructions, was recorded. Blood pressure was also measured at this time, using an automated 
arm blood pressure machine (Omron Digital Automatic Blood Pressure Monitor MX3 Plus, 
Omron Health Care Co., Ltd, Kyoto, Japan). Next, patients were advised to sit up slowly and 







3.2.3.  Modified shuttle walking test procedure 
The modified 15-level SWT was used for this experiment. This test is analogous to the original 
incremental test (Singh et al., 1992) but has 15 levels instead of 12. The modified version is 
useful for monitoring patient groups who may be able to complete the original 12-level protocol. 
Patients were required to walk on a gymnasium floor, which was marked by two cones, set 0.5 m 
from either end of a 10 m course (see figure 3.1). Throughout the first level, the operator was 






Figure 3.1. The shuttle walking test diagram 
The speed at which the patient was required to walk was indicated by an audio signal from a CD 
player. The start of the test was indicated by a triple bleep, while a single bleep indicated that the 
subject had to be next to the cone, rounding the cone, change direction and continue back to 
reach the second cone. The test started with a speed of 0.5 m·s
-1
, and the subject had to complete 
three shuttles per minute. At the end of each level one more shuttle was added, and the walking 




. A change in speed was indicted by a second audible 
signal. Instructors also reminded patients to walk faster after each minute. Patients were allowed 
to run at any time during the test. The MSWT has 15 levels; the number of shuttles, the walking 





















(ACSM 2005,  
Woolf-May & 
Ferrett 2008) 
1 0.50 1.80 1.12 3 30 3.2 
2 0.67 2.41 1.50 4 70 3.4 
3 0.84 3.03 1.88 5 120 3.6 
4 1.00 3.63 2.26 6 180 3.9 
5 1.18 4.25 2.64 7 250 4.2 
6 1.35 4.86 3.02 8 330 4.6 
7 1.52 5.47 3.40 9 420 5.0 
8 1.69 6.08 3.78 10 520 5.5 
9 1.86 6.69 4.16 11 630 6.0 
10 2.03 7.31 4.54 12 750 6.6 
11 2.20 7.92 4.92 13 880 7.1 
12 2.37 8.53 5.30 14 1020 7.7 
13 2.54 9.14 5.68 15 1170 8.4 
14 2.71 9.75 6.06 16 1330 9.1 
15 2.88 10.36 6.44 17 1500 9.9 
 
Test termination criteria were as follows: (a) by the participant, when s/he was unable to 
continue the test because of breathlessness, other symptoms or because they were unwilling to 
continue (voluntary withdrawal), (b) by the operator, when the participant failed to reach the 
marker (by 0.5 m) on time, (c) the achievement of 85% of the predicted maximum HR: 210-
(0.65×age), or a RPE ≥ 15 (Borg 1998) and (d) completion of all levels. 
Heart rate was monitored during the test and was recorded at the end of each level, using short-
range telemetry (Polar Electro Sports Tester S810 I), while the RPE scale (6-20) was used to 
determine the perceived exercise intensity at the end of each level (see table 3.5) (Borg 1982). 
During the procedure, a lap marker was indicated in the monitor HR watch by pressing the 






































Very, very hard 
At the end of the test, the maximum HR was recorded, and the patient was asked to sit on a chair 
for this. Blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) was 
measured as soon as possible after test termination while the participant remained seated. The 
patient was advised to relax and breathe in a normal way. After one minute of resting, HR and 
blood pressure were measured again. Patients remained in the sitting position until their HR was 
within ± 10 bpm of the pre-exercise HR. The time to this point from the end of the test was also 
recorded.   
3.2.3.1.  Heart rate measurements 
Heart rate was recorded at the beginning of the test (resting HR), at the end of each level of the 




from the difference between the maximum exercise HR and the one that was recorded one 
minute after the end of the test. Total HR recovery time was also recorded as time to resting HR 
± 10 bpm (Cole et al., 1999; Jouven et al., 2005). 
3.2.3.2.  Heart rate data transfer  
Heart rate data from the Polar monitor were transferred and filtered using a desktop computer 
and the Polar Precision Performance 3.0 training software, version 3.01.005.  
All measurements were repeated eight weeks after the first assessment. 
3.2.4.  Statistical analysis  
Statistical analysis was carried out using SPSS version 16.0 (SPSS inc., Chicago, IL, US), 
whereas calculations were performed in Microsoft Office Excel 2003 (Microsoft Corporation, 
Washington, US). Data were presented as mean and standard deviation, unless otherwise stated. 
The variables that were used in this protocol were: modified shuttle walking distance (MSWD) 
(m), maximum HR, RPE, HR recovery in 1 minute, and total HR recovery time.  
3.2.4.1.  Reliability analysis 
Different statistical measurements were used to evaluate the reliability and agreement of the two 
assessments. First, the change in mean scores between the test and retest was calculated for all 
the above variables. Differences between the two MSWTs were evaluated by using the paired-
samples t-test for waist circumference, BMI, SBP and HR recovery, with the significance level 
set at p<0.05. Relationships for each of the variables between the two trials were tested using 




Intraclass correlation coefficient (ICC) Level 3.1 (Atkinson and Nevill 1998) and the limits of 
agreement (LoA) test (Bland and Altman 1986) were used to assess the test–retest reliability of 
total walking distance and maximum walking speed. ICC values greater than 0.7 were taken to 
indicate good reliability (Pallant 2007). 
Agreement between the two assessments was estimated by using the repeatability coefficient 
(twice the standard deviation of the differences) (Bland and Altman 1986). The measure of 
agreement was evaluated using a graphical method, in line with Bland and Altman’s (1986) 
recommendations. Specifically, the difference in MSWD between the first and the second 
assessment was plotted against the mean of the sum MSWD for each subject. Next, the mean and 
standard deviation of the differences in MSWD were calculated. The standard deviation of this 
difference was multiplied by 2 and added to the mean difference to create the 95% limits of 
agreement (LoA), which were drawn as lines on the graphs. The 95% confidence interval of the 
difference in MSWD was estimated by using the one sample t-test.  
3.3.  Results 
3.3.1.  Changes in physiological measurements due to phase  IV cardiac rehabilitation 
Table 3.6 provides values for the physiological measurements taken eight weeks apart during 
phase IV CR using the MSWT as an assessment tool. None of the patients completed the 15-
level protocol MSWT (1500 m). MSWD ranged from the minimum 120 m to the maximum 880 
m. A paired-samples t-test was conducted to evaluate the changes in the physiological variables 
between the two MSWTs. There was a statistically significant difference (p<0.05) in recovery 
times, the SBP measurements (both pre-exercise and post-exercise) and waist circumference 
measurements, but not in any other physiological variables (MSWD, maximum HR, RPE score, 




recovery time from trial 1 (6.12±4.17 min) to trial 2 (4.88±4.31 min): t=1.71, p<0.05 (two-
tailed). The mean decrease in recovery time was 1.24 min, whereas the magnitude of the 
differences in the means was small: d=0.29 (Cohen 1988). A non-significant small increase 
between the two assessments was found for MSWD (difference 7m) and maximal walking speed 
(difference 0.05 m·sec-1). Small non-significant decreases were also noticed, across the two 
MSWTs, in the RPE score (difference 0.6), maximum HR (difference 1 bpm) and HR recovery 
(difference 2 bpm). Moreover, the resting HR remained unchanged.  
Other physiological variables, such as blood pressure (SBP, DBP), which were measured pre- 
and post-exercise, showed a marked decrease between the two trials. The SBP showed a 
statistically significant decrease of 7 mmHg in the pre-exercise measurements and 11 mmHg in 
the post-exercise measurements between the two trials, while the DBP mean decreased by 1 
mmHg between the two trials in both pre-exercise and post-exercise measurements. The body 
mass remained almost unchanged between the two MSWT assessments, whereas the mean waist 




Table 3.6.    Physiological responses and physical characteristics at the two assessments (trial 1 and trial 2) (n=30) 
 
       Trial  1 
 
        Trial 2 
 
Variable 
Mean (SD) Mean (SD) 
 









MSWD (m) 502 (161) 509 (146) -7 (-44 to 29) -0.41 0.685 
Maximal walking speed (m·sec
-1
) 1.65 (0.29) 1.70 (0.25) -0.05 (-0.12 to 0.03) -1.31 0.199 
METs achieved 5.45 (0.77) 5.57 (0.73) -0.12 (-0.33 to 0.09) -1.19 0.245 
RPE score 14.5 (1.4) 13.9 (1.5) 0.6 (-0.12 to 1.18) 1.69 0.103 
Maximum HR (bpm) 128 (18) 127 (18) 1 (-3.99 to 5.64) 0.35 0.727 
Resting HR (bpm) 68 (11) 68 (17) 0 (-5.87 to 5.25) -0.11 0.910 
HR recovery (bpm) 36 (17) 34 (17) 2 (-5.08 to 9.43) 0.61 0.544 
Time to recovery (min) 6.12 (4.17) 4.88 (4.31) 1.24 (0.36 to 2.12) 2.88 0.007 
Pre-exercise SBP (mmHg) 143 (19) 136 (22) 7 (0.92 to 12.25) 2.38 0.024 
Pre-exercise DBP (mmHg) 79 (8) 78 (10) 1 (-2.26 to 4.13) 0.60 0.555 
Post-exercise SBP (mmHg) 180 (30) 169 (29) 11 (4.51 to 16.66) 3.57 0.001 
Post-exercise DBP (mmHg) 83 (14) 81 (13) 1 (-2.12 to 4.32) 0.70 0.488 
Body mass (kg) 77.8 (12.7) 77.5 (12.6) 0.25 (-0.86 to 0.67) 0.78 0.442 
Waist Circumference (cm) 96.1 (11.6) 95.4 (11.2) 0.77 (-3.67 to -0.20)  2.37 0.025 
Definition of abbreviations: MSWD=modified shuttle walk distance; bpm=beats per minute; METs=metabolic equivalents; RPE=Borg rating of perceived 





3.3.2.  Test–retest reliability 
3.3.2.1.  Correlations 
Correlation alone is not a good measure of reliability, as it cannot measure variance (how much 
variability there is) among patients (Bartko et al., 1991). It has, however, been used in previous 
studies and so is included here for reasons of comparability (Bradley et al., 2000; Fowler et al., 
2005). 
Table 3.7 presents the correlations for each of the physiological variables between the two 
incremental assessment tests. There were significant and strong correlations between trials for 
MSWD (Pearson’s r=0.80; p<0.001), maximal walking speed (Pearson’s r=0.76; p<0.001), 
maximum HR (Pearson’s r=0.76; p<0.001) and time to recovery (Pearson’s r=0.85; p<0.001); 
while a moderate non-significant relationship was recorded for HR recovery (Pearson’s r=0.35, 
p=0.06). There was no significant correlation between the two MSWTs for the RPE score. These 
relationships are represented by the plots shown in figure 3.2.  
Table 3.7.   Correlation between the 2 trials (trial 1 vs. trial 2) (n=30) 
Variables Pearson r P value 
 
MSWD (m) 0.80 <0.001 
Maximal walking speed (m·sec
-1




Maximum HR (bpm) 0.76 <0.001 
HR recovery (bpm) 0.35 0.06 
Time to recovery (min) 0.85 <0.001 
Definition of abbreviations: MSWD=modified shuttle walking distance; RPE=Borg rating of perceived 
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      c.     d. 
             
e.     f. 
 
Figure 3.2. (a, b, c, d, e).  Regression line for the relationship of each variable in the two 
modified shuttle walk tests. 
a. total distance, b. maximal walking speed, c. peak Borg rating of perceived exertion (RPE scale), 
d. maximal heart rate, e. heart rate recovery and f. time to recovery. 




3.3.2.2.  Test–retest reliability and agreement 
There were no statistically significant differences in the MSWD between the first and second 
assessment (see table 3.6). Table 3.8 shows test–retest reliability in terms of the ICC with 95% 
confidence intervals for each variable (MSWD, maximum HR, RPE, HR recovery in 1 minute, 
and total HR recovery time). The ICC was high for MSWD (0.80), maximal walking speed 
(0.76), maximum HR (0.77) and time to recovery (0.85); while it was low for maximum RPE 
value (0.28) and HR recovery (0.35) (see table 3.8).  
Table 3.8.   Reliability statistics: Test–retest reliability of the modified shuttle walking test (n=30) 
Variables ICC 95% confidence intervals (CI) 
Lower Bound    Upper Bound 
P value 
MSWD (m) 0.80 0.62 0.90 <0.001 
Maximum walking speed (m·sec
-1
) 0.76 0.55 0.88 <0.001 
RPE score 
 
0.28 -0.08 0.58 0.064 
Maximum HR (bpm) 0.77 0.55 0.88 <0.001 
HR recovery (bpm) 0.35 -0.01 0.63 0.028 
Time to recovery (min) 0.85 0.71 0.93 <0.001 
Definition of abbreviations: MSWT=modified shuttle walking test; RPE=Borg rating of perceived exertion; 
m=metres; bpm=beats per minute 
The within-subject standard deviation, the repeatability coefficients and the limits of agreement 
plots (for MSWD) are shown in table 3.9 and figure 3.3, respectively. The coefficients of 
repeatability for the repeated MSWT were 196 m for MSWD, 0.38 m·sec
-1 
for maximal walking 
speed, 3.4 units for RPE score, 24 bpm for maximum HR and 38 bpm for HR recovery. A 




patient’s performance between the two assessments could be expected to be within -44 m and 29 
m.  
The test (see figure 3.3) showed a mean test–retest bias of -7 m with LoA from -203 m to 189 m, 
for MSWD; and a mean test–retest bias of -0.05 m·sec
-1
 with LoA from -0.43 m·sec
-1
 to 0.33 
m·sec
-1
, for maximal walking speed. This indicates that, in a retest situation, 95% of patients 
exposed to this protocol would be expected to walk distances ranging from 203 m less to 189 m 
more than a baseline score.  
 
Figure 3.3.   Limits of agreement plot (Bland and Altman plot). Intraindividual differences 
between performances on two incremental shuttle walking tests (test MSWT vs retest MSWT) 
plotted against the mean of the sum scores, in phase IV cardiac rehabilitation. The central line 
represents the mean of the intraindividual differences and the flanking lines represent the 95% 




Table 3.9.    Agreement statistics: Mean difference (95% confidence intervals) and repeatability coefficient for trial 1 vs. trial 2 
 Mean (SD) difference 95% confidence interval  Repeatability coefficient 
(RC) 
Limits of agreement 
(mean±RC) 
MSWD (m) -7 (98.2) -44  to  29 196 -203  to  189 
Maximal walking speed (m·sec
-1
) -0.05 (0.19) -0.12  to  0.03 0.38 -0.43  to  0.33   
RPE score 0.5 (1.7) -0.1  to  1.1 3.4 -2.9  to  3.9 
Maximum HR (bpm) 1 (12) -1  to  1 24 -23  to  25 
HR recovery (bpm) 2 (19) 0  to  1 38 -36  to  40 
Time to recovery (min) 1.2 (2.3) 0.4  to  2.1 4.6 -3.4  to 5.8 




3.4.  Discussion 
Measurements of exercise performance are essential in order to assess the functional capacity of 
CR patients and to evaluate the intervention or changes brought about by CR programmes. 
Conventional clinical or laboratory-based measurements are the gold standard for measuring 
VO2max but tend to be complicated, expensive and time consuming. Many alternative exercise 
tests have been developed in order to make cardiorespiratory assessment simpler. The SWT is an 
affordable alternative to treadmill testing, but its reliability has only been tested over short test–
retest durations (Singh et al., 1992; Bell et al., 1995; Jolly et al., 2008).   
All participants were patients with cardiovascular disorders, including MI survivors, angina, 
post-revascularisation interventions (CABG, PCI), HF, arrhythmias, hypertension; only 7% were 
chronic obstructive pulmonary disease patients. All were attending phase IV CR, and all had at 
least one cardiac risk factor and were clinically stable. Some attended the phase IV CR 
programme more regularly than others. Some had joined more than two years previously with 
others had attended for just ten weeks. These differences may not have affected the final 
experimental results since phase IV is a follow-up CR programme for maintaining exercise 
performance, which was expected to have been built up during phase III CR. Physical activity 
patterns are usually established by the end of phase III CR, and remain stable during phase IV 
(Woolf-May and Ferrett 2008). Thus, the long-term reliability of the MSWT can be assessed in 
phase IV CR, as this is a maintenance phase in which no significant improvements in functional 
capacity are expected (Woolf-May and Ferrett 2008). Due to the nature of the programme, it is 
unlikely that significant, systematic gains in functional capacity will occur in groups of patients. 
The functional capacity of individual patients is, however, likely to vary due to many factors, 




3.4.1.  Total distance versus maximal walking velocity: which is the most valid outcome 
measure for the modified shuttle walking test performance?  
Total distance covered and/or maximal walking speed constitutes the test’s score (Singh et al., 
1992). In daily life, routine walking distance is an important factor. Walking speed also plays an 
important role in performing everyday activities, and both elements have proven to be significant 
factors in estimating clinical status and mobility (Van Herk et al., 1998). 
In contrast with the 6-MWT, equal distances in the MSWT do not necessarily represent equal 
levels of exertion. For instance, it is harder to ‘cross’ a stage than to complete an additional 
shuttle within a stage. For instance, going from shuttle 40 (7
th
 shuttle in level 7) to shuttle 42 
(last shuttle of level 7) requires no change in speed. It is, therefore ‘easier’ to do this than to go 
from shuttle 42 to shuttle 43 (1
st
 shuttle of level 8) (see table 3.4). The latter change requires the 
participant to be able to walk at a greater speed (with a greater physiological demand) but would 
provide only 30 m extra to the score, as opposed to the 60 m gain seen in the first example, 
which requires no change of speed. Distance, in this case, when it is measured over an 
incremental course, should not be considered as interval scale data but ordinal.  
Walking speed seems the obvious measure by which to evaluate functional capacity and has 
been used to describe MSWT performance. However, as previous MSWT reliability studies 
report only on distance walked (MSWD in metres) (Fowler et al., 2005; Campo et al., 2006; 
Jolly et al., 2008), this metric will be used here to discuss the results of this study for purposes of 
comparability.  
3.4.2.  Comparison of results with previous data 
The distance covered and the maximal walking speed achieved at the end of the test was used to 




509 (±146) m in the trial 2. In other studies, undertaken using patients with pulmonary disorders 
(chronic obstructive pulmonary disease, chronic airflow limitation) as the sample, lower scores 
for MSWD were found, with mean values of 378 m (Singh et al., 1992), 375 (±137)  m (Singh et 
al., 1994), and 307 (±89.3) m (Rosa et al., 2006). Studies with cardiac patients as a sample 
recorded higher values in total distance, in contrast with pulmonary studies; however, the rates 
were still lower than the present results.  
Lewis et al. (2001) studied a sample of patients following heart transplantation achieved a 
maximum mean MSWD of 401.3 (±129) m in the third assessment. Fowler et al.’s (2005) 
sample of patients who had undergone CABG surgery recorded a highest mean distance of 487 
(±147.6) m after three assessments made using the SWT. Arnold et al. (2007) used the SWT to 
investigate the effects of once- versus twice-weekly CR and found that the post-rehabilitation 
(twice weekly intervention) mean distance was 557 (±171) m. Sandercock et al. (2007) found a 
mean total distance of 597 (±235) m in the second SWT assessment, in a CR population. Woolf-
May and Ferrett’s (2008) sample, of post-MI patients who attended phase IV CR programmes, 
measured a mean total distance of 430 (±109) m in the first assessment. Jolly et al. (2008) 
recorded the highest mean distance of 414.8 (±157.5) m in a cardiac population in the second 
assessment using the SWT.  
The mean MSWD of 505 m seen here is comparable with other studies of cardiac patients 
(Fowler et al., 2005; Arnold et al., 2007; Sandercock et al., 2007; Woolf-May and Ferrett 2008). 
The present study, however, is the first to assess long-term (>10 week) attendees of phase IV 
CR. It was necessary for the research design, clinically stable patients to attend a maintenance 





3.4.3.  Reasons for test termination 
In the present study only 40% and 37% of the total number of patients, for the first and second 
assessment respectively, reached their maximum predicted HR, as determined by the age-related 
formula 85%×[210-(0.65×age)]. Breathing disorders and fatigue were the most common reasons 
that led the patients to terminate the test. Ventilator factors in combination with cardiovascular 
factors can limit exercise tolerance in typical patients with cardiovascular disorders. This agrees 
with data from Verschuren et al. (2006), who stated that cardiovascular tests are good tools for 
measuring cardiorespiratory capacity.  
3.4.4.  The reliability of the modified shuttle walking test 
The short-term reliability of the SWT has been assessed previously in both pulmonary and 
cardiac populations (Singh et al., 1992; Arnott 1997; Bradley et al., 2000; Fowler et al., 2005). 
The results of the present study showed no statistically significant difference in the MSWT score 
between the two assessments. There was a small, non-significant increase (7 m) in MSWD and 
maximal walking speed (0.05 m·sec-1) between the trials. RPE and maximum HR were decreased 
by 0.6 units and 1 bpm respectively; there were no changes in the resting HR. Although some 
changes were noticed in respect of the MSWT results, they were only small changes and not 
statistically significant. A statistically significant difference between the two MSWTs was 
noticed only in the recovery time rates and the SBP (pre- and post- exercise) measurements, 
which might be due to test familiarisation.  
Strong, significant correlations were recorded between trial 1 and trial 2 for MSWD and 
maximal walking speed, maximum HR and total time to recovery. These results agree with 
Fowler et al. (2005), who carried out a piece of research using three MSWTs and an incremental 




They found strong correlations between the distances in the two tests; however, higher RPE and 
HR scores were achieved for the treadmill test and these might be the result of greater 
cardiorespiratory stress during that test. 
In the present study, high long-term reliability (8 weeks) was observed for the same variables 
(MSWD, maximal walking speed, maximum HR and total time to recovery). There was also a 
high internal consistency for the MSWT score measured by Cronbach’s alpha. The ICC values 
for MSWD, maximal walking speed, maximum HR and total time to recovery were 0.80, 0.76, 
0.77 and 0.85 respectively, while the ICC values were low for RPE score and HR recovery. The 
results indicate that each of the MSWT’s outcome variables (MSWD, maximum HR, RPE, HR 
recovery and recovery time) has different repeatability. However, no reports of the ICC of the 
MSWT over long periods of testing were available in the literature.  
3.4.4.1.  Reliability and learning effects 
The test–retest reliability of any measurement is challenged by both systematic bias (i.e., practice 
effects) and random error (i.e., measurement error, biological variation). The ICC values for 
MSWD (R=0.80) and maximum walking speed (R=0.76) are both in excess of the critical value 
(R=0.70) deemed to indicate reliability in previously research (Fowler et al., 2005). The ICC is a 
dimensionless coefficient and is prone to inflation if there is a wide range of mean scores, as in 
the present study. ICC suggested the test was reliable, but these data were also analysed using 
the LoA. LoA was used because it assesses both systematic and random variation in MSWD, and 
because it provides ‘real world’ values for test–retest changes in distance for use by clinicians 
and researchers. 
The systematic bias from test to retest was low (-7 m), indicating that there was no learning 




and refute the findings of studies (Singh et al., 1992; Fowler et al., 2005; Jolly et al., 2008) 
suggesting the need for a practice test to obtain reliable MSWT results.   
The creators of the test demonstrated that a practice test was necessary to secure the reliability of 
the results in chronic obstructive pulmonary disease patients (Singh et al., 1992). This means 
clinicians can ensure a reliable output if they suggest that patients perform at least one practice 
SWT. Arnott (1997), however, found no significant changes in distance walked when the SWT 
was repeated in cardiac patients, and noted that practice tests for the SWT were unnecessary for 
obtaining reliable measurements of functional capacity in cardiac patients. Later, Bradley et al. 
(2000) suggested that test practice is not necessary if it is used to assess functional capacity in 
adult patients with stable cystic fibrosis who are familiar with the test.  
Fowler et al. (2005) suggested the learning effect may influence SWT results and that the 
potential benefits of CR interventions may not always be identified. Thus, a practice walk was 
recommended by the authors (Fowler et al., 2005), in order to overcome the natural variability of 
the test and to ensure the reliability of the output. Jolly et al. (2008) utilised a practice SWT and 
a second SWT to assess cardiac patients and to explore if the recommended practice test was 
necessary. They recommended the need for a practice walk before the assessment; they also 
noticed an improvement in the MSWD after a practice walk.  
What must be borne in mind from the above: firstly, the issue over whether or not a practice 
SWT is necessary had not been resolved; and secondly, these studies used short (day to day) or 
very short (within day) test–retest protocols. Patients retested over such short periods will 
remember previous test scores and may set goals to beat previous scores. Furthermore, SWT is a 
field test devised for clinical application. In a clinical setting, it is unlikely that practice tests will 




therefore, use a simple test–retest design, as this is what is most commonly used in a clinical 
setting. 
As no systematic bias was shown, the present study suggests that no practice effect was present 
when the tests were used at clinically valid intervals (eight weeks). Several patients needed the 
test protocol explaining again from the start for the purposes of the retest. It seems unlikely that 
these patients would remember their performance measures over such a long period.  
In order that test–retest reliability is deemed satisfactory, the LoA should be smaller than the 
minimum expected difference in MSWD which the test will be used to detect. From previous 
studies (Fowler et al., 2005; Arnold et al., 2007; Sandercock et al., 2007), it was determined that 
a 100 m improvement in MSWD could be expected over a six to eight week outpatient phase III 
CR programme. 
The large LoA (-203 m to 189 m) were greater than values from previous test–retest studies, that 
did not use practice walks (Bradley et al., 2000; Fowler et al., 2005), and are well in excess of 
the proposed 100 m critical value. Unfortunately, this seems to be the first time where this 
‘critical value’ was calculated and was mentioned. These data suggest, in the population studied 
here at least, that the MSWT contains too much random variation in MSWD to be used, 
successfully, to monitor changes in functional capacity. 
The lower test–retest reliability is most likely due to assessing long-term reliability, as opposed 
to day-to-day variation in MSWD as in previous studies (Fowler et al., 2005; Campo et al., 
2006; Jolly et al., 2008). The wide LoA show that individuals’ MSWD varied considerably from 
trial 1 to trial 2. Despite no mean group change (systematic bias), some patients’ MSWD greatly 
improved, while the MSWD of others clearly declined. The long test–retest duration 




the trials, some patients attended CR sessions more regularly than others; patients missed 
sessions due to illness, musculoskeletal problems, holidays or, in one case, a minor operation. 
Just as, it is conceivable that such factors may negatively influence MSWD, it is equally 
conceivable that some of individuals, whose MSWD greatly improved, may have increased their 
training volume between trial 1 and trial 2. Such individual variations in behaviours that may 
affect MSWD are a limitation of the current study.  
There was no systematic variation from test to retest in terms of learning effect or 
homoscedascity. The LoA plot shows that six patients’ MSWD changed by less than one shuttle 
(10 m) between the two assessments while others declined by over 200 m. It is beyond the scope 
of this study to identify changes in individuals that may have been associated with such changes 
in MSWD, but it seems that the two patients outlined above may be outliers. In accordance with 
Bland and Altman’s (1986) instructions, these two outliers were excluded and the analysis 
repeated. The repeatability coefficient was still large at ±146 m.  
Changes were also found in resting blood pressure and total time to HR recovery from test to 
retest in some but not all patients, possibly indicating that the notion of a clinically stable patient 
may be a misnomer. Psychological variables might also have had an impact on MSWD.  
3.4.5.  Study limitations  
The lack of a practice test could also be perceived as a weakness of this study, but it is also 
possible that this actually increased the study’s generalisability. There is good evidence for a 
short-term learning effect on the MSWT, meaning that a practice walk is preferable. In a clinical 
setting, it is unlikely that time or money would be available for a practice walk prior to a 




changes in functional capacity during CR have not used a practice walk (Fowler et al., 2005; 
Arnold et al., 2007).   
We made no psychological measures prior to either test and so cannot comment on such factors 
as motivation of fear, but they may also have had an impact on MSWD. Neither were individual 
variations in behaviours such as habitual walking or exercise taken to into account. These also 
may have affected test performance and reliability. 
3.5.  Conclusion 
Previous studies had demonstrated the reliability of the SWT for patients with CVD by using 
only short-term tests (same day trials, day-to-day trials, up to a maximum of one week). This 
study examined the long-term reliability of an incremental MSWT in stable cardiac patients who 
were clients in phase IV CR. The results showed small changes in the mean MSWD between the 
two assessments, a good long-term reliability (ICC) of the MSWT and large LoA between the 
two assessments.  
In conclusion, clinicians can be confident that they can use the MSWT to monitor changes in 
functional capacity in groups of CR patients. The lack of systematic bias suggests that only one 
MSWT trial pre- and post-CR is needed to monitor changes in CR. A practice walk is not 
required to assess long-term changes in functional capacity. Monitoring of individuals may be 
difficult, especially if there are potential factors that may impede performance on the test. 
Changes in symptoms, muscle pain, changes in medication, frequency of exercise training and 
motivation may all play a role in creating the large random variation in performance (MSWD) 
seen here in clinically stable cardiac patients. Thus, further studies to elucidate other 
physiological and potential psychological factors, which may predispose such patients to large 




This study has been published as: ‘Pepera, G. McAllister, J. Sandercock, G. (2010). Long-term 
reliability of the incremental shuttle walking test in clinically stable cardiovascular disease 
patients. Physiotherapy, 96, 222-227’.  
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CHAPTER 4.  BIOMECHAICAL PREDICTORS OF THE MODIFIED SHUTTLE WALKIG TEST 
PERFORMACE I PATIETS WITH CARDIOVASCULAR DISEASE 
4.0.  Abstract 
The shuttle walking test is a reliable measure of cardiorespiratory capacity. There are a number 
of biomechanical parameters that may affect the performance score. The purpose of this study 
was to evaluate the influences of biomechanical parameters on a modified shuttle walking test 
(MSWT) in clinically stable cardiovascular disease patients, and to provide a preliminary 
reference equation to account for biomechanical (dis)advantage when performing the test.  
Sixteen cardiac patients (56% males, 44% females, mean age: 69.1±7 years), who were attending 
a phase IV (UK classification) cardiac rehabilitation programme, volunteered for the study. All 
the patients were assessed twice (with 8 weeks between assessments) using the MSWT. 
Modified shuttle walking distance (MSWD) was used as the outcome performance variable. 
Anthropometric data (mass, stature, body mass index [BMI], waist circumference, leg length) 
were recorded prior to the start of the first test. During the test, the number of steps taken in 
every shuttle was recorded and then the step length was calculated. Patients’ balance was 
assessed on a Kistler force plate, with eyes open and closed. Gait and ground reaction force data 
were collected during the MSWT through video recordings and the force plate measurements. 
Pearson’s product–moment correlation coefficients were calculated to assess the biomechanical 
correlates of test performance. Stepwise linear regression analysis was used in order to identify 
the predictors of test performance (m). 
The mean MSWD was 479 (±139) m in trial 1 and 499 (±138) m in trial 2. MSWD correlated 
most strongly with step length measured at the 2/3
rd




and stature (trial 1: r=0.74, trial 2: r=0.69; p<0.05) in both trials. Step length was the best 
predictive measure of MSWD, followed by stature. Stepwise regression revealed step length as 
the best independent predictor. Given the rarity of step length assessment in clinical practice, the 
next most powerful predictor of performance, stature, was entered in a subsequent model, which 
explained 55% of the variance found in the test performance.  
This study demonstrated that taller patients can be expected to perform better on the MSWT than 
shorter patients with similar clinical characteristics. The regression equation generated here 
could be used to predict an individual’s performance and remove some of the bias towards taller 
patients.  
4.1.  Introduction  
Cardiovascular disease (CVD) patients usually present with levels of functional capacity, 
exercise tolerance and daily physical activity that are lower than age-matched controls (Ades et 
al., 2006). Low functional capacity may be more a result of decreased activity levels in chronic 
CVD than part of the disease aetiology. Most rehabilitative cardiovascular exercise programmes 
focus on increasing the patient’s functional capacity and muscular strength (Darnley et al., 
1999). 
Gait and mobility can play an important role in the assessment of both musculoskeletal and 
cardiopulmonary systems. Functional walk tests, such as the six-minute walking test (6-MWT) 
(Guyatt et al., 1985) and the incremental shuttle walking test or modified shuttle walking test 
(MSWT) (described in Chapter 3, see ‘Long-term reliability of the modified shuttle walking test 
in clinically stable cardiovascular disease patients’), were originally developed to evaluate 




Walk tests are typically used as measurements of functional status to record progression during 
rehabilitation.  
In British CVD patients, the most commonly used functional capacity test is the shuttle walking 
test (SWT), originally developed by Singh et al. (1992) as the 12 stage incremental SWT, which 
was subsequently modified to the 15 level version used today (Bradley et al., 1999, 2000). 
Initially the SWT was developed for evaluating functional capacity in patients with chronic 
obstructive pulmonary disease, whereas it has been demonstrated recently that the test is reliable 
when compared with the gold standard test – the Maximal Graded Treadmill Exercise (Singh et 
al., 1994; Lewis et al., 2001; Fowler et al., 2005). 
4.1.1.  The modified shuttle walking test 
As outlined in Chapter 3, the incremental or modified SWT (MSWT) is now routinely used in 
cardiovascular and pulmonary rehabilitation centres (Singh et al., 1992; Tobin and Thow 1999; 
Francis et al., 2000; Morales et al., 2000; Lewis et al., 2001; Solway et al., 2001; Zwierska et 
al., 2004; Fowler et al., 2005; Campo et al., 2006; Jolly et al., 2008; Woolf-May and Ferrett 
2008). The SWT can be used to evaluate the functional capacity of individuals and, by this 
means, the effectiveness of different rehabilitation treatments; it can also be used to determine 
prognosis of cardiopulmonary disease (Singh et al., 1992, Morales et al., 2000; Lewis 2001; 
Solway et al., 2001). Cardiorespiratory conditions, functional capacity, habitual exercise and age 
are all variables, which may influence SWT performance (Singh et al., 1992; Payne and Skehan 
1996; Lee et al., 2005). What has not been thoroughly examined is whether MSWT performance 
is also related to gait parameters, despite their importance in the analogous 6-MWT.  
There is some evidence of biomechanical influences on the 6-MWT in healthy adults (Enright 




al., 2006; Chetta et al., 2006; Poh et al., 2006; Jenkins et al., 2009); however, there are no 
published reports concerning the anthropometric and gait variables associated with MSWT 
performance. The studies noted above were limited to collecting simple anthropometric data and 
have not evaluated the potential associations between gait parameters and walk test performance. 
The primary outcome measure of the MSWT is the distance walked (MSWD), and it is possible 
that anthropometric and gait parameters may affect the MSWD.  
Biomechanical inefficiencies in walking are common among the elderly (Payne and Skehan 
1996). Enright and Sherrill (1998) conclude that the gradual reduction of muscular mass and 
strength and the increase of pathologies that occurs with ageing are responsible for low 
performance in the 6-MWT. The 6-MWT protocol is less strictly standardised than other 
exercise tests, creating a degree of measurement variability (Revill et al., 1999). The 6-MWT 
allows rest periods for patients with severe cardiorespiratory problems (such as heart failure [HF] 
patients), whereas the MSWT requires participants to increase their exercise intensity output 
until pre-determined termination criteria are met. The MSWT provokes graded cardiovascular 
responses, which are not produced by the 6-MWT (Turner et al., 2004). Due to these differences, 
and because the British Association of Cardiac Rehabilitation (BACR) suggests the use of the 10 
m SWT as the major assessment component in a cardiac rehabilitation (CR) programme, the 
SWT was used here to evaluate performance stable CVD patients who exercise regularly.  
4.1.2.  Biomechanical components of modified shuttle walking test 
In contrast with the gold standard assessment (graded exercise treadmill test), the MSWT 
requires patients to change direction through 180
o
 at regular intervals, making the test more 
difficult than treadmill walking (Revill et al., 1999) and creating very different biomechanical 




Turning is a gait parameter found in many everyday activities, but it may prove difficult, 
especially for the elderly or for people with particular neuromuscular disorders, because of the 
demands it places upon balance. Other biomechanical parameters may also influence the MSWT 
performance score and these clearly warrant further investigation.  
An exercise test with many turns, like the MSWT, requires proficient balance control. The faster 
a patient walks, the greater the deceleration required before turning in order to re-orientate the 
centre of mass, and the greater the propulsive impulse required to accelerate the body in the new 
direction (Seeley et al., 2008). Hence, the more biomechanical inefficient a person is, the more 
difficult it will be to undertake a test involving many turns. 
Solway et al. (2001) conducted a systematic review of cardiorespiratory tests, such as the 6-
MWT and the MSWT. They concluded that it was controversial to compare performance on 
these tests, where the participant walks along a hallway and numerous turns are performed, with 
exercise performance on a treadmill, in which no turning is involved. This is because energy 
expenditure and performance results seem to vary between protocols. It is clear that both 
practices have their own advantages (Solway et al., 2001), however; the treadmill, for example, 
does not require the participant to turn, but some of the participants are unaccustomed to walking 
on a moving belt where they cannot control the pace.  
In order to clarify how biomechanical factors (turning time, number of steps needed to turn, 
turning strategy, balance, stature, leg length and step length) may affect MSWT results, a 
separate analysis of these gait parameters will be undertaken. In the two following subsections, 





4.1.2.1.  Turning 
Turning is used during everyday activities, where two turns are usually required for every ten 
steps taken in daily life. Turning is a complex manoeuvre: the participant needs to decelerate the 
forward motion, select one of the two turning strategies (step turn or spin turn), rotate the body 
laterally, use the forward leg as an axis towards the turning direction and, finally, make the step 
in that direction, while accelerating again (Hase and Stein 1999; Taylor et al., 2005) (see figure 
4.1). The foot that is planted on the ground in front of the body during the deceleration effort 
controls the timing of muscle activities for producing the braking force (Fy). Different 
mechanisms of deceleration are used to decrease the speed of walking before turning, depending 
on the timing within the step cycle and the nature of the task (Yang and Winter 1985; Hase and 
Stein 1998, 1999).  
Functional mobility and balance interact to achieve movements in everyday life (walking, 
standing, sitting, turning). They also interact with a number of variables, such as the type of 
turning, the speed, the turning time and the number of steps needed to complete the turn (Hase 
and Stein 1999; Demura and Uchiyama 2007). Healthy people, either without or with few 
chronic conditions (chronic obstructive pulmonary disease, diabetes, HF, CHD) tend to have 
better mobility (Gorgon et al., 2007). These people may perform turning tasks more easily than 
those with a high number of chronic complications. For instance, elderly cardiac patients with 
several pathologies usually have poorer mobility due to attenuated functional locomotion system 
performance.  Being elderly is associated with a decrease in functional mobility. Changes in gait 
characteristics occur to reduce the risk of falling. Older people usually decrease gait speed, 
cadence and step length, while increasing their turning time and the number of steps used during 
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Figure 4.1(a, b).   The two turning strategies; a. step turn and b. spin turn  
(R: Right foot, L: Left foot) 
 




Turning time is used as an index of mobility (Imms and Edholm 1981). These authors assessed 
the mobility of 70 participants (aged 60–90 years) with different activity levels and pathologies 
(post-stroke, post-myocardial infarction or the weakness associated with age), by involving them 
in different tasks. Turning time on a walkway showed a high correlation with walking speed 
(Pearson’s r=-0.824; p<0.001; n=51), the time taken to complete the task (Pearson’s r=0.584) 
and the number of gait abnormalities during the effort (Pearson’s r=0.491), but not age. People 
with several pathologies in daily life needed more time to complete a task and more time to turn. 
As turning is a feature of almost all daily activities, this population may find difficult to cope 
with everyday tasks. This may lead to reduced physical activity and, therefore, poor functional 
capacity.  
Shkuratova et al. (2004) compared 20 healthy young participants (mean age: 25±6 years) with 20 
healthy older participants (mean age: 72±5 years) in terms of several walking tasks, with and 
without turns. There was a significant negative relationship between age and walking speed, but 
no significant relationship between age and turning. Older people did not increase their speed 
and step length during walking as much as young adults, which was proposed as a potential 
strategy for older people to maintain their balance.  
Van Herk et al. (1998) compared two walking protocols in a sample of patients with mobility 
disabilities following a stroke; a straight walking course for 10 m and a 5 m walking course with 
turns. Patients required significantly more time for the turning task than the 10 m straight walk 
(p<0.001). Patients took an average of 3.2 seconds longer to complete the 2 x 5 m walk task with 
turn, compared with the 10 m straight course. The walking speed varied considerably between 
conditions; some patients required less time to complete the turning task than the straight 
walking task. The authors suggested that a 10 m task created greater psychological stress in some 




appeared easier for some of the patients and resulted in faster gait speeds. Van Herk et al. (1998) 
found that a 5 m walk with turns was an acceptable alternative to 10 m straight walking for these 
patients. Such data suggest that, in a test like the MSWT, with repeated turns, participants may 
take more time to complete the test because of the extra time and effort spent during turning.  
Turning influences walk performance by requiring more time and more effort from the 
participant to complete a turning task. Because turning is an important feature of walking, the 
next section will discuss turning strategies and the effect that these might have on walking 
performance.  
4.1.2.1.2.  Turning strategy  
During most turns, humans use one of two turning strategies – the step turn or the spin turn 
(Hase and Stein 1999). These strategies are classified depending on the action of the leg the 
participant uses for braking. For example, when turning left, the step turn is a strategy by which 
the right foot is placed in front of the participant in order to turn left. The base of support is on 
the right leg first, and then shifts to the left; the participant rotates the left hip, steps to the left 
leg, then to the right, completes the turn and continues walking (see figure 4.1.b).  
The spin turn is a turning strategy in which the participant begins with their left foot in front and 
turns left by spinning the body around the left leg. It is named the “spin turn” because the body 
spins around one foot, which is the axis for turning (see figure 4.1.b) (Hase and Stein 1999). 
Furthermore, the spin turn can be divided into two sub-turning strategies: the crossover and the 
pivot turn (Taylor et al., 2005). Both of these turns move towards the same side as the stance 
limb. The crossover turn occurs when the stance limb remains ‘rooted’ to the ground as the 




limb pivots about the ball of the foot, rotating the whole limb and body towards the new 
direction. 
The step turn is easier and provides better stability than the spin turn, as well as having lower 
neuromuscular demand. This is why most people prefer to use this strategy in everyday 
functional activities with turns. The improved stability is due to a wider base (wider steps) with 
the centre of gravity always between its boundaries; this turn retains a larger contact surface with 
the floor. This is at the cost of an increase in turning time and the number of steps taken during 
turning. A step turn requires less muscular effort and joint angular displacement than the spin 
turn, as well as less rotation speed of the upper body and less push-off power by the soleus (Patla 
et al., 1991; Hase and Stein 1999; Taylor et al., 2005). 
For anyone with poor balance or decreased mobility, a step turn is usually the safest way to turn. 
In middle-aged (26- to 57-year old) healthy participants, both of the processes (step turn and spin 
turn) are so smooth that, at the end of the turn, the walking procedure continues with few or no 
disturbances in timing or to walking speed (Hase and Stein 1999). So, it is clear that there are 
many strategies and that CVD patients with heterogeneous levels of functional capacity are 
likely to turn in different ways. 
Turning increases the motor control requirements and, therefore, the risk of falling in the elderly 
adults (Tinetti et al., 1988). During turning, the body must work harder against gravity to 
maintain an upright posture (Huxham et al., 2001; Kirtley 2006). The mechanism that keeps the 




4.1.2.2.  Balance  
Balance control or stability is the ability of the body to keep its centre of mass within the 
boundaries of the base support after a perturbation. Everyday examples of such perturbations 
include walking and turning (Karlsson and Frykberg 2000). Ageing and pathologies such as 
neurological and muscular disorders interact with the balance system, which create increases in 
body sway; a decline in balance control and stability inevitably changes the dynamics of motion 
and posture (Hase and Stein 1999; Karlsson and Frykberg 2000; Huxham et al., 2001). Poor 
balance and postural stability are related to visual conditions, such as low-lighting levels and 
visual disorders – glaucoma and hyperopia, for example. Such conditions lead to an increase in 
postural sway and risk of falling (Lord and Menz 2000; Black et al., 2008; Friedrich et al., 
2008).   
Choy et al. (2003) demonstrate that body sway and postural stability are significantly related to 
age and visual stimulation. Their study shows a decreased ability to balance when the visual 
input is removed (when eyes are closed). The literature suggests that body sway, balance control 
and falls are significantly related to age, visual stimulation and other visual disorders. In the 
elderly, visual disorders are commonplace, provoking an increase in postural sway and the risk 
of falls. Balance changes with aging, and people with impaired balance tend to change their gait 
characteristics (such as step length, cadence and walking speed), and need more time to walk and 
turn. Gait characteristics, balance and turning seem to relate to each other and together they 
affect walking performance.  
4.1.3.   Relationships between biomechanical variables (balance, step length, cadence, 
walking speed, braking force, total vertical impulse and turning)  
Pathologies of the locomotor system may affect gait parameters such as step length and walking 




walking speed because of balance impairment. They spend more time in the double-support 
phase of walking, utilise a greater number of steps and need more time to turn, compared with 
healthy controls (Carpinella et al., 2007). Thus, turning appears to increase hypokinetic 
characteristics in elderly Parkinson’s disease patients, in order to increase stability.  
Imms and Eoholm (1981) showed that turning time correlated poorly with age but was 
negatively and very strongly correlated with walking speed (Pearson’s r=-0.824, p<0.001). They 
found that elderly people without pathology of the locomotor system preferred to change their 
step length instead of their cadence. This infers that older people may prefer to make wider steps 
in order to obtain a wider base of support to prevent falls. 
The process of turning requires the deceleration of walking speed a few steps before the turn. In 
order that the walker decelerates properly and maintains body stability, the direction of the turn 
should be known at least one step before turning (Patla et al., 1991; Hase and Stein 1999). In the 
MSWT, both the direction and the turning movement are known to the participant; thus, they 
may be able to better adapt to the turning effort by preplanning and taking more steps to turn.  
To summarise, balance is attenuated in the elderly, affecting a decrease in the step length, 
turning time, the number of steps needed to turn, gait speed and gait cadence. The next section 
will discuss how balance can affect MSWT in elderly patients.  
4.1.4.  Does turning affect walking test performance? 
Walk tests are commonly used to evaluate functional capacity. Most field tests, however, include 





Beaumont et al. (1985) compared the results of two self-paced 12 minute walking tests, 
performed on different ‘courses’ (a hospital corridor including a turn and a flat treadmill) in 
pulmonary patients. They found no significant difference in distance walked, step length or 
average speed. The use of two very different protocols (corridor and treadmill) makes the 
interpretation of the results difficult. There is no information given about how long the corridor 
was or how long participants had to walk before turning. Participants may have been unfamiliar 
with the treadmill, while walking along a corridor is closer to an everyday situation.  
Swerts et al. (1990) used the twelve-minute walking test in pulmonary patients and found that 
patients performed better (significantly higher distance walked and walking speeds) along a 100 
m corridor than on a treadmill. The result was independent of any difference in heart rate, 
indicating that the intensity of exercise was similar across the two trials. Stevens et al. (1999) 
supported these findings by showing that the majority of patients who undertook the 6-MWT 
walked further along a hallway than on a treadmill. Both studies concluded patients were more 
familiar with walking along a corridor than accelerating on a treadmill, which required more 
effort to utilise supplementary voluntary movement.  
Conversely, Revill et al. (1999) found that patients with chronic obstructive pulmonary disease 
walked further on a treadmill than along a corridor, when performing the endurance SWT 
(externally controlled, constant paced test) at all intensities. In this study, patients were asked to 
perform three endurance SWTs, three treadmill endurance tests and an incremental SWT. The 
intensity of these endurance tests was calculated individually for each patient and related to 75%, 
85% and 95% of each patient’s maximum incremental SWT performance. Again, the heart rate 
responses provoked during the endurance SWT were similar to those achieved during the 
treadmill endurance test. The difference in distance covered between the two tests was explained 




assists in the backwards movement of the foot. Another explanation would be that the SWT 
along the corridor is more biomechanically demanding than the treadmill test, due to the turning, 
decelerations on corners, lateral displacements and accelerations; however, the authors were 
unable to determine among these factors.  
A further study of the 6-MWT involved 761 patients with obstructive pulmonary disease 
(Sciurba et al., 2003). There was no effect of course length on the 6-MWT for straight courses 
(range: 15-50 m). There was, however, an effect of course layout. Patients who performed the 
test on continuous courses (circular or oval corridors, ranging in length from 56 to 121 m) 
walked 28 m further than those tested on straight corridors. The layout of the course and thus, the 
different biomechanical parameters (turns), may affect performance. Nevertheless, different 
groups of patients with different clinical characteristics were used in each trial, creating 
limitations in design and reducing generalisability of the results.  
The American Thoracic Society (ATS) a medical association whose standing is recognised 
globally– hence the use of ATS protocols here. Recently (2002), the ATS recommended that 
when the 6-MWT is performed along straight, short corridors; patients need more time to reverse 
direction, reducing the total walking distance. This might be because of the time and effort 
required to turn. The ATS guidelines suggest, therefore, that the 6-MWT should be performed 
along a straight corridor course at least 30.5 m long, in order to limit the number of turns 
(American Thoracic Society 2002).  
More recent studies have compared the 10 m SWT with the 6-MWT in terms of chronic 
obstructive pulmonary disease patient performance. The significant difference in distance 
covered between the two tests may provide an opportunity to analyse the effect of the different 




and the 6-MWT (performed along a 28 m corridor), in a sample of elderly pulmonary patients. 
The authors compared patients’ performance at the two different tests. They found a significant 
difference in the mean distance covered; with the incremental SWT, the mean score was 307 
(±89.3) m and with the 6-MWT, the mean score was 515.5 (±102.3) m (p<0.001). The 6-MWT 
was found to produce more stress on the cardiovascular system (as measured by higher heart 
rates and higher levels of dyspnoea), despite the 10 m SWT requiring double the number of turns 
compared with the 6-MWT along a 28 m hallway. This might be explained by the different 
layout of the two tests: the 10 m SWT is an incremental test, which requires the patient to 
exercise intensively for a relatively shorter period of time, while navigating many turns along the 
course.  
In a comparison between a 6-MWT along a flat 30 m walkway and a 10 m endurance SWT in 
patients with cardiopulmonary disorders (Pepin et al., 2007), the SWT was more physiologically 
demanding than the 6-MWT. Mean walking speed was similar for both tests, but patients found 
it more difficult to maintain walking speed on the 10 m SWT, as this test required more 
alterations in direction and more numerous accelerations and decelerations compared with the 6-
MWT performed on a 30 m course. Patients found the SWT more demanding, but were able to 
increase their endurance time and thus cover more distance in SWT. The authors concluded that 
it was easier for patients to increase endurance time than to increase walking speed, due to the 
different biomechanical test designs, which effects bronchodilation responsiveness. The 
mechanism by which bronchodilation may have an impact on patients with respiratory disorders 
is, however, unclear. Difference in the findings between the two studies mentioned above cannot 
be explained only in terms of test design. Different methodologies of the tests must also be 
considered. Due to its incremental and externally paced structure, physiological responses to 




The SWT requires the participant to make a 180º turn every 10 m and this seems to require an 
additional effort in order to maintain their balance and posture stability. Anthropometric 
characteristics, such as: stature and leg length, may affect gait and, by extension, these factors 
may influence test results. 
4.1.5.  Aim and hypothesis  
The aims of this study were to investigate the influence of these anthropometric (stature, leg 
length, step length) and gait parameters (turning time, steps needed to turn, braking force, 
vertical impulse) on MSWD in clinically stable CVD patients. This work is intended to provide a 
preliminary reference equation to account for biomechanical (dis)advantage when performing 
the test.  
The results and discussion of this chapter will attempt to reference the following hypothesis: Gait 
and anthropometric parameters can predict a significant proportion of variance in MSWD, in 
clinically stable CVD patients.  
4.2.  Methods 
4.2.1.  Participants 
Sixteen adults (9 males and 7 females) aged 55 to 80 years volunteered for this study. All were 
members of a phase IV (UK classification) CR programme, the ‘Phoenix Club’, which is held at 
the University of Essex (same population as Chapter’s 3 population). All participants had been 
enrolled in the community-based, long-term maintenance CR programme for a minimum of ten 
weeks. All the participants were patients with cardiac disorders; they were either involved in 
revascularisation intervention (coronary artery bypass graft [CABG] or percutaneous coronary 




surgery. Some patients joined the CR programme because of HF, stable angina and arrhythmias. 
The patients had finished phase III CR at a local Colchester Hospital or been referred to phase IV 
CR by their general practitioner. All patients were defined as clinically stable (asymptomatic), 
according to the BACR (2006) criteria. The patients were supported by medication (β-blockers, 
nitrates, aspirin, statins), and they were free from lower limb injuries, musculoskeletal or 
neurological disorders, illness or post-operative limitations. The descriptive characteristics and 
baseline measurements of the patients are presented below (see table 4.1). 
Patients were briefed verbally and in writing on the procedure, and they gave written informed 
consent. The study was approved by the Ethics Committee of the University of Essex and 
conformed to the declaration of Helsinki (World Medical Association 2009) guidelines for 
research with human participants. Criteria for exclusion from the study included lower limb 
injuries, neurological disorders, illness or post-operative limitations, all of which could affect 
gait. The patients continued taking their medication throughout the study. The study took place 




Table 4.1. Descriptive characteristics and baseline measurements of participants 
Clinical characteristics and baseline 
measurements 
Values 
Number of patients 16 
Age   (years)  (mean ± SD)  69.1 ± 7.0 
Sex  (%) Males= 9 (56%) – Females=7 (44%) 
Body mass  (kg)   (mean ± SD)  81.7 ± 10.94  
Stature     (cm)  (mean ± SD)  
                Median value  (25
th
 percentile)  
                Median value  (75
th percentile) 
167 ± 10  
162  
176  
BMI   (kg·m
-2
)  (mean ± SD)  29.3 ± 3.7  
Leg Length   (cm)   88 ± 8  
Medical History/Reason for joining CR  
MI 
Stable Angina                                                              
Surgical procedure (CABG, PCI)                                                                                                                    
Heart Failure      
Arrhythmias                                               
  
n=2   (13%) 
n=5   (31%) 
n=11 (69%) 
n=2   (13%)                                                
n=2   (13%)                                                                                                                                                                
Medication 
         β-blockers 
         Nitrates 
         Aspirin  
         Statin  
         Other 
 
n=10 (63%)  
n=4  (25%) 
n=7  (44%)  
n=4  (25%)  
n=5  (31%) 
Definition of abbreviations: BMI=body mass index; MI=myocardial infarction; CABG=coronary artery 
bypass graft; PCI=percutaneous coronary intervention 
4.2.2.  Protocol 
All patients were assessed twice, with eight weeks between assessments; during this period they 
continued to attend phase IV CR. Each of the patients performed both the balance test and the 
modified shuttle walking test (MSWT), as described below. In order to ensure consistency, each 
patient was given a primary assessment prior to testing, which required them to fill in a Pre-
Exercise Health Questionnaire; this was followed by an interview on their medical, 




4.2.2.1.  Anthropometric Assessment 
First anthropometric measurements were taken including: stature, body mass and leg length. 
Stature was recorded using a stadiometer (Seca 240 stature measuring rod) and body mass was 
recorded with a weight scale (Seca 888 Class III Floor Scale) without shoes. From these 




). Waist circumference was 
measured at the level of the natural waist (the narrowest place between ribs and the iliac crest 
[Lohman et al., 1988]). Leg length was recorded by assessing the distance between anterior 
superior iliac spine and the medial malleolus, as shown in figure 4.2 (Hof 1996). There is an 
equation to estimate stature from leg length; both stature and leg length were, however, 
measured to provide more accurate results.  
 
 




4.2.2.2.  Balance test 
In order to assess the stability status for each patient in the sample, static body sway tests with 
eyes open and eyes closed were performed before the MSWT test. These evaluated the visual 
effect on balance control and followed standard practice for balance testing. 
The balance test was performed on a Kistler piezoelectric force plate (Kistler 9281C, Kistler 
Instruments AG, Winterthur, Switzerland). Data were collected for 30 seconds, using a 
frequency of 50 Hz. The patients were advised to stand comfortably on the force plate with both 
feet within the plate’s boundaries and their arms held loosely by their sides. They wore their own 
shoes. Two types of visual input (eyes open and eyes closed) were used to activate different 
sensory conditions. When the patients stood with their eyes open, they were advised to look at a 
spot placed in front of them at eye level (Karlsson and Frykberg 2000). The balance test was 
used only once, before the second assessment.  
There are several methods available for assessing postural balance. Here, a decision was taken to 
estimate postural balance by calculating the standard deviations of the centre of pressure, x-y, 
during the balance test with eyes open and eyes closed respectively, because this method is 
reliable, valid and frequently used in clinical practice (Middleton et al., 1999; Era et al., 2006). 
Bioware Software (version 3.21, Kistler Instrument Corporation) was used for the data 
uploading.  
4.2.2.3.  Modified shuttle walking test procedure 
In this study, the shuttle walking test was modified slightly, so that the patients walked in an 
anticlockwise direction (see figure. 4.3). The MSWT was performed by each patient, as 





Figure 4.3.  Diagram of the modified shuttle walking test - Turn in an anticlockwise direction 
During the test, the number of steps taken in every shuttle was recorded. Step length was 
estimated by dividing the length of the course (nine metres – the straight portion of the course) 
by the number of steps in each shuttle (Hof 1996).  
4.2.2.4.  Turning: force plate data 
A piezoelectric force plate (Kistler 9281C, Kistler Instruments AG, Winterthur, Switzerland) 
was used to record the peak braking force (Fy) and the total vertical impulse (Iz) at the end of the 
10 m walkway. The vertical impulse gives an indication of support during gait (Seeley et al., 
2008) and turning (Strike and Taylor 2009). Horizontal ground reaction force (GRF) data were 










frame with the centre of mass (determined from the kinematic data) body reference frame 
(Glaister et al., 2007). The force plate was positioned at the end of the 10 m walkway and was 
set to work at a frequency of 500 Hz for periods of 5 seconds. Fy was defined as the minimum 
recording of the Fy curve, where Iz was the area under the vertical force (Fz) curve (see figure 
4.4). The data were recorded on a computer connected to the force plate. Bioware (version: 3.21, 
Kistler Instrument Corp.) software was used for the force plate data recording.  
 
Figure 4.4.  Illustration of raw Iz (area between the blue line and the zero) and peak raw peak Fy 
(green line) 
 
Patients were asked to walk freely along the 10 m walkway and to turn on the flush-mounted 
force plate. To ensure that the data were not affected by changes, patients requested not to alter 
their gait. Three satisfactory measures (first, middle and last shuttle) were collected at each speed 
(see table 4.2). Satisfactory measures were those which recorded only clean, full foot strikes. 
Any footfalls that fell outside the boundaries of the plate or data resulting from double support 
were ignored (Kirtley 2006) (see figure 4.5).  
 




Levels o of shuttles Shuttles recorded 
1 3 1, 3 
2 4 2, 4 
3 5 2, 4 
4 6 1, 3, 5 
5 7 1, 3, 5, 7 
6 8 2, 4, 6, 8 
7 9 2, 4, 6, 8 
8 10 1, 3, 5, 7, 9 
9 11 1, 3, 5, 7, 9, 11 
10 12 2, 4, 6, 8, 10, 12 
11 13 2, 4, 6, 8, 10, 12 
12 14 1, 3, 5, 7, 9, 11, 13 
13 15 1, 3, 5, 7, 9, 11, 13, 15 
14 16 2, 4, 6, 8, 10, 12, 14, 16 
15 17 2, 4, 6, 8, 10, 12, 14, 16 
 
 
                       Figure 4.5.  Clean full step on the force plate (Kirtley 2006) 
 
4.2.2.5.  Video recording 
Every turn on the plate was recorded with a Sony CCD-TRV20E camera, mounted on a tripod, 
level with the force plate. From the video data, the turning style, the turning time, and the 




Two turning strategies were used to interpret the turning style of the patients – the step turn and 
the spin turn. As mentioned in the introduction, turning strategies are differentiated by the leg 
that the participant uses in front for braking. In the step turn, patients used the right foot in front, 
in order to turn left; while in spin turns, the patient had the left foot in front and turned left by 
spinning the body around the left leg (Hase and Stein 1999).  
Turning time and number of steps used for turning were recorded one step before turning, from 
either foot heel strike, until the end of the turn. ‘End of the turn’ was defined as the first heel 
strike with all toes, pelvis and thorax facing the hallway directly opposite the cone (Hase and 
Stein 1999). The software used for the video analysis was SiliconCoach Pro (version 6.1.5.0, 
SiliconCoach Ltd, New Zealand).  
4.2.2.6.  Data processing  
Prior to the analysis, step length was normalised to leg length by dividing step length by leg 
length, to control its influence on step length (Hof et al., 1983). Ground reaction force data were 
averaged (Fy and Iz) across the three satisfactory trials for each speed, and then they were 
converted to dimensionless quantities in order to remove the effect of body size. Peak braking 
force (Fy) was divided by body mass, and the vertical impulse (Iz) was divided by the sum of 
body mass and the square root of l/g, where g is the acceleration due to gravity (g=9.81 m·s
-1
) 
and l is leg length (Kirtley 2006; Seeley et al., 2008).  
4.2.2.7.  Variables used 
The independent variables were divided into three categories: static variables (age, stature, leg 
length), dynamic variables (step length, braking force –Fy, total vertical impulse -Iz, number of 




normalised to leg length). The dynamic variables and normalized dynamic variables were 




, penultimate and final levels of the test, in order that the analysis 





, antepenultimate and the last level of the test (see table 4.3). 
Dependent variables were the maximum walking speed achieved and the total distance covered 
(MSWD). Braking force (Fy) and total vertical impulse (Iz) were normalised as described, prior 
to performing the analysis. 
Table 4.3.  Variables used in the study 
Static variables Dynamic variables ormalized dynamic variables 
Age Step length Step length normalized to leg length  
Stature Balance  
Leg Length Braking force (Fy)  
 Total Vertical impulse (Iz)  
 Number of steps needed to turn  
 Turning time  
 Turning style  
4.2.3.  Statistical analysis  
Data were presented as means and standard deviations. The median value of stature was also 






 percentile of the 
distribution).  
Differences between the two MSWTs were evaluated using the paired-samples t-test. The paired-
samples t-test examined the difference between the two balance tests. Relationships and 
statistical significance for each of the variables measured during the two tests were evaluated 




low participant numbers (n=16). According to Tabachnick and Fidell (2007), a sample of n≥138 
patients (n>50+[8×m], where m=number of independent variables used) would actually be 
needed.  
After determining which variables were most strongly related to test performance, stepwise 
linear regression analysis was performed. The stepwise model was chosen in favour of other 
models because the objective was to identify the lowest number of variables that influenced the 
test results most greatly. Two stepwise models were used: model one contained all the 
independent variables, which show at least some correlation with performance (r>0.3); 
(regression analyses were performed separately for each of the trials). To establish a clinically 
useful equation, a second regression analysis was performed, containing only variables that were 
both strongly correlated with performance and routinely recorded in CR. Colinearity diagnostics 
were performed for all predictor variables (Meyers et al., 2006). The lower limit of normal 
(LLN) in MSWT performance was determined by using the lower 5
th
 percentile of a normal 
distribution (Pellegrino et al., 2005).   
Statistical analysis was performed using SPSS version 16.0 (SPSS inc., Chicago, IL, US), 
whereas calculations were carried out in Microsoft Office Excel 2003 (Microsoft Corporation, 
Washington, US). The statistical significance was set at level 0.05.  
 
 
4.3.  Results 




Table 4.4 provides descriptive values for the measurements of the two assessments, made eight 
weeks apart during phase IV CR using the MSWT as an assessment tool. None of the patients 
completed the 15-level protocol MSWT (1500 m). The MSWD ranged from 210 to 750 m. The 
MSWD and the maximal walking speed that was achieved at termination of the test were used to 
prescript the MSWT score. In this study, the mean MSWD was 479 (±139) m in trial 1, and 499 
(±138) m in trial 2; the mean maximal walking speed was 1.65 (±0.23) m·sec
-1





No significant difference was observed in the MSWT score (MSWD, maximal walking 
speed) between the two assessments
 
(p>0.05).  
The only variable that showed significant differences between trials was the step length. Step 




 stages but not at the penultimate 




 Table 4.4.   Modified shuttle walking test: Comparison of the two trials (trial 1 vs. trial 2)   
trial 1           trial 2  





Maximum walking speed (m·sec
-1
) 13 1.65 0.23 16 1.65 0.25 <0.001 1.000 
MSWD (m) 13 479 139 16 499 138 -1.8 0.092 
Balance eyes opened to eyes closed  0 - - 11 0.0051 0.0022 - - 
Balance -eyes closed- 0 - - 11 0.0065 0.0024 - - 
1/3
rd
 of maximal level         
No of Steps to turn  11 4.27 0.47 16 0.41 0.2 0.335 0.221 
Turning time (sec) 11 2.7 0.63 16 2.5 0.28 1.33 0.212 
Step length (m) 16 0.61 0.078 16 0.70 0.079 -4.75 <0.001 
Normalized Step length  16 0.69 0.069 16 0.79 0.067 -4.36 0.001 
Fy (N/kg) 10 -1.66 0.45 14 -1.95 0.42 2.15 0.064 
Iz (1/3 of total test) 10 6.52 0.85 15 6.51 0.77 0.067 0.948 
2/3
rd
 of maximal level         
No of Steps to turn  9 4 0 16 3.9 0.17 1 0.347 
Turning time (sec) 9 2.26 0.37 16 2.24 0.21 0.148 0.886 
Step length (m) 15 0.72 0.11 16 0.76 0.095 -3.029 0.009 
Normalized Step length  15 0.81 0.078 16 0.86 0.066 -3.14 0.007 
Fy (N/kg) 9 -2.69 0.65 15 -2.56 0.42 -0.69 0.51 
Iz  9 6.04 0.84 15 5.55 0.68 1.19 0.268 
Penultimate level         
No of Steps to turn 12 4.08 0.29 16 3.84 0.28 2 0.07 
Turning time (sec) 12 1.82 0.43 16 1.91 0.23 -0.825 0.427 
Step length (m) 16 0.77 0.14 16 0.8 1.12 -1.78 0.096 
Normalized Step length 16 0.87 0.11 16 0.90 0.082 1.33 0.208 
Fy (penultimate level) (N/kg) 13 -2.98 0.68 15 -3.17 0.63 1.083 0.302 
Iz (penultimate level) 13 5.23 1 15 5.08 0.41 0.449 0.662 
Maximal level         
No of Steps to turn 10 4.05 0.16 16 3.87 0.43 1.15 0.279 
Turning time (sec) 11 1.7 0.23 16 1.8 0.25 -1.068 0.311 
Step length (m) 16 0.77 0.17 16 0.82 0.13 -1.4 0.175 
Normalized Step length 16 0.87 0.14 16 0.92 0.09 -1.51 0.153 
Fy (maximal level) (N/kg) 10 -3.3 1.02 15 -3.8 0.95 1.27 0.237 
Iz (maximal level) 11 4.63 0.55 15 4.8 0.59 -0.775 0.456 




4.3.2.  Correlations 
Due to the exploratory nature of this chapter, this section only discusses those statistical findings 
that are particularly noteworthy (that is, they show statistical significance). This is because a 
large number of potential variables were examined, meaning that the initial correlation analysis 
output was rather large.  
4.3.2.1.  Correlations for step length      
Patients’ stature and leg length were correlated with their step length at all stages of the test. The 
correlations tended to increase from the 1/3
rd
 level of the total test to the penultimate level, where 
they were strongest for both variables in both trials. In general, the correlations were also slightly 
stronger in trial 2 compared with trial 1 (see table 4.5). When the step length was normalised for 







Table 4.5.   Correlations for the “step length” variable in the two trials 
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Step length-Leg length 16 0.824 <0.001  16 0.812 <0.001 
Step length-Number of steps to turn 11 NS NS  16 -0.541 0.03 
 
Penultimate level 

















Step length-Leg length 16 0.78 <0.001  16 0.781 <0.001 




4.3.2.2.  Correlations for turning  
Turning was evaluated by recording the number of steps that the patients needed to turn and the 
turning time. Correlations between turning variables and other biomechanical measures were 
mainly found in trial 2. Significant associations were found between the number of steps that the 
patients needed to turn and turning time at the penultimate level of the MSWT.  
3umbers of steps needed to turn 
The number of steps required for turning correlated significantly with braking force at the 
penultimate level, while the number of steps required for turning was found to have a negative 
association with the patient’s stature and leg length at the 2/3
rd
 level of the total test and at the 
penultimate level respectively (see table 4.6).  
Turning time 
Braking force and total vertical impulse were correlated with the time that the patients needed to 
turn at the initial and last levels of the test. Patient’s posture was associated significantly with 
turning time at the penultimate level of the test (see table 4.7).  
Preferred turning strategy 




 stages of the test, while they 
used a spin turn at the penultimate and maximal level where the walking speed increased, which 
resulted in a step length increase and the ‘other’ foot landing on the plate, resulting in a spin turn. 
Furthermore, it was noted that most of the patients carried out a step turn if they were starting the 
turn with their right foot, and a spin turn if they were using their left foot. Thirteen of the patients 
used the step turn as the dominant strategy. However, in terms of performance, no difference was 





Definition of abbreviations: MSWT=modified shuttle walking test; Fy=braking force;  Iz= vertical impulse; 3S=non significant 
 
Definition of abbreviations: MSWT=modified shuttle walking test; Fy=braking force; Iz= vertical impulse; 3S=non significant 
Table 4.6.   Correlations for the “number of steps” variable in the two trials 





 Pearson r P value   Pearson r P value 
2/3
rd
 of total test No of Steps to turn-Stature 9 NS NS  16 -0.607 0. 013 
 













No of Steps to turn- Fy 11 NS NS  15 0.577 0.024 
 
Penultimate level 
No of Steps to turn- Step length 12 NS NS  16 -0.541 0.03 
Table 4.7.  Correlations for the “turning time” variable in the two trials 







 Pearson r P value   Pearson r P value 
Turning Time-Fy 10 NS NS  14 0.648 0.012 1/3
rd
 of total test 
Turning Time-Iz 10 0.64 0.046  15 0.603 0.017 
 

















 Turning Time-Fy 11 NS NS  15 0.561 0.03 




4.3.2.3.  Correlations for balance  
Static balance was measured only in the second assessment (trial 2) and did not show any 
significant correlation with any of the other variables. Moreover, balance did not correlate 
significantly with age (see table 4.8).  
Definition of abbreviations: 3S=non significant 
4.3.2.4.  Correlations for test performance (modified shuttle walking distance) 
The predictors of test performance were divided, as noted, into three groups: static measures, 
dynamic measures and normalized dynamic variables. Measurements of the lower extremities 
taken during physical examination were referred to as static measurements, while biomechanical 
measurements recorded during gait analysis were referred to as dynamic variables (McMulkin et 
al., 2000).  
Static measurements  
The static measurements, stature and leg length, were the ones that correlated with test 
performance in both of the trials (see table 4.10).  
 
Table 4.8.  Correlations for the “balance” variable in the second assessment 
                                  Trial 2 
 
Variables 
 Pearson r P value 
 






















Dynamic measurements and normalized dynamic measurements 
Dynamic measurements and normalized dynamic measurements– step length, Fy and Iz, and 
number of steps taken to turn – were the only ones that showed a significant correlation with 
MSWT performance. In particular, step length and step length normalised to leg length were 
both significantly associated with the MSWT score at all stages of the test. The associations 
tended to decrease from the 1/3
rd
 level of the total test to the penultimate level in trial 1. Total 




 levels of the total test 
in the second assessment, while braking force was found to have a negative association with the 
trial 2 score at the penultimate level. The number of steps taken when turning correlated 
negatively at the 2/3
rd





Table 4.9.  Correlations between gait and anthropometric parameters and modified shuttle walking distance in the two trials, in phase IV cardiac 
rehabilitation 
 
                 trial 1 
     





 Pearson  
R 




MSWD – Stature 16 0.741 0.001  16 0.688 0.003 
MSWD - Leg length 16 0.808 <0.001  16 0.762 0.001 
 
MSWD - Age  16 0.051 0.852  16 -0.016 0.954 
MSWD - Step length 15 0.826 <0.001  16 0.563 0.023 1/3
rd
 of total test 
MSWD – Iz 10 NS NS  15 0.526 0.044 
 













MSWD - Step length 15 0.826 <0.001  16 0.826 <0.001 




  of total test  
MSWD – Iz 9 NS NS  15 0.708 0.003 
 













MSWD - Step length normalized 16 0.512 0.042  16 0.574 0.020 
 
Penultimate level 
MSWD – Fy 13 NS NS  15 -0.632 0.012 
 















 MSWD - Step length normalized 16 0.471 NS (0.065)  16 0.535 0.033 




4.3.3.  Multiple linear regression analysis 
Stepwise linear regression analysis was used to assess the ability of selected variables to predict 
patients’ MSWT performance. The variables selected for this analysis were significantly 
correlated (r>0.3) with test performance (MSWD and maximal walking speed) (Pallant 2007). 
Walking speed seems the obvious measure by which to evaluate functional capacity and has 
been used to describe MSWT performance. Previous MSWT studies report only MSWD (Fowler 
et al., 2005; Campo et al., 2006; Jolly et al., 2008), this metric was, therefore, used to analyse the 
biomechanical predictors of the MSWT, for comparability. 
The regression used only those independent variables for which the coefficient correlation with 
the other independent variables was less than 0.75, in order to minimise multicollinearity and 
avoid high correlation between the variables (Meyers et al., 2006). The probability of F for entry 
was set at 0.05 and for removal at 0.1; these counted as the statistical criteria that the dependent 
variables needed to attain in order to be included in the analysis.  
4.3.3.1.  Prediction of test performance  
Trial 1 
Using MSWD as the dependent variable, the only variables that met the assumptions described 




, penultimate and maximal levels of the test) and step 
length normalised to leg length (at the 2/3
rd
, penultimate and maximal levels of the test). 
Ultimately, however, stepwise analysis included only step length at the 2/3
rd
 stage of the whole 
test, since this was the only variable that met the statistical criteria for inclusion. In this model, 
68.3% of MSWD was explained by step length at the 2/3
rd




standard error of 74 m on the estimation. The coefficient (β value) was found to be 997.1 m. The 
intercept value (A) was -230.6 m.  
Trial 2 





penultimate and maximal levels of the test), number of steps to turn (2/3
rd
 stage of the whole 
test), normalised step length (2/3
rd





stages of the test) and Fy (at the penultimate level). Ultimately, however, the stepwise analysis 
only included step length (at the 2/3
rd
 stage of the whole test) since this was the only variable to 
meet the statistical criteria for inclusion. In this model, 68.2% of MSWD was explained by step 
length at the 2/3
rd
 stage of the test, with a standard error of 85.37 m. The β value was 1203.9. 
The intercept value (A) was -415.7.  
4.3.3.2.  Validating predictors of modified shuttle walking test performance  
Stepwise regression analysis indicated that step length at the 2/3
rd
 level of maximal test 
performance was the best predictive measure for performance, followed by stature, in both trials.  
As step length is a dynamic measure, it is probably not practical to measure this in routine 
clinical assessment. In order to measure step length, a practice MSWT would be neccesary and 
the relatively complex procedures outlined here would need to be followed. The variable next 
most highly correlated with performance in regression analysis was stature. Regression analysis 
was repeated using only stature to predict performance; data from trial 1 were used (see equation 
4.1a). This model explained 55% of the variation in performance.  
The accuracy of the prediction equation was assessed by predicting performance in trial 2. The 




predicted value on the dependent variables (the predicted MSWD in metres), A is the Y intercept 
(the value Y when the X value is zero), X indicates the rate of the independent variable (stature) 
and B are the coefficients assigned to each of the independent variables in the regression 
analysis. Y value can be predicted for each patient, as the patient’s own X values were entered 
(Tabachnick and Fidell 2007).  
Actual MSWD showed a high correlation with predicted MSWD (Pearson’s r=0.69, p=0.003) 
when stature was entered into the equation model. Predicted MSWD was computed by using the 
equation form for each individual. The 5
th
 percentile of MSWT performance distribution of trial 
1 was 200 m, so the lower limit of normal range (LLN) was computed by subtracting 200 m 
from the equation (see equation 4.1b).  
Equation 4.1a. MSWD = (10.7 × stature, cm) – 1316 
Equation 4.1b.  MSWD(LLN)  = (10.7 × stature, cm) – 1116                                                                        
where: MSWD=distance walked in modified shuttle walk test (m); LL3=lower limit of normal range 
4.4.  Discussion   
The SWT is used in the evaluation of the majority of remaining CVD populations, while it 
includes a number of biomechanical parameters that might influence SWT performance. Many 
researchers have used the 10 m SWT to gain information on potential deficiencies in the 
locomotor system (Bradley et al., 1999; MacSween et al., 2001; Chown et al., 2008). There is no 
way, however, to determine whether biomechanical predictors (anthropometric features, balance 
and turning characteristics, for instance) affect SWT results. This study aimed to investigate 
which biomechanical predictors affect the MSWT score, how they are associated with test 
performance and how these findings can be used in clinical CR practice. As far as it has been 
possible to ascertain, the present study is the first to examine the biomechanical predictors and 




The findings of this chapter will be subdivided and each subsection will discuss individual 
predictors of; step length, turning and test performance. Finally, this section will present and 
justify the biomechanical variables that can predict MSWT performance and discuss the 
importance of this finding for the clinical CVD population will be analysed.  
4.4.1.  Biomechanical predictors of the modified shuttle walking test  
In order to assess the influence of these variables on the MSWT, a series of correlations was 
initially tested between various biomechanics variables and the MSWT outcome measures of 
distance walked (MSWD) and maximum walking speed. Total distance covered and maximal 
walking speed constituted the test’s score, whereas static (stature, leg length, balance) and 
dynamic (number of steps to turn, turning time, turning strategy) biomechanical measures were 
studied for their association with the MSWT performance.  
Walking speed is the obvious measure for MSWT performance; MSWD was used to analyse the 
test’s biomechanical predictors, and this will be further examined in this discussion. This is 
because previous SWT studies used the distance walked to describe SWT performance (Fowler 
et al., 2005; Campo et al., 2006; Jolly et al., 2008), which is probably due to its use in self-
pacing 6-MWT. Also, MSWD refers to real numbers, is more tangible and shows improvement 
in patients. Thus, MSWD was used as the outcome performance measure for reasons of 
comparability. The following sections will follow the division given in the results section and 
will discuss the predictors of step length, turning and test performance (MSWD).  
4.4.1.1.  Step length associations 
Unsurprisingly, stature and leg length were associated with step length at all levels of the MSWT 




would express a linear relationship with step length (Owings and Grabiner 2004). Murray et al. 
(1964) reported that while walking short people have the shortest stride and tall people have the 
longest; however, the relationship between people’s stature and walking speed remains ill-
defined and thus it will be discussed in the following subsections according to the findings of 
this research.  
4.4.1.2.  Turning associations 
The nature of the MSWT protocol means that it is not simply a walking test. It involves turning 
every 10 m during the test. Turning might also, therefore predict of MSWD. At faster walking 
speeds, the number of steps required for turning was significantly correlated with turning time 
and braking force (Fy); while turning time was significantly correlated with both braking force 
(Fy) and total vertical impulse (Iz). This means that as the number of steps taken for turning 
increases, more time is required to complete the turn. Thus, greater deceleration and acceleration 
forces are being produced to maintain stability and turn the body to continue with the walking 
task.  
Turning variables, such as number of steps and turning time, were correlated throughout the test 
with anthropometric characteristics, including stature and step length, suggesting that taller 
people tend to have longer step lengths and thus need less steps to complete a turn. Taller people 
are perhaps able to cope better with the increase in speed needed in the latter stages of the test 
than those with shorter step lengths. Turning speed seems to follow walking speed, which was 
controlled by the test, and on the later levels of the test, taller patients spent less time and took 
fewer steps to turn. 
Turning strategy did not seem to be change at different test levels and the different required 




they used a spin turn for the last levels. That is, when walking speed was increased. Thus, the 
‘other’ foot will land on the plate and a spin turn will be used in order to turn quickly, rather than 
an extra step taken to ensure a step turn. In general, though, the step turn strategy was observed 
more often during the MSWTs.  
In the present study, and in common with the results of previous studies (Hase and Stein 1999; 
Akram et al., 2010), the step turn was preferred by the elderly participants, as it is simpler, 
biomechanically less demanding and a more stable strategy compared to the spin turn. Step turns 
are characterised by greater muscle activation and better deceleration control before turning. 
Taylor et al. (2005) used a three-dimensional analysis to compare the two turning strategies. 
They concluded that participants used the step turn strategy more often, as it is simpler, less 
demanding on the muscles, provides a greater base of support, greater safety and stability.  
In this study, the turns were standard and planned; the patients were advised to turn to the left at 
the end of the 10 m walkway. In previous studies (Hase and Stein 1999; Taylor et al., 2005), 
where both turning directions (right and/or left) were used, the direction of turning does not, 
however, seem to play an important role in the results.  
4.4.1.3.  Predictors of test performance (modified shuttle walking distance) 
Three categories of potential MSWT predictors were examined in the present study; turning 
parameters, balance and finally anthropometric characteristics. These are described below.  
4.4.1.3.1.  Effect of turning on walking test performance 
The recording of turning parameters has been used as an assessment of mobility (Imms and 
Edholm 1981). The results of the present study showed that turning variables are not associated 




and the time taken to complete functional tasks in participants with different pathologies (post-
stroke, post-myocardial infarction or weakness associated with chronological age). The authors 
divided the participants into subgroups based on their activity level, but the absence of a control 
group (such as young adults with normal gait and mobility, or adults who exercise regularly) 
with which results can be compared is a limitation in this study.  
Van Herk et al. (1998) found that patients with mobility disorders (post-stroke) require more 
time to complete a turning task than a straight walking task. However, the walking speed varied 
considerably between conditions: some patients required less time to complete the turning task 
than the straight walking task. This might be explained by the different daily activities of each 
patient, or by the different psychological effects that each of the test conditions may create. The 
sample of patients in the present study consisted of cardiac patients with normal gait who 
exercised regularly for long periods of time. The turning issue seems only to affect pathologies 
that include mobility disorders. Thus, it is logical that these findings did not show any significant 
correlation with turning, because the present sample was free from locomotor limitations. The 
present results are in agreement with previous data (Beaumont et al., 1985), which demonstrated 
that the 12-minute walking test performance does not relate to turning in pulmonary patients. 
This study used two different walkways (a hospital corridor with a turning, and a flat treadmill).  
Studies in the literature have compared functional walking tests (such as the 6-MWT, the twelve-
minute walking test and the SWT) performed along a corridor and on a treadmill (Swerts et al., 
1990; Revill et al., 1999; Stevens et al., 1999). Two studies found that patients reached higher 
scores when they had to walk along a corridor rather than on a treadmill (Swerts et al., 1990; 
Stevens et al., 1999), while another showed the opposite (Revill et al., 1999). This significant 
variation in results might be due to the fact that some patients may be more familiar with 




factors, and according to the results of this research, it can be suggested that turning parameters 
are not related to MSWD in stable CR patients.  
4.4.1.3.2.  Effect of balance on walking test performance 
Different features of a task may increase or decrease posture stability, when balance is defined as 
the capacity of the body to control acceleration forces (Massion 1996; Huxham et al., 2001). 
During demanding movements, such as turning, increased acceleration forces affect the body in 
general, resulting in changes to biomechanical parameters. During turning, the body’s centre of 
mass lies near the extreme of the base support for most of the task and therefore the body’s 
balance control system works to maintain the centre of mass as much as possible within the 
limits of base support, ensuring postural stability (Winter 1995; Huxham et al., 2001).  
Because of this, balance was assessed while patients stood silently with eyes open and with eyes 
closed. No statistically significant relationships were found between balance with turning 
variables (number of steps taken to turn, turning time) and MSWT score (maximal walking 
speed, total distance). Paquette et al. (2008) observed age-related changes in turning variables 
during the turn task in healthy adults. These authors also noted a reduction in walking speed 
during turning, and an increase in turning time and step length for older people, compared with 
young adults. They suggested that older people are more cautious about foot placement because 
of their impaired balance and locomotor abnormalities, preferring to use a hip strategy, 
especially during difficult tasks (where many biomechanical parameters are presented), such as 
turning. The patients in the present study, who were older people, seemed to use a similar (or the 
same) kinematic strategy; thus, no special skills in balance control are needed to achieve better 




Carpinella et al. (2007) compared patients with Parkinson’s disease with healthy elderly people 
and found that the former took more steps during the turning task and required more time to turn. 
In their protocol, patients had to walk straight for 2 m, reach the force plate, make a 90º turn and 
continue walking in the new direction for 2 more metres. It must be remembered, though, that 
Parkinson’s disease is a neurological disorder with special clinical features, causing disabilities 
in mobility, which cannot necessarily be compared with the effects of other diseases (such as 
cardiovascular and cardiopulmonary disease).  
The correlations between balance and biomechanical variables during turning (Fy, Iz) were also 
very weak at all levels of measurement. No significant interaction between balance and age was 
found. The present results agree with those of Shkuratova et al. (2004), who found no 
statistically significant relationships between age and turning parameters, although they did find 
that older people had a shortened stride and lower walking speed as compared with younger 
adults. Kang and Dingwell (2008) also arrive at the same result. Older people utilise a specific 
strategy (shorter step length and lower walking speed) in order to maintain their posture stability, 
especially during more demanding tasks.  
As noted by Huxham et al. (2001), the absence of any statistically significant correlation 
between balance and MSWT variables (including the biomechanical turning parameters) 
underlies the difficulty of balance assessment. Especially with samples such as those used in the 
present research, where patients were all members of a long-term follow-up training CR 
programme and are accustomed to exercise, the evaluation of balance and the selection of the 
most appropriate balance test to administer becomes more difficult.  
In addition, the present results did not show any significant difference between the two balance 




and postural stability decrease with age, that various pathologies accompany ageing (Hase and 
Stein 1999; Karlsson and Frykberg 2000), and that the sensory system (vision) is related to the 
balance and stability of the body (Lord and Menz 2000; Black et al., 2008; Friedrich et al., 
2008). The visual system is responsible for the proactive balance mechanism that is mostly 
utilised during active movement rather than in silent standing (Huxham et al., 2001). In 
removing visual help during standing, balance does not appear to be influenced to any great 
extent. 
Above all, the current study suggests that balance is not significantly related to MSWD. The 
present work used the static balance test, as is commonly used with elderly people; however, 
turning strategies require a dynamic balance. Several studies have shown that both static and 
dynamic clinical balance tasks are reliable and can identify the state of the balance control 
system (Heitmann et al., 1989; Allum et al., 2001; Gill et al., 2001).  
4.4.1.3.3.  Association of anthropometric and gait parameters with walking test     
performance 
In contrast with turning gait variables, several anthropometric characteristics (stature, leg length 
and step length) supported the hypothesis regarding predictors of MSWD. Step length 
throughout the test, particularly, was highly correlated with MSWD. This was true even when 
step length was normalised to leg length as the relation with walking distance remained 
significant. Corrected step length values were only correlated with MSWD during the latter test 
stages. 
At the beginning of the test, patients walked at an artificially slow pace; to do so they took small 
steps. Later on in the test, they felt more at ease and were able to walk as normal; they 




patients who were able to make longer steps managed to reach the markers on time; and, thus, 
they could continue to the next stage. Patients who took small steps during the latter test levels 
either voluntarily withdrew due to fatigue, or the experimentor stopped them, as they were 
unable to increase their speed and performed the shuttle on time. These patients, who managed to 
increase their step length at the later stages of the test, obtained better scores in the MSWT.  
Taller patients had longer step length and appeared better able to cope with the increases in 
walking speed needed at the later stages of the test. Shorter patients were less able to increase 
walking speed by increasing step length during latter test stages, resulted in poorer MSWD. This 
can be theoretically illustrated by calculating the Froude number for the MSWTs based on ± 1SD 
of the mean leg length. The Froude number (v
2
/gl; where v is velocity, g is gravitational 
acceleration and l is leg length) provides a dimensionless number which normalises walking 
speed to leg length (Steudel-Numbers and Weaver 2006). By calculating this number based on 
leg length we can see that tall patients walked at a lower Froude number as the shuttle speed 
(level) increased compared to short patients. Thus the taller patients were walking at a relatively 
lower proportion of their maximal velocity than short patients, and the walk to run transition 
speed (0.5 Froude) (Gatesy and Biewener 2009) occurred approximately one shuttle later. This 
model can also be used to predict maximal walking speed and again shows a bias toward the 
taller patient. Therefore taller patients, who could continue to increase step length at later stages 
of the test, were more able to obtain better scores in the test.  
This finding is partly in agreement with Imms and Eoholm (1981), who found that walking 
speed correlated very strongly with stature, leg length and step length. As the MSWT is 
incremental in nature, walking speed is always positively associated with distance walked (Singh 
et al., 1992). Hence, characteristics such as long step length and greater stature, which are 




speed is determined by variations of both step (stride) length and cadence. In the present study, 
cadence (number of steps per minute) was not recorded. Imms and Edholm (1981) noted that the 
variation of step length in their elderly population was greater than the variation in cadence. 
Thus, the increase in walking speed in the population of the present study may be due more to 
the changes in step length than to alterations of cadence. 
There was no difference in the MSWD between the two trials. Longer step length during the 
initial levels of the test was the only variable that was significantly different between trials. This 
may indicate some adaptation or learning response to the test protocol. Step length, however, 
correlated with MSWD in both trials. This demonstrates, once more, that cardiac patients who 
exercise regularly may need some time or more practice to walk in a normal way, especially at 
the first levels of the test, where the movement is not physically demanding. Walking at speeds 
slower than those preferred can lead to inefficient or ‘awkward’ gait patterns (Nymark et al., 
2005). Some patients may need a practice MSWT to adapt their gait speed (Fowler et al., 2005; 
Jolly et al., 2008), however it has been argued in Chapter 3 that these potential gait adaptations 
via a practice MSWT do not influence MSWD. 
4.4.1.3.4.  Which is the best predictor of modified shuttle walking test performance? 
Despite measuring a number of walking and turning gait parameters, only one gait parameter and 
two anthropometric characteristics predicted MSWD. Step length at 2/3
rd
 of individual maximal 
walking speed, stature and leg length were all independently associated with MSWD. Regression 
analysis showed that step length was the most important predictive value for MSWD, but that 
stature was also significantly correlated with MSWD. In routine clinical assessment, stature is 
easily assessed, as it is a static measure. Step length, however, is a changeable, dynamic 




amongst the elderly. This is because they display great variability in their step length during 
walking – a fact that has been attributed to their decreased muscular strength, especially in the 
leg muscles, resulting in frequent changes in step length during walking, and higher risks of falls 
(Brach et al., 2001; Kang and Dingwell 2008).  
Thus, it was decided that although step length is the best overall predictor of MSWD, a second 
stepwise linear regression analysis should be carried out, omitting step length. Given that step 
length is closely related to leg length and stature, a final regression analysis was performed, 
using only stature to predict MSWD. The use of stature as the predictor of MSWD has clinically 
utility, because it is easy to measure and is used in the calculation of BMI. 
This finding is in agreement with other studies, which have used only static variables (stature, 
age and body mass, or BMI) in their equation for predicting 6MWD in healthy adults (Enright 
and Sherrill 1998; Troosters et al., 1999; Gibbons et al., 2001; Enright et al., 2003; Camarri et 
al., 2006; Chetta et al., 2006; Poh et al., 2006; Jenkins et al., 2009). Particularly, Enright and 
Sherrill (1998) established predictive equations to estimate the expected distance walked in the 
6-MWT for healthy adults (see equation 4.2). Enright (2003) suggested that lower scores 
correlated significantly with factors such as shorter stature (shorter step length), participants 
being elderly, higher body mass, female sex, a shorter course distance (more turns), 
cardiopulmonary diseases and musculoskeletal disorders. Enright and Sherrill (1998), however, 
studied a healthy population and it needs revalidation in CVD patients, while the findings cannot 
be generalised from the 6-MWT to the MSWT. 
Equation 4.2.  Enright and Sherrill (1998) 
men: 6MWD = (7.57 × stature, cm) – (5.02 × age, yrs) – (1.76 ×  body mass, kg) – 309                    
women: 6MWD = (2.11 × stature, cm) –(5.78 ×  age, yrs) – (2.29 × body mass, kg) + 667 




In the present study, stature accounted for 55% of the variance in the MSWD. Each additional 1 
cm of stature predicts that patients will complete an additional shuttle during the test. The mean 
stature for women (n=7) and men (n=9) in the present study were 159 cm and 174 cm 
respectively. Using the prediction equation generated here, in a population with similar clinical 
characteristics to the present sample, it could be suggested that male CVD patients can walk, on 
average, 160.5 metres more (i.e., 16–17 more shuttles) in the MSWT than women, due to stature 
differences between the two sexes.  
It appears obvious that taller cardiac patients have an advantage over shorter patients when 
performing an MSWT. In CR programmes, patients usually present with a number of co-
morbidities. CVD patients often prefer to walk slowly, while it is not very easy for them to speed 
up, even though they are fit. The MSWT is an incremental test, which increases in speed 
gradually at each level. During the later levels, the speed gets quite fast, allowing to the patients 
to run if they are able to do so. The findings show that taller people benefit more in contrast with 
shorter ones, as the former are able to obtain longer strides and complete the shuttle. According 
to phenomenon of regression towards to the mean suggestion, CVD patients who are high 
performers >610 m (75
th
 percentile) can only improve marginally, whereas low performers <370 
m (25
th
 percentile) can improve much more. This phenomenon, in combination with these 
results, means that tall cardiac patients >176 cm (75
th
 percentile) are likely to improve their 
MSWD only slightly, in contrast with short patients <162 cm (25
th
 percentile), who can improve 
greatly after a particular intervention (for example, with CR in the form of exercise activities) 
(Ostermann et al., 2008).  
These findings indicate that the interpretation of MSWD is not accurate and the MSWT is unfair, 
without taking stature into account. For instance, if the MSWD is not corrected to stature, (i) 




intensity training in CR; (ii) while tall patients won’t be able to show real improvement in their 
functional capacity after an exercise intervention. Surprisingly, no one has ever examined the 
association of stature with MSWT in cardiac population.  
4.4.2.  Study limitations  
The application of the above findings might be limited by some methodological issues. One 
limitation of this study is the sample used, which was relatively small to demonstrate statistically 
significant relationships between weakly associated pairs of variables. This sample does, 
however, represent typical participants in a long-term CR programme. Moreover, as far as has 
been ascertained, no other study in the literature examines the biomechanical predictors for 
MSWT in the cardiac population. This study may serve as the basis for further studies with 
larger samples. Furthermore, the patients were all members of a long-term follow-up (phase IV) 
training CR programme and are accustomed to exercise. Less conditioned patients, such as those 
entering earlier phases of rehabilitation (phase III CR, UK classification) may demonstrate 
different associations between gait predictors and MSWD.  
Another limitation is the measurement of the balance test, which was conducted only once for 
eyes open and once for eyes closed. It might be more accurate to perform three measurements for 
each test, with periods of rest in between, so that the mean value can be used for the 
measurements. It remains problematic, however, to select an appropriate way of assessing the 
balance for patients who are accustomed to exercise.  
4.5.  Conclusion  
Previous research has attempted to demonstrate the usefulness of the MSWT in assessing 




mortality; however, the participants in these studies were patients with HF, meaning that their 
results cannot be generalised to all CVD patients. There are no existing data on biomechanical 
parameters that may affect patient’s MSWD. The MSWT is one of the most popular functional 
assessment tests for cardiac patients and it is important that these biomechanical parameters 
should be identified as they relate to the performance of this test. There are a few studies that 
have demonstrated that stature is associated with 6MWD, suggesting that taller people can walk 
further than shorter people, for the purposes of this test. The problem is that the study refers to 
healthy people and thus the results cannot be generalised for the CVD population.  
The findings of the present study are important with regard to clinical practice in CR. These data 
show that tall patients have an advantage in the MSWT and that practitioners should account for 
stature when interpreting MSWD. By interpreting distance as a percentage of the stature-
predicted value, practitioners would gain a more meaningful assessment of individual patient’s 
functional capacity on his/her admission to a CR programme. Adding this simple, predictor 
(stature) to the standard assessment of functional capacity may help clinicians to provide more 
realistic expectations and functional improvement targets after a treatment (such as CR). Such 
modified targets may also make prescribed exercise intensity more accurate and, therefore safe 
as well as allowing the CR patient to experience real success. 
These pilot data are the first to provide specific regression equations to estimate MSWD. While 
there is a clear need for a larger study to independently validate the present findings, these data 
may enhance the use of the MSWT as a prognostic tool in stable cardiovascular patients. This 
study has, however, potentially eliminated the need to further investigate certain gait parameters 
(turning variables, balance) which are time consuming and expensive. This small study may 
allow for a larger, more economical study to be conducted using the simple anthropometric 
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CHAPTER 5.  PREDICTORS OF THE SIX-MIUTE WALKIG TEST PERFORMACE I HEART 
FAILURE PATIETS  
5.0.  Abstract  
The six-minute walking test (6-MWT) is a simple, safe and inexpensive measure, used to 
evaluate functional capacity, effects of interventions and to provide prognosis in heart failure 
(HF) patients. The purpose of this research was to identify the routine, simple measures 
associated with 6-MWT performance and to establish a reference equation to predict 6-MWT 
performance.  
Seventy-one HF patients (82% males, 18% females, mean age: 76.3±8.6 years, mean body mass 
index: 28.7±5.1 kg·m
-2
), who were enrolled in a chronic disease assessment programme, 
completed the 6-MWT. Baseline clinical assessment took place prior to testing and included 
stature, body mass, body mass index, medical and pharmacological history, ventricular function 
and New York Heart Association (NYHA) functional class. Patients walked along a 15 m 
corridor between two cones for six minutes. Patients were allowed to rest if necessary. The 
number of steps taken in every 15 m shuttle was recorded, and step length was calculated. The 
total distance walked during the 6-MWT (6MWD) was used to indicate performance. The 
relationship between 6MWD and potential predictors was assessed using Pearson correlation and 
multiple stepwise regression analysis. Multinomial logistic regression was used to determine the 
factors associated with poor 6MWD (≤300 m). Threshold values were identified for dependent 
(total distance 300 m) and independent variables (age >/< 75; stature >/< 172 cm; body mass 
index >/< 25 kg· m
-2
; step length >/< 0.63 m; walking pace index >/< 50%; resting heart rate >/< 
80 beats·min
-1
; left ventricular ejection fraction >/< 45%). Odds ratios with 95% confidence 




The mean 6MWD was 319 (±126) m for males and 253 (±95) m for females. For males (n=58), 
significant correlations were observed between 6MWD, stature (r=0.254) and age (r=-0.376) for 
p<0.05. For females (n=13), significant correlations were observed between 6MWD and stature 
(Pearson’s r=0.598, p<0.05) only; age (Pearson’s r=-0.416, p=0.16) and body mass (Pearson’s 
r=0.366, p=0.218) were correlated moderately with 6MWD but not significantly. Univariate 
multinomial logistic regression analysis showed that body mass index >25 kg·m
-2
 (OR=12.7, 95% 
CI=1.45 – 111) and age >75 years (OR=4.9, 95% CI=1.24 – 19) were independent predictors of 
poor 6MWD (<300 m). Sex-specific regression equations using age and anthropometric data 
explained 40% and 52% of the variance in 6MWD in males and females, respectively. 
Clinical variables such as ventricular function were unrelated to 6MWD in HF patients. Age, 
stature, body mass index/or body mass were independent predictors of 6MWD; these should be 
taken into account when the test is used to assess HF patients’ functional capacity. These 
variables appear particularly important when 6MWD is used to categorise patients according to 
known prognostic cut-off points. 
5.1.  Introduction  
As discussed in Chapter 2 (see ‘Introduction to cardiovascular diseases and cardiac 
rehabilitation: a review in the literature’), heart failure (HF) is a major cause of death and 
hospitalization worldwide (Majeed et al., 2005; Papadopoulos et al. 2008; Levitan et al., 2009). 
The European Society for Cardiology (ESC) guidelines state that the prevalence of HF is between 
2% and 3% in the general population; this increases with age and reaches 10-20% by 70 to 80 
years old (Dickstein et al., 2008). In the UK, the prevalence of HF is 8.3 per 1000 population, 
increasing with age from 0.02% at the age of 35 years to 12.5% in those over 85 years old 




medical condition that affects a large part of the population, accounts for most hospital 
readmissions and relates to poor quality of life for these patients (Jaarsma et al., 1999; Hobbs et 
al., 2002). A serious, progressive disorder such as HF demands new investigations in the 
assessment, prognosis and treatment of the disease.  
5.1.1.  Heart failure: definition  
Heart failure may be caused by several disorders, resulting in loss or dysfunction of myocardial 
muscle tissue. HF is indicated as a syndrome when the left ventricle is unable to maintain cardiac 
output, meaning that the oxygen supply in the body is insufficient. According to SIGN (the 
Scottish Intercollegiate Guideline Network 2007) and ESC guidelines (Dickstein et al., 2008), HF 
is characterised as a syndrome having the following typical features:  
• breathlessness at rest or during exertion, fatigue, ankle swelling; 
• signs of fluid retention, such as tachycardia, tachypnoea, pulmonary congestion, oedema; 
• objective evidence of cardiac dysfunction at rest.  
In terms of clinical symptoms and cardiac function, HF is usually progressive (Heart Failure 
Society of America 2006).  
5.1.2.  Heart failure: classification  
There are many categorisations of HF. This is carried out according to either side of the heart 
involved, the symptoms and the degree of functional impairment. HF may affect one or both 
sides of the heart; being characterised as either left-sided (left ventricular dysfunction [LVD]) or 
right-sided HF (right ventricular dysfunction [RVD]). The effects of LVD, in which the left 
ventricle of the heart is functionally impaired, are insufficient blood supply to the systemic 
circulation, reduced left ventricular ejection fraction (LVEF), limited blood return into the 




SIGN 2007; Dickstein et al., 2008; Hunt et al., 2009). The signs of LVD are exertional 
dyspnoea, pulmonary oedema, short breath, cyanosis, cold skin and hypertension. RVD, in 
which the right ventricle of the heart is functionally impaired, is usually the result of advanced 
LVD. When the left ventricle fails to work properly, blood often returns back to the lungs, 
triggering pulmonary circulation disorders and thus RVD. The results of RVD are a variety of 
pathologies, like pneumonia, pulmonary embolism and acute right ventricular infarction (Hunt et 
al., 2005; Dickstein et al., 2008; Hunt et al., 2009).  
LVD may then be sub-divided into two further types: left ventricular systolic dysfunction and left 
ventricular diastolic dysfunction. Left-ventricular systolic dysfunction refers to a syndrome where 
the left ventricle is unable to contract enough to pump oxygen-rich blood into the systemic 
circulation; while in left ventricular diastolic dysfunction, the left ventricle loses the ability to fill 
with enough blood during the relaxation period between each beat. This often occurs due to 
increased left ventricle muscle stiffness or mitral valve damage.  
Clinicians usually assess HF severity using the NYHA functional classification system 
(American Heart Association 1994; Heart Failure Society of America 1999; Heart Failure Society 
of America 2006) (see table 5.1). This classification is based on symptoms observed during 
everyday activities.   
The European Society of Cardiology (ESC) guidelines (Dickstein et al., 2008) classify HF in 
relation to three categories, according to duration and the severity of the symptoms: a) new onset 
HF describes new symptoms; b) transient HF refers to recurrent symptomatic HF, and c) chronic 
heart failure describes persistent HF, which might be stable or might worsen, leading to hospital 





Table 5.1. YHA functional classification in patients with heart failure (AHA 1995; HFSA 1999, 
2006) 
Class  Severity according to symptoms and functional capacity 
Class I  
(Mild) 
Patients with cardiac disease who are able to do any physical activity without 
discomfort. Regular physical activity does not cause fatigue, palpitation or dyspnea.  
Class II 
(Mild) 
Patients with cardiac disease, but with slight limitation of physical activity. They feel 
comfortable at rest. Regular physical activity results in fatigue, palpitations, or dyspnea.  
Class III 
(Moderate) 
Patients with cardiac disease with marked limitation of physical activity. They feel 
comfortable at rest. Minimal physical activity causes fatigue, palpitation or dyspnea.  
Class IV 
(Severe) 
Patients with cardiac disease with inability to carry on any physical activity without 
discomfort. They have symptoms of cardiac insufficiency present at rest (angina 
symptoms). If any physical activity is undertaken, discomfort is increased. 
 
5.1.3.  Heart failure risk factors  
Hypertension and previous MI are the major risk factors for HF, increasing the likelihood of HF 
occurrence by 2 to 3 times (Gottdiener et al., 2000; He et al., 2001; Wilhelmsen et al., 2001; 
Abramson et al., 2001a, 2001b; Schocken et al., 2008). The Framingham Heart Study 
demonstrated that hypertension increases the risk for developing HF two-fold in men and three-
fold in women (Levy et al., 1996; Schocken et al., 2008). An increased systolic blood pressure 
and an increased HR predict HF development than an increased diastolic blood pressure (Haider 
et al., 2003). Hypertension promotes an increase in afterload, triggering abnormal myocyte cell 
growth (hypertrophy), myocardial fibrosis and loss of myocardial contractile function. All these 
parameters decrease the functional myocyte reserve myocardial blood flow and flow reserve 
(Gradman and Alfayoumi 2006; Schocken et al., 2008).  
Diabetes mellitus is an independent risk factor for HF, increasing the risk of HF development by 




Kenchaiah et al., 2004b; Schocken et al., 2008). Every 1-mmol·l
-1
 -higher fasting plasma glucose, 
creates a 1.1 fold increase in the risk of HF hospitalisation (Held et al., 2007).  
Obesity is an independent risk factor for HF, due to increased cardiac demand, preload and 
afterload, neurohormonal upregulation, sleep-disordered breathing and chronic kidney disease 
observed in obese patients (Kannel et al., 1974; He et al., 2001; Kenchaiah et al., 2002, 2004a, 
2004b). Obese people have double the risk of HF than normal-weight people (Kenchaiah et al., 
2004a; Schocken et al., 2008). Findings from the Framingham Heart Study showed that, for each 
unit increase in body mass index (BMI), there is a
 
5% increase in the risk of HF in men and 7% in 
women (Hubert et al., 1983). More recent studies demonstrate that normal-weight HF patients 
have a higher incidence of morbidity and mortality than obese HF patients (Curtis et al., 2005; 
Fonarow et al., 2007). This apparently paradoxical outcome may be due to unmeasured markers 
(such as plasma norepinephrine, brain natriuretic peptide concentrations) (Curtis et al., 2005) or 
increased catabolic stress that occurs in underweight or normal-weight HF patients (Fonarow et 
al., 2007). However, further investigation is needed on this topic to investigate the mechanisms 
by which a high BMI appeared to be protective against hospitalization and morbidity in HF 
patients.  
Several other risk factors associated with HF to a lesser extent than those listed above include: 
smoking, excessive alcohol consumption, dyslipidemia, sleep-disordered breathing, chronic 
kidney disease, albuminuria, C-reactive protein homocysteine, natriuretic peptides, anaemia, 
unhealthy dietary habits, increased heart rate (HR), low socioeconomic status, psychological 
stress and genetic factors (Schocken et al., 2008). The presence of these traditional risk factors 





The prevalence of HF increases with age. Particularly in women, the incidence of HF increases 
more than two-fold between 65 and 85 (Kannel et al., 1999; Kitzman et al., 2001; Levy et al., 
2002; Kenchaiah et al., 2004b). Men have an increased overall incidence of HF in contrast with 
women, because of their increased risk of CHD (Gottdiener et al., 2000; He et al., 2001; 
Wilhelmsen et al., 2001; Abramson et al., 2001a, 2001b; Schocken et al., 2008). 
5.1.4.  Prevention of heart failure  
Coronary heart disease constitutes the major cause of HF disease; due to atherosclerotic CHD, 
less blood is supplied to the heart, damaging the heart muscle and so the cardiac pump 
performance. Thus, the prevention of HF should be focused firstly on CHD prevention, via 
management of hypertension, dyslipidemia and diabetes (McKee et al., 1971; Gottdiener et al., 
2000; He et al., 2001).  
5.1.5.  Clinical assessment of patients presenting with heart failure 
Early diagnosis of HF is crucial for effective treatment (Lewis 1933). ESC 2008 guidelines and 
the updated ACC/AHA 2009 guidelines recognise that the information obtained from the patient 
interview and physical examination are usually the main tools for identifying the presence, 
aetiology and severity of HF. The interview assessment is based on clinical symptoms, signs and 
medical history. The physical examination includes assessment of body mass, stature, BMI 
calculation, pulse, orthostatic blood pressure, jugular venous distension, peripheral oedema, lung 
function (respiratory rate, rales, pleural effusion) and third and fourth heart sounds (Dickstein et 
al., 2008; Hunt et al., 2009).  
Laboratory tests are also used to identify the presence and level of the disorder. The most 




tests. Resting ECG is regarded as the gold standard in detecting left ventricular remodelling or 
hypertrophy, or previous myocardial infarction (Hunt et al., 2005; Dickstein et al., 2008). Atrial 
and ventricular arrhythmias are common findings in patients with HF (Wenger et al., 1990). 
Atrial fibrillation is usually prognostic marker for the severity of HF (Stevenson and Stevenson 
2004).  
An echocardiogram is an ultra-sound test, which measures the left ventricular size, volume, 
function and wall thickness. LVEF is one of the most commonly clinical parameter that is usually 
taken during an echocardiogram and is used to evaluate the left ventricular function. The ESC 
(2008) characterised an LVEF <45–50% as left ventricular systolic dysfunction. Also, left 
ventricular end-diastolic diameter (LVEDD) >55–60 mm, and left ventricular end-systolic 
diameter (LVESD) >45 mm refer to HF abnormality.  
A chest x-ray may also be used to detect cardiac enlargement, pulmonary congestion or pleural 
fluid accumulation. Blood tests, including serum electrolytes, blood glucose, liver function tests, 
lipid profile and thyroid function, are also commonly used in HF diagnosis (Hunt et al., 2005; 
Dickstein et al., 2008). Taken together, these tests provide useful information about heart muscle 
function. The NYHA classifications use functional capacity in their definition of HF, and one of 
the key observable features of the HF patient is low functional capacity. Because of this, there has 
been much scientific interest in assessing functional capacity in HF patients (Hunt et al., 2005).  
5.1.6.  Functional capacity assessment of patients presenting with heart failure 
Cardiac insufficiency due to HF means there is a decreased oxygen supply to the whole body, 
including the skeletal muscles. HF patients can present dyspnea, muscle fatigue and exercise 
intolerance. These symptoms usually affect the patient’s functional capacity. Functional capacity 




of the cardiovascular system to deliver oxygen into the muscle tissues. The assessment of 
functional capacity and cardiac (in)sufficiency can provide diagnostic and prognostic information 
about patients with suspected HF (Fleg et al., 2000).  
At the initial assessment, the patient is usually asked to describe activities that they would like to 
carry out but are not able to perform. Sometimes the clinician asks the patient to perform some 
specific tasks, like walking and climbing stairs. Many methods have been investigated to describe 
the functional limitation of HF patients. One of the most common is the NYHA functional 
classification, described above (Hunt et al., 2005). Both individually administered questionnaires 
and NYHA classification are unable to measure functional capacity accurately. However, both 
tests are based on the patient’s self-assessment, and because they cannot measure exercise 
tolerance accurately their accuracy in assessing the functional capacity of HF patients is also 
limited. 
Exercise testing of HF patients is a practical assessment tool for delivering a variety of outcome 
measures, which can be interpreted in many ways. The interpretation of exercise testing outcomes 
not only provides diagnostic and prognostic information about HF patients, but also shows 
responses to treatment and can assist in the selection of cardiac transplant candidates (Aaronson 
et al., 1997; Osada et al., 1998; Ramos-Barbon et al., 1999; Lewis et al., 2001). 
The gold standard assessment of the functional capacity test is typically a laboratory-based cycle 
ergometer, or treadmill exercise protocols, due to their ability to provide a direct and easy 
measurement of maximal functional capacity via expired gas analysis (maximal oxygen uptake 
[VO2max]) (Weber et al., 1982). Treadmill exercise appears to be more valid than the cycle test in 
determining VO2max in patients with HF. Cycle ergometer exercise typically results in a 10% 




smaller muscle mass during cycling (Page et al., 1994; Lainchbury and Richards 2002). 
Treadmill walking tests involve exercise with both upper and lower body muscles. HF patients 
reach higher levels of oxygen uptake during the treadmill test than during cycle ergometer test, 
which involves only the lower body muscles in exercise (Jondeau et al., 1992).  
As well as the practical differences between the two protocols (treadmill and cycle ergometry), 
both have some disadvantages that make them difficult to use in HF patients who typically 
presents with multiple disorders. Familiarisation with the equipment and the protocol are 
important in order for participants to satisfactorily perform these tests. Most HF patients are 
elderly and often not accustomed to cycling or treadmill walking. Often, such patients do not feel 
comfortable enough to exercise with a mask and a nose clip when the test is used for gas analysis, 
as well (Page et al., 1994; Lainchbury and Richards 2002). It should also be emphasised that 
maximal cardiopulmonary tests are not used frequently in patients with a severe disease, such as 
HF, as patients are often unable to cope with maximal effort tests (SEOSI Investigators 1997; 
Demers et al., 2001).  
For all these reasons, and others referred to in Chapter 3 (see ‘Long-term reliability of the 
modified shuttle walking test in clinically stable cardiovascular disease patients’), alternative, 
practical, inexpensive and simple functional capacity tests based on walking have been 
developed. The six-minute walking test (6-MWT) is one of the most used functional capacity 
assessment tests for HF patients. It has been tested for its reliability, validity, use in HF prognosis 




5.1.6.1.  Six-minute walking test  
5.1.6.1.1.  Development 
As mentioned in Chapters 3 and 4, the 6-MWT was originally developed by Guyatt et al. (1985a) 
and is a functional capacity sub-maximal test for patients with HF. This test has been used to 
assess patients with pulmonary diseases (Steele 1996; Redelmeier et al., 1997) and cardiovascular 
diseases patients (CVD) (Faggiano et al., 2004; De Feo et al., 2009). The 6-MWT is a functional 
capacity assessment test used for patients with severe cardiac dysfunction or who cannot be 
assessed with maximal exercise tests (such as treadmill or cycle ergometer tests) (Guyatt et al., 
1985a; Peeters and Mets 1996; Larsen et al., 2001). Such traditional maximal exercise assessment 
protocols may be difficult and uncomfortable (for the reasons referred to above) for elderly and 
severely limited patients, such those with HF (Guyatt et al., 1985a). 
During the original 6-MWT protocol, the participants are instructed to walk repeatedly shuttles of 
a 33 m course and to cover as much distance as possible in six minutes (Guyatt et al., 1985a). 
They are allowed to determine their own pace and are permitted short rest periods during the test 
if necessary. At the end of a 6-min period, the test is terminated, and the distance walked during 
the 6-MWT (6MWD) is calculated by the tester. A functional capacity test should, also, be both 
valid and reliable for appropriate use in clinical practice.  
5.1.6.1.2.  Six-minute walking test: validity, reliability and sensitivity  
Reliability and validity are two necessary features of any test of functional capacity. A third 
feature, linked to validity, is sensitivity, which is the ability of the test to detect changes in 




sensitive assessment of functional capacity in patients with HF. These studies are discussed 
below.  
Validity and reliability  
Zugck et al. (2000) evaluated the validity of the 6-MWT in patients with stable HF (n=113), by 
comparing 6MWD with a symptom-limited cycle ergometer exercise test during which VO2max 
was recorded. Ten patients repeated the 6-MWT three times within three days. The results 
showed high reliability of the 6-MWT with an intraclass correlation coefficient of R=0.96. The 
authors also examined the ability of 6-MWT to predict individual VO2max. They demonstrated a 
high correlation between distance covered during the 6-MWT and both the actual (r=0.68, 
p<0.01) and the predicted VO2max (r=0.61, p<0.01). Over a follow-up period (381±170 days), 
both 6-MWT and cycle exercise test were performed two times by 28 patients and three times by 
14 patients. Thus, the authors suggested an equation form for follow-up performance in stable HF 
patients, based on the 6-MWT and the cyclo-ergometer test (see equation 5.1). 
Equation 5.1.  Zugck et al. (2000) 
VO2max (at follow-up) = [VO2max (at initial visit)] × [6MWD (at follow- up)/6MWD (at initial visit)] 




); 6MWD=distance walked in six-minute walking test 
(m) 
These authors (Zugck et al., 2000) recommended this equation for individual prognosis in HF. 




have almost double the risk of 




, at 1-year. This equation, however, is not 
routinely used in clinical practice as it requires the performance of two different exercise tests. 
This process is time consuming, while the cycle ergometer test may be unsuitable for elderly HF 




Kervio et al. (2004) assessed the validity of the 6-MWT by comparing it with a symptom-limited 
treadmill exercise and its reliability in patients with moderate HF (n=24). The 6-MWT was 
reliable and gave similar results to a sub-maximal treadmill exercise test, equal to nearly 90% of 
VO2max. The authors found differences in VO2max and maximal HR values at different times of 
day, and suggested that such daily differences are critically important for the accurate assessment 
of functional capacity in HF patients. The authors also suggested that the 6-MWT should be 
performed at a consistent time of the day in order to evaluate VO2 and HR with more accuracy. 
They also recommended validation of the results across a larger sample and the assessment of 
daily 6-MWT reliability in patients with severe HF.  
Roberts et al. (2006) validated the 6-MWT against a treadmill exercise test, using 38 clinically 
stable patients (post-MI or post-revascularisation). Patients were assessed twice (before and after 
8 weeks of exercise training) using both the sub-maximal treadmill test and the 6-MWT. The 
exercise intensity of the 6-MWT was lower than the treadmill test: a higher HR was observed at 
the end of the treadmill test. Neither test was able, however, to identify improvements in 
cardiovascular function and workload achievement after the exercise programme. The authors 
concluded that the 6-MWT was a valid and safe assessment tool, which can give the same results 
as a sub-maximal treadmill exercise test of nearly 85% of the age-predicted maximum HR.  
Reliability  
Demers et al. (2001) examined the reliability of the 6-MWT by assessing the effects on this test 
of drug treatments such as angiotensin II receptor antagonist and β-blockers. The authors 
reported high reliability of the 6-MWT after assessing 768 HF patients twice at baseline, and 
then again at 18 and 43 weeks. Each set of measurements was averaged. It was concluded that 
the 6-MWT is a highly reproducible (ICC=0.91 after 43 weeks) assessment tool for HF patients 




that examined the reliability of the 6-MWT over such a long-term (12 months), however, the 
clinical conditions (such as co-morbidities of hypertension, diabetes mellitus, chronic obstructive 
pulmonary disease) were not controlled.  
Ingle et al. (2005) described the 6-MWT as a convenient test of functional capacity in HF 
patients, by demonstrating the long-term (1 year) reliability in this patient group. The authors 
used a questionnaire to assess perceived symptoms during physical exertion. The authors took 
into account the patients’ clinical conditions; patients who reported unchanged symptoms after a 
1-year follow-up evaluation were used for the reliability analysis. The 6-MWT was sensitive 
enough to detect self-perceived symptom changes, and that when the symptoms did not change, 
the 6MWD was reproducible. Ingle et al. (2005) used a large cohort of patients (n=1,077) at the 
initial assessment; the reproducibility analysis, however, was only based on 7% of the cohort 
(n=74), and it seems likely that this is a very selective subsample, from which it may not be easy 
to generalise. One limitation of the study was the large variation in 6MWD observed, especially 
in women. This is might be due to many factors not measured in their protocol, including 
psychological status. Psychological impairment (i.e., distress, depression) is a common condition 
in HF and is associated with deterioration of HF symptoms, functional capacity and quality of life 
over time (Steptoe et al., 2000; Rumsfeld et al., 2003; Opasich et al., 2008). These psychogenic 
symptoms may affect 6MWD (Gottlieb et al., 2009).  
Sensitivity 
Meyer et al. (1997) used the 6-MWT and a symptom-limited cycle ergometer test to assess 
hospitalised patients (n=18) with severe HF enrolled in a three-week exercise programme and in a 
three-week activity restriction programme. There was a significant (65%) increase in walking 
distance after exercise training but a non-significant decline after activity restriction. The 




ergometer test. The authors concluded that the variation in 6MWD can be used to identify the 
short-term effects of exercise interventions in patients with severe HF.  
A randomized controlled study (Owen and Croucher 2000) examined the effects of a twelve-
week exercise programme involving elderly HF patients with an average age of 81 years. The 6-
MWT was used to evaluate functional capacity and showed a significant (20%) improvement in 
6MWD: an increase in walking distance of 40 m. A control group showed a significant decrease 
in their 6MWD after twelve weeks, which the authors described as being a result of the natural 
development of the disease. This was despite no significant change in their NYHA classification 
or quality of life as assessed by the Living With Heart Failure Questionniare (LWHQ). This 
indicates the high sensitivity of the 6-MWT in investigating not only improvement but also 
deterioration in the functional capacity of HF patients after an exercise programme.  
A waiting list controlled study (Wright et al., 2001) of 239 CVD patients, suggested the 6-MWT 
was a simple and effective test which can be used to diagnose an improvement in the functional 
capacity of CVD patients who embarked on a specific six-week cardiovascular exercise 
programme. This study of 209 patients, who entered the CR programme, and a control group of 
30 patients, who delayed joining the CR programme for six weeks, showed that CR improves 
significantly 6MWD in the cardiac population (p<0.001). There were no follow-up data to assess 
the reliability of the 6-MWT or longer term changes in 6MWD.  
It is clear from this discussion that the 6-MWT is reliable, valid and has a justified role in 
measuring functional capacity and limitation in HF patients. The test is easy to perform, and the 
results are easy to interpret (Larsen et al., 2001). Functional capacity is an excellent prognostic 




Jouven et al., 2005). A number of studies have also focused on the 6-MWT as a potential 
prognostic marker of mortality for the HF population, and these are discussed below.  
5.1.6.1.3.  Heart failure and prognosis: the role of the six-minute walking test 
A number of variables can be used in the prognostic evaluation of patients with HF. Some are 
clinical measures tests, such as type-B natriuretic peptide, C-reactive protein (blood tests) or 
LVEF (echocardiography) (de Groote et al., 2004; Anand et al., 2005). Others are measured 
during clinical exercise testing, such as peak oxygen consumption, ventilatory efficiency, HR 
response and the 6-MWT (Francis et al., 2000; Davies et al., 2006; Kubrychtova et al., 2009).  
de Groote et al. (2004) found that plasma levels of type-B natriuretic peptide (BNP), in 
combination with VO2max, were independent prognostic indicators of risk stratification in patients 
with stable HF. They reported that patients with a BNP ≥109 pg·ml
-1





had a greater likelihood of mortality within two years; they had double the likelihood of 
cardiovascular mortality compared with patients with a BNP <109 pg·ml
-1
. Anand et al. (2005) 
demonstrated that C-reactive protein (CRP) was an independent predictor of HF and mortality. 
They reported that higher levels of CRP were associated with adverse clinical outcomes (a worse 
hemodynamic and neurohormonal profile, increased risk of ischaemic/non-ischaemic events) and 
increased risk of mortality. 
The prognostic capability of VO2max determined from treadmill exercise is well established in HF 
patients. There is significant variation in prognostic VO2max cut-off points. Reduced VO2max is 










implies a good prognosis, within 2 years with medical treatment in patients with HF (Opasich et 




Such clinical prognostic markers are valuable in laboratory assessments, because they are 
predictive in detecting the severity of HF disease. Such measures are not easy to obtain in routine 
clinical practice; they are costly and time consuming. Conversely, the 6-MWT offers an easy, 
quick, low-cost prognostic measurement. The prognostic value of 6-MWT in HF patients is well 
established; and will be discussed below. However, it would be worthwhile identifying the 
parameters (clinical and non-clinical measures) associated with 6MWD and individual 
cardiovascular prognosis. For instance, some non-modifiable factors (anthropometric, age, sex) 
might be able to overestimate or underestimate the individual patient’s prognosis. In this case, the 
prognostic cut-off points or individual walking performance should be corrected to these 
prediction parameters.  
5.1.6.1.3.1.  Analysis of prognostic studies 
The Left Ventricular Dysfunction Study (Bittner et al., 1993) was one of the first large-scale 
(n=898) studies to demonstrate that the 6-MWT could be used as a prognostic marker in patients 
with HF. Distance walked in the 6-MWT correlated significantly with 1-year mortality; patients 
who achieved MSWD scores of less than 300 m had a higher risk (OR=1.77, 95% CI=1.38 – 
2.26) of dying or being hospitalised over one year compared with patients who achieved >300 m.  
Cahalin et al. (1996) evaluated patients with advanced HF (n=45) who had been referred for heart 
transplantation evaluation. The patients underwent both a symptom-limited cycle ergometer test 
and a 6-MWT. Distance walked was related to VO2max and they devised the relevant equation 
(see equation 5.2).  
Equation 5.2. Cahalin et al. (1996) 
VO2max = (0.03 x 6MWD) + 3.98 









The authors (Cahalin et al., 1996) also reported that a 6MWD of less than 300 m increased the 
likelihood of death or hospital admission for inotropic or mechanical support for transplantation 
within the next 6 months (40% versus 12%, p=0.04). Walking a distance of more than 300 m in 
the 6-MWT failed to predict long-term or event-free survival, in this group of patients. This 




, which was a significant predictor of 
long-term survival. 
Roul et al. (1998) found that poorer 6MWD (≤300 m) could predict mortality and morbidity 
(hospitalisation for HF) in patients with mild-to-moderate HF (NYHA class II or III). The study 
was performed in 121 patients followed over 1.53 (±0.98) years using a symptom-limited cycle 
ergometer test with VO2max and a 6-MWT. The 6MWD correlated significantly with the VO2max 
from the cycle ergometer test. When a distance of 300 m was used as a threshold, the 6-MWT 
was a significant prognostic indicator for mortality and morbidity in this population. They 
demonstrated that the percentage of short-term (500 days) event-free survivals were almost 75% 
for patients who walked between 370 m and 450 m and 50% for patients who walked ≤370 m in 
the 6-MWT. Similarly, Rostagno et al. (2003) investigated whether the 6-MWT could be used as 
a simple and reliable tool for prognosis of cardiac death in patients with mild to moderate HF 
(n=214). They found that patients with a 6MWD of less than <300 m had higher mortality rates at 
36 month follow-up compared with those who scored >300 m (82% versus 62%, p=0.01).  
Curtis et al. (2004) found that HF patients who walked <200 m in the 6-MWT had an increased 
risk of death over a 32-month period compared with those who walked >200 m (43.9% versus 
23.3%, p<0.001). They suggested that 200 m was a preferable threshold point for mortality 
prognosis in HF patients. This is in opposition to most other studies which have recommended 
300 m. Curtis et al. (2004) found that although all-cause mortality for patients who walked <200 




more than 200 m (201-300 m, 301-400 m, and >400 m) were similar. Similar results were 
confirmed in more recently study (Arslan et al., 2007), when stable mild-to-moderate HF patients 
(n=43) were studied. The death risk was higher in patients who walked ≤300 m in the 6-MWT 
and in patients whose LVEF was ≤0.30%. There were several limitations to this study (Arslan et 
al., 2007), including a small sample size and the fact that a significant percentage of the initial 
patients were lost in the follow-up (30%) and the relatively short study duration. Despite this, the 
6-MWT was found to be a reliable and independent predictor of cardiac death.  
Conversely, Opasich et al. (2001) found that, in 315 patients with moderate-to-severe HF, 6-
MWT distance did not correlate with cardiac function (haemodynamic data), while it was 
moderately correlated with functional capacity measured by cycle ergometer. The 6-MWT did 
not provide additional useful prognostic information in this population and could not be used to 
complement or replace VO2max measurements and NYHA classification. There were 
methodological differences between this and other studies, which may explain different findings. 
The participants were patients with more severe HF than those who participated in the above 
studies. Moreover, the authors reported that no encouragement was given to patients during the 
test, while the test was repeated twice, with only a 30 min interval between test administrations, 
and the average score was taken as the walking performance distance for each patient. Factors 
such as learning effect, tiredness resulting from the shortness of the interval between the two tests 
and the lack of encouragement, might have created limitations in terms of the participants being 
able to reach their anaerobic threshold during the 6-MWT. Nevertheless, assessment in routine 
clinical practice differs from laboratory assessment, since it usually includes only one 6-MWT – 
thus avoiding these problems.  
Ingle et al. (2006) investigated clinical values related to poor 6MWD in 571 HF patients. Being 




HR, elevated serum creatinine and NT-proBNP were all associated with poor 6MWD. The 
authors attempted to demonstrate the relationship between clinical measures and functional 
capacity, but failed to clarify which variables were ‘cause’ and which were ‘effect’. This might be 
due to methodological limitations, such as a lack of detailed examinations of their patients' 
medical histories. The results remain valuable because poor 6MWD (<300 m) relates to a high 
incidence of morbidity and mortality in HF patients and thus all the clinical measures associated 
with poor 6MWD can also aid prognosis. Ingle et al. (2007) also performed a follow-up study at 
36.6 months (initial population of 1,592 HF patients), and demonstrated that the 6-MWT was an 
independent predictor of mortality in this population. This was true especially for patients with 
severe left ventricular systolic dysfunction. NT-proBNP was the strongest independent predictor 
of mortality in this population.  
Measures of LVEF are considered important prognostic indicators in HF. Traditionally low 
LVEF (≤50%) provides poor prognosis in HF (Ahmed et al., 2002; Gottdiener et al., 2002). New 
guidelines suggest that left ventricular systolic dysfunction is diagnosed only when LVEF is 
<45% (ESC 2008). Recent data showed that preserved LVEF (≥50%) does not necessarily imply 
freedom from increased risk of mortality, while they suggested that reductions in HF mortality 
risk are higher in patients with low LVEF (≤50%) (Bhatia et al., 2006; Owan et al., 2006). A 
variety of alternative clinical (cholesterol, triglycerides, hypertension and diabetes mellitus) and 
non-clinical (sex, age) variables describing the HF population also influence the likelihood of 
mortality.  
Assessment of such clinical predictors requires specialist equipment and advanced training for 
clinicians and is thus not easy to carry out in daily clinical practice. In this case, reliable, simple 
and easily used measures, like the 6-MWT, can be used as a simple prognostic marker of cardiac 




and prognostic indicator of mortality and morbidity (hospitalisation) in patients with mild-to-
moderate and advanced HF. Other clinical measures can also be used as determinants of poor 
6MWD and, thus, of a poor prognosis. Clinical measures, like LVEF, are not associated with 
poor 6MWD (Ingle et al., 2007). There seem to be other factors influencing the 6MWD.  
A review of the literature reveals an absence of research regarding how simple measures, 
including anthropometry, gait characteristics or basic clinical measures, may affect 6MWD in an 
HF population. In particular, researchers have not studied the effect that anthropometric and gait 
measures, such as step length and pacing index, might have on 6MWD in the HF population. 
Prognostic studies have not considered non-clinical factors (anthropometric and gait), when 
determining thresholds for 6-MWT in HF patients. These shortcomings in the clinical literature 
exist, despite established evidence that such factors influence walking test performance. These 
data are discussed below. 
5.1.6.1.4.   Associations between anthropometric variables and six-minute walking test  
performance in healthy adults 
There is good evidence for associations between anthropometric variables and 6MWD in healthy 
adults (Enright and Sherrill 1998; Troosters et al., 1999; Gibbons et al., 2001; Enright et al., 
2003; Camarri et al., 2006; Chetta et al., 2006; Poh et al., 2006; Jenkins et al., 2009). In all of 
these studies, age and stature were included as independent predictors of 6MWD. Within these 
studies, it is acknowledged that taller and younger healthy people can walk further in the 6-MWT 
than shorter and older people; but it is not known whether taller and younger HF patients can 
walk further in the 6-MWT than shorter and older patients. Creating prediction equations in 
healthy adults might be useful, but authors have assumed that the same basic parameters (age, 
sature, sex, weight, BMI) influence 6MWD in HF patients. There is only one similar study in a 




prediction equations. Further discussions of these studies will appear in the discussion section 
(see section 5.4).  
Given that exercise prescription and even some clinical decisions may rest on a patient’s 6MWD, 
it would seem important to know whether anthropometric and gait parameters significantly 
influence 6MWD. This study will clarify whether the predictors of 6MWD are the same as those 
in healthy adults. These issues should be investigated further to help in the improvement of 
cardiac assessment, rehabilitation and prognosis in this population. 
5.1.7.  Aims 
The results and discussion of the findings in this chapter will discuss the two aims of this study.  
i. to identify whether routinely measured, non-clinical (sex, age, anthropometric and gait 
parameters) and clinical characteristics can predict 6MWD in HF patients.  
ii. to establish a reference equation for individual prediction of 6-MWT distance in patients 
with HF.  
These indicators can be used to describe the 6MWD more efficiently in the individual patient, on 
his/her admission to a CR programme.  
5.2.  Methods 
5.2.1.  Participants 
Seventy one adult volunteers (58 males and 13 females; aged 52 to 91 years) with stable HF 
volunteered for the study. Of these, 93% had left ventricular systolic dysfunction (LVEF ≤ 40%) ; 
7% had diastolic HF. All patients were in stable NYHA functional classes I-III. The functional 




the patients were taking treatment for stable HF, including angiotensin-converting enzyme (ACE) 
inhibitors, diuretics, β-blockers, statins, cardiac glycoside, aspirin, anticoagulants and others. 
Table 5.2 summarises the clinical characteristics of the study population.  
Patients were recruited from a community HF clinic and were clinically reviewed as part of a 
routine screening appointment. Inclusion criteria were evidence of left ventricular systolic 
dysfunction and symptoms of HF (NYHA class I-IV). Patients had suffered from the disease for 
at least six months before the study. Patients were studied when they were clinically stable, 
without any changes in medication during the previous three weeks. Patients with severe 
locomotor limitations were excluded from this study. Heart failure was defined in accordance 
with guidelines from the National Institute for Clinical Excellence (NICE) (2003) and the 
European Society of Cardiology (Remme and Swedberg 2002).  
The study conformed to the declaration of Helsinki (World Medical Association 2009) guidelines 
for research with human participants. The protocol was approved by the Hull and East Riding 




Table 5.2.  Clinical characteristics and baseline measurements of the heart failure patients (n=71) 
Variable Value 
Age   (years)  (mean ± SD)  76.3 ± 8.6 
Sex   
     Males 





    Left ventricular systolic dysfunction 
    Diastolic heart failure 
 
93 
 7  
NYHA class (mean ± SD) 
  Class  I (%) 
  Class  II (%) 
  Class III (%) 




Body mass (kg) (mean ± SD) 84.2 ± 17.6  
Stature  (cm)  (mean ± SD)   
                       Median value                 




)   (mean ± SD)  28.7 ± 5.1  
LVEDD (mm)  (mean ± SD) 46.8 ± 9.1  
LVEF (mean ± SD) (%) 42.2 ± 12.1 
LVESD (mm) (mean ± SD) 47.1 ± 11.3  
ECG rhythm  
    Sinus 
    Atrial fibrillation  
    Vetricular pacing 






Resting HR (bpm) 67 ± 13  
ACE inhibitors n=53 (75%) 
β-blockers n=57 (80%) 
Diuretics  n=55 (78%) 
Statin  n=46 (65%) 
Aspirin  n=38 (54%) 
Cardiac glycoside (Digoxine) n=12 (17%) 
Anticoagulant (Warfarin) n=23 (32%) 
Other n=64 (90%) 
Definition of abbreviations: 3YHA=3ew York Heart Association; BMI=body mass index; LVDD=left 
ventricular end-diastolic diameter; LVEF=left ventricular ejection fraction; LVSD=left ventricular end-systolic 




5.2.2.  Protocol and measurements 
Patients were assessed once as described below. Each participant was given a primary assessment 
prior to the 6-MWT, which required them to fill in a Pre-Exercise Health Questionnaire, followed 
by an interview to establish their medical and pharmacological history.  
5.2.2.1.  Anthropometric assessment 
Before the test, anthropometric measurements of stature and body mass were made. Stature was 
recorded using a stadiometer (Seca 240 stature measuring rod) and body mass was recorded, 
without shoes, using a weight scale (Seca 888 Class III Floor Scale). From these measurements, 





5.2.2.2.  Cardiovascular assessment 
Cardiovascular assessment included medical history of any heart problem, pharmacological 
history, NYHA functional class (I-IV), an electrocardiogram (ECG) (model: Cambridge Heart 
Inc, US), a comprehensive transthoracic echocardiogram (model: Vivid 7 dimension, GE 
Healthcare, US) and the 6-MWT. Current use of diuretic, antihypertensive, antiarrhythmic and 
anticoagulant medications was recorded. A 12-lead electrocardiogram recorded participants’ 
resting HRs and heart rhythms.  
Left ventricular function, including LVEDD, LVESD and LVEF were determined from two-
dimensional echocardiography. LVEF was calculated using Simpson’s formula from 
measurements of end-diastolic and end-systolic volumes on apical two-dimensional views, 
following the guidelines of Schiller et al. (1989); left ventricular systolic dysfunction was 




5.2.2.2.1.  Six-minute walking test procedure 
The 6-MWT was conducted according to the standardised protocol of Guyatt et al. (1985a) 
except that a 15 m course was used instead of the recommended 33 m course (Guyatt et al., 
1985a). A 15 m course was used, as this is commonly reported in clinical settings. Patients were 
instructed to walk, at their own maximal pace, along the 15 m flat, obstacle-free corridor, with 
chairs placed 0.5 m from the end of the course. The test was supervised by a trained research 
assistant and a cardiologist was present throughout. Patients were instructed as follows: ‘Turn 
180° every 15 m, and cover as much distance as possible during the six minutes’. Patients were 
allowed to take rest stops if they needed them, but they were instructed to continue walking as 
soon as they felt able to do so. Time remaining was called every second minute. Standardised 
verbal encouragement was provided after 2 minutes and 4 minutes (American Thoracic Society 
2002). Patients walked unaccompanied so as not to influence walking speed. After six minutes, 
patients were instructed to stop and total distance covered was calculated to the nearest metre. 
Patients who failed to complete the test (walking for six minutes) were asked provide a reason for 
stopping. The total distance covered during the 6-MWT was recorded in metres.  
5.2.2.2.1.1.  Gait analysis 
The numbers of steps was counted every 15 m during the test. Step length series (per 15 m) were 
calculated by dividing the course length (15 m) by the number of steps walked along the course. 
Subsequently, for each patient’s step length series, the mean and standard deviation step length 
were calculated.  
The mean and standard deviation values used only four step length series, which were recorded 
between 60 m and 120 m. The first two and the last step length series were removed from this 




The time taken to walk each 15 m course was recorded, and the average speed for each 60 m was 
calculated. The pacing index was calculated as the percentage decline from peak walking speed: 
Pacing Index=[minimum speed in 60 m (m·sec 
-1
) /maximum speed in 60 m (m·sec 
-1
)] × 100.  
5.2.3.  Statistical Analysis  
Data were presented as means and standard deviations. The median values of age, stature and step 






 percentile of 
the distribution). Relationships and statistical significance for each of the variables measured 
(total distance covered, age, stature, BMI, step length, LVEF, resting HR and pacing index) were 
tested using Pearson’s product moment coefficient. An independent-samples t-test was also 
conducted to compare the 6MWDs for males and females.  
The outcome measure for the 6-MWT was the distance walked in metres (6MWD). After using 
the correlation to determine which variables were most strongly related to 6MWD, the next stage 
involved performing a stepwise linear regression analysis to assess the combined associations. 
Independent variables significantly associated with 6MWD were entered into a model to predict 
6MWD. Finally, regression analysis was repeated, and reference equations were constructed 
separately with the data split by sex. The stepwise model was chosen in favour of other models 
because the objective was to identify the lowest number of variables that had most influence on 
the test results. The regression used only those independent variables for which the coefficient 
correlation with the other independent variables was r<0.75, in order to minimise multicolinearity 
and to avoid high correlation between the variables (Meyers et al. 2006). The probability of F for 
entry was set at 0.05 and for removal at 0.1; these counted as the statistical criteria that the 




potential predictors were examined: sex, age, stature, BMI, step length, LVEF and pacing index. 
The dependent variable was the 6MWD.  
Multinomial logistic regression was also performed to determine factors associated with poor 
6MWD (≤300 m). Threshold values were identified for dependent (total distance 300 m) and 
independent variables (age 75; stature 172 cm; BMI 25 kg·m
-2
; step length 0.63 m; pacing index 
50%; resting HR 80 bpm
-1
; LVEF <45%) (see table 5.3). Dependent and independent variables 
were encoded by using 0 and 1 for this analysis (see table 5.4). Results were expressed as odds 
ratios with 95% confidence intervals (CI).  
Statistical analysis was carried out using SPSS version 16.0 (SPSS inc., Chicago, IL, US), 
whereas calculations were illustrated in Microsoft Office Excel 2003 (Microsoft Corporation, 





Table 5.3. Threshold points for dependent and independent variables 
Variables Threshold values Identifications  
6MWD (m)  
 
300  
(Bittner et al., 1993; Roul et al., 
1998; Rostagno et al., 2003; Ingle 
et al., 2006; Arslan et al., 2007) 
≤ 300: poor performance 
> 300: good performance 
Age (median; yrs)  75 ≥ 75: old  
< 75:  young 
Stature (median; m) 172  ≥ 172: tall 
< 172: short 
BMI (kg·m
-2
) 25  
(World health organization 1998) 
> 25: overweight 
≤ 24.9: normal-weight 
Step length (median; m) 0.63 ≥ 0.63: long step 
< 0.63: short step 
Pacing index 50% ≥ 50%: non-deceleration 
< 50%: deceleration 
Resting HR  (bmp) 80  
(Ingle et al., 2006) 
> 80: high HR 
≤ 80: normal HR 
LVEF (%)  45 
(ESC 2008) 
≥ 45: good LVEF 
< 45: poor LVEF 




Table 5.4.  Dependent and independent variables encoding 
Variables Code ‘0’ Code ‘1’ 
6MWD low performance good performance 
Sex Male female 
Age Older younger 
Stature Short tall 
BMI Overweight normal-weight 
Step short step long step 
Pacing index Deceleration non-deceleration 
Resting HR high HR normal HR 
LVEF poor LVEF normal LVEF 
Definition of abbreviations: 6MWD=six-minute walking distance; BMI=body mass index; HR=heart rate; 




5.3.  Results 
5.3.1.  Descriptive analysis 
Table 5.1, above, presented some of the baseline descriptive characteristics of the HF group. Of 
the 71 patients, 54 (76%) completed the 6-MWT. The mean 6MWD was 319 (±126) m for males 
and 253 (±95) m for females (for the group overall: 6MWD=307±123 m, range: 90-530 m).
 
 
5.3.2.  Predictors of test performance (distance walked) 
5.3.2.1.  Correlations between clinical measurements and six-minute walking test 
performance 
Stature was significant and positively associated with 6MWD, while age had a significant but 
negative association with 6-MWD (see table 5.5).  
Table 5.5.  Correlations between total distance achieved during the 6-MWT and independent 
variables (for all heart failure patients) 
                 6-MWT 
Variables 
 Pearson r P value 
6MWD – Age 71 -0.422 0.000 
6MWD – Stature 71 0.351 0.003 
6MWD – Body mass 71 0.031 0.801 
6MWD – BMI 71 -0.163 0.174 
6MWD –  Step length 67 0.094 0.448 
6MWD – Pacing index 57 0.15 0.283 
6MWD – Resting HR 52 0.009 0.947 
6MWD – LVEF  60 -0.116 0.378 
Definition of abbreviations: 6MWD=six-minute walking distance; BMI=body mass index; LVEF=left 





Data were divided by sex, and the correlations were repeated. In male HF patients (n=58), 
significant correlations were observed between 6MWD, stature (Pearson’s r=0.254, p=0.045) and 
age (Pearson’s r=-0.376, p=0.004). Respectively, for females (n=13), significant correlations 
were observed between 6MWD and stature (Pearson’s r=0.598, p=0.031) only; age (Pearson’s r=-
0.416, p=0.157) and body mass (Pearson’s r=0.366, p=0.218) were correlated moderately with 
6MWD but not significantly (see table 5.6).  
Table 5.6.  Correlations between total distance achieved during the six-minute walking test and 
independent variables (for males and females separately) 
Males                        Females 
 
Variables 
 Pearson r P value  Pearson r P value 
6MWD – Age 58 -0.376 0.004 13 -0.416 0.157 
6MWD – Stature 58 0.254 0.045 13 0.598 0.031 
6MWD – Body mass 58 -0.122 0.362 13 0.366 0.218 
6MWD – BMI 58 -0.233 0.078 13 0.117 0.704 
6MWD –  Step length 56 0.089 0.515 11 -0.247 0.464 
6MWD – Pacing index 46 0.193 0.199 9 -0.224 0.562 
6MWD – Resting HR 48 -0.050 0.737 12 -0.003 0.992 
6MWD – LVEF  42 0.019 0.904 9 0.055 0.888 
Definition of abbreviations: 6MWD=six-minute walking distance; BMI=body mass index; LVEF=left 
ventricular ejection fraction; HR=heart rate 
 
The independent-sample t-test showed no statistically significant difference in 6MWDs between 
males (319±126 m) and females (253±95 m), t (71)=1.77, p=0.08 (two-tailed). The magnitude of 
the difference between the means (mean difference=66 m, 95% CI: -8.36 to 140) was, however, 




5.3.2.2.  Regression Analyses 
5.3.2.2.1.  Multiple Linear Regression Analysis  
Variables correlated (r>0.3) with 6MWD were further analysed using multiple stepwise linear 
regression analysis to identify which were independently associated with 6MWD. Regression 
analysis used only those variables for which the coefficient of correlation with other variables 
was r<0.75, to minimise multicollinearity and avoid high correlation between the variables 
(Meyers et al., 2006).  
Age and stature were the only variables entered into the regression analysis. Stepwise analysis 
showed that age was the only variable that met the statistical criteria for inclusion. In this model, 
42.2% of 6MWD was explained by age, with a standard error of estimation of 113 m. The β value 
was -6. The intercept value (A) was 762.1 m. (see equation 5.3). Predicted results were calculated 
using the regression equation Y=A+(B×X), where Y is the predicted value of the dependent 
variables (predicted 6MWD, m), A is the Y intercept (the value Y when the X value is zero), X 
indicates the rate of the independent variable (age) and B are the coefficients assigned to each of 
the independent variables in the regression analysis (Tabachnick and Fidell 2007).  
For 6-MWT the equation for predicting 6MWD is:  
Equation 5.3.  
6MWD = 762 - (6 × age, yrs) 
where: 6MWD=distance walked in six-minute walking test (m) 
The regression analysis was extended to include category variables such as sex. In the sex-
specific equation models, 40% of variance in 6MWD was accounted for by age and stature in 
males, and 52% was accounted for by age, stature and body mass in females (see equation 5.4).  





For males: 6MWD = 142 + (3.1 × stature, cm) - (4.9 × age, yrs)                                   
For females: 6MWD = 259 + (4.6 × stature, cm) - (6.6 × age, yrs) – (2.9 × body mass, kg) 
where: 6MWD=distance walked in six-minute walking test (m) 
5.3.2.2.2.  Logistic regression analysis 
Direct logistic (multinomial logistic regression) was performed to determine the factors 
associated with poor 6MWD (≤300 m). The model contained eight independent variables (sex, 
age, stature, BMI, step length, pacing index, resting HR, LVEF). The threshold values that were 
identified for dependent and independent variables are shown in table 5.3.  
The overall model was statistically significant (p=0.008) and explained 25.3% (Cox and Snell R 
square) and 34.8% (Nagelkerke R squared) of the variance in 6MWD. The model could correctly 
classify 74.6% of cases. As shown in table 5.7, only two of the independent variables (age and 
BMI) made a statistically significant contribution to the model. Independent predictors of poor 
6MWD (≤ 300 m) included high BMI>25 kg·m
-2
 (OR=12.7; 95% CI: 1.45 to 111) and age>75 
years (OR=4.9; 95% CI: 1.24 to 19). These indicate that overweight HF patients (BMI>25 kg·m
-
2
) were 12.7 times more likely than normal-weight patients (BMI<25 kg·m
-2
), and older HF 
patients (≥ 75 years) were 4.9 times more likely than younger patients (< 75 years), to achieve 
less than 300 m in the 6-MWT. LVEF did not make a significant contribution to the model; 
however, the odds ratio (OR=0.52; 95% CI: 0.15 to 1.82) showed that patients with LVEF<45 
mm were 48% less likely to achieve less than 300 m in the 6-MWT than patients with normal 






Table 5.7. Logistic regression predicting the likelihood of achieving less than 300 m in the six-minute 
walking test 
95.0% C.I.for Odds Ratio  Odds 
Ratio Lower Upper 
 
P value  
Sex (male vs. female *) 0.82 0.15 4.63 0.822 
Age (older vs. younger *) 4.86 1.24 19.01 0.023 
Stature (short vs tall *) 1.23 0.31 4.92 0.764 
BMI (overweight vs. normal-weight *) 12.73 1.45 111.82 0.022 
Step length (short step vs. long step *) 0.72 0.22 2.38 0.584 
Pacing index (deceleration vs.  non-deceleration *)  2.96 0.19 46.64 0.440 
Resting HR (high HR vs. normal HR *) 1.05 0.31 3.61 0.934 
LVEF (poor LVEF vs.  normal LVEF *) 0.52 0.15 1.82 0.307 
BMI=body mass index; LVEF=left ventricular ejection fraction; HR=heart rate 
* The referent value (OR=1) in each variable respectively is: female; younger; tall; normal-weight; long step; 
non-deceleration; normal LVEF).  
The analysis was repeated with the same variables, except that age (expressed as a continuous 
variable) in years was used as a covariate. Table 5.8 shows that again only two of the independent 
variables (age and BMI) made a statistically significant contribution to the model. The odds ratio 
for age indicates that for every additional year the patients were 1.13 times more likely to walk 
<300 m when controlling for other independent factors in the model. This set of variables 








Table 5.8. Logistic regression predicting the likelihood of achieving less than 300 m during the six-
minute walking test, using age as a continuous variable 
95.0% C.I. for Odds Ratio 
 
Odds 
Ratio Lower Upper 
 
 
P  value 
Sex (male vs. female *) 0.997 0.16 6.11 0.997 
Stature (short vs. tall *) 1.27 0.31 5.19 0.739 
BMI (overweight vs. normal-weight *) 11.73 1.34 102.51 0.026 
Step length (short step vs.  long step *) 0.62 0.18 2.18 0.458 
Pacing index (deceleration vs. non-deceleration *) 4.42 0.21 91.33 0.336 
LVEF (poor LVEF vs.  normal LVEF *) 0.63 0.17 2.30 0.487 
Resting HR (high HR vs. normal HR *) 1.13 0.33 3.92 0.847 
Age (continuous variable) 1.13 1.03 1.23 0.009 
BMI=body mass index; LVEF=left ventricular ejection fraction; HR=heart rate 
* The referent value (OR=1) in each variable respectively is: female; younger; tall; long step; non-aceleration; 
normal LVEF).  
 
5.4.  Discussion  
5.4.1.  Introduction  
According to the American Thoracic Society (ATS 2002) guidelines, the 6-MWT is a useful self-
paced functional capacity assessment test for patients with moderate to severe pulmonary or 
cardiac diseases. The 6-MWT is an easily administered tool, used to evaluate the results of post-
operative or non-operative interventions (Meyer et al., 1997; Gualeni et al., 1998; Opasich et al., 
2004; Fiorina 2007; Nilsson et al., 2008). Most studies use the 6-MWT to analyse the effects of 
an intervention in a cardiac population (Guyatt et al., 1985a; Wright et al., 2001; McKelvie et al., 




Distance walked during the 6-MWT is used to identify HF patients with severe functional 
impairment, to provide prognosis for those patients who have fewer complications and to show 
change due to interventions. The ATS (2002) stated that there was no definitive result on which 
would be the best choice to describe the changes in 6MWD after an intervention: absolute value, 
percentage change or change in the percentage of predicted value. Since there were no studies in 
the field, they recommended that 6MWD can be expressed as an absolute value until relevant 
research is published.  
The ATS (2002) also stated that descriptive values, such as age, stature, body mass and sex, are 
independently associated with 6MWD in healthy adults (Enright and Sherrill 1998; Troosters et 
al., 1999; Gibbons et al., 2001; Enright et al., 2003; Camarri et al., 2006; Chetta et al., 2006; 
Poh et al., 2006; Jenkins et al., 2009). This suggests that such variables should be carefully 
considered by clinicians when they try to determine patients’ functional capacity by analysing 
single measurements from the 6-MWT. Despite these recommendations, none of the prognostic 
studies (Bittner et al., 1993; Cahalin et al., 1996; Roul et al., 1998; Rostagno et al., 2003; Curtis 
et al., 2004; Arslan et al., 2007) have corrected their prognostic cut-off values to age and 
anthropometric variables.    
Fiorina et al. (2007) reported 6-MWT results with both absolute values (in metres) and 
percentages of predicted values by using Enright and Sherrill’s (1998) equation form based on 
anthropometric variables. They suggested that expressing functional capacity as a percentage of 
predicted value was more accurate, because anthropometric limitations could be excluded. The 
implications of HF on 6MWD were not taken into consideration, since the equation was based on 
a healthy population. In this case, the accuracy of their results is open to question. There are 




et al., 1999; Gibbons et al., 2001; Poh et al., 2006; Jenkins et al., 2009), but data are only 
available in relation to healthy populations.  
In light of the ATS recommendations, and the gap in the existing literature, the primary aim of 
the present study was to identify simple, measurable determinants (sex, age, anthropometric, gait 
parameters or clinical characteristics) of 6MWD in HF patients. This is of great importance for 
clinical practice, as clinicians may be able to use simple measurable values to predict expected 
functional capacity in patients with HF. Individual 6MWD can then be expressed as a percentage 
of predicted value in populations with similar demographic characteristics to the present sample. 
As mentioned in Chapter 4 (see ‘Biomechanical predictors of the modified shuttle walking test    
performance in patients with cardiovascular disease’), both the modified shuttle walking test 
(MSWT), which is an incremental functional capacity test, and the 6-MWT can be used to 
measure the functional capacity of CVD patients. The 6-MWT is a less rigid protocol, ideal for 
use in severe CVD patients, such as the HF patients in the present sample. In this study, the 6-
MWT was used with HF patients, and the cut-off point was a 6MWD of 300 m. This is because 
this value is a prognostic indicator of mortality and morbidity in HF patients (Cahalin et al., 
1996; Rostagno et al., 2003; Arslan et al., 2007). 
5.4.2.  Comparison of current results with previous data 
Distance walked during the 6-MWT has been used to determine the functional capacity of many 
HF patients. The mean 6MWD in this sample was 305 (±123) m, in patients with an average 
LVEF of 42%. The mean 6MWD in HF patients ranges between 310 m in patients with a mean 
LVEF of 20% (Cahalin et al., 1996) and 466 m in patients with a mean LVEF of 19% (Rostagno 
et al., 2003). Most studies report 6MWDs between these values, for mild to severe HF patients 




al., 2007). The recorded mean 6MWD is lower than that to be found in most other studies, while 
it seems to be close to the results found by Cahalin et al. (1996) and Passantino et al. (2006). 
Reasons for this variability in results between studies are discussed below.  
The variability in 6-MWT results among studies may be due to internal (i.e., LVEF, severity of 
HF) or external (design and layout of test) factors. Faggiano et al. (1997) stated that patients with 
severe HF (i.e., NYHA class IV) walk typically less than 335 m in the 6-MWT, while patients 
with milder HF (i.e., NYHA class II) tend to walk more than 500 m. Patients in the present study 
had mild to severe HF, which may partly explain the low mean MSWD, less than 335 m 
(307±123 m). Other factors may also be associated with 6MWD.  
Possible external factors creating variability include course layout, encouragement and 
instructions (Guyatt et al., 1985b; Sciurba et al., 2003; Bansal et al., 2008). The present research 
used the shortest length track among several studies (see table 5.9). It might be logical to think 
that more turns relate to lower values for 6MWD. It has been shown previously, however, that 
course length does not have any significant effect on 6MWD (Sciurba et al., 2003). This concurs 
with data from Chapter 4, where turning variables were found not be associated with distance 
walked in MSWT. The MSWT is broadly comparable to the 6-MWT in terms of its physical 
demands.  
Track layout (circular, oval or straight) can influence 6MWD (Sciurba et al., 2003; Bansal et al., 
2008). The present study used a straight track layout and standardised instructions and 
encouragement (Guyatt et al., 1985a). Previous researchers gave no encouragement to 
participants (Cahalin et al., 1996; Opasich et al., 2001; Zugck et al., 2000). Guyatt et al. (1985a) 
made the original investigations into use of the 6-MWT, but they did not suggest the use or non-




into consideration, and the same standardised protocol should be used for both HF and chronic 
obstructive pulmonary disease patients. The ATS suggests the use of standardised phrases for 
encouragement during the test (American Thoracic Society 2002). These recommendations were 
used in the present study.  
Internal factors that can influence the variability of 6-MWT results include general characteristics 
(age, stature, sex, BMI, nationality), physiological (severity of HF, exercise habits and 
medication) and psychological factors (motivation, fear). This research showed that age and 
stature were associated significantly with 6MWD. The average age of the HF patients in this 
study was higher than other studies with HF patients (see table 5.9). The present sample was 
similar to those of Ingle et al. (2006), however, and the 6-MWT results are in close agreement 
with their studies. It is possible that the low mean 6MWD reported, in the present study, was due 
to the high mean age of the present research group in contrast with other studies. Increased age 
related to lower functional capacity (6MWD). The high mean age of the study group is a possible 
reason for the variation in 6MWD among studies. 
The correlations between age, stature and 6MWD, are consistent with findings in healthy 
populations (Enright and Sherrill 1998; Troosters et al., 1999; Gibbons et al., 2001; Poh et al., 
2006; Jenkins et al., 2009). These studies aimed to establish prediction equations for 6-MWT 
based in healthy adults that can be used by the clinicians to provide patients with a measure of 
their expected 6MWD in the absence of disease. The mean 6MWD in these studies was 545 
(±129) m, and the mean 6MWD in the present study was 307 (±123) m. The large difference in 
mean 6MWD between these two groups (healthy cohorts-present HF cohort, mean 
difference=238 m) is mainly due to different health conditions. HF is characterized by 
progressive loss of functional capacity (Kokkinos et al., 2000; Pina 2010). The above discussion 




thus, the findings of healthy cohorts cannot easily be generalised to the clinical population. 
Moreover, estimation of the expected 6MWD in the absence of disease, for HF patients, is 
probably not clinical useful. HF is considered a chronic progressive progressive disorder 
(Kokkinos et al., 2000), and HF patients may not be expected to restore functional impairment to 
the levels of healthy adults.  
Regression equations based on HF population, that could estimate the expected 6MWD for these 
patients are essential, because they could show the real magnitude of an individual’s functional 
limitation and performance expectations when compared to similar cases. As far as this research 
has been able to ascertain, the present study is the first that aims to identify anthropometric and 
gait predictors of 6MWD and provide the relevant equations for prediction of 6MWD, in HF 
population.  
In the present study not all the patients completed the six minutes duration in the walking test. 





Table 5.9.  Review of six-minute distance walked for heart failure patients 
Reference Patient characteristics  
* 
Variables: Age (years), 
Stature (cm),  
BMI (kg·m
-2
)           
LVEF (%) 6-MWT:  
track length (m) 
6MWD (m)  
Cahalin et al. (1996) Severe HF, n=45 Age: 49 ± 8  20 ± 6 51  310 ± 100 
Zugck et al. (2000) Mild to Severe HF,  n=113 Age: 54 ± 12 19 ± 7  132  466 ± 107 
Opasich et al. (2001) Moderate to Severe HF, n=315 Age: 53 ± 9  26 ± 8  34  389 ± 9.88 
Rostagno et al. (2003) Mild to Severe HF,  n= 214 Age : 57.9 ±  9.8 Class I: 52.5± 12.8 
Class II: 42.7±15.1 
Class III: 33.1±14.2 
25  Class I: 427 ± 71 Class 
II: 367 ± 90 Class III: 
242 ±  100 
Ingle et al. (2006) Moderate HF,  n=571 Age: 70 ± 11 
Stature: 168 ± 10  
BMI: 28 ± 5  
32.1 ±  8.4  15  337 ± 103  
Passantino et al. (2006) Severe HF, n=476  Age : 63.6  ± 11.9 
BMI: 26.7± 5.2 
29.8 ± 9.7  60  326  ± 107  
Arslan et al. (2007) Stable HF, n=43 Age: 62 ± 10 35 ± 6  25  400 ± 108 
Present study Mild to Severe HF, n=71  Age: 76 ±  9 
Stature: 171 ± 9  
BMI: 28.7 ± 5.1     
42.2 ± 12.1  15 305 ± 123 m 
Definition of abbreviations: 6MWD=six-minute walking distance; HF=heart failure; BMI=body mass index 




5.4.2.1.  Reasons for test termination 
In the present study, 76% of the patients completed the 6-MWT by walking continuously for the 
full six minutes. The most common reasons that led patients to terminate the test were: 
breathlessness (61%), leg and back pain (44%), chest pain (11%) and tiredness (11%). HF is 
associated with loss of muscle strength and endurance (Witte and Clark 2008). Skeletal muscle 
contains ergoreceptors, which are sensitive to the level of work performed. When the intensity of 
exercise is progressively increased, a greater number of motor units are recruited, leading to 
increased ventilation and sympathetic activation (ergoreflex) until fatigue (Pepera et al., 2008; 
Witte and Clark 2008). The exaggerated ergoreflex in HF patients can explain disordered 
breathing and fatigue (Witte and Clark 2008). Witte and Clark (2008) found that fatigue and 
breathlessness as reasons for exercise test termination during stress testing are unrelated to 
increased mortality in HF patients. This suggests that the main cause forcing the participant to 
stop the test is the individual’s functional capacity. However, the research question arising from 
this is whether 6MWD is associated with other individual internal parameters (sex, age, 
anthropometric, gait or simple clinical characteristics) and how these parameters could predict an 
individual’s 6MWD. 
5.4.3.  Predictors of the six-minute walking test in heart failure patients 
The present analysis considered a number of clinical and non-clinical measures known or 
hypothesised to influence 6-MWT distance, including step length, resting HR, pacing index, 
LVEF and NYHA class. The results showed that functional capacity, as expressed by 6MWD, 
was associated with non-clinical variables. From linear stepwise and logistic regression analysis, 
it was concluded here that age and anthropometric variables (stature, body mass and/or BMI) are 




In particular, linear regression stepwise analyses showed that younger, taller (and thinner, for 
females) HF patients were expected to attain better scores in the 6-MWT than older  and shorter 
patients. The fact that age and stature were associated with 6MWD is in agreement with a 
previous study (Ingle et al., 2006), which reported that HF patients >75 years have an increased 
likelihood of poor functional capacity (<300 m).  
Logistic regression analysis showed that HF patients aged >75 years and/or with a BMI>25 kg·m
-
2
, have an increased likelihood of poor functional status (6MWD) than younger and normal-
weight HF patients. These associations of age and BMI with 6MWD are in agreement with Ingle 
et al. (2006). Despite being more focused on clinical cardiovascular determinants of the 6-MWT, 
they showed that simple measures, age and BMI, predicted 6MWD well.  
In view of the present results, it seems that the functional capacity of HF patients is 
independently associated with age, stature and overweight. The results show that functional 
capacity in HF patients is reduced in elderly (>75 years) and overweight people (BMI >25 kg·m
-
2
). The gradual loss of muscle mass and strength observed with increased age and progressive HF 
is associated with poor exercise tolerance (Fleg and Lakatta 1988; Tolep and Kelsen 1993; Evans 
et al., 1995). This age-related loss of exercise performance explains the shorter distance covered 
in HF patients >75 years. Being overweight increases the demand for blood flow to supply the 
tissues, increases cardiac workload and cardiac output, and results in reduced functional capacity 
and thus shorter 6MWD by those with a BMI >25 kg·m
-2
 (Enright et al., 2003; Gallagher et al., 
2005). 
These associations are important and have clinical relevance. For instance, the 300 m cut-off 
point is widely used in clinical practice. According to this reference equation model, the same 






percentile for males) 75-year-old male, suggesting that one therapeutic goal should be the 
increase of exercise tolerance for such an HF patient. Conversely, this performance is the 
expected ‘well for age and stature’ functional capacity for a short (<171 cm, 25
th
 percentile for 
males) 75-year-old male, which suggests that a less intense, less stressful, safer and more 
inexpensive programme could be aimed at in relation to the maintenance of functional capacity 
for this HF patient.  
This study demonstrates that sex, age and anthropometric variables (stature, body mass) must be 
considered when interpreting 6MWD. Until now, no study had determined whether the same 
factors are associated with 6MWD in HF patients. It was also expected that stature would be 
associated with 6MWD, based on the previous findings in relation to MSWT (see Chapter 4) and 
on the inclusion of stature in prediction equations based on healthy controls (Troosters et al., 
1999; Gibbons et al., 2001; Enright et al., 2003; Camarri et al., 2006; Chetta et al., 2006; Poh et 
al., 2006; Jenkins et al., 2009). Since the most of the HF patients were men, regression analysis 
of male-only data showed that age and stature both predicted 6MWD. The equation suggested a 3 
m per cm of stature expected gain in 6MWD and a 5 m loss per increased year of age. This model 
explained 40% of the variance in 6MWD.  
It was further hypothesised that gait parameters might influence 6MWD. Step length was 
measured, and a pacing index formulated to investigate this. A longer step length infers greater 
mechanical efficiency in a walking test (Donelan et al., 2002), and a constant pace in stepping 
indicates a comfortable, submaximal work rate (Shephard et al., 1968). That neither measure 
correlated with 6MWD is surprising. This was particularly so concerning step length, which 
correlates with stature, which predicted 6MWD well. The relatively small sample size and 
relative crudeness of these assessments may underlie this lack of association, but it should be 




do not need to account for variance in such measures when evaluating 6MWD. Clinically, this is 
good news; as such measures are laborious and time consuming, whereas both measures 
identified here are important predictors when taken as part of routine clinical assessment. 
Another, complex measurement, LVEF was not included in the final multivariate model of 
regression analysis, meaning that it does not significantly predict 6MWD. This finding is in 
agreement with previous studies showing that LVEF is a poor indicator of exercise intolerance 
and functional capacity in HF patients (Franciosa et al., 1981; Muller et al., 1992; Lele et al., 
1996; Kudtarkar et al., 2010). Ingle et al. (2007) demonstrated that while NT-proBNP was an 
independent predictor of poor 6MWD, LVEF was not. Both NT-proBNP and LVEF correlate 
with cardiac function; LVEF reflects cardiac output. The 6-MWT provides an assessment of 
functional capacity, whereas cardiac function is mainly assessed on clinical evaluation (i.e., 
echocardiography, blood tests) (Kuster et al., 2002). The present study was designed to assess the 
functional capacity of HF patients and not their cardiac function.  
Muller et al. (1992) measured cardiac output and regional blood flow at rest and in response to 
treadmill exercise test, in a group of HF (n=30) patients and healthy adults (n=10). They found 
that cardiac output in HF patients was lower than the healthy adults, at rest and during the test. 
The regional blood flow to the tissues was, also, reduced, but the proportion of blood flow did not 
remain the same to all organs, compared with the controls. Particularly, the proportion of blood 
flow to the gut and kidneys and tissues (skeletal muscles) was reduced, indicating that the blood 
flow to the cerebral and coronary arteries remained the same. The authors concluded that 
haemodynamic factors (i.e., cardiac output) do not correlate with exercise tolerance and 
symptomatic impairment, due to redistribution in blood flow. Because HF patients’ symptoms 
(i.e., fatigue, dyspnoea) are related to skeletal muscle blood flow, the authors suggested that 




identifying symptoms in this population. Overall, assessment of functional capacity is 
independently associated with great prognostic importance in HF patients (Kuster et al., 2002), 
confirming the usefulness of the 6-MWT in this population. 
5.4.3.1.  Linear versus logistic models 
Similar results were found with both linear regression and logistic analysis. In both the linear and 
logistic models there was a relationship between age and 6MWD. The linear analysis showed that 
stature and body mass statistically influence 6MWD in women, while logistic analysis showed 
associations between the ratio of body mass and stature (BMI) with MSWD for both sexes. This 
difference is probably due to the limitation of linear analysis, for homoscedasticity and normally 
distributed variables (Lawrence and Arthur 1990), and the fact that regression results were 
stratified by sex while logistic results were estimated in relation to both sexes combined.  
With regard to the fit of the models to the data, the linear models explained 40% and 52% of the 
variance in males and females respectively. This is better than that achieved in the healthy 
population (Enright and Sherrill 1998; Enright et al., 2003) it still leaves 60% and 48% of the 
variance unexplained, meaning that more predictor variables should be added to the equations. 
The logistic equation model fits the data better, as it correctly predicts 75% of the cases. Linear 
and logistic statistics differ in their nature; however, in this study, the logistic model seems 
stronger than the linear model and there is no similar study available to which these findings can 
be compared.  
5.4.4.  Comparison of the six-minute walking test prediction equation model with 
previously published equations 
This is the first research to generate a regression equation of 6MWD based on simple non-clinical 




functional capacity in patients with mild to moderate HF. The use of such a prediction model has 
the potential to be important in clinical practice. Such models allow prediction of an individual’s 
expected functional limitation due to factors beyond their control; they are mainly based on non-
modifiable factors (age, stature). The predictive equations provide information about performance 
expectations and, through this, indicate the desired improvement in functional capacity following 
a therapeutic intervention (such as an exercise CR programme). In this instance, 6MWD can be 
expressed as a percentage of the predicted value based on anthropometric variables (American 
Thoracic Society 2002; Fiorina et al., 2007; Jenkins et al., 2009). A normalised 6MWD value is 
more realistic than an absolute value, because the clinicians can then evaluate the individual’s 
6MWD and extent of individual functional limitation, when compared to a relevant age-matched 
‘control’.  
Overall, 48% to 60% of variance in 6MWD of the HF population remains unexplained by these 
sex-specific models. The unexplained variance may be due to many modifiable factors not 
measured here, including habitual daily activities, psychological status (i.e., motivation), 
differences in the severity of patients' medical condition and medication. Approximately, 80% 
and 75% of the patients were receiving β-blockers and ACE inhibitors respectively. Beta-
blockers show no association with 6-MWT performance in HF patients; however, ACE 
inhibitors cause dyspnea on exertion and reduce exercise tolerance (Lipkin et al., 1986), 
contributing likely to these differences of variation. However, the present analysis considered a 
number of clinical measures thought to influence absolute 6MWD, including LVEF and NYHA 
functional class but these were unrelated to 6MWD. The unexplained variance is, therefore, 
similar to that observed in healthy populations.  
Several studies have published 6-MWT values in healthy populations with different age ranges, 




stature) (Enright and Sherrill 1998; Troosters et al., 1999; Enright et al., 2003; Camarri et al., 
2006; Jenkins et al., 2009). The unexplained variance in 6MWD, in these healthy populations, 
ranges from 34% to 80% (see table 5.10). These reference models were constructed from normal, 
healthy populations. Healthy populations can sometimes act as age-matched control values for 
HF patients; however, as it was mentioned above the results of a larger study based on HF 
patient groups would have more validity. These studies are described below.  
Enright and Sherrill (1998) established equations for prediction in healthy adults, taking into 
account sex, age and BMI. They proposed that their equation models should apply for healthy 
Caucasian adults, aged 40 to 80 years old; when the participants perform the 6-MWT for the first 
time and have standardised encouragement during the test. Their reference equations, based on a 
single 6-MWT, account for only 40% of the variation in 6MWD. There was no revalidation of the 
results in the non-healthy population and their predictive models can not be generalisable to HF 
patients. Due to functional limitations, HF patients are expected to achieve lower scores (MSWD) 
in 6-MWT than healthy adults (it was reviewed above).  
Troosters et al. (1999) found that sex, age, stature and body mass significantly influenced 6MWD 
in healthy adults, and that these factors can be used to judge functional capacity in healthy 
populations. The participants performed the 6-MWT twice, and they achieved a better 6MWD in 
the second test. The authors concluded that a practice 6-MWT was recommended in order for the 
results to be more accurate. The sample population was not large enough, however, to validate 
the results. According to the sample size calculation described by Tabachnick and Fidell (2007), a 
sample size larger than 122 should have been used in this study (Troosters et al., 1999).  
Gibbons et al. (2001) found that 6MWD was related to sex, stature and age in healthy young 




that 86% of healthy adults had a better 6MWD after the first practice walk and proposed the 
necessity of two practice walks for people with cardiorespiratory disorders. They also proposed 
that the improvement in 6MWD was a result of a learning effect, which could be misinterpreted 
as an improvement in functional capacity after treatment.  
Enright et al. (2003) used the 6-MWT to assess a large cohort of elderly people (2,281, including 
122 participants with HF). The authors showed that participants with cardiovascular disorders did 
not walk as far as the other participants. They only reported predictive equations that took into 
account sex, stature, body mass and age, for healthy elderly people. This study produced the most 
clinical useful and valid findings of all the others, because their prediction equations based on a 
large cohort, including CVD patients. On the other hand, the study suffers from two important 
weaknesses. Firstly, there were no referred equation models for CVD patients and their reference 
equations might overestimate predicted 6MWD in CVD population. Secondly, their models 
explained only 20% of the total variance in 6MWD, which might be due to large variations in 
individual health status. Their sample included healthy subjects and patients with different 
medical conditions, such as CVD, pulmonary disease, stroke, arthritis, diabetes.  
Camarri et al. (2006) found that sex, stature and FEV1 were independent predictors of 6MWD in 
healthy Caucasian males. Their equation explained 33.9% of the variance in 6MWD. The authors 
used the best performance from three 6-MWT trials. This fact complicates their results, since it is 
unclear how many practice walks are needed before the use of their reference equation form. 
Chetta et al. (2006) investigated the predictors of 6MWD, including clinical (oxygen saturation, 
pulse rate, respiratory rate, breathlessness perception), sex, age and anthropometric measures 
(stature, body mass) in healthy Caucasian adults. The final equation accounted for 42% of the 




significant effect of anthropometric characteristics on clinical values in relation to 6MWD. 
However, the sample was of healthy, young to middle-age adults, and there is no further data for 
the older population.  
Poh et al. (2006) established an equation including age, stature, body mass and percentage of 
predicted maximum HR, in order to estimate 6MWD in healthy Singaporeans adults. They found 
no significant relationship between BMI and 6MWD, which was probably due to the fact that 
only 8.6% of the participants were obese. They also suggested, as in previous studies (Troosters 
et al., 1999; Gibbons et al., 2001), the necessity of a practice walk for more reliable results. Their 
equation explained a high percentage of variance (78%), indicating that their equation model 
produced accurate results; nevertheless, there was no further revalidation of the results. This was 
the only study which explained higher variance in 6MWD than the present study. Their equation 
model, however, is very limited for three reasons. First, their sample was small and 
unrepresentative of the healthy adult population. Secondly, the cohort that they used was around 
10–12 cm shorter than other populations (i.e., Caucasians) and, thus, it cannot be applied to other 
ethnic groups. Lastly, the equation model includes the variable %predHRmax, so it is not possible 
to use it in individuals taking medication that influences the HR response (i.e., β-blockers).  
Most recently, Jenkins et al. (2009) used sex, age and anthropometric data (stature and BMI) to 
predict 6MWD in healthy Caucasian adults, while also they compared their equation with 
existing equations. They reported that previous regression equations overestimated performance 
in females. Their predictive forms explained 40% to 43% of variance. There was, however, no 
revalidation of their results.  
Table 5.10 shows several established prediction equations for the 6-MWT and demonstrates the 




methods and different populations. Clinicians should use normative values or equation forms that 
are suitable to the clinical characteristics (pathology, severity of the disease, age, race) of the 
participant and the method employed during the test (number of repetitions, encouragement, 
course layout).  
The use of 6MWD predictive equations derived from healthy cohorts might not be accurate to 
predict performance in HF populations. In healthy populations, walking for six minutes rarely 
represents maximal exercise capacity. In the studies which produced the predictive equations in 
healthy populations, participants walked, continuously, for six minutes during the test (Enright 
and Sherrill 1998; Gibbons et al., 2001; Enright et al., 2003; Camarri et al., 2006; Chetta et al., 
2006; Poh et al., 2006; Jenkins et al., 2009). This is often not the case in HF patients and was not 
so in the present study, where only 76% of the patients completed the 6-MWT. In HF patients, 
walking in the 6-MWT is usually maximal, and six minutes of continuous exercise often 
unachievable due to fatigue and dyspnoea (Clark et al., 2000). Thus, prediction regression 
equations were developed in the present work, with a single 6-MWT, over a 15-m course, with 
standard encouragement to patients, and it is applicable to British HF (mild to severe) patients, 




Table 5.10.  Prediction equations for the six-minute walking test 
Reference  Sample characteristics Country/Race Reference equations for walk distance in meters * 
Enright and Sherrill (1998) Healthy adults, aged: 40-80 yrs,  
n=290 (F=117, M=173) 
US 6MWDmale = (7.57 × stature) – (5.02 × age) – (1.76 × body mass) – 309 
6MWDfemale = 667 + (2.11 × stature) – (5.78 × age) – (2.29 × body mass) 
Troosters et al. (1999) Healthy adults, aged: 50-85 yrs, 
n=51 (M=29, F=22) 
Belgium 6MWDmale = 269.31 + (5.14 × stature) – (5.32 × age) - (1.80 × body mass)  
6MWDfemale = 218 + (5.14 × stature) – (5.32 × age) - (1.80 × body mass) 
Gibbons et al. (2001) Healthy adults, aged: 20-80 yrs, 
n=79 (M=41, F=38) 
Canada 6MWDmale = 868 – (2.99 × age) 
6MWDfemale = 793.3 – (2.99 × age) 
Enright et al. (2003) Elderly adults, aged: 73-83 yrs, 
n=1809 (M=715, F=1,094) 
US 6MWDmale = 510 + (2.2  × stature) - (0.93 × body mass) - (5.3 × age)  
6MWDfemale = 493 + (2.2  × stature) - (0.93 × body mass) - (5.3 × age) 
Camarri et al. (2006) Healthy adults, aged: 55–75 yrs 
n=33 (M=33, F=37) 
Caucasians 6MWDmale = 216.9 + (4.12 × stature) – (1.75 × age) – (1.15 × body mass) 
6MWDfemale = 182.86 + (4.12 × stature) – (1.75 × age) – (1.15 × body mass)  
Chetta et al. (2006) Healthy adults, aged: 20–50 yrs, 
n=102 (M=48, F=54) 
Caucasians 6MWDmale = 518.9 + (1.25 × stature) – (2.816 × age) – 39.07 
6MWDfemale = 518.9 + (1.25 × stature) – (2.816 × age) 
Poh et al. (2006) Healthy adults, aged: 45-85 yrs,  
n=35 (M=16, F=19) 
Singapore 6MWD = (5.5 × %predHRmax) + (6.94 × stature) – (4.49 × age) - (3.51 × 
body mass) – 473.27 
Jenkins et al. (2009) Healthy adults, aged: 45-85 yrs, 
n=109 (M=48, F=61) 
Caucasian 
Australians  
6MWDmale = 1005 – (5.68  × age) + (0.89 × stature) 
6MWDfemale = 602 – (2.97 × age) + (2.05 × stature) – (5.50 × BMI) 
Present study  HF adults, aged: 56 – 91 yrs, 
n=71(M=58, F=13) 
UK 6MWDmale = 142 + (3.1 × stature) – (4.9 × age)                             
6MWDfemale = 259 + (4.6 × stature) – (6.6 × age) – (2.9 × body mass)    
Definition of abbreviations: M=values for males; F=values for females; 6MWD=six-minute walking distance; HRmax=maximal heart rate; BMI=body mass index 




5.4.5.  Study strengths 
All the data were gathered on HF patients, and it seems that this is the only study presenting 
equations for prediction of 6MWD that accounts for simple non-clinical variables. This work 
proposes that the determinants of poor performance in the 6-MWT – suggesting a bad prognosis 
for HF – depend on age and anthropometric variables such as stature and body mass (for females 
only); many of which are not under the control of the patient or the clinician. Overweight HF 
patients (BMI >25 kg·m
-2
) and patients older than 75 years are expected to cover less than 300 m 
in the 6-MWT. Overweight patients have an almost 13-fold increased likelihood and the elderly 
(>75 years) have a 5-fold increase, in the risk of poor prognosis and hospitalisation. It is 
suggested that 6MWD should be expressed not only as an absolute value but also as a percentage 
of predicted value in HF patients. The predicted value can be calculated by using only the 
individual’s age and anthropometric characteristics as a variable.  
These prediction variables have both scientific and clinical value. These variables should be taken 
into account by the prognostic studies. For instance, very short HF patients are more likely to 
walk ≤300 m in 6-MWT, which according to previous prognostic studies indicates poor 
prognosis. Stature is a non-modifiable predictive variable for 6-MWT in HF population. The 
prognostic cut-off pints should be adjusted for this variable and revalidated, then, in this 
population. 
These results are, also, very important to clinical practice in the CR field for two main reasons. 
Firstly, the prognostic stratification of HF patients by using baseline non-clinical features – BMI 
and age – is useful, as it can divide patients into subgroups with different functional capacity 
expectations. These two basic non-clinical features, BMI and age, can detect whether a HF 




prediction models could have significant potential for use in clinical practice. Such models allow 
prediction of an individual’s expected functional limitation due to non-modifiable factors (age, 
stature and body mass); they also provide information about performance expectations after an 
exercise CR programme. In this case, 6MWD can be expressed as a percentage of predicted value 
based on age, stature and body mass (for females only) (American Thoracic Society 2002; 
Fiorina et al., 2007). Having these simple measurable prognostic markers (age and BMI) already 
in the assessment will help the clinician to state realistic expectations and functional 
improvement targets after a therapeutic treatment (i.e., in CR), which will be safe and will allow 
the patient to experience real success. 
A further valuable feature of this study is that it has eliminated a large number of gait parameters 
from the prediction of 6MWD. The results presented in Chapter 4 suggest that step length is a 
positive predictor of MSWT performance, and it was predicted that this might be the case in the 
present study. The analysis of gait was time consuming and labour intensive and would not be 
tolerated well by staff in routine clinical use. It is perhaps fortunate that none of the gait variables 
predicted performance. Gait analysis limited the overall sample size of this study, but as they now 
appear unimportant a larger study can be carried out, concentrating on predictions based on age, 
BMI and/or stature. Given that these are routinely available in patient records, such a study could 
be retrospective in nature with a large enough sample size to provide sex-specific equations. Even 
more useful would be the assessment of the prognostic value of ‘adjusted’ 6MWD values against 
raw scores. This could be achieved via re-analysis of existing data.  
5.4.6.  Study limitations 
A limitation of this study could be the fact that there were no psychological measures in the 




scores. Also, no physical activity habits were estimated before the test. It would be useful to 
identify how much variance in 6MWD this variable (physical activity) can predict. A physical 
activity level estimation would address more thoroughly the sources of 6-MWT variation.  
Furthermore, the patients in this study were considered to be overweight (with an average BMI of 
28.7 kg·m
-2
), meaning that the present prediction equations form is more applicable to the 
overweight or obese HF population. The equations presented here based on physical 
characteristics of a European population, and they may not be acceptable for application in 
populations with lower average BMI (i.e., Asian).  
A last limitation of the present study is that the sample size did not allow revalidation of the 
predictive equations (using the split half method for example). Further investigations are required 
to address this limitation (i.e., revalidation of present equations to ascertain suitability for use in 
HF population). 
5.5.  Conclusion  
This research is unique as it presents equations based on non-invasive, clinically available 
variables to predict 6MWD in HF patients. This study confirms that the predictors of 6MWD are 
the same as those in healthy adults. Non-modifiable variables (stature, sex) accounted for a large 
percentage of the variance in the 6-MWT. Thus, the clinicians can accept with confidence the 
existing prediction equations for 6MWD and interpret 6MWT performance in a meaningful way 
(percentage of predicted value). At present, such interpretation remains rare in the scientific 
literature. Prediction equations may also help to set a more effective, simple and safe CR 




The study was conducted with a set of complex variables in a small sample; thus it is essential 
that the study is continued and the results revalidated in a larger sample size with the second set 
of simpler variables identified here. 
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CHAPTER 6. ORMATIVE VALUES FOR FUCTIOAL CAPACITY TESTIG I CARDIAC PATIETS 
AD THE IFLUECE OF ATHROPOMETRIC MEASURES O PERFORMACE 
6.0.  Abstract 
 
Functional capacity testing provides an important prognostic tool. National guidelines 
recommend the use of functional capacity tests to evaluate improvements resulting from 
attending cardiac rehabilitation (CR) programmes. Previous chapter showed (see Chapter 4 
‘Biomechanical predictors of the modified shuttle walking test performance in patients with 
cardiovascular disease’) that anthropometric factors are likely to influence modified shuttle 
walking test (MSWT) performance in the cardiac population. The aims of this study were, firstly, 
to establish a validation of Chapter 4’s prediction equation based on the phase IV CR (UK 
classification) population, and secondly, to improve this equation for use in phase III CR. A 
further focus of the current study was to determine prior to CR the normal values and ranges for 
improvement in functional capacity with the MSWT. 
Distance walked in the MSWT (MSWD) was measured across 159 cardiac patients (77% males, 
23% females, mean age: 68.1±9.4 years; mean body mass index: 81.8±15.7 kg·m
-2
), at the start 
of their programme and after six weeks of phase III CR. Anthropometric data (mass, stature, 
body mass index, waist circumference) and routine clinical measurements (resting blood 
pressure) were recorded prior to and after receiving CR. The assessment also included patients’ 
primary diagnosis, type of cardiac surgery, time from event/intervention and time between pre- 
and post- rehabilitation assessment. Differences in pre- and post- rehabilitation values were 
evaluated with a paired-samples t-test. Pearson’s correlation coefficients and stepwise linear 




the magnitude of change in the MSWD during CR. The study cohort was divided into two 
groups – a development group and a validation group. An equation model for the prediction of 
pre-rehabilitation MSWD was developed with the development group and was validated using 
the validation group. Pearson’s product moment coefficient, intraclass correlation coefficient 
(ICC) and limits of agreement were also used to assess the validation of the equation model 
developed in Chapter 4 (see equation 4.1a), and for the validation of the new equation model for 
prediction of pre-rehabilitation MSWD in the phase III CR population. Finally, an one-way 
anova was performed to investigate differences in MSWD and MSWD improvement, among 
patients with different surgical diagnoses.  
Mean MSWD was 292 (±136) m in pre-rehabilitation assessment and 420 (±186) m in post-
rehabilitation assessment. Validation analysis showed a low accuracy for equation 4.1a in the 
phase III CR cohort (ICC=0.16 and LoA=81 m). Stepwise regression indicated that age, stature 
and sex were the best predictive measures for pre-rehabilitation MSWD. The model explained 
62.3% (SE=114 m) of the variance in MSWD. Validation analysis of this model showed a small 
systematic bias of 5 m but a low ICC of 0.28. Repeated stepwise regression analysis for the 
prediction of the magnitude of change in MSWD during CR showed that stature was the best 
determinant, explaining 37% of the variance. An analysis of the variance demonstrated a 
significant difference in the magnitude of MSWD change (p<0.005), between the group of 
patients involved in different surgical diagnoses.  
Age, stature and sex were independent predictors of pre-rehabilitation MSWD, while stature was 
an independent predictor of the magnitude of MSWD change during CR. These factors should be 
accounted for when the MSWT is used to assess patients’ functional capacity during phase III 




patients at the start of CR, and when decisions are being made about patients at discharge from 
CR, according to known prognostic standards.  
6.1.  Introduction  
6.1.1.  Cardiac rehabilitation service: difficulties and recommendations 
Cardiac rehabilitation (CR) programmes after a cardiac event or surgery improve exercise 
capacity, psychological status and prolong survival (Oldridge et al., 1988; O'Connor et al., 1989; 
Jolliffe et al., 2000). Despite almost universal acceptance of the health benefits of exercise-based 
CR for cardiac patients, and the established safety of CR programmes (see Chapter 7 ‘Safety of 
exercise training and exercise testing for cardiac patients, in a supervised, community-based 
cardiac rehabilitation programme’), only 25% of post-myocardial infarction (MI) patients, 75% 
of patients who had coronary artery bypass graft surgery (CABG), and 20% of patients who had 
undergone a percutaneous coronary intervention (PCI) were enrolled in a CR programme 
(Bethell et al., 2007).  
A national survey of 28 CR centres (Brodie et al., 2006) demonstrated deficiencies in CR 
services including; insufficient staff numbers, unsuccessful service delivery, failure to meet 
patient needs, insufficient numbers of exercise sessions and  a lack of exercise testing. In total, 
79% of responding centres offered fewer sessions than suggested by SIGN (Scottish 
Intercollegiate Guidelines Network 2002). Two of the main reasons for the poor provision of CR 
were lack of financial support in many CR centres and lack of cooperation from cardiologists to 
persuade them to promote CR. According to Brodie et al. (2006), 71% of CR centres performed 
exercise capacity tests when the patients were enrolled in the programme, while only 39% of the 
centres assessed patients’ exercise capacity at the end of the CR sessions. It is obvious that not 




the change in exercise status due to CR, as recommended (National Institute for Clinical 
Excellence [NICE] 2007).  
6.1.2.   The importance of exercise capacity evaluation and the use of normative values in    
cardiac rehabilitation service improvements 
Both NICE (2007) and SIGN (2002) recommend the use of exercise capacity testing when a 
patient enters an exercise-based phase III CR programme to help prescribe exercise at the correct 
levels of intensity; they also recommend such testing at the end of the CR sessions to evaluate 
improvements resulting from programme attendance. Exercise capacity testing helps clinicians to 
prescribe an individualised, safe and effective CR programme.  
The use of normative values of exercise capacity at the start of phase III CR programmes, and 
testing of exercise capacity improvement after a CR programme, can stratify patients by 
comparing their performance at the start of the programme against established norms; it would 
also set realistic expectations for improvement. Evaluating performance against normative data 
would allow CR programmes to be individualised, perhaps less stressful, less dangerous and 
potentially shorter or longer depending on patient need. CR services could be brought closer to 
patients’ needs and potentially be less expensive. Moreover, established norms in exercise 
capacity improvement after a CR programme might provide motivation to patients who 
participate in such programmes (Ades et al., 2006) and to cardiologists in giving higher priority 
to CR.  
6.1.2.1.   ormative values for exercise capacity in cardiac rehabilitation: incremental     
treadmill testing 
Normative values and predictive nomograms for exercise capacity through maximal oxygen 




(AHA), (Ades et al., 2006). Based on 2,896 coronary heart disease (CHD) patients entering CR, 
the AHA established predictive VO2max equations, accounting for patient sex and age (see 
equation 6.1). They created nomograms of VO2max stratified by age, sex and diagnosis. After 
normalisation of VO2max for body mass, there was significantly lower VO2max (22% for females 
and 39% for men) between age groups ranging from 40-80 years. VO2max was lower in patients 


















). The latter might be due to longer hospitalisation and the longer 
recovery period required after CABG surgery. The authors re-assessed 504 of the patients who 
completed 36 CR sessions and showed an increase of 17% in exercise capacity. There are no 
comparable data provided for exercise capacity after CR nor examined the effect of stature on 
exercise capacity, which seems to be clinical important. The clinical importance of stature in the 
prediction of exercise performance in CVD population was proved in previous chapters (see 
Chapter 4 ‘Biomechanical predictors of the modified shuttle walking test performance in patients 
with cardiovascular disease’ and Chapter 5 ‘Predictors of six-minute walking test performance 
in heart failure patients’) 
Equation 6.1.  (Ades et al., 2006) 
For males: VO2max = 33.970 – (0.242 × age, yrs) 
For females: VO2max = 21.693 – (0.116 × age, yrs) 





These normative values (Ades et al., 2006) are expressed as units of oxygen consumption 
normalised to body mass. Such values might be readily applicable to the US cardiac population, 
but they are less useful for a UK CR population. In the UK, exercise capacity for CR patients is 
more commonly expressed as metres of distance walked during specific walking tests (functional 




Rehabilitation [BACR] 2006) recommend the use of the incremental shuttle walking test (SWT) 
or six-minute walking test (6-MWT) to assess functional capacity in cardiac patients.  
As mentioned in Chapter 5, distance walked in 6-MWT can be converted into VO2max (Cahalin et 
al., 1996); while VO2max and distance walked in the SWT can also be converted into an estimated 
value of metabolic equivalents (American College of Sports Medicine [ACSM] 2005). The 
metabolic equivalent (MET) is a widely used physiological unit and expresses energy cost of 
physical activities. It is defined as the ratio of metabolic rate during an activity to a standard 
metabolic rate while seated and resting (Byrne et al., 2005). The definition of MET appears 
problematic in clinical populations, including CVD patients (Byrne et al., 2005; Savage et al., 





, overestimated resting oxygen consumption in 23-36% of CVD patients. This value 
depends on disease status, lean body mass, age and sex of the patient (Byrne et al., 2005; Savage 
et al., 2007).  
Established MET values (ACSM 2005) appear accurate for healthy populations but less so for 
cardiac patients (Woolf-May and Ferrett 2008). Woolf-May and Ferrett (2008) measured 31 
post-MI patients who participated in phase IV CR along with 19 healthy adults. All patients 
performed the SWT; healthy participants performed the SWT and a treadmill test using walking 
speeds derived from SWT. VO2max was obtained during exercise testing. As expected, healthy 
adults walked further in the SWT than cardiac patients. MET values were significantly higher in 
cardiac patients compared with healthy participants, at each SWT level. In cardiac patients, MET 
values were similar at different walking speeds on the SWT and the treadmill. MET values may, 
therefore, underestimate exercise capacity (oxygen consumption) in CR patients. Woolf-May 
and Ferrett (2008) concluded that where direct measure of VO2max is not taken, extra caution is 




recommended that, ‘new cardiac patient-based reference MET values’ should be established and 
validated for use in the CR population. This research has not been undertaken. 
Given such problems, estimated functional capacity in METs may be inaccurate in CVD 
patients, when the equation for estimating METs is based on healthy participants. This suggests 
an even greater the need to establish normative values for functional capacity testing, measured 
in distance walked, for the most frequently used walking tests in the UK. Reference values exist 
for the 6-MWT in post-cardiac surgery patients (see ‘Fiorina et al., 2007’ below) and although 
cardiac surgery patients (CABG, PCI) make up 78% of CR patients in UK (Bethell et al., 2007) 
the 6-MWT is not routinely used.   
6.1.2.2.   ormative values for functional capacity in cardiac rehabilitation: the six-minute 
walking test  
Fiorina et al. (2007) provided normative values for distance walked in the 6-MWT, based on 
1,370 patients admitted for intensive CR following CABG, valve replacement or other cardiac 
surgery. Sex, age, diabetes mellitus and the type of cardiac surgery all significantly contributed 
to the prediction of 6-MWT distance. The distance walked was lower with increased age, while 
men walked 60-74 m further than women across all age groups. After CABG, patients walked 
significantly further in the 6-MWT than patients who had undergone other surgeries.  CR was 
conducted twice daily for 2.1 (±0.4) weeks (mean 30 sessions).  Following the CR programme, 
348 patients were re-assessed, showing a 46% increase in distance walked. The authors did not 
consider the patients’ medical treatment after cardiac surgery, nor changes during CR. Thus, it is 
unclear whether the medications used had an influence in terms of exercise tolerance. The CR 
programme used was also not consistent with current guidelines (SIGN 2002; BACR 2006), 




The major limitation of this Italian study in terms of UK CR is that only 10% of CR services in 
the UK use the 6-MWT to assess functional capacity (Brodie et al., 2006).  
The 6-MWT is largely restricted to use in heart failure (HF) (Cahalin et al., 1996; Faggiano et 
al., 2004). The SWT is more physiologically demanding than the 6-MWT, due to the 
incremental increase in intensity during the test and its continuous nature. Thus, the SWT is 
more valid in assessing functional capacity in less severe cases of clinically stable CR patients. 
The SWT is recommended by UK clinical guidelines (SIGN 2002) as a valid and reliable 
measure for determining functional capacity before and after CR, in patients who have 
experienced an MI, and patients who have undergone cardiovascular surgery or pacemaker 
insertion (Payne and Skehan 1996; Tobin and Thow 1999; Francis 2000; Lewis et al., 2001; 
Woolf-May and Ferrett 2008). Chapter 3 (see ‘Long-term reliability of the modified shuttle 
walking test in clinically stable cardiovascular disease patients’) demonstrated, for first time, the 
long-term (>8 weeks) test-retest reliability of SWT.  
Functional capacity has good prognostic value in CVD patients and is unique among CVD risk 
factors in that it can only be improved with exercise and not treated pharmacologically. A 
number of studies have demonstrated improvements in functional capacity when the SWT is 
performed after a CR programme, but there is a wide range of in performance values among the 
studies. It is necessary to establish performance indicators that measure the effectiveness of CR 
as a treatment to increase functional capacity. There appear to be no established normative 
values for the SWT in the literature to suggest what an expected or effective improvement in 






6.1.3.  Functional capacity assessment in phase III cardiac rehabilitation  
6.1.3.1.  Functional capacity in cardiac rehabilitation patients, assessed by the shuttle 
walking test 
Next, is a brief review of the literature concerning SWT performance values in patients 
participating in phase III or centre-based CR. Table 6.1 summarises these studies, detailing 
patient cohorts, the number of CR sessions, the duration of the CR programme, its outcomes and 
improvement. Tobin and Thow (1999) found a significant improvement of 117 m in the SWT 
after a long (12 weeks) hospital-based CR programme. This was the largest increase among all 
studies reviewed (see table 6.1). The authors did not give clear details about patients’ daily 
activities outside the class, which may have influenced their functional capacity, while the small 
sample (n=19) does not allow for broad generalisations. Fowler et al. (2005) found an increase of 
82 m in SWT performance following an exercise-based CR programme. Unfortunately, the 
authors gave no information regarding the number of sessions patients attended. If, as is 
common, only one weekly session was attended (as is common in the UK), patients took part in 
only six sessions in total during the CR programme. This might explain the smaller improvement 
in functional capacity achieved.  
Arnold et al. (2007) used the SWT to assess the effects of once- versus twice-weekly CR in post-
MI patients and they demonstrated an improvement of 101 m and 89 m respectively. Over the 
six-week period, a small number of training sessions were as effective as a larger number of 
training sessions. The lower number of training sessions might be more economical, which is an 
important issue noted earlier. The patients were asked to record home activities diaries, but it is 
not clear how this information was included in the analysis or measured outcomes. Sandercock et 
al. (2007) showed larger improvements in functional capacity (109 m) following CR in CVD 




did not perform the SWT. This study did not put restrictions on activities during the research 
period. These results suggest that training had induced a large improvement in functional 
capacity, in this population.  
Continuing the theme of reducing CR costs, Robinson et al. (2009) used the SWT in 100 low 
risk CVD patients to determine whether they could be fast-tracked to community-based phase IV 
CR, instead of beginning phase III hospital-based programme. The patients were randomly 
divided into two groups. One group attended hospital-based phase III CR (n=54); the other a 
community-based phase IV CR group (n=46). The phase III group showed a mean improvement 
of 58 (±12) m and the phase IV group showed a mean improvement of 60 (±25) m after a six-
week CR programme using the SWT. There was no significant difference in performance 
between groups (p>0.5). The authors concluded that both services were effective in improving 
functional capacity and suggested that the fast-track service is safe and encourages long-term 
exercise adherence. Despite these positive conclusions, this study reports the smallest 
improvement in functional capacity after CR among all the above studies (see table 6.1). The 
source of this difference in functional improvement between the above study (Robinson et al., 
2009) and previous studies (Tobin & Thow 1999; Fowler et al., 2005; Arnold et al., 2007; 
Sandercock et al., 2007) is likely to be due to regression towards the mean suggestions 
(Ostermann et al., 2008) rather than by the treatment in question. According to the theory of 
regression toward the mean, patients with the highest baseline performance values (as in 
Robinson et al.’s study) tended to show less improvement at re-assessment following a CR 
programme (Ostermann et al., 2008).  
These studies highlight the effectiveness of CR exercise intervention by comparing pre- with 
post- intervention SWT performance. The training stimulus varied from six to twelve weeks 




studies reviewed here are supported by a survey carried out across England in 28 CR centres. 
The survey showed that the mean length of the CR courses was 7.1 weeks, and the mean number 
of exercise sessions offered was 11.6 (Brodie et al., 2006).  
After exercise training, the mean improvement in SWT distance was 93 m, while the mean 
percentage of improvement is 19% (based on meters) or 9.5% (based on estimated METs). The 
magnitude of the differences in the means represents a moderate effect size of d=0.48 (Cohen 
1988). Using the data presented in table 6.1 a Pearson’s correlation showed that there was no 
significant association between functional capacity improvement and CR exercise duration, or 
between improvement and the number of training sessions (p>0.5). This seems to be consistent 
with Arnold et al.’s (2007) results, where no additional benefit was found in a 12-session CR 
exercise programme versus a 6-session programme. Both programmes had a similar influence on 
outcome measures. 
To determine whether the MSWT is valid, it is necessary to compare it as an evaluative tool with 




Table 6.1. Review of functional capacity improvement during centre-based outpatient cardiac rehabilitation, assessed by the modified shuttle walking test 





























Tobin & Thow (1999) CABG 
n=19 
N/A N/A N/A 117 N/A N/A N/A 12 24 
Fowler et al. (2005) CABG 
n=39 
481 ± 138 5.5 ± 3.9 563 (SD N/A) 82 17 0.5 9.1 6 N/A 
Arnold et al. (2007) MI 
A: n=85  
B: n=121  
A: 409 ± 166 
B: 469 ± 153 
A: 5.0 ± 3.9 
B: 5.5 ± 3.9 
A: 510 ± 191 
B: 557 ± 171 
A: 101 










6 A: 6 
B: 12 




488 ± 214 5.5 ± 4.2 597 ± 235 109 22.3 0.5 9.1 8 8 
Robinson et al. (2009) MI, CABG 
n=54 
618 ± 165 6.0 ± 3.9 676 ± 177 58 9.4 0.6 10 6 6 
Mean 493  5.5 581 93  19 0.5 9.5 9.5 11 
 Definition of abbreviations: SWD=distance walked in shuttle walking test; MI=myocardial infarction; CABG=coronary artery bypass graft; PCI=percutaneous coronary  




6.1.3.2.  Exercise capacity in cardiac rehabilitation patients, assessed by the treadmill test 
Studies that used the SWT to evaluate functional capacity improvement in CR patients are 
limited. There are, however, numerous studies using treadmill testing, to demonstrate exercise 
capacity (measured as oxygen consumption) improvement during phase III CR. Table 6.2 
highlights the main findings regarding changes in exercise capacity after hospital-based 
outpatient (phase III, UK classification) CR assessed by  treadmill testing. Applying a meta-
regression approach to the data presented in table 6.2, a Pearson’s correlation showed a high 
negative correlation between exercise capacity improvement and duration of the CR programme. 
This was true when exercise capacity was expressed either as an absolute value in METs or as 
percentage improvement from baseline (r1=-0.93, r2=0.88, respectively; p<0.005).  
Changes in exercise capacity were not significantly associated with the number of CR exercise 
sessions (p>0.5). These associations mean that shorter exercise programmes can be as effective 
as longer programmes, while the number of sessions does not relate to the programmes’ 
effectiveness. This might be a result of large variance in CR programmes and in the cohorts used 
in different studies; some might have used a more intense but shorter exercise programme than 
others. Not all studies provided information regarding the mean number of sessions attended. 
Some of the studies, included in table 6.2, used a CR programme over eight weeks (Ades et al., 
1995; Lavie and Milani 1995; Balady et al., 1996; Carlson et al., 2000; Seki et al., 2003; Adams 
et al., 2008; Seki et al., 2008; Onishi et al., 2010); however, two studies have demonstrated that 
after six to eight weeks of outpatient phase III CR, patients do not further improve their exercise 




Table 6.2.  Review of exercise capacity improvement during centre-based outpatient cardiac rehabilitation, assessed by the treadmill test 









Miller et al.  (1984) MI 
n=61 
2.1 ± 1.4 2.0 N/A 8 24 
Ades et al. (1995) MI, CABG 
n=60 
N/A N/A 16  12  N/A 
Lavie & Milani (1995) CHD 
n=458 
6.6 ± 2.2 2.4 38 14 36 
Balady et al. (1996) MI, CABG, PCI 
n=500 
7.3± 3 N/A 36 10 N/A 
Carlson et al. (2000)  MI, CABG, PCI 
n=78 
6.7 ±1.7 0.4 6.3 24 72 
Seki et al. (2003) CHD 
n=38 
6.7± 1.0 0.1 1.3 24 24 
Adams et al. (2008) MI 
n=210 
6.6 ± 2.7 2.1 32 12 N/A 
Seki et al. (2008) CHD 
n=20 
6.8 ± 1.0 0.5 7.7  24 24 
Onishi et. al. (2010) CHD 
n=37 
6.4 ± 0.9 0.2 3.6 24 24 
Mean 6.1  1.1 17.6 17 34 




6.1.3.3.   Differences in exercise capacity improvement between studies performed using the 
treadmill test and those using the shuttle walking test 
A comparison of the data in tables 6.1 and 6.2 shows that the mean exercise capacity 
improvement after CR, (as METs or percentage improvement), is higher in studies that used the 
treadmill test than those using the SWT. This might be due to many potential factors such as, the 
higher sensitivity of treadmill testing for detecting exercise capacity changes or walking speed 
differences between the two tests. For example, in the modified Bruce treadmill protocol the 
grade but not the speed is increased at each stage whereas for the SWT only the speed is 
increased at each stage. Differences may be attributable to lower baseline values for exercise 
capacity in studies used the treadmill test (regression toward the mean) or perhaps the inaccuracy 
of MET values in CVD cohorts (Savage et al., 2007; Woolf-May and Ferrett 2008). There are 
also differences, however, in the training stimuli between the two groups of studies. The mainly 
US-based CR programmes which have used the treadmill test tend to be longer and contain a 
greater number of exercise sessions than the SWT studies.  
Due to systematic differences in both the training stimulus and the exercise assessment protocols 
these two groups of studies are difficult to compare. A study using a UK training protocol (8 
sessions over 8 weeks) that assessed changes in exercise capacity via treadmill testing would, 
however, rectify this situation. 
6.1.4. How to improve the accuracy of exercise capacity assessment  
Given the importance placed upon increasing exercise (functional) capacity in CR, it is 
surprising how few data are available to evaluate whether the ‘typical’ UK service is effective. 
Table 6.1 contains all the available data on UK CR services (n=356). Most are cohort studies 




effectiveness of a CR system is to perform a service evaluation research. Service evaluation has 
been defined as ‘the systematic collection of research data to assess effectiveness of 
organisations, services, and programmes (i.e., health service interventions) in achieving 
predefined objectives’ (Shaw 1980, cited in Bowling 2002). Service evaluation research takes 
place in ‘real-world’ NHS settings and does not allow the researcher to control aspects of the 
research process to the same degree as do other research designs (such as randomised controlled 
trials). Service evaluation is usually performed to meet specific local requirements.  
Service evaluation can also give important knowledge regarding normal values and ranges for 
improvement in functional capacity tests (i.e., SWT), in CR. Their use could improve patient 
care in CR and help practitioners make informed choices regarding their recommendations to 
patients at their discharge from the programme. For instance, if a patient’s functional capacity 
has not improved during phase III CR, it may be decided that they should be retained on the 
programme or strongly encouraged to enrol in a phase IV programme.  
There seems little doubt that if normative values for functional capacity tests are used to inform 
practice, could improve the accuracy of functional capacity assessment. In Chapter 5, an 
extended analysis was presented regarding data from previous studies, in which anthropometric 
variables were used to predict functional capacity test performance in healthy adults (Enright and 
Sherrill 1998; Gibbons et al., 2001; Enright et al., 2003; Camarri et al., 2006; Chetta et al., 2006; 
Poh et al., 2006; Jenkins et al., 2009), with only one study that evaluated anthropometric 
associations in a clinical population (Ingle et al., 2006).  
These studies all concerned the 6-MWT and no comparable data exist for the SWT. A pilot study 
has already been completed (see Chapter 4) with sixteen phase IV CR patients, where it was 
suggested that taller CVD patients have an advantage over shorter patients when performing the 




performance and remove some of the bias towards taller patients. These results are very 
important to the clinical practice of CR. Methodological issues, such as small sample size, a non-
validated equation and the nature of the CR cohort, indicated limited scope for generalisation. 
Taking into account the importance of the findings and the limitations derived from the pilot 
study, there is a need for further investigation in this area.  
6.1.5.  Aims and hypothesis  
The two primary aims of this chapter are to determine normative values for functional capacity 
before and after CR, and the magnitude of change in functional capacity in phase III CR patients 
from a typical cohort. Secondary aims were to revisit Chapter 4 in a larger, phase III cohort and 
examine the anthropometric predictors of MSWT performance (distance walked in MSWT 
[MSWD]).  
6.2.  Methods 
6.2.1.  Participants 
The sample comprised 159 (122 males and 37 females) patients aged 36 to 87 years. Data from 
the records of the previous 12 months (September 2009 – September 2010) for cardiac patients 
referred for CR at two UK NHS trusts (Broomfield hospital and West Cumberland hospital) 
were examined. The cardiac care providers (specialist CR nurses) working within each hospital 
were responsible for identifying patients. A list of patients, with access to their records, was 
provided by the CR nurse in charge of care provision. Patient records were assessed, including a 
description of CR services, patients’ characteristics, time from operation or event to enrolment in 
the rehabilitation centre, pre-rehabilitation and post-rehabilitation assessment measurements, and 
time from pre-rehabilitation assessment to post-rehabilitation assessment. Table 6.3 summarises 




All procedures were approved by the University of Essex Ethics Committee, the National 
Research Ethics Service (NRES) and conformed to the declaration of Helsinki guidelines (World 




Table 6.3. Descriptive characteristics and baseline measurements of participants 
Clinical characteristics and baseline measurements Values 
Number of patients 159 
Sex (%) Males=122 (77%) – Females=37 (23%) 
Age (years) (mean ± SD)  68.1 ± 9.4 
Body mass (mean ± SD)  Pre-rehab: 81.8 ± 15.7 
Post-rehab: 80.6 ± 15.0  
Stature (cm) (mean ± SD)  
 Median value (25
th
 percentile)  
 Median value (75
th
 percentile)  
170 ± 8.5 
165 
175 
BMI (kg · m
-2
) (mean ± SD)  Pre-rehab: 28.3 ± 4.4 
Post-rehab: 28.0 ± 4.9 
Waist circumference (cm) (mean ± SD) Pre-rehab: 78.1 ± 16.1 
Post-rehab: 76.1 ± 21.8 
Medical primary diagnosis (%) 
  CHD 
 NSTEMI         
 STEMI 
 Valvular heart disease  
 Other 




n=7 (4.4%)       
n=18 (11.3%)  
n=6 (3.8%)  
n=7 (4.4%)                    
Surgical diagnosis  
 CABG 
 PCI 
 Valve replacement  
 Other 







Smokers n=15 (9.4%) 
Diabetes  n=30 (18.9%) 
Time from surgical intervention procedure or event (weeks) 7.6 ± 4.6 
Time to retest (weeks) 7.2 ± 2.3 
Medication  




 Ace Inhibitor 
 GTN 
Pre-rehab  
n=121 (76.1%)  
n=117 (73.6%)  
n=139 (87.4%)  
n=33 (20.8%)  
n=98 (61.6%) 








Definition of abbreviations: CHD=coronary heart disease; 3STEMI=non-ST-segment myocardial infarction; 
STEMI=ST-segment myocardial infarction; CABG=coronary artery bypass graft, PCI=Percutaneous 




6.2.2.  Cardiac rehabilitation exercise programme 
All the patients had been enrolled in a hospital-based phase III CR (UK classification) 
programme for six weeks. The patients joined the CR programme at a mean of 7.6 (±4.6) weeks 
after an acute cardiac episode or surgical intervention. The CR programme followed the BACR 
guidelines (2006) and consisted of two supervised sessions per week, involving 12 exercise 
sessions over a period of six weeks. Supervisory personnel included (CR) specialised 
physiotherapists and exercise staff, who were trained in life support techniques. The sessions 
consisted of 60 minutes of circuit-based exercise, with 15-minutes warm-up, 30-minutes main 
conditioning component and 15-minutes cool down. The warm-up included mobility exercises 
and stretches; the main component of the session included cardiovascular and strength exercises 
using exercise equipment (an arm, cycle and rowing ergometers, progressive resistance 
equipment, balance equipment, steppers, free-weights) at an intensity of 60 to 75% of their age-
predicted maximal heart rate (HR); the cool-down included gently paced recovery exercises, 
mobility exercises and stretches.  
6.2.3.  Cardiac rehabilitation assessment 
Patients were referred to the CR programme by their cardiologists. Patients included in phase III 
CR underwent cardiac assessment at entry to and at the completion of the programme, with a 
mean of 7.2 (±2.3) weeks between the two assessments. The assessment included medical and 
pharmacological history, a primary health assessment (pre-exercise health questionnaire, resting 
HR and resting blood pressure measurement), anthropometric assessment and exercise testing. 
Anthropometric assessment included measurements of stature, body mass and waist 
circumference. BMI was then calculated as follows: mass (kg)/stature (m
2
). All patients 
participated in the sub-maximal modified shuttle walking test (MSWT), as described in Chapter 




6.2.4.  Statistical Analysis  
Descriptive analysis was used to describe the sample under examination here. Data were 
presented as mean and standard deviations. The median value of stature was calculated; Stature 






 percentile of the distribution). A paired-
samples t-test was conducted to evaluate the changes in the functional capacity and the 
physiological variables during phase III CR. 
In order to evaluate how well (validate) the prediction equation 4.1a, developed in Chapter 4 
(pp.196), for estimating MSWD of patients ending phase III CR, a Pearson’s product moment 
coefficient, an intraclass correlation coefficient (ICC) and limits of agreement (LoA) test (Bland 
and Altman 1986) were calculated. The Bland and Altman (1986) method sets limits of 
agreement and confidence intervals around the average difference between the actual and 
predicted MSWD. In order to use this method, first step was to calculate the difference in 
MSWD (predicted-actual) for each patient and then to plot these individual difference MSWDs 
against individual average MSWDs. The average MSWDs were calculated by summing the 
individual actual and predicted MSWD and then dividing this sum by two. The standard 
deviation (SD) of the difference MSWDs is used to set the upper (+2SD) and lower limits of 
agreement (-2SD). It would be expected most of the MSWDs (95%) to lie between ±2SD, if the 
difference MSWDs are normally distributed. The smaller the limits of agreement (the smaller the 
error variance), the greater the predictive accuracy of the equation (Heyward and Wagner 2004). 
Due to low accuracy of equation 4.1a, another regression analysis based on the current phase III 
CR population was performed. The current population was randomly divided into two groups 
(development population and validation population). For this purpose, an electronic program 




Relationships between variables measured during the pre-rehabilitation assessment were tested 
in the development population using a correlation coefficient (Pearson’s product moment or 
Spearman’s rank). After determining which variables were most strongly related to MSWD 
(r>0.3), stepwise linear regression analysis was performed to assess the combined associations in 
the development population. The accuracy of the new equation model was evaluated in the same 
way as was done for equation 4.1a (Pearson’s product moment coefficient, ICC and LoA test).  
In order to assess the factors that might associate with magnitude of change in functional 
capacity during phase III CR, stepwise regression analysis was performed. Prior to the regression 
analysis, difference in MSWD between pre- and post- rehabilitation assessment was calculated 
per each individual, and a correlation coefficient (Pearson’s product moment or Spearman’s 
rank) was used to determine which variables were most strongly related to MSWD (r>0.3).  
In all cases, the stepwise linear model was chosen in favour of other models because the 
objective was to identify the lowest number of variables that most influenced the test results. The 
regression used, only, those independent variables for which the coefficient correlation with the 
other independent variables was less than 0.75, in order to minimise multicollinearity and to 
avoid high correlation between the variables (Meyers et al., 2006). The probability of F for entry 
was set at 0.05 and for removal at 0.1; these were set as the statistical criteria that the dependent 
variables needed to attain in order to be included in the analysis.  
After determining the predictors of the MSWT, the next step was to establish normative values 
for male and female patients separately. Thresholds values were identified for predictors and 
they were encoded by using 0 and 1. Then, mean values of MSWD for each subgroup were 
computed via univariate analysis. One-way ANOVA was performed to investigate differences in 




analysis was performed using SPSS version 16.0 (SPSS inc., Chicago, IL, US); calculations were 
presented in Microsoft Office Excel 2003 (Microsoft Corporation, Washington, US). The 
statistical significance was set at the 0.05 level.  
6.3.  Results 
6.3.1.  Changes in physiological measurements due to cardiac rehabilitation in phase III 
Table 6.4 provides values for the physiological measurements taken before and after phase III 
CR. There was a statistically significant increase in MSWD, between the two assessments: t=-
12.1, p<0.001 (two-tailed). Of particular note, there was also a significant increase in SBP (4 
mmHg) between the two assessments: t=-2.4, p<0.05 (two-tailed). A small and non-significant 
decrease between the two assessments was found for body mass (0.17 kg) and waist 





















MSWD (m) 292 (136) 420 (186) -128 (-148 to -107) -12.1 <0.001 
RPE score 11.4 (2.1) 11.7 (2.1) -.3 (-1.3 to 0.6) -0.65 0.518 
Maximum HR (bpm) 88 (17) 89 (15) -1 (-4 to 3) -0.34 0.733 
HR 5 min after the end of the test (bpm) 68 (13) 70 (12) -2 (-5 to 1) -1.55 0.130 
Resting SBP (mmHg) 133 (19) 137 (19) -3.74 (-6.81 to -0.67) -2.40 0.017 
Resting DBP (mmHg) 76 (9) 76 (9) -0.23 (-1.69 to 1.22) -0.32 0.752 
Body mass (kg) 80.7 (14) 80.6 (15) 0.17 (-0.63 to 0.97) 0.43 0.668 
BMI (kg·m
-2
) 28 (3.8) 28 (4.9) -0.06 (-0.57 to 0.45) -0.25 0.800 
Waist Circumference (cm) 96.1 (11.6) 95.4 (11.2) 0.7 (-4.41 to 4.32)  -0.02 0.982 
Definition of abbreviations: MSWD=distance walked in modified shuttle walking test; RPE=Borg rating of perceived exertion; bpm=beats per minute; 




6.3.2.  Validating the prediction equation developed in Chapter 4 
The correlation and level of agreement between actual and predicted MSWD, by using equation 
4.1a, were weak. Due to the lengthy data analysis, the results of this section (6.3.2.) are included 
in appendix A1. Another regression analysis was, therefore, performed using the variables 
outlined in Chapter 6; a new MSWT prediction equation was created.  
6.3.3.  Predictors of the modified shuttle walking test in phase III cardiac rehabilitation  
The cardiac population in this study was split randomly into two groups; development group 
(n=79) and validation group (n=80). In the development group, the mean MSWD was 287 
(±142) m in the pre-rehabilitation assessment; in the validation group, the MSWD was 295 
(±131) m.  Sex, age and stature were the only variables that showed a significant correlation with 
MSWD in the development group. In particular, age was negatively and moderately associated 
with MSWD, while stature and sex showed a positive, moderate association with MSWD (see 





Table 6.6. Correlations between independent variables and modified shuttle walk distance in the 
phase III cardiac rehabilitation (development group) 
Variables  Spearman rho P value 
MSWD – Sex * 79 0.508 <0.001  
MSWD – Diabetes mellitus * 79 -0.153 0.178 
Variables  Pearson r P value 
MSWD – Age 79 -0.351 0.002 
MSWD – Stature 77  0.412 <0.001 
MSWD - Body mass 79  0.181 0.110 
MSWD - BMI 77 -0.088 0.448 
MSWD - SBPresting 79 -0.142 0.212 
MSWD - DBPresting 79 0.100 0.378 
MSWD - Time from procedure or event 75 - 0.117 0.318 
Definition of abbreviations: MSWD=distance walked in modified shuttle walking test; BMI=body mass index; 
SBP=systolic blood pressure; DBP=diastolic blood pressure 
* Data were coded: for Sex- Male=1, Female=0; for Diabetes mellitus- Yes=1, 3o=0 
 
Next, the independent variables, sex, age and stature, which were correlated (r>0.3) with MSWD, 
were further analysed using multiple linear regression analysis (Pallant 2007). The regression used 
only those independent variables for which the correlation coefficient with the other independent 
variables was less than 0.75, in order to minimise multicollinearity and to avoid high correlation 
between the variables (Meyers et al., 2006).  
The regression analysis showed that age, stature and sex should be included in the final model. In 
this model, 62.3% of MSWD was explained by age, stature and sex, with a standard error of 114 
m.  The predicted result was calculated by using the following regression equation: Y=A+(B×X), 
where Y is the predicted value of the dependent variables (predicted MSWD in m), A is the Y 
intercept (the value Y when the X value is zero), X indicates the rate of the independent variable 




regression analysis (Tabachnick and Fidell 2007). Predicted MSWD would be computed by using 
the equation form for each individual. 
The intercept value (A) was -115 m. The coefficient (β value) for age was -6.1; the coefficient 
for stature was 4.4; and the coefficient for sex was 97 (see equation 6.1a). The 5
th
 percentile of 
pre-rehabilitation MSWD distribution for development group was 60 m, so the lower limit of 
normal range (LLN) was computed by subtracting 60 m from the equation (see equation 6.1b). 
The predictive equation for MSWD produce was:  
Equation 6.1a. MSWD = (4.4 × stature, cm) – (6.1 × age, yrs) + (97 × sex) - 115 
Equation 6.1b. MSWD(LLN) = (4.4 × stature, cm) – (6.1 × age, yrs) + (97 × sex) - 175 
where: MSWD=distance walked in modified shuttle walking test (m); LL3=lower limit of normal range; sex: M 
=1, F=0 
 
6.3.4. Validation of the prediction equation developed in the phase III cardiac 
rehabilitation cohort 
The accuracy of the prediction equation developed in the phase III development CR population 
(development group) was assessed by predicting MSWD in the validation CR population 
(validation group). The predicted result was calculated by using the regression equation 6.1a.  
6.3.4.1.   Correlations between actual and predicted distance walked in the modified shuttle 
walking test in the validation population 
Actual MSWD had a significant correlation with predicted MSWD (Pearson’s r=0.307, p=0.006) 
when age, stature and sex were entered into the equation model. This relationship between 





Figure 6.3. Regression line for the relationship between actual pre-rehabilitation and predicted pre-
rehabilitation performance (using equation 6.1a) 
6.3.4.2.   Agreement between actual and predicted distance walked in the modified shuttle 
walking test, in phase III cardiac rehabilitation 
The ICC between actual and predicted MSWD with 95% confidence intervals (post-
rehabilitation MSWD) was low, at 0.28 (p=0.007). The mean difference and the limits of 
agreement (for MSWD) are shown in table 6.7 and figure 6.4. The standard deviation (130 m) of 
the difference MSWDs indicates that the difference between predicted and actual MSWD could 
be expected to be within -255 m and 265 m.  
Table 6.7. Agreement statistics: Mean difference (95% confidence intervals) between  predicted- and 
actual pre- rehabilitation distance walked in modified shuttle walking test (using equation 6.1a) 
 
Mean (SD)  
Difference 
95% confidence 
 interval from the 
mean difference  
2SD Limits of agreement 
(mean±2SD) 
MSWD (m) 5 (130) -24 to 35 260 -255 to 265 





Figure. 6.4. Limits of agreement plot (Bland and Altman plot) (using equation 6.1a). Intraindividual 
differences between performances in walking-test scores (predicted-actual distance walked) plotted 
against the mean of the sum scores, in training group (phase III cardiac rehabilitation). The central line 




6.3.5.  Multivariate determinants of change in modified shuttle walking distance.  
The difference in MSWD between pre- and post-rehabilitation assessment was calculated for 
each individual. The mean difference was 25 (±46) m. The correlations between independent 









Table 6.8. Correlations between independent variables and change in modified shuttle walk 
distance in the phase III cardiac rehabilitation (n=159) 
Variables  Spearman rho P value 
MSWDchange – Sex* 149 0.030 0.718 
MSWD – Diabetes mellitus * 149 -0.008 0.918 
Variables  Pearson r P value 
MSWDchange – Age 149 -0.277 0.001 
MSWDchange – Stature 145  0.190 0.281 
MSWDchange - Body mass 149  -0.139 0.091 
MSWDchange – BMI 145 -0.086 0.306 
MSWDchange – Waist circumference 46 -0.015 0.922 
MSWDchange - SBPresting 149 -0.199 0.015 
MSWDchange - DBPresting 149  0.003 0.973 
MSWDchange – Time to retest 123 0.168 0.064 
Definition of abbreviations: MSWD=distance walked in modified shuttle walking test; BMI=body mass index; 
SBP=systolic blood pressure; DBP=diastolic blood pressure 
* Data were coded: for Sex- Male=1, Female=0; for Diabetes mellitus- Yes=1, 3o=0 
Since none of the variables had a correlation >0.3 with the change in MSWD, all the variables 
were first checked for multicollinearity and then entered into the stepwise regression analysis. 
Body mass was excluded from the analysis due to high collinearity with BMI (VIF>10) (Meyers et 
al., 2006).  
The linear regression analysis showed that only stature significantly predicted MSWD in the 
final model, explaining 37% of the variance. The intercept value (A) was found to be 764 m. The 
coefficient (β value) for stature was -4.2 (see equation 6.2a). The 5
th
 percentile of change in 
MSWD distribution was 40 m, so the lower limit of normal range (LLN) was computed by 





For the MSWT, the equation for predicting change in MSWD in phase III CR is:  
Equation 6.2a. MSWDchange = 764 - (4.2 × stature, cm)  
Equation 6.2b. MSWDchange(LNN) = 724 - (4.2 × stature, cm)  
where: MSWD=distance walked in modified shuttle walking test (m) 
 
6.3.6.  ormative values for functional capacity and magnitude of change in functional 
capacity during phase III cardiac rehabilitation  
The threshold values that identified predictors are shown in table 6.9; they represent median 
values of normal distributions.  
Table 6.9.  Threshold points for predictors 
Variables Threshold values Identifications  
Age (median; yrs)  69 
 
≥ 69: old  
< 69: young 





≥ 172: tall 
≤ 172: short 
Females: 
≥ 160: tall 
≤ 160: short 
Tables 6.10, 6.11 and 6.12 present the normative values of pre-rehabilitation MSWD, post-
rehabilitation MSWD and magnitude of change in MSWD, respectively. The highest values of 
MSWD (pre- and post- rehabilitation) and change in MSWD were recorded for males who were 
younger than 69 years and taller than 172 cm, while the lowest values were recorded by females 










Table 6.10. ormative values for pre-rehabilitation modified shuttle walking test performance  
 Male               Female 
 Young 
< 69 years 
Old 
≥ 69 years 
Young 
< 69 years 
Old 
≥ 69 years 
Short (M<172cm; F<160cm) 330 ± 111 m 
n=26 
267 ± 114 
n=29 
176 ± 61 m 
n=8 
236 ± 93 m 
n=7 
Tall (M ≥ 172 cm; F ≥ 160 cm) 391 ± 114 m 
n=28 
309 ± 156 
n=39 
221 ± 93 m 
n=9 
147 ± 59 
n=13 
Definition of abbreviations: M=values for males; F=values for females 
 
 
Table 6.11. ormative values for post-rehabilitation modified shuttle walking test performance  
 Male Female 
 Young 
< 69 years 
Old 
≥ 69 years 
Young 
< 69 years 
Old 
≥ 69 years 
Short (M<172 cm; F<160 cm) 484 ± 191 m 
n=25 
408 ± 155 m 
n=27  
332 ± 137 m 
n=8 
330 ± 59 m 
n=7 
Tall (M ≥ 172 cm; F ≥ 160 cm) 553 ± 234 m 
n=25 
402 ± 158 m 
n=37  
364 ± 91 
n=8 
233 ± 67 
n=12 
Definition of abbreviations: M=values for males; F=values for females 
 
 
Table 6.12. ormative values for magnitude of change in modified shuttle walking test performance  
 Male Female 
 Young 
< 69 years 
Old 
≥ 69 years 
Young 
< 69 years 
Old 
≥ 69 years 
Short (M<172 cm; F<160 cm) 152 ± 119 m 
n=25 
133 ± 94 m 
n=27  
156 ± 124 m 
n=8 
94 ± 61 m 
n=7 
Tall (M ≥ 172 cm; F ≥ 160 cm) 168 ± 184 m 
n=25 
86 ± 133 m 
n=37  
158 ± 107 
n=8 
88 ± 73 
n=12 






6.3.7.  Differences in modified shuttle walking test performance between patients with 
different  surgical diagnoses 
Patients were divided into four subgroups according to type of surgical intervention: 1) coronary 
artery bypass graft surgery (CABG), 2) percutaneous coronary intervention (PCI), 3) valve 
replacement (VR), 4) none. One-way between groups analysis of the variance was used in order 
to find the impact of different interventions/invasive treatments on pre-rehabilitation MSWD and 
on changes to MSWD during CR.  
There was no statistically significant difference in pre-rehabilitation MSWD (p>0.05): F1 (3, 
154)=2.58, p=0.055, while there was a significant difference in the magnitude of MSWD 
change: F2 (3, 145)=4.11, p=0.008, among the elective subgroups. The mean values for pre-
rehabilitation MSWD are presented in table 6.13 and figure 6.5, while the mean values for 
MSWD change are presented in table 6.14 and figure 6.6, for the different elective subgroups. 
Higher mean values of MSWD (305±130 m) and MSWD change (146±123 m) were achieved by 
patients who had received CABG (see table 6.9 and 6.10).  
 
Table 6.13. Distance walked during the modified shuttle walking test in pre-rehabilitation 
assessment related to surgical diagnosis 
                           MSWD (m) 
Surgical diagnosis  
Mean SD 
CABG 98 305 130 
PCI 29 304 148 
VR 21 251 146 
NONE 10 199 102 
Definition of abbreviations: MSWD=distance walked in modified shuttle walking test; CABG=coronary artery 






Figure 6.5. Box plot of differences in the pre-rehabilitation modified shuttle walking test performance 
(MSWD) among the surgical subgroups.  
The upper edge of each box indicates the 75 percentile and the lower edge the 25 percentile of MSWD. 
The line in the box indicates the 50th percentile of MSWD (median value). The ends of the vertical lines 
(whiskers) indicate the minimum and maximum MSWD. The points outside the whiskers are outliers. 
Symbols are used to label outliers (o) and extremes (*). The label outliers range between between 1.5 and 
3 box-lengths from the 75th percentile or 25th percentile. The extreme values are MSWD values more 
than 3 box-lengths.  
MSWD=distance walked in modified shuttle walking test; CABG=coronary artery bypass graft surgery; 
PCI=percutaneous coronary intervention; VR=valve replacement 
Table 6.14. Distance walked during the modified shuttle walking test in pre-rehabilitation 
assessment related to surgical diagnosis 
                                   MSWD (m) 
Surgical diagnosis   
Mean SD 
CABG 94 146 123 
PCI 24 46 132 
VR 21 137 115 
NONE 10 131 144 
Definition of abbreviations: MSWD=distance walked in modified shuttle walking test; CABG=coronary artery 







Figure 6.6. Box plot of differences in modified shuttle walking test performance (MSWD) change during 
phase III cardiac rehabilitation, among the surgical subgroups 
The upper edge of each box indicates the 75
th
 percentile and the lower edge the 25
th
 percentile of MSWD 
change. The line in the box indicates the 50
th
 percentile of MSWD change (median value). The ends of 
the vertical lines (whiskers) indicate the minimum and maximum MSWD change. The points outside the 
whiskers are outliers. Symbols are used to label outliers (o) and extremes (*). The label outliers range 
between between 1.5 and 3 box-lengths from the 75
th
 percentile or 25
th
 percentile. The extreme values are 
values more than 3 box-lengths.  
MSWD=distance walked in modified shuttle walking test; CABG=coronary artery bypass graft surgery; 
PCI=percutaneous coronary intervention; VR=valve replacement 
6.4.  Discussion  
There are a number of reasons for performing an exercise test in CR patients; to confirm 
diagnosis of CHD, to monitor disease progression, to determine prognosis, to prescribe 
treatment, to evaluate exercise capacity at baseline and after an exercise-based CR treatment 
(Kraus et al., 2007). The MSWT is a common practical field test, in which the absolute value in 




programme (Singh et al., 1994; Fowler et al., 2005), while its role in prognosis and exercise 
prescription has not been well investigated.  
Research to date has not examined the anthropometric or clinical predictors of MSWD in a 
cardiac population, despite a wealth of data showing such variables predict 6MWD in healthy 
adults (Enright and Sherrill 1998; Gibbons et al., 2001; Enright et al., 2003; Camarri et al., 2006; 
Chetta et al., 2006; Poh et al., 2006; Jenkins et al., 2009). A pilot study was carried out on a 
phase IV population, (see Chapter 4). The present chapter aims to compensate for some of the 
limitations described in Chapter 4. Thus, one of the purposes of the present study was to validate 
the equation developed (see equation 4.1a) in a larger sample of CR patients.  
The discussion of findings will be subdivided into subsections in order to address the multiple 
aims of the study. The primary aim was to construct a more fair evaluation system enabling a 
more effective prescription of exercise therapy, by refining the prediction equation for MSWD 
and by establishing normal values for the functional capacity of patients in CR. 
6.4.1.  Changes in functional capacity: comparison with previous data 
The results of the current study showed that six weeks of phase III CR improves functional 
capacity, as assessed by the MSWT. Only five studies have previously evaluated the 
effectiveness of CR intervention using the MSWT (Tobin and Thow 1999; Fowler et al., 2005; 
Arnold et al., 2007; Sandercock et al., 2007; Robinson et al., 2009). Similar to the present 
findings, all these previous studies showed improvement in MSWD, but responses were 
relatively heterogeneous; ranging from 58 to 117 m after six to twelve weeks (6 to 24 sessions) 




The usefulness of the SWT as a predictor of prognosis and mortality in cardiac patients is not yet 
known. Using treadmill data, Franklin et al. (2003) demonstrated that a 1 MET increase in 
exercise capacity corresponds to a 10% reduction in mortality. When MSWD was converted to 
METs (Woolf-May and Ferrett 2008) the present study showed a mean improvement of 0.4 
METs due to CR. The expression of functional capacity as METs may not be wholly accurate for 
CVD populations (Woolf-May and Ferrett 2008), but it still shows an improvement in functional 
capacity and a reduction in risk for CVD mortality. Direct measures of oxygen consumption 
during the SWT are not routinely taken in clinical practice, while estimates of VO2max are 
usually used when it is necessary. MET values were derived from the ACSM equations in 
healthy people as there are no established MET values for the various SWT stages derived from 
CVD population.  
The improvements recorded here (128 m or 44% from baseline MSWD or 0.4 METs) were 
larger than in all the previously mentioned studies (see tables 6.1. and 6.2), which together, 
report a mean improvement of 93 m or 9.5% (based on estimated METs) from the baseline 
measurement (Tobin and Thow 1999; Fowler et al., 2005; Arnold et al., 2007; Sandercock et al., 
2007; Robinson et al., 2009) (see table 6.1). Studies using treadmill tests report a mean 
improvement (measured in METs) of 17.6% (Miller et al., 1984 Ades et al., 1995; Lavie and 
Milani 1995; Balady et al., 1996; Carlson 2000; Seki et al., 2003, 2008; Adams et al., 2008; 
Onishi et. al., 2010) (see table 6.2). The large improvement in functional capacity observed in 
the present study may represent regression towards the mean, where patients with a low-baseline 
values show more improvement at the re-assessment following an intervention (Ostermann et al., 
2008). 
The present data show lower pre- and post- rehabilitation values (292 m and 420 m, respectively) 




variation in MSWT outcomes between studies is probably due, amongst other factors, to 
different sampling strategies. In contrast with the present study, all previous studies, except that 
undertaken by Arnold et al. (2007), assessed volunteers. The present study was not a cohort 
study as participants did not volunteer to take part but gave an overview of outcome assessment 
issues in CR using service evaluation. It aimed to present realistic values from a non-selective 
CR population. There were no specific exclusion criteria for survey patients, and all patients 
eligible for the CR services evaluated were able to participate. It is likely that patients included 
in this study had a higher number of disorders than those in other studies. The present sample 
also has the highest mean age compared with previous data (see table 6.1). Plotting a regression 
line for the relationship between mean age and MSWT outcomes among different studies 
showed that age can explain 61% of the variance in MSWD (see figure 6.7).  
Using younger patients than the present study, Arnold et al. (2007) recorded MSWT outcomes 
similar to those in the present study than in others. Participants were post-MI patients with a 
mean age of 62 years compared with the present mean age of 68 years; they were assessed at a 
time when the mean time from pre-rehabilitation testing to hospital discharge was five weeks, 
compared with the current mean time of 7.6 weeks. These findings are in agreement with the 
previous study, which demonstrated that post-MI patients can perform better in the MSWT than 
patients with some other types of heart disease (i.e., valvular heart disease); age is associated 
with poor MSWD; and the longer the time period that has elapsed between pre-rehabilitation 
assessment and hospitalisation, the poorer the expected exercise capacity (Ades et al., 2005).  
The present study has several strengths; it comprises a large CR data set from two different 
hospitals, obtained recently (between 2009 and 2010). This is the second largest study of pre- 
and post- programme MSWT data in a CR population. Arnold et al. (2007) assessed a large 




as it was mentioned above. Jolly et al. (2009) assessed a larger cohort (n=179) using the MSWT; 
they were also involved in centre-based CR. These patients were assessed only at the end of the 
CR programme for safety reasons. The reason given for this was because they were recruited a 
few days after MI, but this cohort did not only include MI patients. The cohort was assessed after 
long-term (12 months) CR, and they recorded slightly lower post-rehabilitation outcomes than 
the present study. As the MSWT was not performed when patients started the CR programme, 
there are insufficient data here for comparison with the present findings. 
 
Figure 6.7. Regression line for the relationship between mean age and post-rehabilitation modified 
shuttle walking test performance, among different studies (Fowler et al., 2005; Arnold et al., 2007; 
Sandercock et al., 2007; Robinson et al., 2009, present study) 
MSWD=distance walked in modified shuttle walking test 
6.4.2.  Testing the accuracy of the stature-based equation in predicting shuttle waking test 
performance in patients exiting phase III cardiac rehabilitation  
The prediction equation developed in Chapter 4 (see equation 4.1a), based on the testing of phase 




CR. Post-rehabilitation data was used here, as an increase in functional capacity is usually 
established by the end of phase III CR and remains stable during phase IV (Woolf-May and 
Ferrett 2008). The present findings showed that the prediction equation developed in the pilot 
study did not yield similar estimates of MSWD as those reported in the validation sample. For 
brevity, these results have been excluded, but a further discussion of this subsection is included 
in appendix A2.  
6.4.3.  Predictors of shuttle walking test performance in cardiac patients entering hospital-
based cardiac rehabilitation  
The present study, addressed many of the limitations outlined in the pilot study of Chapter 4 (i.e., 
small sample and a well-trained group, who were accustomed to exercise). An attempt was made 
to improve the clinical validity of results by making a new prediction equation model for 
MSWD. The research was similar to Chapter 4 but repeated in a larger, less conditioned cardiac 
population who were entering an earlier phase of CR. The variables used in the current study 
were more easily measured than some of those used in the pilot study. The present study did not 
include a measurement of step length; it was previously stated that step length is a changeable 
and dynamic measure and clinicians need practical measurement procedures for regular use in 
clinical assessment. Only age, anthropometric and some clinical measures were taken in order to 
identify predictors of MSWD in phase III CR.  
The results of this study showed that age, sex and anthropometric variables are significantly 
associated with MSWD. These can be used to predict MSWD in cardiac patients entering phase 
III CR. Age, stature and sex must be considered when interpreting MSWD as they explain 62.3% 
of the variance in MSWD. Stature was expected to be associated with MSWD, in accordance 
with findings from the pilot study (see Chapter 4) and as stature is included in prediction 




2003; Camarri et al., 2006; Chetta et al., 2006; Poh et al., 2006; Jenkins et al., 2009). This, in 
combination with the fact that the equation model based on the pilot study (see equation 4.1a) 
gave a lower variance in the results it predicted (55%), indicates that the present prediction 
equation had improved and has given more accurate results for MSWD.  
Approximately 38% of variation in MSWD remains unexplained by the present equation. This 
variance is most likely to be due to many of factors not measured; cardiac function, daily physical 
activity, motivation and stress. The time elapsed from an event or surgical intervention until 
admission to phase III CR was not included in the final multivariate model of regression analysis, 
as it did not have significant predictive value for MSWD. The longer the time which had elapsed 
from leaving hospital to baseline assessment, the poorer the functional capacity recorded. Ades et 
al. (2005) also reported an age-associated decline in exercise capacity when assessed by the 
treadmill test which was particularly evident when a long time has elapsed between hospitalisation 
and testing. Of note was their finding that older cardiac patients delayed entry into CR after the 
event or intervention compared with younger patients.  
There are three observations that can be made about the prediction equation generated here. First, 
it supports the conclusion reported in the pilot study that taller CVD patients have an advantage 
over shorter patients and that they generally perform better in the MSWT. Second, younger 
patients are expected to attain better MSWD than older patients. This is in agreement with the 
present results obtained by using the 6-MWT in HF patients. Third male CVD patients tend to 
walk 97 m further (approximately 10 shuttles) in the MSWT than females. This difference in 
MSWD between sexes is smaller than the one estimated in the pilot study (16 shuttles more in 
males than females). Due to the small number of patients, sex was not included in the analysis for 
the pilot study. The difference in performance was estimated after accounting for the mean 




Specifically, the prediction model implies a 4.4 m gain in expected MSWD per cm of stature, and 
a 6.1 m loss per increase year of age. Validation of this equation showed a significant correlation 
but low test–retest reliability between actual and predicted MSWD. The LoA plot (see figure 6.4) 
shows that the relationships between the actual and predicted values seem not to be linear, and the 
equation model generated here tends to overestimate poor performers and underestimate good 
ones. A more complex statistical technique may be needed, but this cannot be carried out within 
the remit of the current thesis due to its already wide scope. 
6.4.4.  Predictors of magnitude of change in shuttle walking test performance, due to phase 
III cardiac rehabilitation 
Stature was the only variable able to predict change in MSWT. The stature-based equation for 
the prediction of the magnitude of change in the MSWD (see equation 6.2a) suggests 20 m 
(approximately) less expected improvement in MSWD due to CR, per 5 cm of patient stature. 
Taller CVD patients are, therefore, more likely to attain higher initial MSWT scores than shorter 
patients, shorter patients are expected to record more improvement in a re-assessment with 
MSWT after CR. This suggestion had been assumed in Chapter 4 and was revalidated here. 
While 37% of the MSWD change can be explained by this equation, 63% remain unexplained. 
This variance is likely due to individual differences in response to exercise training. This 
variation in individual response may arise from internal or external sources, such as individual 
clinical characteristics, health condition or even physical activity habits outside the class.   
Marchionni et al. (2003), used treadmill tests to assess change in exercise capacity after an eight-
week (40 sessions) CR programme in post-MI patients (n=161) and confirmed that age, sex and 
the type of exercise programme (home-based or hospital-based) could predict changes in 
exercise capacity. The authors assessed a number of independent variables; but interestingly did 




provide information concerning the percentage of variance explained by their equation model, 
and the overall goodness of fit of their model is not known.  
The association between stature and the magnitude of change in MSWD across phase III CR was 
significant. Moreover, men and women are expected to have the same improvement in functional 
capacity during CR, even though it is assumed that men will show higher MSWD in the pre-
rehabilitation assessment. Short CVD patients (i.e., 165 cm: 25
th
 percentile) are expected to 
improve by 42 m, or by a factor of 2.5 more than tall CVD patients (i.e., 175 cm: 75th percentile) 
from start to finish of six weeks of phase III CR. Also, the equation model 6.2 suggests that 
MSWD improvement dropped steadily by 42 m per 10 cm increase in stature, while patients 
taller than 182 cm are not expected to improve their functional capacity with the MSWT during 
an exercise-based CR programme. 
Time from test to retest did not have significant predictive value for the magnitude of change in 
MSWD observed during CR. However, it was shown that the longer the time that had elapsed 
between pre- and post- rehabilitation assessment, the higher the change expected in MSWD. This 
suggests that a longer duration of phase III exercise-based CR might facilitate greater 
improvements in functional capacity, without necessarily increasing the number of exercise 
sessions. Some patients delayed the time for post-rehabilitation assessment due to holidays. 
There was no control group in the present study and so there was no way to investigate that 
functional capacity improvement was absolutely due to exercise and not due to simply natural 
recovery.  
Overall, aside from environmental factors, it would be interesting to analyse the impact of 





6.4.5.  Is there any difference in modified shuttle walking test performance among patient 
groups with different surgical diagnoses? 
Different surgical interventions (CABG, PCI, VR, none) had no significant association with pre-
rehabilitation MSWT outcomes, but did show significant associations with the magnitude of 
improvement in the MSWT after CR. Patients receiving CABG had both the highest initial 
MSWD values and  MSWD changes after six weeks of CR than patients who had undergone 
other surgical interventions. 
Fiorina et al. (2007) found absolute distance walked in the 6-MWT was higher in CABG patients 
than in patients who had undergone other cardiac surgeries (i.e., valvular replacement). They 
also found significantly lower 6MWD in post-surgical patients compared with post-MI patients 
who had not undergone surgical intervention. The 6-MWT was performed within 2 weeks of 
surgery, meaning that post-surgical factors such as prolonged bed rest, post-sternotomy pain and 
respiratory dysfunction, could have affected these results. In the present study, baseline 
assessment was performed a mean of 7.6 ± 4.6 weeks after the event or surgical intervention. 
This is sufficient time for post-surgical wounds to heal and for physical activity to have taken 
place.  
In contrast with the present findings, Ades et al. (2006) found significantly lower pre-
rehabilitation treadmill test performance in CABG patients compared with those receiving PCI 
or suffering MI. The authors suggested this may be because CABG patients are usually 
hospitalised longer and thus they need longer recovery time than post-MI or PCI patients. There 
are a number of methodological differences between the present study and that of Ades et al. 
(2006). Ades et al. (2006) recorded oxygen consumption, not physical work capacity, as was 




explain the difference in performance between the two studies. The study population consisted of 
UK cardiac patients, whereas Ades et al. (2006)’s study consisted of US cardiac population.  
6.4.6.  The utility of the developed prediction equation models and normative values, in 
clinical practice 
Predictive equations and normative values were developed in the current study. Clinicians may 
prefer to use normative tables or equations to estimate patients’ expected functional capacity. 
Both methods provide similar performance expectations. Development of nomograms, that could 
quickly provide an accurate individualized estimate of predicted functional capacity, might also 
be a useful tool to develop for the clinicians.  To be accurate, such nomograms would need to be 
based on a larger sample size or a more varied approach than the present study. Particularly the 
population should include more females. 
6.4.6.1.  Utility of predictive equation models  
The equation models developed in this chapter can be used to estimate the percentage of 
predicted functional capacity in patients entering phase III CR, and the percentage of predicted 
functional capacity improvement during phase III CR.  
Estimating functional capacity at the start of CR (see equation 6.1) 
The percentage of predicted functional capacity recorded on the MSWT can be determined using 
only age, stature and sex. Any result higher than 100% demonstrates better than average 
functional capacity, meaning that the patient could potentially be ‘fast-tracked’ to community-
based phase IV CR, omitting phase III CR, in order to save time, money and speed the return to 




suggesting that the main focus of exercise should be an increase in functional capacity for that 
patient.  
Estimating functional capacity at the end of CR (see equation 6.2) 
By using only stature and functional capacity improvement, assessed by the MSWT after phase 
III CR, the percentage of predicted change in functional capacity for stature can be ascertained. 
In this case, any result higher than 100% shows that the goal for functional capacity 
improvement has been achieved, and the patient can continue on to a maintenance (phase IV) CR 
programme. Any result lower than 100% indicates low improvement during the exercise 
programme and it could be decided that the patient should be retained on the programme, while 
encouragement could also be given for an increase in home activities.  
6.4.6.2.  Utility of normative values 
The normal values shown here give ranges of functional capacity (pre- and post-rehabilitation) 
and ranges of improvement after a CR programme, based on age, sex and stature. Such values 
are used by clinicians to interpret raw scores of metres walked. These values show that younger 
and taller patients have an advantage when performing the MSWT.  
In female patients, the lowest pre-rehabilitation MSWDs were recorded in older patients who 
were shorter in stature, while the highest post-rehabilitation MSWDs and highest change in 
MSWD were similar to those for males, that is, they were achieved by younger and taller 
patients. This is in contrast with equation 6.1, which shows that taller and younger patients, 
independent of sex, can perform better in the MSWT at their entrance to CR. This difference 





The normative values for men and women clearly demonstrate the difference between the sexes, 
while they can also show the difference in achieved MSWD for any age or stature group. In 
general, the younger and taller a patient, the greater MSWD improvement due to CR is expected 
across sexes. These findings are in contrast to the idea related to the regression towards the 
mean, and outlined in Chapter 4; that short CVD patients can record more improvement in 
MSWD after CR intervention, in contrast with tall CVD patients. One possible explanation 
would be that taller CVD patients are always better able to cope with the increases in walking 
speed needed at the later stages of the test, and they obtain better MSWD than shorter patients. 
6.4.7.  Study limitations  
A significant limitation of this study was that the prediction equation models were created from 
data collected only from two hospital-based CR centres in the UK. The present cohort showed 
low pre-rehabilitation functional capacity in comparison with previous studies, and there is no 
available information about whether the patients had followed any recommended exercise 
programme after hospitalisation, or whether they came directly into phase III CR. Moreover, no 
details regarding patients’ physical activity outside the class were recorded, which may influence 
functional outcomes. However, even though some previous studies referred to collecting 
information on patients’ home activities, there is no evidence that the authors integrated this 
recorded information into the final statistical analysis or measured outcomes. The failure to use 
this information in the analysis might be due to its potential complexity. Some patients’ records 
lacked complete medical information, such as left ventricular ejection fraction (LVEF). This may 
have benefited the present study, however, previous chapter (see Chapter 5 ‘Predictors of six-
minute walking test performance in heart failure patients’) showed that clinical variables, such 




A further limitation is the small number of females involved in this study. It would be ideal if the 
number of male and female patients was equal; however, the data were retrieved from two sets of 
hospital-based CR records and the patients did not take part in any selective participation. Thus, 
this population represents real CR participation. The lack of a gold standard test (treadmill tests 
or cycle ergometer tests) to compare the MSWT against could also be perceived as a weakness 
of this study. This comparison would be useful in order to check the validity of the MSWT in 
this cohort. Also, as it was mentioned above, this study used a single cohort design. The lack of a 
"usual care" comparison control group could be accounted as a limitation of the study. However, 
the present study does not contain cohort data but real national CR data from different hospitals. 
Each CR centre evaluates the functional capacity of CR patients through only a particular 
exercise test. Thus, it was not really possible to have a control group; also, it was not possible to 
have both MSWT and treadmill/cycle ergometer test records from the same CR cohort. 
A further limitation involves the nature of the data set used to validate the reference equation for 
the prediction of pre-rehabilitation MSWD; the validation group were members of the same 
cohort as the development group. The validation process confirmed non-linear relationships 
between actual and predicted values, suggesting that a more complex statistical analysis might be 
required, which was not carried out here because of space constraints. The equation model 
generated here tends to overestimate or underestimate MSWD. All data were drawn from two 
CR centres, meaning that the patients would be likely to have similar characteristics. It would be 
useful to revalidate the reference equation developed here across other CR cohorts. 
A final limitation involves the nature of the test protocols used. Following hospital discharge the 
target heart rate in CR might be based on the patient’s MSWD. It seems obvious that if the 
MSWT is used in prescription of exercise in CR, tall cardiac patients should be set higher MET-




expected to improve their MSWD during CR less than short patients. This might be a limitation 
of the test; however, the target of CR is to help the cardiac patients to reduce their cardiovascular 
risk by increasing their functional capacity levels. Unfortunately, except the data of Lewis et al. 
(2001), collected in a HF population, no studies have addressed the role of MSWT as prognostic 
predictor in cardiac patients. As yet, there is no clear MSWT performance threshold associated 
with improved survival in the general cardiac population. This seems not to be a real problem, 
because according to the above findings each individual can have his or her own functional 
capacity targets based on the normative values developed here. 
6.5.   Conclusion  
Previous studies have provided prediction equations and reference values for functional capacity 
that could be used to stratify the population by comparing them against a known standard. 
However, the already published data are based either on a healthy population or on a different 
type of test (the treadmill or 6-MWT). The MSWT is recommended by UK guidelines as the 
most popular assessment; it is a reliable, simple exercise test for the CVD population. Reference 
values of functional capacity expressed in METs should be avoided, as they underestimate 
aerobic capacity in the CR population.  
The current study is unique and has a number of clinical implications. Firstly, 159 MSWTs were 
performed at the entrance to and after six weeks of phase III CR in a CVD cohort. Only one 
MSWT was performed pre- and post- rehabilitation, since Chapter 3 indicated no need for a 
practice test to obtain reliable results. It is assumed this represents a valid assessment in this 
patient cohort. The present results showed that the mean pre-rehabilitation MSWD was lower 
than in previous studies, while the improvement in mean MSWD was higher than in all previous 




the most from a CR programme. Second, the reference equations generated here show that age, 
stature and sex should be accounted for in the estimation of functional capacity at the entrance of 
the patient into phase III CR; while only stature should be accounted for in the estimation of 
functional capacity improvement during CR. Using these equations, functional capacity at the 
start of CR and functional capacity improvement can be expressed as a percentage of predicted 
value, which can help practitioners in making informed choices regarding their recommendations 
to patients. Third, the normative values developed here can be used as reference points to predict 
functional capacity and the magnitude of functional capacity improvement, in a group of male or 
female patients, within specific cut-off limits for age and stature. 
This is the first investigation to provide normative values for MSWT performance (MSWD) in a 
CR population. The research revealed a number of areas that would benefit from future 
investigation. The recommended step is to update the normative values in a larger cohort derived 
from several hospital-based CR records in the UK, in order to reduce any possible interference 
from investigators that might influence results. Data from Chapters 4 and 6, suggest that taller 
CVD patients can always record greater MSWD improvement due to CR than shorter patients. 
Further studies are required to confirm this hypothesis.  
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CHAPTER 7.  SAFETY OF EXERCISE TESTIG AD EXERCISE TRAIIG FOR CARDIAC PATIETS, 
I A SUPERVISED, COMMUITY-BASED CARDIAC REHABILITATIO PROGRAMME 
7.0.  Abstract 
Exercise is well recognised as a tool for assessment, prevention and management of 
cardiovascular disease. Cardiac patients are encouraged to join in supervised exercise cardiac 
rehabilitation programmes after cardiac risk stratification based on their functional capacity test 
performance. However, the cardiovascular safety of supervised functional walk testing and 
exercise training in a community-based cardiac rehabilitation centre has not been clearly 
justified. The aim of this study is to identify cardiovascular events that might occur during the 
shuttle walking test and exercise training in a community-based cardiac rehabilitation 
programme.  
Eleven cardiac patients (55% males, 45% females, mean age: 67.2±6.9 years – testing group) 
and twenty-two cardiac patients (59% males, 41% females, mean age: 66.3±8.6 years – training 
group) were assessed through ambulatory electrocardiogram monitoring during the modified 
shuttle walking test (MSWT) and exercise training in a phase IV (UK classification) cardiac 
rehabilitation programme, respectively. During assessment, testing group patients were required 
to walk up and down a 10 m course at increasing speeds using the 15 level MSWT; training 
group patients were required to participate in an exercise-based cardiac rehabilitation 
programme. All of them were regular members of phase IV cardiac rehabilitation. A cardiologist 
verified the presence or absence of a cardiovascular event. Frequency of the cardiovascular 
events was reported for the two groups. Patients were divided into an event-free subgroup and a 
cardiac event subgroup. Differences in functional capacity between the two subgroups were 




between incidences of cardiovascular events with poor functional capacity (distance walked in 
MSWT <450 m).  
No major cardiovascular event related to hospitalisation was detected in testing or training 
group. The most clinically important event was silent myocardial ischaemia, which occurred in 
27.3% of the testing group patients, and in 18% of the training group patients. There was no 
significant difference in functional capacity between the event-free subgroup and the subgroup 
with cardiovascular events in both testing and training groups (p>0.05). A chi-square test showed 
no significant association between poor functional capacity and risk for cardiovascular events in 
either testing group or training group [Testing group: x
2
 (11)=0, p=0.99, phi=0.24; Training 
group: x
2
 (22)=2.1, p=0.15, phi=-0.42]. Among patients with poor functional capacity, minor 
cardiovascular events were found in half of those who were assessed during exercise testing with 
the MSWT, and in all of those who were assessed during exercise training.  
The results confirm that there is no risk of major cardiovascular events during exercise testing 
with the MSWT or exercise training in phase IV CR patients. This is probably due to the overall 
good functional capacity of patients involved in programmes designed for CR maintenance. Poor 
functional capacity does not seem to be associated with the risk of a cardiac event during 
exercise. It is suggested that the MSWT and exercise training can be carried out safely in 
supervised phase IV CR settings. 
7. 1.  Introduction  
Numerous investigations have demonstrated the utility of cardiovascular evaluation during 
physical exertion in diagnosis, prognosis and management of coronary heart disease (CHD). 
Physical exertion is a common physiological stressor of the cardiovascular system, able to derive 




Morris et al., 1991; Gordon and Kohl 1993; Franklin et al., 1998; Fleisher et al., 2007). The use 
of an electrocardiogram (ECG) during rest or exercise remains the gold-standard non-invasive 
diagnostic tool in the identification of cardiovascular diseases (CVD).  
7.1.1.  Basic uses of the electrocardiogram and ambulatory electrocardiogram monitoring 
The use of an ECG involves the analysis of the recording of electrical signals during rest, which 
gives information on the heart’s activity. Traditional ECG is used to identify arrhythmia, and it is 
crucial for identifying changes in the cardiac rhythm associated with myocardial ischaemia and 
infarction, the dysfunction of cardiac pacemakers, pericarditis, cardiomyopathy and electrolyte 
imbalances. A detailed analysis of the ST-segment can identify the location and the extent of 
damaged myocardium; it can also identify the type of pathology – myocardial infarction (ST-
segment elevation) or ischaemia (ST-segment depression) (Fisch 1989). 
Ambulatory ECG is used extensively in clinical practice, during exercise testing or cardiac 
exercise programmes, in order to evaluate the response of the heart rhythm to exercise activity in 
patients who have heart disease (i.e., previous MI). It can be used to identify cardiovascular 
events during exercise, which may improve the evaluation and stratification of patients at the 
start of a CR exercise programme (Cantwell and Fletcher 1974; Savage et al., 1979; Pavy et al., 
2006).  
7.1.2.  Risk of cardiovascular events during exercise testing in cardiac rehabilitation  
Exercise testing is a common, useful cardiovascular assessment tool both in diagnosis and 
rehabilitation. Exercise testing is usually performed either to identify exercise-induced ischaemia 
as a diagnosis of CHD or to assess functional capacity and exercise tolerance in patients with 




2000) recommends the use of ECG-monitored exercise testing for older people entering a 
vigorous exercise programme, in order to minimise exercise-induced cardiovascular events.  
Treadmill and cycle ergometer exercise tests are the most common exercise testing methods. As 
mentioned in previous chapters, functional capacity exercise tests, such as the shuttle walking 
test (SWT) and the six-minute walking test (6-MWT) are frequently used to evaluate functional 
capacity in patients with cardiovascular dysfunction.  
Exercise testing is considered to be a safe assessment procedure when conducted by experienced, 
well-trained and appropriately qualified medical staff that is able to recognise abnormalities 
during exercise. There remains some concern over cardiovascular events during exercise testing 
due to increased myocardial work, which may cause an imbalance between myocardial oxygen 
demand and supply. The risk of severe cardiovascular events during exercise testing is 
historically low, especially in those using continuous ECG monitoring (Haskell 1978). Other 
studies demonstrate that although the incidence of major cardiovascular events during exercise 
testing is low, the prediction of these events is difficult in most cases and independent of ECG 
monitoring or non-monitoring techniques (Van Camp and Peterson 1986; Pavy et al., 2006).  
Gibbons et al. (1989) examined the risk of cardiovascular events during treadmill testing over a 
period of 16 years. They reported only five severe cardiovascular events and one death among 
almost 72,000 tests. These events were recorded during the first eight years of the survey, and no 
events or deaths were observed during the last 45,000 tests. The authors demonstrated that 
exercise-induced events in a test environment are rare, and that exercise testing is a safe 
cardiovascular assessment when it occurs under medically supervised administration. Most of 
the participants in this survey were, however, healthy adults, while only a very small percentage 




that the use of exercise testing is safer in healthy adults than in CHD patients. Coronary heart 
disease is the most common pathological factor in sudden death during exercise, due to 
atheromatic plaque rupture and thrombosis in the coronary arteries (Thompson et al., 2007).  
Gordon and Kohl (1993) summarised an analysis of eight published surveys and reported 
estimated rates of sudden death or acute myocardial infarction (MI) during exercise testing 
ranging from 0 to 5 per 100,000 tests in patients with CHD. The authors reported that the risk of 
cardiovascular events was higher in post-MI patients and in those with potentially malignant 
ventricular arrhythmias.  
Pavy et al. (2006) surveyed 42,419 exercise stress tests in 65 cardiac rehabilitation (CR) centres 
and found that the risk of cardiovascular events during exercise stress testing was 1.4 per 10,000 
tests. They recorded only five events in patients who had been recently involved in a 
percutaneous coronary intervention (PCI) with stent and one cardiac arrest, which was 
resuscitated, while no deaths occurred during exercise testing. The main event during exercise 
testing was ischaemia in patients with coronary artery stenting over the short term after surgery, 
and the authors concluded that the events were caused because of previously untreated coronary 
artery stenosis. 
According to this brief review of the literature, it is obvious that cardiovascular events during 
laboratory-based exercise testing are rare, but they do still occur and are somewhat 
unpredictable. As mentioned in previous chapters, the traditional laboratory-based cycle 
ergometer or treadmill exercise protocols have commonly been replaced in daily clinical practice 
by reliable functional capacity tests (i.e., the SWT, or 6-MWT). There is, however, little 
information regarding the safety of these functional capacity exercise tests when used to assess a 




CABG (coronary artery bypass graft) patients among whom they noted only one episode of >1 
mm ST-segment depression. The very low number of cardiovascular events during exertion in 
Tobin and Thow’s (1999) study leads to important queries about whether this was the result of 
low individual effort during exertion, producing less stress on the cardiovascular system, or the 
result of the successful treatment of coronary arteries during surgical intervention. These queries, 
combined with the fact that their study focused on a small and very selective subsample (post-
CABG patients), increase the necessity for new studies in this field.  
 
Table 7.1.  Summary of event rates during exercise testing 
Study  Patients Exercise tests  Cardiovascular incidence rates 
per 10,000 exercise tests  
Gibbons et al. (1989)  34,295 71,914 treadmill tests overall events: 0.83 
nonfatal event: 0.70 
fatal event: 0.14 
Pavy et al. (2006)  25,420 42,419 bike or treadmill tests overall events: 1.42 
nonfatal event: 1.18 
resuscitated cardiac arrests: 0.24 
fatal event: 0 
Tobin and Thow (1999)  19 19 shuttle walking tests  overall events: 1 per 19 tests 
7.1.3.  Risk of cardiovascular events during exercise training in cardiac rehabilitation  
Cardiac patients are usually encouraged to participate in a programme of increased physical 
activity and programmed exercise due to the benefits derived from exercise training in this 
population (Haskell 1978).  
The benefits of exercise training, as part of a CR programme, were described in detail in Chapter 
2 (see ‘Introduction to cardiovascular diseases and cardiac rehabilitation: a review in the 
literature’). Exercise prescribed as part of a comprehensive CR programme acts as 




improves quality of life and reduces morbidity and mortality in the cardiac population (Gill et 
al., 2000; Hambrecht et al., 2000; Pasquali et al., 2001). Data from two meta-analyses of more 
than 4,000 patients each estimated that the total mortality for CHD patients who participate in 
exercise-based CR was significantly reduced by 20% to 27%, when compared with patients not 
involved in programmes (O'Connor et al., 1989; Jolliffe et al., 2000). 
Increased myocardial oxygen delivery and improved myocardial contractility are some of the 
main benefits of exercise training. However, increased myocardial work due to exercise can 
cause an imbalance between myocardial oxygen supply and demand in the heart, which is a 
trigger for myocardial ischaemia or cardiac arrest in patients with established CHD (Haskell 
1978). There is some evidence documenting major cardiovascular events during exercise among 
CVD patients (see table 7.1).  
Haskell et al. (1978) surveyed 30 exercise programmes in North America, commencing on 
average 9 weeks after MI or cardiac surgery, with a mean of three exercise sessions per week. 
The programmes contained mainly aerobic types of exercise, such as walking, jogging, games 
and calisthenics. Twenty-eight exercise programmes included pre-training assessment with a 
health questionnaire, a resting ECG recording and blood pressure measurements. In two exercise 
programmes, patients were monitored with telemetry ECG during exercise using a cycle 
machine, treadmill walking or rowing. The authors found the following cardiovascular event 
rates during participation in these supervised exercise programmes.  
The total number for all events (fatal and nonfatal) was 47, representing an event rate of 1 per 
26,715 patient hours. In particular, there was one nonfatal event per 34,673 patient hours and one 
fatal event per 116,402 hours. Both fatal and nonfatal events were significantly lower in the two 




recorded in the 28 non-monitored programmes (ratios fatal/nonfatal ranges: 10/1 to 35/1). 
According to the authors, however, the medical supervision of the 28 non-monitored 
programmes was not close enough to identify changes in patients’ symptoms and prevent them 
from developing cardiovascular events. The highest number of cardiovascular events (72%), 
especially cardiac arrest, occurred during warm-up or cool down or at the end of the session. 
However, there were differences among the programmes that were not mentioned, while there is 
no information on the intensities at which the different programmes were used. The reduction of 
the occurrence of events with the use of ECG-monitoring, and the fact that there was no 
information on exercise intensities during training, do not make it clear whether the 
programmes’ characteristics had any effect on these cardiovascular events. 
Van Camp and Peterson (1986) surveyed 167 medically supervised CR exercise programmes; 
and they estimated that the cardiovascular event rates per million patient exercise hours were 8.9 
for resuscitated cardiac arrests, 3.4 for MIs and 1.3 for fatal events. The low rate of fatal cardiac 
arrests was associated with the medically supervised CR programmes and the immediate 
activation of emergency cardiac care.  
Franklin et al. (1998) examined the incidence of cardiovascular events during medically 
supervised exercise in a CR programme over a 16-year period, where they showed a lower 
incidence of cardiac arrests (3.4) but a higher incidence of nonfatal MI (8.9) than previous study 
(Van Camp and Peterson 1986). The CR exercise programme was medically supervised, and all 
cardiac arrests were successfully resuscitated. Franklin et al. (1998) recorded cardiovascular 
events among moderate-to-high-risk patients, and highlighted the importance of risk 
stratification to identify those patients at increased risk for exercise-related cardiovascular 
events. The authors also reported that the presence of a physician during exercise training is not 




patients before their induction into an exercise programme. Medical supervision and ECG 
monitoring during exercise may be obligatory only in high-risk situations (Wenger et al., 1995).  
Pavy et al. (2006) surveyed 65 CR programmes and reported a risk of cardiovascular events 
during exercise of 20.2 per million patient exercise hours. During exercise training, overall 15 
events were induced: 47% of them were angina, 27% arrhythmias, 6.7% pericarditis, 6.7% 
ventricular tachycardia, 6.7% cardiac tamponade and 6.7% resuscitated cardiac arrest. Neither 
fatal incidences nor MI were reported in this study. The authors found a low rate of 
cardiovascular events, which may again be due to the combination of effective risk stratification 
of the patients prior to entering into the rehabilitation programmes and the well-supervised 
sessions by specialised staff able to offer emergency medical treatment when required.  
It is obvious from the research outlined above, that the incidence rates during exercise are lower 
in more recent studies which are based on supervised CR exercise programmes. During CR, the 
overall cardiovascular event rates range from 12.3 to 37.4 per million patient hours of exercise. 
Fatal cardiac events are more rarely reported, and range from 8.6 per million patient hours of 
exercise in 1978 to zero in the present day (2006) (see table 7.2). 
Nevertheless, most of the studies above examined cardiovascular events during exercise-based 
outpatient (UK phase III) rehabilitation. According to UK guidelines, phase III typically begins 
four weeks after MI or six weeks after heart surgery and usually consists of clinically well-
supervised sessions, which take place in hospital settings (Thompson et al., 1996; Bethell et al., 
2009). Phase IV CR, following phase III, is a long-term community-based exercise programme 
where the goal is the maintenance of physical activity and life-style changes in cardiac patients 
(Bell et al., 1995; British association for cardiac rehabilitation [BACR] 2006). Phase IV CR can 




risk stratification of the patients before entering this phase has not always been carried out. 
Usually, patients who finish phase III CR proceed directly to phase IV CR. There is little 
information concerning the risk of cardiovascular events during phase IV CR, leaving it unclear 
how necessary cardiac risk stratification is, alongside monitoring and medical supervision during 




Table 7.2.  Summary of event rates during exercise based cardiac rehabilitation   
Study  Patients Patients exercised hours  Exercise programme Cardiovascular incidence rates per 
million patient hours of exercise 
Haskell et al. (1978) 13,570 1,629,634  30 supervised exercise programmes, 
aerobic exercise, mean sessions=3/week 
overall event rate: 37.4 
nonfatal event: 28.8 
fatal event: 8.6  
Van Camp & Peterson (1986) 51,303 2,351,916 167 supervised CR exercise programmes 
aerobic exercise 
overall event rate: 12.3 
nonfatal MIs: 3.4 
resuscitated cardiac arrests: 8.9 
fatal event: 1.3 
Franklin et al. (1998) 3,335 292,254 1 supervised CR exercise programme,  
- Phase 2: aerobic (50min), 3/week,  
- Phase 3: aerobic and resistance exercise,  
1/week 
overall event rate: 12.3 
nonfatal MIs: 10.3 
resuscitated cardiac arrests: 6.8 
fatal event: 0.0 
 
Scheinowitz and Harpaz (2005) 3,511 338,688 1 supervised CR exercise programme, 
aerobic exercise (60–90 min), 2/ week. 
overall event rate: 17.0 
nonfatal event: 32.5  
nonfatal MIs: 0.0 
resuscitated cardiac arrests: 3.0 
fatal event: arrest: 3.0 
Pavy et al. (2006) 25,420 743,471 65 supervised CR exercise programmes, 
aerobic exercise (60min), 3-7/week 
overall event rate: 20.2 
nonfatal event: 20.2 
resuscitated cardiac arrest: 1.3  
fatal event: 0.0 




7.1.4.  Risk management in exercise testing and training 
Although event rates during exercise testing and training are low, events still occur during 
exercise. Exercise testing seems to present a greater risk than exercise training. The higher risk 
rates estimated during exercise testing and exercise training were 0.37 per 10,000 patient hours 
of exercise and 1.42 per 10,000 tests, respectively. 
In order, that cardiovascular events during exercise may be minimised, the American Heart 
Association (AHA) provides guidelines that can be used to grade patients according to their 
pathological and functional characteristics (Fletcher et al., 2001; Myers et al., 2009). Pre-training 
and pre-testing cardiovascular risk assessment – including medical history and physical 
examination – can reduce the likelihood of adverse events during exercise by identifying patients 
at greatest risk (Fletcher et al., 2001). The AHA guidelines emphasise the importance of ECG 
monitoring during an exercise training programme, suggesting that moderate to high risk CVD 
patients should be medically supervised with ECG-monitoring during exercise training until it 
can be determined whether exercise training can safely be tolerated by the patient; at this point, 
safe individual intensity levels can be set (Fletcher et al., 2001).  
To summarise, exercise training has a well-established role in reducing overall risk of cardiac 
death in the CVD population. On the other hand, the risk of a sudden cardiac event is elevated 
during and after exercise. As mentioned above, the increased risk is not great when exercise 
occurs in supervised CR settings and when patients exercise regularly. Accordingly, exercise 
undertaken following specific guidelines seems to be safe for patients. Thus, it would be 
interesting to verify to what extent a common exercise testing programme and a regular exercise 





7.1.5.  Aim  
There are clear benefits of functional capacity testing over laboratory-based exercise tests to risk 
stratify patients for CR. The importance of the role of exercise as a beneficial treatment for 
cardiac patients is not in question here. The aim of this study was to verify to what extent a 
recommended exercise testing protocol (SWT) and an exercise training session are safe for a 
mixed cohort of CR patients. 
7. 2.  Methods 
7.2.1.  Study population  
Eleven CVD patients (6 males and 5 females, aged 56 to 78 years: testing group) were monitored 
whilst undertaking a sub-maximal MSWT; twenty-two CVD patients (13 males and 9 females, 
aged 52 to 78 years: training group) were monitored during phase IV CR exercise training. 
Seven of the twenty-two patients were monitored during both exercise testing and exercise 
training. All patients were considered clinically stable and low risk, according to BACR (2006) 
criteria. The patients had varying cardiac conditions. The majority of participants were post-
vascularisation patients (CABG or percutaneous coronary intervention [PCI]). They also 
included patients with stable angina, patients who had suffered from an, or patients who had 
undergone both an MI and a surgical procedure on the heart. They were under medical treatment 
during the assessment (β-blockers, nitrates, aspirin, statins). The population’s descriptive 
characteristics and baseline measurements are presented in table 7.3. 
All the patients were enrolled in a Phase IV CR programme at the University of Essex. All had 
completed the ten-week phase IV rehabilitation programme and used the exercise classes to 
maintain gains in functional capacity realised here and in phase III rehabilitation. Exclusion 




had a defibrillator or pacemaker fitted. Patients were recruited by informing them both orally and 
with written information regarding the scope, methods and procedure of the study. Written, 
informed consent was then obtained from each participant. All procedures were approved by the 
University of Essex Ethics Committee and conformed to the declaration of Helsinki guidelines 
(World Medical Association 2009) for research with human participants. The study took place 
between March 2009 and January 2010. 
Table 7.3. Descriptive characteristics and baseline measurements of patients 
Clinical characteristics and baseline 
measurements 
Testing group: Values 
from patients monitoring 
during the MSWT 
Training group: Values 
from patients monitoring 
during the exercise 
training  
Number of patients 11 22 
Age   (years)  (mean ± SD)  67.2 ± 6.9 66.3 ± 8.6 
Sex   (%) Males=6 (55%)  
Females=5 (45%) 
Males=13 (59%)   
Females=9 (41%) 
BMI   (kg·m
-2
)  (mean ± SD)  27.2 ± 2.6 28.1 ± 4.0  
Waist circumference   (cm)  (mean ± SD) 95.5 ± 9.4 98.3 ± 10.3 
Resting HR   (bpm)   (mean ± SD) 65.6 ± 11.7 65.1 ± 11.1 
Resting SBP   (mmHg)    (mean ± SD) 126 ± 19 136 ± 22 
Resting DBP   (mmHg)    (mean ± SD) 78 ± 10 76 ± 9 
Medical History/Reason for joining CR 
MI                                                                                                                
Stable Angina                                                              
Surgical procedure (CABG, PCI)                                                                                                                    







n=3   (14%) 
n=9 (41%) 
n=17 (77%)                                               
n=1 (4.6%)                                                                                     
β-blockers n=9 (82%) n=16 (73%) 
Nitrates  n=2 (18%) n=7 (32%) 
Aspirin  n=4 (36%) n=17 (77%) 
Statin  n=2 (18%) n= 10 (46%) 
Other n=3 (27%) n= 7 (32%) 
Definition of abbreviations: BMI=body mass index; CR=cardiac rehabilitation; MI=myocardial infarction; 







7.2.2.  Study design 
Before the initial testing began, each participant received a primary health assessment (pre-
exercise health questionnaire, resting heart rate and blood pressure measurement) and interview 
(medical and pharmacological history). Stature was recorded using a stadiometer (Seca 240 
stature measuring rod) and body mass was recorded, without shoes, using a weight scale (Seca 





) (see table 7.3). Resting heart rate and blood pressure (systolic and diastolic) were 
measured, using an automated arm blood pressure monitor (Omron Digital Automatic Blood 
Pressure Monitor MX3 Plus, Omron Health Care Co., Ltd., Kyoto, Japan).  
Before testing started, testing group patients who were to perform the MSWT were fitted with a 
Polar heart rate monitor (Polar Electro Sports Tester S810I, Heart Rate Monitor, Kempele, 
Finland) to determine heart rate frequency and their predicted termination point. All patients 
were monitored with an ambulatory ECG event monitor (C.NET5000, version 1.2, Cardionetics 
Ltd., United Kingdom), either during the MSWT (testing group) or during the CR class (training 
group). Three ECG electrodes on a monitor cable were applied to the chest at pre-determined 
locations, based on traditional clinical ECG monitoring. Before ECG electrode placement, the 
patient’s skin was prepared by shaving any significant chest hair around the position of the 
electrode pads. The patient’s shaved skin was then cleaned and wiped with a surgical alcohol 
wipe and was allowed to dry before electrode pad placement. As figure 7.1 shows, the three ECG 
electrodes were placed as follows: right upper sternum – just below the sternal angle (RA); left 
upper sternum – just below the sternal angle (LA); and left fifth intercostal space – the left 
midclavicular line (V4) (Cardionetics 2010). The device was placed into a pouch fitted to the 
patient’s waist using a particular type of belt. Next, testing group received oral instructions for 





Figure 7.1. Electrode pads placement on the patient (http://www.cardionetics.com/electrodes.php) 
 
Major cardiovascular events were defined as one of the following: MI requiring hospitalisation, 
ventricular fibrillation, ventricular tachycardia requiring treatment, atrial arrhythmias requiring 
treatment, asystole, stroke and death. Minor cardiovascular events were defined as: isolated 
ventricular arrhythmias or atrial arrhythmias not requiring intervention, chest pain and 
bradycardia not requiring intervention (Gibbons et al., 1989).  
7.2.3.  Modified shuttle walking test procedure 
The MSWT was performed according to the method described in Chapter 3 (pp.130-131). 
The modified 15 level SWT, which was first developed by Singh et al. (1992), was used for the 
requirements of this study. This is analogous to the original incremental test (Singh et al., 1992) 
but has 15 levels instead of 12. The modified version is useful for monitoring patient groups who 
may be able to complete the original 12 level protocol. Patients were required to walk on a 
gymnasium  floor, which was marked by two cones set 0.5 m from either end of the 10 m course. 
During the first course, the operator was walking alongside the participant to maintain the correct 
pace. 
The speed at which the patient was required to walk was indicated by an audio signal from a CD 
player. Initial walking speed, indicated by an audible signal, was 0.5 m·s
-1






 each minute. A change in speed was indicted by a second audible signal. Instructors also 
reminded patients to walk faster after each minute. Patients were allowed to run at any time 
during the test.  The MSWT was terminated when the patient (a) felt too breathless or fatigued to 
continue at the required speed, (b) failed to complete the shuttle within the allowed time, (c) 
reached  85% of the predicted maximal heart rate: 210-(0.65×age), (d) reached RPE ≥ 15 (Borg 
1998), or (e) completed all the levels. 
Heart rate was monitored during the test and was recorded at the end of each level, using short-
range telemetry (Polar Electro Sports Tester S810i), while the Borg Perceived Exertion (RPE) 
scale (6-20) was used to determine the perceived exercise intensity at the end of each level (Borg 
1982). During the procedure, a lap marker was indicated in the heart rate monitor by pressing the 
button of the Polar at the end of its level until the end of the test. At the end of the test, the 
maximum heart rate was recorded, while the patient was asked to sit on a chair. The patient was 
advised to relax and breathe in a normal way.  
7.2.3.1.  Heart rate data  
Heart rate was recorded at the end of each level of the test. Heart rate data from the Polar 
monitor were transferred and filtered to remove signal noise associated with movement using a 
desktop computer and the Polar Precision Performance 3.0 training software, version 3.01.005.  
7.2.4.  Exercise training programme          
The programme provides additional phase IV CR capacity in the local area and offers the 
opportunity of life-long supervised exercise. This programme consisted of two supervised 
sessions per week, made up of 60 minutes of circuit-based exercise classes. Patients were 




physiotherapist specialised in cardiac rehabilitation, also trained in immediate life support 
methods. The CR programme followed the BACR guidelines (2006) and was designed to 
maintain the functional capacity gains achieved in phase III CR. Exercise sessions comprised: a 
15-minute warm-up, including mobility exercises and stretches; a 35-minute main conditioning 
component, including cardiovascular and strength exercises at an intensity of 60% to 80% of the 
age-predicted maximal heart rate, or at 12 to 15 on the RPE scale; and a 10-minute cooling down 
period, including gently paced recovery exercises, mobility exercises and stretches. During this 
component, patients had access to a variety of exercise equipment, such as arm ergometers, 
rowing ergometers, progressive resistance equipment, balance equipment, steppers and free 
weights. 
7.2.5.  ECG data from event monitoring  
ECG data from the Cardionetics ambulatory ECG monitor was transferred, and event reports 
were collected using a desktop computer and the Cardionetics Connect software, version 2.0. At 
the end, a cardiologist verified the presence or absence of each cardiovascular event. 
7.2.6.  Data analysis  
Data were presented as means and standard deviation, unless otherwise stated. Frequency of the 
events was reported for both groups. Patients were divided into an event-free versus cardiac 
event subgroups. Baseline differences in functional capacity between the two subgroups were 
examined using two-sample t-tests (for continuous variables) and chi-square tests (for nominal 
variables). A chi-square test was performed to determine associations between incidences of 
cardiovascular complications with poor functional capacity (SWT <450 m). The sample was also 
divided into groups based on their functional capacity assessed by a previous MSWT, using cut-




walked in MSWT [MSWD] with 0=low functional capacity (MSWD<450 m), 1=good functional 
capacity (MSWD ≥ 450 m) (Morales et al., 2000). For the patients (n=7) who were monitored 
during exercise training and exercise testing (MSWT), a binary logistic regression was 
performed to predict the incidence of cardiovascular events during the MSWT. Dependent and 
independent variables were encoded by using 0 and 1 for this analysis. The coding was done as 
follows: 0=no event and 1=event. The odds ratio was calculated. All statistical analyses were 
performed using SPSS version 16.0 (SPSS inc., Chicago, IL, US), whereas calculations were 
illustrated in Microsoft Office Excel 2003 (Microsoft Corporation, Washington, US). The 
statistical significance was set at the 0.05 level. 
7.3.  Results  
The same data analysis process was used for the two study conditions (ECG recording during 
exercise testing and ECG recording during exercise training).  
7.3.1.  ECG event monitoring during exercise testing (modified shuttle walking test)  
During exercise testing with the MSWT, 11 patients were recorded using ECG monitoring, 
involving 6 males (55%) and 5 females (45%) (mean age: 67.2±6.9 years). Most of the cardiac 
patients (64%) had had a surgical procedure involving their hearts (CABG, PCI). There were 
also patients with stable angina or arrhythmias (27%), while fewer patients (13%) had suffered a 
MI. According to the pharmacological history, all the patients were taking medication, while 




7.3.1.1.  Cardiovascular events using an ECG-recording system 
According to the ECG recordings, 8 (73%) of the patients had cardiovascular events. These 
involved 5 males and 3 females (mean age: 64±9 years), with a medical history of heart surgery 
(CABG or PCI), angina, previous MI and arrhythmias, and with functional capacity levels 
assessed with the MSWT of 508 (±120) m (range: 370-750 m) or 5.6 (±0.8) METs (range: 4.6-
6.6 m). Among these, the more important cardiovascular event was ischaemic ST-segment 
depression, involving 3 patients (2 females and 1 male) (mean age: 63±6 years) with a history of 
previous MI and heart surgery (PCI). Their recorded functional capacity levels during the 
MSWT were 445 (±106) m (range: 370-630 m) or 5.1 (±0.6) METs (range: 4.6-6.0 METs) (see 
table 7.4).  
7.3.1.2.  Event-ECG recordings verified by cardiologist 
The ECG recordings were reviewed by a cardiologist, who found that 7 (64%) of the patients had 
cardiovascular events during the MSWT; the accuracy of the recordings was verified as 82% (the 
cardiologist was in agreement with 9 of the 11 event cases) (see table 7.5).  
7.3.1.2.1.  Frequency of cardiovascular events based on the cardiologist’s review  
According to the cardiologist’s review of the ECG recordings, of the 11 patients, 5 (45.5%) had 
atrial ectopic beats, 4 (36.4%) had isolated ventricular ectopic beats, 3 (27.3%) had ischaemic 
ST-segment depression, 2 (18.2%) had an atrial fibrillation event, 1 (9.1%) had a bradycardia 
event (under 50 bpm), while 4 (36.4%) of the patients were free from cardiovascular events (see 






Table 7.4. ECG event monitoring during the modified shuttle walking test performance (n=11) 
       Functional Capacity     ECG event data Patient  Sex Age  
(years) 
Medical History  Pharmacological History  
 MSWD (m) METs  





Type of event 
1 M 78 CABG β-blockers, aspirin 480 5.5 Y  AEBs                 
2 M 70 CABG β-blockers, other 710 6.6 Y  AEBs, bradycardia 




410 5.0 N No event 
4 M 64 CABG β-blockers, aspirin 750 6.6 Y  AEBs, Isolated VEBs 
5 M 69 PCI, arrhythmias β-blockers, aspirin, statin 620 6.0 Y AEBs, Isolated VEBs, 
AF, Ischaemic ST 
depression 
6 F 69 Angina, arrhythmias aspirin, ACE-inhibitor 520 5.5 N No event 
7 M 72 CABG β-blockers, other 580 6 N No event 
8 F 67 MI β-blockers, other 370 4.6 Y 
 
AEBs, Isolated VEBs, 
Ischaemic ST 
depression 
9 M 75 CABG β-blockers, nitrates 660 6.6 Y AEBs 
10 F 59 MI, Hypertension diuretics, statin  520 5.5 Y AEBs, Ischaemic ST 
depression 
11 F 56 
Angina β-blockers, aspirin 
480 5.5 Y Isolated VEBs, AF 






Table 7.5. ECG event monitoring during the modified shuttle walking test performance: cardiologist’s verification (n=11) 
        ECG event data verification by Cardiologist 
Patient ECG event data 
agree/disagree no event/major/minor 
1 AEBs                 agree  minor 
2 AEBs, bradycardia disagree (no event) no event 
3 No event agree no event 
4 AEBs, isolated VEBs disagree (only isolated VEBs) minor 
5 AEBs, isolated VEBs, AF, Ischaemic ST-segment depression agree minor 
6 No event agree no event 
7 No event agree  no event 
8 AEBs, Isolated VEBs, Ischaemic ST-segment depression  agree  minor 
9 AEBs agree 
minor 
10 AEBs, Ischaemic ST-segment depression agree 
minor 
11 Isolated VEBs, AF agree 
minor 




Table 7.6.   Event rates during the modified shuttle walking test (n=11) 
            ECG event data               Cardiologist’s verification 
Event  Frequency  % total event  Frequency  % total event  
Event-free  3 27.3 % 4 36.4 % 
Atrial fibrillation event 2 18.2 % 2 18.2 % 
Atrial ectopic beats 7 63.6 % 5 45.5 % 
Isolated ventricular ectopic beats 4 36.4 % 4 36.4 % 
Bradycardia event (under 50 bpm) 1 9.1 % 1 9.1 % 
Ischaemic ST-segment depression 3 27.3 % 3 27.3 % 




7.3.1.3.  A comparison between cardiovascular events and functional capacity  
The independent-samples t-test was conducted to compare functional capacity – expressed by 
the MSWD in metres – in the event-free group and in the group that experienced cardiovascular 
events. The cardiologist’s ECG reviews were used here. Within the small group of patients, there 
was no significant difference in functional capacity between the event-free group (n=3, 
mean=503±86 m) and the group that experienced a cardiac event (n=8, mean=573±132 m); t 
(11)=-0.85, p=0.4. The mean difference between the two groups was -70 m, with 95% CI: -259 
to 118 m. The magnitude of the difference between the means was moderate: d=0.63 (Cohen 
1988).  
A chi-square test for independence indicated no significant association between poor functional 
capacity and risk for cardiovascular events: x
2
 (11)=0, p=0.99, phi=0.24. The phi coefficient 
value is considered a small effect between functional level and potential event (Cohen 1988). 
Also, half of the low performers (< 450 m in MSWT) and 77.8% of the high performers (≥ 450 

















n  1 1 2 
% within MSWD  50.0% 50.0% 100.0% 
% within Potential Event 33.3% 12.5% 18.2% 
MSWD < 450 m  
% of Total 9.1% 9.1% 18.2% 
n 2 7 9 
% within MSWD 22.2% 77.8% 100.0% 
% within Potential Event  66.7% 87.5% 81.8% 
MSWD ≥  450 m  
% of Total 18.2% 63.6% 81.8% 
n 3 8 11 
% within MSWD  27.3% 72.7% 100.0% 
% within Potential Event 100.0% 100.0% 100.0% 
Total 
% of Total 27.3% 72.7% 100.0% 
Definition of abbreviations: MSWD=distance walked in modified shuttle walking test 
7.3.2.   ECG event monitoring during phase IV cardiac rehabilitation: programmed     
exercise session 
During exercise training in phase IV CR, 22 patients were recorded, including 13 males (59%) 
and 9 females (41%) (mean age: 66.3±8.6 years). Most of the cardiac patients (77%) had 
undergone a surgical procedure on the heart (CABG, PCI), while there were a number of 
patients (41%) with stable angina; a few patients (17%) had been affected by a MI and one 
patient (4.6%) suffered from arrhythmias. According to the pharmacological history, all the 
patients were taking medication; 73% of patients were taking β-blockers (see table 7.3).  
7.3.2.1.  Cardiovascular events using the automated ECG-recording system 
According to the ECG event monitoring reports, 18 (82%) of the patients had cardiovascular 




of heart surgery (CABG or PCI), angina, previous MI and arrhythmias, and with estimated 
functional capacity levels from a previous assessment using the MSWT of 473 (±117) m (range: 
270-710 m) or 5.4 (±0.6) METs (range: 4.6-6.6 METs). Among all the patients, five significant 
cardiovascular events (ischaemic ST-segment depression) had occurred, involving 3 females and 
2 males (mean age: 73±5 years) with a history of heart surgery (CABG or PCI), previous MI and 
angina. Their estimated functional capacity levels, assessed using a previously administered 
MSWT, were 486 (±135) m (range: 330-660 m) or 5.5 (±0.9) METs (range: 4.6-6.6 METs) (see 
table 7.8).  
7.3.2.2.  ECG event recordings verified by a cardiologist 
The ECG recording was manually reviewed by a clinical cardiologist, who found that 16 (73%) 
of the patients had cardiovascular events; the cardiologist verified the accuracy of the recordings 
at 86% (the cardiologist was in agreement with 19 out of 22 event cases) (see table 7.9).  
7.3.2.2.1.  Frequency of cardiovascular events based on the manual review  
According to the cardiologist’s review of the ECG recordings, of the 22 study patients, 15 (68%) 
had isolated ventricular ectopic beats, 4 (18%) had atrial ectopic beats, 4 (18%) had ischaemic 
ST-segment depression, 1 (4.6%) had atrial fibrillation, while 6 (27.3%) of the patients were free 
from cardiovascular events (see table 7.10). 
 
Ischaemic ST-segment depression 
Ischaemic ST-segment depression occurred in 2 females and 2 males (age: 74±4 years) with a 




assessed with a previous MSWT, was 515 (±137) m (range: 330-660 m) or 5.7 (±0.8) METs 
(range: 4.6-6.6 METs) (see tables 7.8 and 7.9).  
Cardiovascular events during programmed exercise  
Taking into consideration the cardiologist’s ECG analysis, 76.5% of the cardiovascular events 
were detected around the time of the main conditioning component of the exercise training, 





Table 7.8. ECG event monitoring during phase IV cardiac rehabilitation exercise (n=22) 











Type of event 
1 M 70 CABG β-blockers, other 710 6.6 Y  AEBs, isolated VEBs 
2 M 78 CABG β-blockers, aspirin 480 5.5 Y isolated VEBs 
3 M 77 Angina Nitrates, aspirin, other 280 4.6 Y isolated VEBs 
4 F 68 Angina, PCI β-blockers, nitrates, aspirin, statin 520 5.5 Y AEBs, ischaemic ST 
depression 
5 F 78 PCI, Hypertention aspirin, other 270 4.6 Y isolated VEBs 
6 F 60 Hypertention β-blockers, other 420 5.0 Y isolated VEBs 
7 M 56 Angina, PCI aspirin, statin 790 7.1 N no event 
8 M 55 MI, PCI β-blockers, nitrates, statin, other 550 6.0 Y isolated VEBs 
9 M 64 CABG β-blockers, aspirin 750 6.6 N no event 
10 F 78 CABG, PCI β-blockers, aspirin, statin 330 4.6 Y isolated VEBs, ischaemic 
ST depression 
11 M 64 CABG aspirin, other  390 5.0 Y AEBs, isolated VEBs 
12 M 76 Angina, 4CABG β-blockers, nitrates, aspirin, statin 550 6.0 Y AEBs, isolated VEBs, 
ischaemic ST depression 
13 M 69 PCI, arrhythmias β-blockers, aspirin, statin 620 6.0 Y isolated VEBs 
14 M 75 CABG β-blockers, nitrates 660 6.6 Y isolated VEBs, ischaemic 
ST  depression 
15 F 52 Angina aspirin, statin 750 6.6 N no event 
16 F 64 PCI β-blockers, aspirin 480 5.5 N no event 
17 M 68 Angina, CABG β-blockers, aspirin, statin 550 6.0 Y isolated VEBs 
18 M 71 MI, 3CABG aspirin, statin 470 5.5 Y AEBs, VEBs 
19 F 56 Angina  β-blockers, aspirin 480 5.5 Y AEBs, isolated VEBs, 
AF 
20 F 56 Angina, PCI β-blockers, aspirin, nitrates, statin 470 5.5 Y isolated VEBs 
21 M 56 Angina, CABG β-blockers, aspirin, nitrates 630 6.0 Y isolated VEBs 
22 F 67 MI β-blockers, other 370 4.6 Y AEBs, isolated VEBs, 
ischaemic ST  depression 
Definition of abbreviations M=values for males; F=values for females; Y=yes, 3=no, CABG= coronary artery bypass graft; PCI=percutaneous coronary intervention; 




Table 7.9.     ECG event monitoring during phase IV cardiac rehabilitation exercise: cardiologist’s verification (n=22) 
ECG event data verification by Cardiologist Patient ECG monitoring event 
Agree/disagree o event/ 
major/minor 
When did it happen? (warm up/main 
component/cool down) 
1 Isolated VEBs agree minor main conditioning component 
2 Isolated VEBs agree  minor main conditioning component 
3 Isolated VEBs agree minor main conditioning component 
4 AEBs, Ischaemic ST-segment depression agree minor cool down 
5 Isolated VEBs agree minor main conditioning component 
6 Isolated VEBs agree minor warm up 
7 No event agree no event - 
8 Isolated VEBs agree minor cool down 
9 No event agree no event main conditioning component 
10 Isolated VEBs, Ischaemic ST-segment depression agree minor main conditioning component 
11 AEBs, Isolated VEBs agree minor main conditioning component 
12 AEBs, Isolated VEBs, Ischaemic ST-segment 
depression 
agree minor main conditioning component 
13 Isolated VEBs agree  minor main conditioning component 
14 Isolated VEBs, Ischaemic ST-segment depression agree minor main component & cool down 
15 No event agree  no event - 
16 No event agree  no event - 
17 Isolated VEBs agree  minor cool down 
18 Isolated VEBs disagree (no event) minor - 
19 AEBs, VEBs, AF agree minor main conditioning component 
20 Isolated VEBs disagree (no event) no event - 
21 Isolated VEBs agree minor main conditioning component 
22 AEBs, VEBs, Ischaemic ST-segment depression partly agree (only VEBs) minor warm-up & main component 




Table 7.10. Events rates during phase IV cardiac rehabilitation exercise (n=22) 
 ECG event data Cardiologist’s verification 
Event  Frequency  % total event  Frequency  % total event  
Event-free  4 18.2 % 6 27.3% 
Atrial fibrillation event 1 4.6% 1 4.6% 
Atrial ectopic beats 5 22.7% 4 18.2% 
Isolated Ventricular ectopic beats 17 77.2 % 15 68.2% 
Bradycardia events (under 50 bpm) 0 0 % 0 0 % 
Ischaemic ST-segment depression 5 22.7% 4 18.2 % 




7.3.2.3.   Association between frequency of cardiovascular events and patient functional    
capacity  
An independent-samples t-test was conducted to compare the functional capacity – expressed by 
the MSWD in metres – recorded during the MSWT in the event-free group, versus the group 
with cardiovascular events. The cardiologist’s ECG reviews were used to group patients for this 
analysis. There was no significant difference in functional capacity between the event-free group 
(n=6, mean=618±160 m) and the group with cardiovascular events (n=16, mean=488±135 m); t 
(22)=1.92, p=0.069. The mean difference between the two groups was 130 m, with 95% CI: -11 
to 271 m. The magnitude of the difference between the means was large: d=0.86 (Cohen 1988). 
A chi-square test for independence indicated no significant association between poor MSWD 
and risk for cardiovascular events: x
2
 (22)=2.1, p=0.15, phi=-0.42. The phi coefficient value 
indicates a moderate degree of interdependence between functional level and potential event 
(Cohen 1988). As can be seen in table 7.11, all patients with low functional capacity (<450 m in 
MSWT) and 60% of patients with good functional capacity (≥ 450 m in MSWT) had an event 
















n  0 7 7 
% within MSWD  .0% 100.0% 100.0% 
% within Potential Event .0% 43.8% 31.8% 
MSWD < 450 m  
% of Total .0% 31.8% 31.8% 
n 6 9 15 
% within MSWD  40.0% 60.0% 100.0% 
% within Potential Event 100.0% 56.2% 68.2% 
MSWD ≥  450 m  
% of Total 27.3% 40.9% 68.2% 
n 6 16 22 
% within MSWD  27.3% 72.7% 100.0% 
% within Potential Event 100.0% 100.0% 100.0% 
Total 
% of Total 27.3% 72.7% 100.0% 
Definition of abbreviations: MSWD=distance walked in modified shuttle walking test 
7.3.3.  Comparison of event outcome data between the two conditions 
Seven patients participated in both of the experimental protocols. Six of the seven patients 
(85.7%) had an event during exercise testing and during exercise training. The binary logistic 
regression analysis showed that patients who had a cardiac event during exercise training were 
over six times more likely to have a cardiac event during the MSWT than those who did not have 
any cardiac event during training (p=0.097).  
 
 
7.4.  Discussion  
 
 
Previous electrocardiographic studies of CR patients have demonstrated that this is a reliable 
way to record the kinds of CVD events commonly evoked during exercise. These studies have 
shown that the frequency of cardiovascular events during medically supervised exercise testing 




ambulatory ECG to record events during walking tests. The present study provides information 
regarding the safety of exercise training during the maintenance phase of phase IV community-
based CR and exercise testing by using a functional walking test – the MSWT. The associations 
were observed between exercise and cardiovascular events in a number of stable CVD patients.  
7.4.1.  Risk of cardiovascular events during exercise testing and training 
The exercise functional capacity MSWT, which was performed by patients who had already 
been enrolled in a CR programme, and the exercise training in phase IV CR, revealed some 
nonfatal cardiovascular events. According to cardiologist-verified ECG data only minor, nonfatal 
cardiovascular events were observed during both the SWT (with an event rate of 0.64 per patient 
per test) and in exercise training (with an event rate of 0.73 per patient per session). Contrary to 
the literature (Haskell et al., 1978; Van Camp & Peterson 1986; Pavy et al., 2006), the present 
study showed that exercise training in phase IV CR is more risky than exercise testing with the 
use of the MSWT. Most of the previous studies used treadmill tests, while in Chapter 3 (see 
‘Long-term reliability of the modified shuttle walking test in clinically stable cardiovascular 
disease patients’), it was stated that the MSWT provokes less stress on the cardiovascular system 
(less physiological stress) than the treadmill test (Singh et al., 1994; Zwierska et al., 2004; 
Fowler et al., 2005). The MSWT seems to be a safe test, because it increases speed 
incrementally during walking.  
The most clinical important event, silent ischaemia, was observed more often during the MSWT 
than during exercise training. This may indicate that the MSWT induces fewer yet potentially 
more serious cardiovascular complications than exercise training. This is likely due to 
differences in work rate and duration of exercise. For example, during the SWT the patients 
eventually achieve exercise at a higher intensity than during circuit-based exercise training, 




Nevertheless, both exercise training and exercise testing in a phase IV CR setting seems to be 
safe, because despite the number of minor cardiovascular events observed, no major 
cardiovascular event was detected and no cardiac event related to hospitalisation, syncope 
episodes or fatality occurred in the present study. The findings agree with those of Hollenberg et 
al. (1998), who found no complex arrhythmias or symptomatic ischaemia during exercise. It 
should be noted, however, that the above study (Hollenberg et al., 1998) was performed among 
people without suspected CVD. The nature of the observed cardiovascular events is discussed 
below.  
7.4.1.1.  Cardiovascular event: Myocardial ischaemia 
The most clinically important event was silent (asymptomatic-painless) myocardial ischaemia 
with ST-segment depression, which was detected in patients with post-PCI, post-CABG, post-MI 
or angina. This event is likely associated with untreated coronary artery stenosis (Pavy et al., 
2006) or more likely, exercise-induced transient oxygen deprivation which results reversible 
perfusion defects (Franklin et al., 1998). 
The survival rate of a silent ST depression ischaemic event during ECG exercise testing was 
similar to non-ST and significantly better than symptomatic ST-changes, in CVD patients during 
a follow-up of 5 years (Mark et al., 1989). This means that silent exercise-induced ST-segment 
depression should not be regarded as a severe cardiac event. A recent study found a significant 
association between silent myocardial ischaemia and sudden cardiac death in men with cardiac 
risk factors (Laukkanen et al., 2009). The latter findings by Laukkanen et al. (2009) cannot be 
used in the present study due to different criteria for subject selection. They used a large sample, 
over 3,000, of middle-aged men without a history of CHD, but with a high number of risk factors 




physical activity. On the other hand, the patients in the present study were CVD patients, who 
took the relevant treatment, minimised the cardiac risk factors and were enrolled in an exercise 
programme for a long period of time. Laukkanen et al. (2009) explained that the highly 
significant relationship between silent ischaemia and cardiac death found in their sample was 
associated with the large number of false positive diagnostic exercise tests. Previous studies 
demonstrated that according to Baye’s rule the presence of false positive or negative exercise 
tests is more likely in asymptomatic (that is, without coronary risk factors) than symptomatic 
individuals (Miranda et al., 1991; Lakka et al., 1994). Thus, the presence of silent myocardial 
ischaemia does not necessarily signify a severe cardiovascular condition. 
7.4.1.2.  Cardiovascular event: Cardiac arrhythmias 
The present study demonstrated a relatively high prevalence of ventricular and atrial arrhythmias 
in this low-risk cohort. These arrhythmias were not related to any major cardiac event during 
exercise. For instance, during exercise (testing and training), events such as non-complex 
ventricular ectopic activity, atrial ectopic and atrial fibrillation were detected in more than half 
(64% to 73%) of patients with PCI, CABG, post-MI or angina. Atrial ectopic beats and 
fibrillation are common events after cardiac surgery. They occur in 15%-40% of patients after 
CABG (Mathew et al., 2004; Villareal et al., 2004; Dogan et al., 2007), 10%-11% of patients 
after PCI (Celik et al., 2005; Gorenek et al., 2007), 5%-10% after MI (Bhatia and Lip 2004), 
37%-50% after a valve replacement (Asher et al., 1998; Banach et al., 2007) and 11%-24%  after 
a cardiac transplantation (Creswell et al., 1993; Pavri et al., 1995). The above data were 
collected at rest, our study showed similar frequencies as atrial arrhythmias were detected in 
45% of patients during the SWT and 23% of patients during exercise training. The high 




vascularisation patients and the fact that they were stress-induced arrhythmias (Bunch et al., 
2004).  
Ventricular ectopic beats (VEBs) were observed in 36.4% of patients during the MSWT and in 
68.2% during exercise training; these are common events of exercise (Dewey et al., 2008). 
During exercise a number of important physiological changes occur, which interact with the 
cardiovascular system. These changes are reflected in an increase of sympathetic nerve activity 
and in the release of hormones and enzymes, such as catecholamines. Vigorous exercise is 
associated with a more than ten-fold increase in circulating catecholamines, a decrease in pH and 
a two-fold increase in serum potassium (Beckerman et al., 2005). These changes can predispose 
people to arrhythmias, which are common and usually well tolerated during exercise.  
Adabag et al. (2005) demonstrated that the ventricular arrhythmias shown on ambulatory 24-h 
Holter ECG traces were poor long-term predictors of sudden cardiac death in a cohort of low-
risk patients with hypertrophic cardiomyopathy. The authors used a broad spectrum of ages 
(from 5 to 89 years old) with a mean patient age of 50 years old. It would be difficult to make a 
comparison with other groups, particular in terms of age group, such as ‘elderly’, which is the 
main cohort of the present study. 
The prognostic value of exercise-induced VEBs also remains unclear (Gibbons et al., 2002; 
Dewey et al., 2008). There is some evidence that exercise-induced VEBs are independent 
predictors of CVD mortality in patients without a pre-existing diagnosis of CHD (Beckerman et 
al., 2005). Beckerman et al. (2005) found that 17% of participants with VEBs induced during 
exercise testing died of cardiovascular causes during a mean follow-up of 6 (±4) years. Exercise-
induced arrhythmias can occur after exercise, during the recovery period, because the levels of 




(Dimsdale et al., 1984; Fleg et al., 1985). If any of these physiological changes occur during rest, 
there is an increased risk of cardiac arrest, particularly for patients with diagnosed CHD 
(Dimsdale et al., 1984; Futterman and Lemberg 2006).
 
Patients with resting VEBs, resting ST-
segment depression and ischaemia during exercise testing are high-risk patients for profound 
CVD effects (Beckerman et al., 2005).  
The current study did not contain a resting ECG that could be used for comparison with the 
exercise data. It cannot be assumed, therefore, that the VEBs recorded were exercise-induced or 
associated with the severity of the CVD. The VEBs recorded in the current study were isolated, 
while 50% of those induced during the MSWT, and 27% of those induced during the exercise 
testing, also recorded an asymptomatic ischaemic ST depression episode. No episodes of 
transient ventricular fibrillation were observed, however, supporting the case that the VEBs were 
physiologically induced by exercise. Of note, the presence of isolated VEBs is not a 
contraindication for exercise (Gibbons et al., 2002). Of more serious concern is the development 
of frequent complex VEBs, recommending a careful clinical follow-up. 
The presence of VEBs can relate to elevated levels of exercise stress. There is a large variability 
in the occurrence of exercise-induced during treadmill testing and so the reproducibility of 
exercise-induced VEBs is low. A second exercise stress test is always required, since there is 
evidence that there is a decrease in the exercise-induced VEBs after the first practice test (Sheps 
et al., 1977). This finding was not explained by the authors (Sheps et al., 1977) as a learning 
effect; it seems to be an outcome of a decrease in myocardial oxygen consumption and a product 
of the pressure-rate, which has not been substantiated. In the present study, only one trial of the 
MSWT was used, since the target was to investigate events during exercise in clinically stable 




7.4.2.  Risk of cardiovascular events related to the components of an exercise training   
programme 
The core components of CR/secondary prevention programmes, including a combination of 
exercise, psychological and educational intervention, were outlined in a Scientific Statement 
from the AHA and the American Association of Cardiovascular
 
and Pulmonary Rehabilitation 
(Balady et al., 2007). Following these recommendations, the exercise programme used in the 
present study included three components: warm-up, main conditioning and cool-down period.  
Most of the events (76.5%) were detected during the main conditioning component of the 
exercise programme, which included moderate levels of aerobic and resistance exercise. When 
the exercise session during CR terminates rapidly, hypotension, bradycardia and arrhythmias are 
the most common events, which usually occur in response to the decrease in venous blood return 
to the heart (Barnard et al., 1973). The current study did not show any major event after the end 
of the exercise session, which might be due to competing the recommended cool-down protocol 
at the end of the test (Balady et al., 2007). Few events were recorded after the main conditioning 
component in the cool-down phase.  
Consequently, it is possible that the relative safety of the exercise training experienced by the 
present study group was the result of a well-supervised exercise programme, which was risk 
stratified and gave special consideration to warm-up and cool-down elements (Balady et al., 
2007).  
7.4.3.   Is it possible to predict the risk of cardiovascular events considering the functional 
capacity level? 
Low exercise capacity (less than 5 METs or 450 m in SWT) is used in risk stratification at entry 




Lewis et al., 2001). Patients who walked <450 m in the MSWT had no greater risk of cardiac 
events during exercise than patients who walked >450 m.  
The present study showed no significant difference for cardiovascular events between patients 
with low and high functional capacity. This may be due to the lack of matched design and the 
low participant numbers. All patients with low functional capacity experienced a cardiac event, 
while only 60% of patients with a high functional capacity had any events. This suggests that 
patients in CR who performed in the MSWT at less than 450 m do not have an increased risk of 
cardiac event during exercise over patients who performed in the MSWT at more than 450 m; 
however, all the low performers will have an event (major or minor) during exercise training. 
The fact that no significant association was found between event-rate and functional capacity 
may be due to the small sample and the fact that all the events recorded were minor. If major 
events with hospitalisation had been recorded, the minor cardiovascular events would have been 
excluded from the analysis. Moreover, the cut-off value of 450 m used may also be inappropriate 
for this population. It was originally used to categorise cardiac patients as high and low 
performers but was developed for use in heart failure patients. This group differ from the present 
cohort as they did not regularly exercise (Morales et al., 2000; Lewis et al., 2001) due to severe 
cardiorespiratory problems, exercise intolerance and fatigue (Troosters et al., 2004).  
7.4.4.  Study limitations  
Within the present study, it is acknowledged that there is a lack of resting ECG data, which could 
have been used for comparison with the ECG during exercise (testing or training). Thus, the 
present study is unable to confirm whether the isolated VEBs recorded here are exercise 
triggered or related to cardiovascular pathology. The presence of isolated ventricular ectopic 




exercise-induced or not, the recommended management of a patient with such events would be 
similar.  
It is further acknowledged that the study monitored 11 patients during exercise testing and 22 
patients during exercise training. The present sample size was relatively small, principally 
because ECG monitoring is not frequently used in the routine evaluation of low-risk, 
asymptomatic, CR patients in the UK. This sample included all non-paced patients attending the 
CR at the time of the study. This sample represents a typical cohort, participating in a long-term 
CR programme. Moreover, this study is based on individual evaluation and aims to point out 
potential events corresponding to patients’ clinical characteristics. Therefore, it is useful here to 
note a brief clinical summary of a patient who had cardiovascular events during both testing and 
training.  
7.4.5.  Case study 
The use of case studies in CR is an effective research approach, because it gives an opportunity 
to isolate and analyse an individual patient. It is used to explore in depth the clinical 
characteristics and medical history of a patient, the effectiveness of a CR programme and 
potential events during exercise or non-exercise tasks. A clinical case study provides the 
opportunity to make more accurate inferences by combining an individual’s characteristics and 
outcome.  
In this study, of particular interest was a 69-year-old man – stature 172 cm and BMI 27 kg·m
-2
 – 
who entered the CR programme after PCI surgery. He had a history of arrhythmias and he was 
used to regular exercise. He was under medication with β-blockers, aspirin and statins during 
exercise. During the MSWT the patient had isolated ventricular arrhythmias, atrial arrhythmias, 




intervention. He showed quite a high performance level in the MSWT (MSWD=620 m, 6.0 
METs). The same patient had isolated VEBs during the exercise training in phase IV CR. Statin 
therapy usually decreases the risk of ventricular arrhythmias (Dewey et al., 2008); however, in 
this case the patient had arrhythmias during both exercise testing and training.  
Although in this study the overall incidence of cardiovascular events during the MSWT was 
lower than in exercise training in phase IV CR, for this patient more events were recorded in the 
MSWT than in exercise training. The results showed that almost 78% of the high performers in 
the MSWT >450 m had a cardiac event during the test, while only 60% of the high performers 
had an event during the exercise programme.  
According to equation 4.1 (see Chapter 4 ‘Biomechanical predictors of the modified shuttle 
walking test performance in patients with cardiovascular disease’), the predicted MSWD for this 
patient, when his stature (172 cm) was entered into the equation model, was 524 m. He 
performed almost 100 m above this predicted MSWD. This might imply that the patient over-
reached himself in an attempt to attain a higher score during the MSWT. This justifies Chapter 
4’s recommendations for using the prediction equation in order to set realistic and safe 
expectations for each individual patient in phase IV CR.  
7.5.  Conclusion  
Some relevant studies already demonstrated the relatively low risks of cardiac events during 
supervised exercise. The present work adds to the body of information regarding the safety of 
exercise training and the MSWT in clinical stable CVD patients. The most important point to be 
drawn from this study is that in exercise-induced testing or training, complex arrhythmias or 
symptomatic ST-segment depression is not induced in cardiac patients enrolled regularly for 




presented data from CR patients are not relevant to the present study cohort, or to the type of the 
exercise testing and the characteristics of the CR exercise programme used here.  
The information that this study provides is that, in community-based settings, the assessment of 
functional capacity with the MSWT and exercise prescription, is safe for phase IV low-risk CR 
patients, if the contraindications for testing and training are followed. The minor cardiovascular 
events, such arrhythmias and silent ST depression, are not be ignored, but are a reason to suggest 
additional CVD assessment and risk modifications. Further investigations should address, firstly, 
the limitations of this work, and whether the presence of isolated ventricular arrhythmias is 
related to exercise; they should then examine the prognostic value of these minor cardiovascular 
events over a longer-term follow-up period.  
Lastly, the present study was based on a cohort of low-risk CR patients. Cross-sectional studies 
should investigate further the possible cardiac complications during exercise among high-risk 
patients (i.e., HF patients, diabetics, patients with depression). Longitudinal study of patients 
who progress from high to moderate risk classifications would also be of great value. 
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CHAPTER 8.  THESIS COCLUSIO 
This chapter is divided into two parts. The first part summarizes the most important features and 
outcomes of chapters 3 to 7. The second part describes the potential overall impact of the thesis 
results on clinical cardiac rehabilitation (CR) practice.  
 
8.1.  Main points of each chapter 
 
Chapter 3.  Long-term reliability of the modified shuttle walking test in clinically stable 
cardiovascular disease patients.  
• Background: Cardiac rehabilitation aims to increase functional capacity. In order to 
verify such changes reliable functional capacity tests are needed. Clinical guidelines 
recommend the use of modified shuttle walk test (MSWT) and the six-minute walking 
test (6-MWT) to assess functional capacity in CR patients. Studies have only assessed its 
test–retest reliability in the short term. 
• Aim: To examine long-term test-retest reliability of MSWT in clinically stable cardiac 
patients. Long-term reliability is important in CR because the MSWT is often 
administered to patients pre- and post- CR, a gap of four to twelve weeks. 
• Methods: The MSWT was completed twice, by clinically stable phase IV CR patients 
(n=30), eight weeks apart. 
• Conclusions:  
- No systematic bias but a relatively large random variation in test performance over the 
test period.  
- The test can be used effectively in CR and there is no need for a practice MSWT in both 




Chapter 4.  Biomechanical predictors of the modified shuttle walking test performance in 
patients with cardiovascular disease.  
• Background: After determining the long-term reliability of MSWT, it was important to 
evaluate which factors influence MSWT performance. There was some evidence that 
performance on the 6-MWT is strongly influenced by age and stature of patients, but no 
comparable data were available for the MSWT.  
• Aim: to evaluate the influences of anthropometric and biomechanical parameters on 
MSWT performance in clinically stable CVD patients.  
• Methods: MSWT was completed twice, by clinically stable phase IV CR patients (n=16).  
• Conclusions:  
- Turning strategy, balance and ground reaction force data appear unrelated to MSWT 
performance. 
- Step length is the most important mediator of MSWT performance, but stature acts as a 
suitable surrogate measure.  
- An additional 1 cm of stature predicts that patients will complete an additional shuttle 
during the MSWT.  
- Clinicians should correct MSWT performance for patient stature. 
 
Chapter 5: Predictors of six-minute walking test performance in heart failure patients 
• Background: The 6-MWT is used to evaluate; functional limitations, the effects of 
interventions and aid prognosis in heart failure (HF) patients. Anthropometric variables 
are determinants of 6-MWT performance in healthy adults. There is not much evidence 




• Aim: to identify if routinely-made measurements (anthropometric, gait and simple 
clinical) could predict 6-MWT performance in HF patients, in the same way as in healthy 
adults.  
• Methods: 6-MWT was completed once, by clinically stable HF patients (n=71).  
• Conclusions:  
- Ventricular function is unrelated to 6-MWT performance in HF patients.  
- Age and anthropometric variables (sex, stature, body mass) are independent predictors of 
6-MWT performance, and they must be considered when interpreting performance in this 
population.  
- 6-MWT performance may be better expressed as a percentage of normal population 
values which account for sex, age, stature and weight. 
- The cut-off point of BMI> 25 kg·m-2 and age >75 years can be used for the prognostic 
stratification of HF patients.  
 
Chapter 6: ormative values for functional capacity testing in cardiac patients and the 
influence of anthropometric measures on performance.  
• Background: The cross-sectional study (Chapter 4) demonstrated that only 
anthropometric variables can be accounted for when MSWT is used to assess patients’ 
functional capacity during phase IV CR.  
• Aim: to determine normative values for functional capacity before and after CR, and the 
magnitude of change in functional capacity in phase III CR patients, through a 
longitudinal study.  
• Methods: MSWT was completed twice (before and after six weeks of phase III CR 




• Conclusions:  
- Age, sex and stature are the best predictive measures for pre-rehabilitation MSWT 
performance 
- Stature is the best predictor of magnitude of change in MSWT performance during phase 
III CR.  
- Normative values can be used to estimate a normal improvement in functional capacity 
for CR patients.  
- Clinicians can make better-informed decisions about patients at the entrance to or 
discharge from a CR programme when normative values are used to interpret test 
performance. 
 
Chapter 7: Safety of exercise training and exercise testing for cardiac patients, in a 
supervised, community-based cardiac rehabilitation programme.  
• Background: There was no information in the literature concerning the safety of exercise 
testing and training in phase IV community-based CR settings. 
• Aim: To verify to what extent a recommended exercise testing protocol (MSWT) and an 
exercise training session are safe for a mixed cohort of CR patients during a long-term 
maintenance programme. 
• Methods: Overall 33 cardiac patients underwent ambulatory electrocardiogram (ECG) 
monitoring during the MSWT (n=11) and exercise training (n=22).  
• Conclusions:  
- Poor functional capacity is not shown to be associated with the risk of a cardiac event 




- Supervised exercise testing and training are accompanied only by minor cardiovascular 
events and they can be carried out safely in community-based CR settings. 
 
8.2.  Clinical implications of thesis results 
 
The findings of the present thesis are important with regard to clinical practice in CR. The 
present results provide several insights into the assessment of functional capacity in CR. This 
information can help clinicians to make the most efficient therapeutic decisions about CR 
patients.  
The MSWT is a simple, cheap, valid and reliable test, which can be used to evaluate the 
functional capacity of patients enrolled in a CR programme. The present thesis (see Chapter 3) 
demonstrated its long-term reliability in a CR population for the first time. Clinicians can use the 
test to assess functional capacity improvement and they can feel confident that any improvement 
in patients’ functional capacity is due to CR and not due to confounding variables such as 
learning effects. Clinicians should be confident that only one MSWT pre- and post-CR is 
sufficient to assess long-term changes in functional capacity with no need for a practice walk. 
Reducing the need for a practice functional capacity assessment can make clinical assessment 
more economical and less time consuming, both of which are important issues for CR.  
The findings of this thesis (see Chapter 4, 5, 6) provided regression equations which can be used 
by clinicians to estimate MSWT and 6-MWT performance (distance walked). Clinicians should 
account for anthropometric parameters when interpreting distance walked. By interpreting 
distance as a percentage of the predicted value, practitioners would gain a more meaningful 
assessment of individual patient’s functional capacity compared with distance alone. This can 
lead to better risk stratification and more accurate exercise prescription for patients entering CR 




Particularly, the percentage of predicted functional capacity recorded on the MSWT can be 
determined using only age, stature and sex (see Chapter 6). Patients who record higher scores 
than 100% of their predicted distance walked on MSWT at the entrance of phase III CR could be 
‘fast-tracked’ to community-based phase IV CR. Patients who perform less than 100% of their 
predicted distance walked should be encouraged to join phase III CR and increase their habitual 
physical activity.  
The BACR (2006) criteria for assessing the suitability of patients to exercise in phase IV CR 
community settings suggest patients should be able to sustain physical activities to a minimum 
level of 5 METS. Patients who perform less than 5 METs or walk <450 m in MSWT at the end 
of phase III CR are classified as high-risk patients and may not be allowed to join phase IV CR. 
However, according to the normative values and prediction equation derived in Chapter 6, males 
who are shorter than 172 cm and older than 69 years are actually expected to perform less than 
450 m in MSWT at the end of phase III CR. Such patients, if they achieve this work rate should 
be considered for entry to phase IV CR. Clinicians should be more cautious, however, when 
making decisions for male patients who perform less than 450 m in MSWT, but are taller than 
172 cm and younger than 69 years. Such patients can often walk >450 and should be encouraged 
to increase their functional capacity until they achieve the expected distance for their height and 
age. Tests should be interpreted and even clinical decisions made according to individual’s 
anthropometric characteristics. In such ways, CR programmes could be tailored to better meet 
patients’ needs while potentially becoming more economical. 
The 6-MWT is commonly used to evaluate the functional capacity of patients with HF. The 
findings in Chapter 5 demonstrated that clinicians can use the gender-specific prediction models 
to evaluate individual’s expected functional limitation in this population. 6-MWT performance 




only). It was known that the performance of 300 m in 6-MWT has clinical prognostic value. 
According to the reference equation model presented in this thesis for 6-MWT (see Chapter 5), 
the same distance walked (300 m) indicates severe reduction in functional capacity for a tall 
(>178 cm) 75-year-old male, suggesting that one therapeutic goal should be an increase in 
exercise tolerance for such an HF patient. Conversely, this performance is expected to be classed 
as doing ‘well for age and stature’ in terms of the functional capacity of a short (<171 cm) 75-
year-old male, and a less intense, less stressful, safer and cheaper programme might be 
recommended, aimed at maintenance of functional capacity for such a HF patient.  
There are many benefits of functional capacity assessment and clinicians should use the MSWT 
or 6-MWT to assess patients’ performance at their start or discharge of a CR programme. These 
tests can be used with confidence but results appear more meaningful if clinicians are willing to 
look beyond the raw score of metres walked. Although, exercise can sometimes trigger 
symptoms in cardiac patients, the present thesis (see Chapter 7) showed that exercise 
prescription is safe for long-term supervised CR patients, if the contraindications to testing and 
training are followed. It is further suggested that when clinicians evaluate low-risk CR patients, 
there is no need for an ECG-monitoring during exercise in community-based CR settings. 
Patients can safely exercise in community-based CR settings.  
These recommendations have the potential to enable clinicians or researchers to prescribe the 
most efficient, economical and safe exercise programme for each individual patient entering CR. 
We are currenlty conducting a longitudinal study based on CR records, taken from several UK 
hospitals, in order to update the normative values of the present study. The final aim is to 
develop functional capacity nomograms which can be easily used to predict patients' expected 




APPEDIX A.  VALIDATIG THE PREDICTIO EQUATIO DEVELOPED I CHAPTER 4 
Appendix A1.  Results 
 
 
6.3.2.  Validating the prediction equation developed in chapter 4 
In order to validate MSWT performance (MSWD), prediction equation 4.1a (Chapter 4, pp.196), 
the correlations were first tested, and then the ICC and LoA between predicted and actual post-
rehabilitation MSWD.  
6.3.2.1.   Correlations between actual and predicted distance walked in the modified shuttle    
walking test 
Predicted MSWD was calculated using the equation based on stature (see equation 4.1a) for each 
individual. The mean MSWD in post-rehabilitation assessment was 420 (±186) m, while the 
mean of the predicted MSWD was 503 (±93) m. A significant but weak correlation was found 
between actual MSWD and predicted MSWD (Pearson’s r=0.194; p=0.019), when stature was 
entered into the equation model. These relationships are represented by the regression equation 






Figure 6.1. Regression line for the relationship between actual post-rehabilitation performance and 
predicted post-rehabilitation performance (using equation 4.1) 
6.3.2.2.  Agreement between actual and predicted distance walked in the modified shuttle 
walking test 
The ICC between the actual and predicted MSWD, with 95% confidence intervals for MSWD 
(post-rehabilitation MSWD), was low 0.16 (p=0.031). The mean difference and the limits of 
agreement (for MSWD) are shown in table 6.5 and figure 6.2. The standard deviation (191 m) of 
the difference MSWDs indicates that the difference between predicted and actual MSWD could 
be expected to be within -301 m and 463 m.  
Table 6.5. Agreement statistics: Mean difference (95% confidence intervals) between  predicted- 
and actual pre- rehabilitation distance walked in modified shuttle walking test (using equation 
4.1) 
 
Mean (SD)  
Difference 
95% confidence interval  2SD Limits of agreement 
    (mean±2SD) 
MSWD (m) 81 (191) 50 to 112 382 -301 to 463 






Figure 6.2. Limits of agreement plot (Bland and Altman plot) (using equation 4.1). Intraindividual 
differences between scores (actual and predicted distance walked) in modified shuttle walking test, plotted 
against the mean of the sum scores. The central line represents the mean of the intraindividual differences and 




Appendix A2.  Discussion 
 
 
6.4.2.  Testing the accuracy of the stature-based equation in predicting shuttle waking test 
performance in patients exiting phase III cardiac rehabilitation  
The prediction equation developed in Chapter 4 (see equation 4.1a), based on the testing of phase 
IV CR patients, was examined for validation purposes using data from patients exiting phase III 
CR. Post-rehabilitation data was used here, as an increase in functional capacity is usually 
established by the end of phase III CR and remains stable during phase IV (Woolf-May and 
Ferrett 2008).  
The present findings showed that the prediction equation developed in the pilot study did not 




between estimated MSWD (see equation 4.1a) and measured MSWD was significant but weak. 
Thus, it is suggested that equation 4.1a does not have application in the prediction of functional 
capacity achieved at the end of phase III CR. These findings suggest that the stature-based 
equation developed in the community based-group cannot be used to predict MSWD in a 
hospital based-group.  
This may be explained by differences in patient recruitment strategies. Equation 4.1a was 
developed in relation to members of a long-term CR programme (10 weeks to over 2 years), who 
were accustomed to exercise. The absolute value of the difference of 82 m in the mean MSWD 
between the community-based group (479±139, 1
st
 trial) and the hospital-based group (420±186 
m, post-rehabilitation assessment) demonstrates differences in physical status between the two 
groups. The 59 m difference between predicted and actual MSWD is not within the acceptable 
difference-range, since the mean MSWD improvement after exercise training is 93 m (see table 
6.1). An ideal case would be a zero difference between predicted and actual MSWD, whereas an 
acceptable difference might be less than half of mean MSWD improvement (i.e. <47 m).  
The ICC and LoA for MSWD were low. The systematic bias between predicted MSWD to actual 
MSWD was 81 m, indicating that the prediction equation overestimates the MSWD and 
cardiovascular capacity levels of phase III CR patients. The mean of the predicted MSWD was 
503 (±93) m. As mentioned earlier, this sample recorded lower mean values for MSWD than 
previous studies. Although the predicted MSWD is higher than the actual MSWD recorded in 
patients exiting phase III CR, it is still lower than in the results of previous studies (Fowler et al., 
2005; Arnold et al., 2007; Sandercock et al., 2007; Robinson et al., 2009). The predicted mean 
value for MSWD is close to the results found in Arnold et al. (2007). The lower MSWT outcome 
in the present study compared with previous studies is explained by the very low-baseline 




information available in any of the studies regarding the habitual activities of the patients, which 
may influence patients’ functional status. 
To summarise, the stature-based equation developed in the pilot study (see Chapter 4) 
overestimates the measured MSWD for the majority of these phase III CR patients. Therefore, 
the stature-based prediction formula is not acceptable for application with a phase III CR 
population. It might, however, have clinical utility in a community-based group (phase IV CR, 
UK classification). The pilot equation needs to be revised using a population similar to that used 
in the pilot study.  
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Appendix C1.  Long-term reliability of the incremental shuttle walking test in clinically 

























Appendix C2.  Biomechanical predictors of the shuttle walking test performance in patients 
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Background & Purpose: Distance walked on shuttle walking test (SWT) is used clinically to 
estimate cardiorespiratory capacity. The purpose of this study was to evaluate the associations 
between anthropometric and gait parameters with distance walked during an incremental SWT.  
Methods: Sixteen (9 males and 7 females) clinically stable cardiac patients performed the SWT 
on two occasions. Anthropometric data (mass, stature, body mass index, waist circumference, leg 
length) and gait characteristics (step length, turning gait) were collected. Linear regression 
analyses were used to identify the predictors of test performance (m). 
Results: Distance walked correlated most strongly with step length (trial 1 and 2: r = 0.83, 
p<0.05) and stature (trial 1: r=0.74, trial 2: r=0.69; p<0.05) in both trials. Stepwise regression 
revealed step length as the best independent predictor. Given the rarity of step length assessment 
in clinical practice, the next most powerful predictor of performance, stature, was entered in a 
subsequent model which explained 55 per cent of the variance in test performance.  
Conclusions: Taller patients perform better on the SWT than shorter patients with similar 
clinical characteristics. The regression equation generated here could potentially be used to 
predict an individual’s performance and remove some of the bias toward taller patients.   
Keywords: Incremental shuttle walking test; cardiovascular disease; predictors 
ITRODUCTIO 





 and ischaemic cardiovascular disease (CVD).
3




tests can provide important information regarding patient’s functional capacity, effectiveness of 
different rehabilitation treatments
4
 and individual's prognostic expectations.
5
   
There are two broad categories of test, those that are self-paced, such as the six-minute walk test
6
 
and those that are externally-paced protocols, such as the incremental SWT.
1
 These field tests are 
reliable, inexpensive, easy to administer and use measures of distance walked to estimate 
functional capacity.
7-9
 Patients often find walking tests preferable to the unfamiliarity of 
treadmill walking.
10
 However, these shuttle-based protocols require patients to turn at regular 
intervals, making the test more difficult than treadmill walking
11
 and creating different 
biomechanical demands compared to straight gait.
12
  
People with high number of chronic complications (respiratory diseases, diabetes, chronic heart 
failure, coronary heart disease) commonly have lower mobility than those with low number of 
chronic events due to poorer functional locomotion system performance.
13
 The more 
biomechanically inefficient a person is, the more difficult it will be for them to undertake such a 
test, like the SWT, which involves many turns.
14
 
There are associations between anthropometric variables and walking test performance in 
healthy adults,
15-21
 but there are no published reports concerning gait influences on test 
performance in clinical population.  Only one study has evaluated anthropometric associations in 
a clinical population.
22
 All these studies concern the six-minute walk test and no comparable data 
exist for the incremental SWT. Studies have also been limited to collecting simple 
anthropometric data and have not evaluated the potential associations between gait parameters 
and walking test performance. 
Stature and thus leg length are likely to influence SWT performance and the ability to increase 
walking speed.
23
 The aim of this study was to assess the associations between anthropometric 




patients. Since walking speed is progressively increased during the SWT it was hypothesised that 
this will bias the taller patient toward an improved shuttle score, regardless of morbidity. 
Furthermore, we tested the hypothesis that gait and anthropometric parameters can predict SWT 
performance in this population.  
METHODS 
Participants 
Sixteen clinical stable (clinically asymptomatic) CVD patients (9 males and 7 females; age 55-80 
years), who were members of a community-based follow-up cardiac rehabilitation programme,
24
 
voluntarily participated in this study with informed consent. Prior to the study all procedures 
were approved by the appropriate ethical committee and conformed to the declaration of 
Helsinki guidelines for research with human subjects.
25
 
All patients had been enrolled on a long-term maintenance, cardiac rehabilitation programme for 
a minimum of ten weeks. The programme comprises twice-weekly, 60-minute circuit-based 
exercise sessions, and is designed to maintain functional capacity gains achieved in outpatient 
cardiac rehabilitation (phase II, US classification).
24
 
All the patients were free of severe locomotor limitations and completed the study protocol 
twice, a minimum of eight weeks apart. Before initial testing, a primary health assessment (pre-
exercise health questionnaire, medical, pharmacological, family history) and anthropometric 
measurements including stature, body mass, waist circumference and leg length
26
 were made. 
Body mass index was calculated (kg·m
-2
). Table 1 summarises the patients’ clinical 





Procedure and data collection 
Shuttle walking test procedure 
Patients performed an incremental SWT
1
 by walking back and forth on a corridor marked by two 
cones set 0.5 m from either end of a 10 m course. Initial walking speed was 0.5 m·s
-1
 and 
increased by 0.13 m·s
-1
 each minute, indicated by an audible signal. During the test, heart rate 
was recorded with a Polar heart rate monitor (Polar Electro Sports Tester S810I, Heart Rate 




The SWT was terminated either when the patient (a) felt too breathless or fatigued to continue at 
the required speed, (b) failed to complete the shuttle within the allowed time, (c) reached 85% of 
the predicted maximal heart rate: 210- (0.65×age), (d) reached RPE ≥ 15 [20], or (e) completed 
all the levels. 
Gait data 
Each turn made at the end of the 10 m walkway was recorded with a a Sony CCD-TRV20E 
video camera and analyzed on SiliconCoach Pro software (version 6.1.5.0). From the video data 
the turning style (i.e., step turn or spin turn),
28
 the turning time, and the number of steps needed 
to complete the turn were collected. Turning time and number of steps used in turning were 
recorded one step before turning, from either foot heel strike, until the end of the turn. End of the 
turn was defined as the first heel strike with the pelvis and thorax facing the opposite cone. 
During the test, the number of steps taken in every shuttle was recorded. Step length was 
estimated by dividing the length of the course (nine meters – straight portion of the course) by 







The independent variables were divided into two categories: static variables (age, stature, leg 
length) and dynamic variables (step length, step length normalized to leg length, number of steps 





penultimate and final levels of the test. Statistical analysis was implemented with SPSS (SPSS 
inc., Chicago, IL, US). Data were presented as means and standard deviation. The median value 
of stature was calculated. Differences between the two SWTs were evaluated by using paired-
samples t-test. Pearson’s correlation coefficients and stepwise linear regression analysis were 
used for the two tests (trial 1 and trial 2). 
Two stepwise models were used: model one contained all the independent variables which 
correlated (r>0.3) with performance (regression analyses were performed separately for each of 
the trials). To build a clinically useful equation we built a second regression model containing 
only variables which were both; strongly correlated with performance, and routinely recorded in 
cardiac rehabilitation. Colinearity diagnostics were performed for all predictor variables.
29
 The 
lower limit of normal (LLN) in SWT performance has been determined by using the lower 5
th
 
percentile of a normal distribution.
30
   
RESULTS 
Shuttle walking distance ranged from 210 to 750 m. There was no significant difference in mean 
performance between trial 1 (479 ± 139 m) to trial 2 (499 ± 138 m), t=-1.8, p=0.092. Shuttle 
walking test performances (m) were normally distributed in both trials. The static measurements: 
stature and leg length and the dynamic measurements: step length and number of steps to turn, 




Stepwise regression analysis indicated that step length at the 2/3
rd
 of maximal test performance 
was the best predictive measure for performance, followed by stature, in both tests. These 
models explained 68.3% (SE = 74 m) and 68.2% (SE = 85 m) of the variation of performance for 
trial 1 and trial 2, respectively. 
As step length is a dynamic measure and probably not practical in routine clinical assessment. 
The variable next most highly correlated with performance in regression analysis was stature. 
Regression analysis was repeated using only stature to predict performance; data from trial 1 
were used (equation 1). This model explained 55% of the variation in performance. The 5
th
 
percentile of SWT performance distribution of trial 1 was 200 m, so the lower limit of normal 
range (LLN) was computed by subtracting 200 m (equation 2). 
SWT (m) = (10.7 × staturecm) -1316                                                    (1) 
SWT (LLN) (m) = (10.7 × staturecm) – 1116                                       (2) 
The accuracy of the prediction equation was assessed by predicting performance in trial 2. 
Actual distance walked in trial 2 was highly significant with predicted distance when stature was 
entered into the equation model (Pearson’s r=0.69, p=0.003). 
DISCUSSIO 
When assessing functional capacity with a standardized walking test in elderly clinical 
populations, non-clinical factors which may potential affect performance need to be considered 
in advance. This is the first prospective study to examine the effect of anthropometric and gait 






Gait and anthropometric predictors of performance 
Despite measuring a number of walking and turning gait parameters, we found only one gait 
parameter and two anthropometric measures which predicted SWT performance. Step length at 
66% of individual maximal walking speed, stature and leg length were all independently 
associated with distance walked.  
Taller patients had longer step length and appeared better able to cope with the increases in 
walking speed needed at the later stages of the test. Shorter patients were less able to increase 
walking speed by increasing step length during latter test stages, resulted in poorer test 
performance. This can be theoretically illustrated by calculating the Froude number for the 
shuttle tests based on the ±1SD of the mean leg length. The Froude number (v
2
/gl; where v is 
velocity, g is gravitational acceleration and l is leg length) provides a dimensionless number 
which normalises walking speed to leg length. By calculating this number based on leg length 
we can see that tall patients walked at a lower Froude number as the shuttle speed (level) 
increased compared to short patients. Thus the taller patients were walking at a relatively lower 
velocity than short patients, and the walk to run transition speed (0.5 Froude)
31
 occurred 
approximately one shuttle level later. This model can also be used to predict maximal walking 
speed and again shows a bias toward the taller patient. Therefore taller patients, who could 
continue to increase step length at later stages of the test, appear more able to obtain better scores 
in the test.  
As the SWT is incremental in nature, walking speed is always positively associated with distance 
walked
1
. Characteristics such as long step length and greater stature, which are associated with 
greater maximal walking speed
32
 are also likely to result in better test performance. Walking 
speed is a combination of step length and cadence, an increase in one or both results in an 




shuttles in order to complete the shuttle. Increases in cadence are limited in the elderly
32
, patients 
will therefore need to increase step length to achieve higher walking speeds. This gives taller 
patients, a natural advantage in walking tests. A study in which cadence and step length are 
monitored during SWT would be needed to test this hypothesis.  
The regression analysis showed that the step length recorded at 66% of maximal walking speed 
was the best predictive measure of performance. Step length is, however, a dynamic measure and 
changeable especially amongst the elderly,
33,34
 while the clinicians need practical measurement 
procedures for regular use in clinical assessment. Stature was the next best predictor of 
performance. We chose, therefore, to use this in preference to step length, due to its simplicity 
and its existing high clinical utility (it is routinely collected for the calculation of body mass 
index as a CVD risk factor). Such a choice is consistent with previous studies, which used only 
static variables (stature, age and weight or body mass index alternatively) in their equation for 
prediction of six-minute walk test performance in healthy adults.
15-21
 
The prediction equation generated here has three consequences. First, taller cardiac patients have 
an advantage over shorter patients and generally perform better in SWT. This is agreement with 
reference models already constructed for six-minute walk test in healthy populations.
15-21
 The 
six-minute walk test is commonly used in chronic heart failure patients, while the SWT is 
recommended for the assessment of stable CVD patients.
1,6
 Second, it is suggested that male 
CVD patients, can walk on average 160 metres further (i.e., 16 shuttles) in the SWT than 
women, due to stature differences between the two sexes (Table 1). Third, due to regression 
towards to the mean
35
 CVD patients who are high performers >610 m (75
th
 percentile of SWT 
performance, normal distribution) are likely to improve only marginally, whereas low performers 
<370 m (25
th 
percentile) might improve to a much greater degree. Our results and the problem of 
regression to the mean imply that although tall >176 cm (i.e., 75
th




distribution) CVD patients are likely to attain higher initial SWT scores than shorter patients, 
short patients <162 cm (25
th 
percentile) are expected to record more improvement in a re-
assessment with SWT after a particular intervention (i.e., CR), in contrast with tall patients. 
Approximately 45% of the variation in SWT performance remains unexplained. This figure is 
within the range of the unexplained variance in predicted 6-MWT in non-clinical populations 
(34-80%).
15-21
 To our knowledge, no previous studies of either the 6-MWT or the incremental 
SWT have analysed spatial/temporal gait parameters. By performing this analysis we have 
demonstrated that it is useful to consider anthropometric but not gait parameters when 
interpreting SWT performance.  
Effect of turning on walking test performance 
Turning negatively affects walking test performance in housebound elderly patients compared 
with those with no limitations to their daily activity.
32
 Despite the relatively high frequency and 
number of turns needed during the test, none of the turning variables we measured were 
associated with SWT performance. Of note, the present sample comprised CVD patients who 
regularly exercised and as such, were largely free from limitations to daily activities. Turning 
may be more important in less-able patients with greater orthopaedic limitations. 
Study limitations 
The application of the above suggestions might be limited by some methodological issues. The 
sample used was relatively small and may lack the statistical power to identify statistically 
significant relationships between more weakly associated pairs of variables. A larger sample 
would allow the generation of generalizable normative data to confirm the present findings. 




Furthermore, the patients were all members of a long-term follow-up training cardiac 
rehabilitation programme and are accustomed to exercising. Less conditioned patients, such as 
those entering earlier phases of rehabilitation may show different associations between gait 
predictors and test performance. This is a potential avenue for further research. 
COCLUSIOS 
The findings of the present study are important with regard to clinical practice in cardiac 
rehabilitation. These data show that tall patients have an advantage in the SWT and that 
practitioners should account for stature when interpreting distance walked. By interpreting 
distance as a percentage of the stature-predicted value, practitioners would gain a more 
meaningful assessment of individual patient’s functional capacity compared with distance alone. 
This may lead to better risk stratification and more accurate exercise prescription when based on 
SWT performance. 
These pilot data are the first to provide specific regression equations to estimate SWT 
performance, and there is a clear need for a larger study to independently validate the present 
findings. This study has, however, potentially eliminated the need to further investigate certain 
gait parameters which are time consuming and expensive. This small study may allow for a 
larger, more economical study to be conducted using the simple anthropometric predictors of 
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Table 1. Descriptive characteristics and baseline measurements of patients 
Clinical characteristics & baseline 
measurements 
Values † 
Number of patients 16 
Age   (years)   69 (9) 
Sex (%) Males: 56, Females: 44 
Stature     (cm)   
                Median value  (25
th
 percentile)  
                Median value  (75
th
 percentile) 
167 (10) ; Males: 174, Females: 159 
162  
176  
Body mass index   (kg · m
-2
)   29.3 (3.7)  
Leg Length   (cm)   88 ( 8)  
Medical History/Reason for joining CR (%) 
           Myocardial Infarction                                                              
Stable Angina                                                              
   Surgical procedure (CABG, PTCA) 
   Heart Failure      





13                                               
13                                                                                                                                                                
Abbreviations: CR, cardiac rehabilitation; CABG, coronary artery bypass graft; PTCA, 
Percutaneous transluminal coronary angioplasty; HR, heart rate 




Table 2.  Correlations between gait and anthropometric parameters and shuttle walking distance in the two trials 
 
Trial 1 






 Pearson r P value   Pearson r P value 
SWD - Stature 16 0.741 0.001  16 0.688 0.003 
 
SWD - Leg length 16 0.808 <0.001  16 0.762 0.001 
1/3
rd
 of total test SWD - Step length 15 0.826 <0.001  16 0.563 0.023 
 

















  of total test  
SWD - Step length normalized 15 0.593 0.02  16 0.523 0.038 
 















SWD - Step length normalized 16 0.512 0.042  16 0.574 0.020 
 















 SWD- Step length normalized 16 0.471 NS †  16 0.535 0.033 
























































































Appendix E4.  BACR Annual Conference (2010), Liverpool, United Kingdom 
 
